

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Dicloxacillin		3116-76-5			
Dicumamol		66-76-2			
Dicyclomine		77-19-0			
didanosine	Inosine, 2',3'-dideoxy- [CAS]	69655-05-6	US 4861769	Antiviral, anti-HIV	Infection, HIV/AIDS
Dideoxyadenosine		4097-22-7			
didox	Benzamide, N,3,4-ethyldioxy- [CAS]	69839-83-4	US 4263322	Anticancer, antimetabolite	Cancer, general
Dienestrol		84-17-3			
dienogest	19-Norpregna-4,9-diene-21-nitile, 17-hydroxy-3-oxo-, (17 $\alpha$ )- [CAS]	65928-68-7	GB 1524917	Menstruation disorders	Endometriosis
dienogest+estradiol	19-Norpregna-4,9-diene-21-nitile, 17-hydroxy-3-oxo-, (17 $\alpha$ )- [CAS] + Estradiol (17 $\beta$ )			Formulation, fixed-dose combinations	Contraceptive, female
Diethadione		702-54-5			
Diethazine		60-91-3			
Diethylbromacetamide		511-70-6			
Diethylcarbarnazine		90-89-1			
diethylpropion	1-Propanone, 2-(diethylamino)-1-phenyl- [CAS]	90-84-6		Formulation, modified-release, <=24hr	Obesity
Diethylstilbestrol		56-53-1			
Difemefrine		80387-96-8			
Difenamizole		20170-20-1			
Difenoxin		28782-42-5			
Difenpiramide		51484-40-3			
	(5R)-5-Ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepino[3',4':6,10]indolizino[1,2-b]quinoline-3,15-dione				
diflometecan		220697-97-7		Anticancer, other	Cancer, general
diflorasone	Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6 $\alpha$ ), (11 $\beta$ ), (16 $\beta$ )- [CAS]	33564-31-7 2557-49-5	US 3960778	Antipsoriasis	
Difloxacin		98106-17-3			
Diflucortolone		2607-6-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
diflunisal	2,4-difluoro-4-hydroxy(1,1'-biphenyl)-3-carboxylic acid	23674-86-4 22494-42-4	GB 1175212	Analgesic, NSAID	Pain, post-operative
Difluprednate		23674-86-4			
Digitalin		752-61-4			
Digitoxin		71-63-6			
digoxin	Card-20(22)-enolide, 3-[(O-2,6-dideoxy-8-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl)-(1-4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy-12,14-dihydroxy-, (3β,3β,12β)- [CAS]	20830-75-5	US 4088750	Formulation, oral, enteric-coated	Heart failure
Dihexyverine		561-77-3			
Dihydralazine		484-23-1			
Dihydrocodeine		125-28-0			
Dihydrocodeinone Enol		466-90-0			
dihydroergocryptine	Ergocryptine, dihydro- [CAS]	25447-68-9		Formulation, other	Depression, general
dihydroergotamine	Ergotaman-3',6'-18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha, 10Alpha)- [CAS]	511-12-6 509-60-4	6495535	Formulation, modified-release, other	Migraine
Dihydroeromorphine		128-46-1			
Dihydrostreptomycin		67-96-9			
Dihydrotactysterol		13682-92-3			
Dihydroxyaluminum		539-68-4			
Diisopromine		5966-41-6			
Disopropyl Paraoxon		3254-66-8			
Diisopropylamine		660-27-5			
diazepam	Benzole acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-diylid-3,1-propanediyl ester, [CAS]	35898-87-4	JP 51095086	Vasodilator, coronary	
Dilevalol		75659-07-3			
difenoxin	2-Furan carboxylic acid, 4-[(dicloroacetyl)methyl]amino phenyl ester [CAS]	3739-61-0 579-36-4		Anteobicide	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
difliazem	1,5-Benzothiazepin-4(5H)-one, 3-(acetyl-oxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-ox)-[CAS]	33286-22-5 42399-41-7	US 4721619 US 5529791 EP 372777	Antianginal	Angina, hypertension, general
<b>Dimecroic Acid</b>		7706-67-4			
<b>Dimefline</b>		1165-48-6			
<b>Dimemorfan</b>		36309-01-0			
<b>Dimenhydrinate</b>		523-87-5			
<b>Dimenoxadol</b>		509-78-4			
<b>Dimephexanol</b>		545-90-4			
<b>Dimercaprol</b>		59-52-9			
<b>Dimetacrine</b>		4757-55-5			
<b>Dimethadione</b>		695-53-4			
<b>Dimethazan</b>		519-30-2			
<b>Dimethindene</b>		5636-83-9			
<b>Dimethisquin</b>		86-80-6			
<b>Dimethisterone</b>		79-64-1			
<b>Dimethocaine</b>		94-15-5			
<b>Dimethoxanate</b>		477-93-0			
<b>Dimethyl Sulfoxide</b>		67-68-5			
<b>Dimethylthiambutene</b>		524-84-5			
<b>Dimetofrine</b>		22950-29-4			
<b>Dimorpholamine</b>		119-48-2			
<b>dinoprostone</b>	Prosta-5,13-dien-1-ol-ic acid, 11,15-dihydroxy-9-oxo-, (6Z,11Alpha,13E,15S)-[CAS]	363-24-6		Formulation, modified-release, <=24hr	Labour, induction
<b>difemecite</b>	Smecta® [CAS]	110070-78-5	FR 2770778	Antidiarrhoeal	Diarrhoea, general
<b>dibemrin</b>	4-[1-(Benzo[pyran-4-one, 7-[(6-O-(6-deoxy-Alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)-5-hydroxy-(3-hydroxy-4-methoxyphenyl)-[CAS]	520-27-4	DE 2602314	Vasoprotective, systemic	
<b>Dioxadrol</b>		6495-46-1			
<b>Dioxaphetyl</b>		467-86-7			
<b>Dioxethidine</b>		497-75-6			
<b>Dioxybenzone</b>		131-53-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Diphemanil		62-97-5			
Diphenadione		82-88-6			
Diphenacyprone		886-38-4			
Diphenhydramine		58-73-1			
Diphenidol		972-02-1			
Diphenoxylate		915-30-0			
Diphenylpyraline		147-20-6			
Diphatarson		515-78-4			
Diphtheria & Tetanus Toxoids And Acellular Pertussis Vaccine Adsorbed					
Dipipanone		467-83-4			
dipivefrin	Propanoic acid, 2,2-dimethyl-, 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester, (+/-) [CAS]	52365-63-6	US 3809714	Antiglaucoma	Glaucoma
Dipyridamole		58-32-2			
Dipyrocetyl		486-79-3			
Dipyrrone		5907-38-0			
diquafosol	Uridine 5'-(pentahydrogen tetraphosphate)-5'-ester with uridine, [CAS]	211427-08-6		Ophthalmological	Dry eye syndrome
diltiazem	Erythronycin, 9-deoxy-11-dioxy-9,11-[nitro[2-(2-methoxyethoxy)ethylidene]oxy]-[ISR3] [CAS]	62013-04-1	DE 2515075	Macrolide antibiotic	Tonsillitis
diosodium pamidronate	Phosphonic acid, (3-aminopropylidene)bis-, disodium salt [CAS]	57246-88-1	EP 177443	Osteoporosis treatment	Hypercalcaemia of malignancy
Disofenin		65717-97-7			
disopyramide	2-Pyridineacetamide, Alpha-[2-[bis(1-methylethylamino)ethyl]-Alphas-phenyl- [CAS]	3737-09-5		Formulation, modified-release, =24hr	Arrhythmia, general
Disulfamide		15876-67-2			
		671-88-5			



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Disulfiram		97-77-8			
Diltazol		18471-20-0			
Dithiazanine		514-73-8			
diltiranol	9-(1H)-Anthracenone, 1,8-dihydroxy- [CAS]	1143-39-0		Formulation, dermal, topical	Psoriasis
Ditocarb		148-18-5			
Dioxanthogen		502-85-6			
Dixyrazine		2470-73-7			
DJ-627			WO 01027115	Anticancer, other	Cancer, general
DK-507k	(+)-7-[(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-3-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate				
DL-Lactic Acid		598-92-3		Quinolone antibacterial	Infection, general
DMDC	Cytidine, 2'-deoxy-2'-methylene-, monohydrochloride [CAS]	113648-25-2	WO 8807049	Anticancer, antimetabolite	Cancer, general
DMXAA	5,6-dimethylxanthinone-4-acetic acid			Anticancer, other	Cancer, lung, general
DNA Stealth Nucleosides			US 8132776	Antiviral, anti-HIV	Infection, HIV/AIDS
Dobesilate		20123-80-2			
dobutamine	1,2-Benzenediol, 4-[2-[(3-(4-hydroxyphenyl)-1-methylpropylamino)ethyl], (+)-] [CAS]	34388-04-2 48748-95-1	US 3987200	Cardio stimulant	
Docarpamine	(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5S,20-epoxy-1,2Alpha,4,7B,10E,13Alphahexahydroxytax-11-en-9-one 4-acetate 2, benzoate. [CAS]	74639-40-0			
docetaxel		114877-28-5 148408-66-6	EP 253738 EP 707487	Anticancer, other Hypolipemic/Antiatherosclerosis	Cancer, breast Hyperlipidaemia, general
docosahexaenoic acid					
docosanol	1-Docosanol [CAS]	861-19-8 128-48-4	EP 469064 EP 577-11-7	Antiviral, other Formulation, dermal, topical	Infection, herpes simplex virus Infection, herpes simplex virus propylhexis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
dofetilide	Methanesulfonamide, N-[4-[2-[methyl(2-[4-(methanesulfonyl)amino]phenoxy)ethyl]aminomethyl]phenyl]- [CAS]	115256-11-8	EP 246597	Antiarrhythmic	Fibrillation, atrial
dolasetron mesilate	1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolin-8-yl ester, (2Alpha,6Alpha,8Alpha,9Alpha), monomethanesulfonate. [CAS]	115956-13-3 115956-12-2	EP 266730	Antiemetic	Chemotherapy-induced nausea and vomiting
Domiphen		61869-07-6			
Domitroban		538-71-6			
		112960-96-8			
domperidone	2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro. [CAS]	57808-06-9	US 4066772	Antiemetic	
donepezil	1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-. [CAS]	120011-70-3 120014-06-4	EP 296560	Cognition enhancer	Alzheimer's disease
donitriptan	Piperazine, 1-(((3-(2-aminoethyl)-1H-indol-5-yl)oxy)acetyl)-4-(4-cyanophenyl)- [CAS]	170912-52-4			
Dopamine		51-61-6		Antinigraine	Migraine
Dopexamine		86197-47-9			
	urea, N-[3-((1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-N'-[4-(2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-				
doxanapimod	(S)-1,2,4-Butanetriol, 3-(2-nitro-1H-imidazol-1-yl)methoxy- [CAS]	285983-48-4		Antiarrhythmic, Immunological	Arthritis, rheumatoid
doxandazole	(S)-1,2,4-Butanetriol, 3-(2-nitro-1H-imidazol-1-yl)methoxy- [CAS]	137339-64-1	WO 9414778	Radiochemosensitizer	Surgery adjunct
doxiphenem	(1R,5S,6S)-2-[(3S,5S)-5-(sulfonylamino)methyl]pyrrolidin-3-ylthio-6-[(1R)-1-hydroxyethyl-1-methylcarbamoyl]-2-am-3-carboxylic acid	148016-81-3	EP 528678	Beta-lactam antibiotic	Infection, urinary tract
dozorlamide	4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(4-ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide (4S-trans) [CAS]	120279-96-1	EP 296879	Antiglaucoma	Glaucoma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
doxazepam + timolol	4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxida (4S-trans) + ethyl 2-propanol, 1-[(1,1-dimethylamino)-3-[(4-(4-morpholinyl)-1,2,5-thiadiazol-5-yl)oxy], (S), (Z)-2-butenedioate (1:1) (salt) [CAS]	120279-96-1 26830-75-8 26921-17-5		Formulation, fixed-dose combinations	Glaucoma
doxalate	Aluminium, {[7-(7-(6-O-(6-deoxy-2,3,4-tri-O-sulfo-4-phenyl-L-mannosylpyranosyl)-2,3,4-tri-O-sulfo-5-O-glucopyranosyl)-6-hydroxy-2-(4-methoxy-3-(sulfoxyphenyl)-4-hydroxyphenol-4-onato(7))tetraacetic-H-hydroxyphenolcarboxylatetetrade- [CAS]	122312-55-4		Antitumor	Ulcer, gastric
doxepine	1-Propanamine, 3-dibenzyl- $\alpha$ -thiaphen-11(6H)-ylidene-N,N-dimethyl- [CAS]	113-53-1		Antidepressant	
Dofetilazone		84625-59-2			
Dofetilazone		113-53-1			
Doxacurium		106819-53-8			
Doxapram		309-29-5			
doxazosin	Piprazazine, 1-(4-amino-5,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]- [CAS]	7419-85-8 40762-15-0	GB 2007656	Antihypertensive, adrenergic	Hypertension, general
Doxefazepam		3254-93-1			
Doxenitoin	1-Propanamine, 3-dibenzyl- $\alpha$ -thiaphen-11(6H)-ylidene-N,N-dimethyl- [CAS]	1068-19-5		Formulation, dermal, topical	Pruritus
doxepin					
doxercalciferol	9,10-secoergosterol-5,7,10(10',22',24',26',28')-pentaene-1,3-diol (1 $\alpha$ Ph, 3 $\beta$ , 5 $\beta$ , 7 $\beta$ , 22 $\beta$ ) [CAS]	54573-75-0	US 5104854	Hormone	Hyperparathyroidism
doxifuridine	Uridine, 5'-deoxy-5-fluoro- [CAS]	3064-09-5	US 4071680	Anticancer, antimetabolite	Cancer, colorectal
doxofylline	1H-Purine-2,6-dione, 7-[(3-dioxolan-2-yl)methyl]-3,7-dihydro-1,3-dimethyl- [CAS]	69975-86-6	US 4187308	Antiasthma	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
doxorubicin	5,12-Naphthoquinone, 10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-xylo-hexopyranosyloxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, [CAS]	23214-92-8	EP 191824	Formulation, optimized, liposomes	Cancer, general
doxycycline	2-Naphthacenecarboxaniline, 4-(dimethylamino)-1,4a,5,6a,6,11,12a-octahydro-3,5,10,12-tetrahydroxy-6-ethyl-, 1,1-dioxo-, (4S)-(4 $\alpha$ Pha,4 $\alpha$ Pha,5 $\alpha$ Pha,5 $\alpha$ Pha,6 $\alpha$ Pha,12 $\alpha$ Pha)-, [CAS]	564-25-0 17085-20-1		Formulation, modified-release, immediate	Periodontitis
doxylamine	N,N-Dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine	469-21-6		Formulation, transmucosal, systemic	Rhinitis, allergic, general
DPC-817	[3-D,2',3'-didehydro-2',3'-dideoxy-5'-fluorocytidine]			Antiviral, anti-HIV	Infection, HIV/AIDS
DPI-3290			US 5681830	Analgesic, other	Pain, general
DQ-113	5-Amino-7-[(8S,4R)-(1-aminocyclopropyl)-3-fluoropropylidene-1-yl]-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-6-methyl-4-oxo-3-cyclopentacarbonylic acid	1679-76-1 82413-20-5 2440-22-4		Quinolone antibacterial	Infection, general
Drofenine		58-19-5			
Droloxifene					
Drometrizole					
Dromostanolone					
dronabinol	6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)-, [CAS]	1972-08-3		Antiemetic	Chemotherapy-induced nausea and vomiting
dronedrona	2-n-Butyl 3-[4-(3-d-n-butylamino-propoxy)benzoyl]6-methylsulfonamidobenzoturan			Antiarrhythmic	Arrhythmia, general
Droperidol		548-73-2			
Dropranilamine		57663-27-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Dropropizine		17692-31-8			
Drosiprenone		67392-87-4			
Drotaverine		14009-24-6			
Drotebanol		03/02/3176			
droxidopa	2H,5H-1,3-Oxazino[5,6-g][1,2]benzothiazine-2,4(3H)-dione, 5-methyl-3-(2-pyridinyl)-, 5,6-dioxide [CAS]				Inflammation, general
Droxidopa	L-Tyrosine, 6,3-dihydroxy-, threo- [CAS]	90101-16-9	EP 99770	Anti-inflammatory	Parkinson's disease
Droxidopa		23651-95-8	EP 128684	Antiparkinsonian	
DUI-125530	1,2-Benzisothiazol-3(2H)-one, 2-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]butyl-, 1,1-dioxide [CAS]	161611-99-0	EP 633260	Anxiolytic	Anxiety, general
duloxetine	2-Thiopropylpropanamine, N-methyl-Gamma-(1-naphthalenyl)oxy-, hydrochloride, (S)- [CAS]	136434-34-9 116539-59-4	US 5362886	Antidepressant	Depression, general
Duramorph		1306-06-5	WO 9428726	Formulation, inhalable, solution	Cystic fibrosis
Durapatite	4-Azaandroster-1-ene-17-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-, (5A,17B)- [CAS]				
dutasteride	N,N-dileucopropyl-4-[4-(3-aminobenzofuro[2,3-b]furan-5-yl)oxy]butoxy]-3-methoxybenzamide	164656-23-9	US 5565467	Prostate disorders	Benign prostatic hyperplasia
DW-1141	(R)-(-)-7-(4-aminomethyl-4-methyl-3-(Z)-methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid			Osteoporosis treatment	Osteoporosis
DW-285a					
DW-471			US 5922871	Quinone antibacterial Antiviral, other	Infection, general Infection, hepatitis-B virus

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
DX-9055a	2-Naphthalenepropanoic acid, 7-(aminomethyl)-; Alpha-[4-[(1-aminomethyl)-3-pyrrolidinyl]oxy]phenyl-, monohydrochloride, pentahydrate, [S-(R*, R*)], [CAS]	155204-81-2		Antithrombotic	Thrombosis, general
DY-9760c	1H-indazole, 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-1-(1H-indazol-4-ylmethyl)-5,6-dimethoxy-, [CAS]	160522-00-9	US 5681954	Neuroprotective	Ischaemia, cerebral
Dyclonine		586-60-7			
Dydrogesterone		152-62-5			
Dymanthine		124-28-7			
Dyphylline		479-18-5			
E-1010	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-oxo-2-ethyl-3-[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-5-pyrrolidinylidene]-4-methyl-7-oxo-, monohydrochloride, (R,S,5S,5S)-, [CAS]	186319-97-1		Beta-lactam antibiotic	Infection, general
E-2101	N-Ethyl-1-[1-(2-fluoroethenyl)piperidin-4-yl]-1H-imid-6-ylacetamide				
E2F antagonists			WO 9606943	Muscle relaxant Anticancer, other	Muscle spasms, general Cancer, general
E-3520	Benzamide, 4-amino-5-chloro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-[(1-methyl-2-butenyl)oxy]-, monohydrochloride, [3(S)-endo]-, [CAS]	151213-86-4	EP 554794	Anilact/Anilactul	Dyspepsia
E-5564	Alpha-D-Glucopyranose, 3-O-decyl-2-deoxy-4-O-(2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[(11Z)-1-oxo-11-octadeceny]amino)-4-O-phosphono-6-D-glucopyranosyl)-2-[(1,3-dioxoletridecyl)amino)- 1-(dihydrogen phosphite), tetrasodium salt [CAS]	185954-98-7	EP 536969	Septic shock treatment	Sepsis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
E-5842	Pyridine, 2-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	220120-14-9		Neuroleptic	Schizophrenia
E-6259	1-(4-Aminosulfonylphenyl)-5-[2,4-difluorophenyl]-4,5-dihydro-3-trifluoromethyl-1H-pyrazole			Antiarthritic, other	Unspecified
EAA-90	2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7-en-2-yl)ethylphosphonic acid	57-08-9		Analgasic, other	Pain, neuropathic
s-Acetamidocaproic Acid		60-32-2			
s-Aminocaproic Acid	1-Butanone, 1-[4-(1,1-dimethylethylphenyl)-4-[4-(diphenylmethoxy)-1-piperidinyl]-1H-imidazole, 1-[2,4-dichloro-10,11-dihydro-5H-iberozole[dicyclohept-5-yl)]- [CAS]	90729-43-4	EP 134124	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
elbasine		126326-82-9			
elberconazole		130104-32-4	ES 2012297	Antifungal	Infection, dermatological
elbrolidine	Benzenesulfonamide, N-[12-[2-(aminomethylamino)-4-(triazolyl)methylthio]ethyl]amino]methylene]-4-bromo- [CAS]	100981-43-9	EP 159012	Antitumor	Ulcer, duodenal
elbasien	1,2-Benzisoxaselenazol-3(2H)-one, 2-phenyl- [CAS]	60940-34-3	EP 44871	Neuroprotective	Hemorrhage, subarachnoid
Eburnamomine		474-00-0			
Ecabapide		104775-36-2			
ecabrel	1-Phenanthrene-9-carboxylic acid, 1,2,3,4,8,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-5-sulfo-, [1R-[1Alpha,4a,8,10a,10aH]]- [CAS]	33159-27-2	DE 3239172	Antitumor	Ulcer, gastric
ecadrell	Glycine, N-[2-[leucyl(methyl)-1-oxo-3-phenylpropyl]-phenylmethyl ester, (S)- [CAS]	86408-72-2			
Ecgonidine		112573-73-6	EP 316377	Antihypertensive, other	Hypertension, general
Ecgonine		484-93-5			
Echothiophate		481-37-8			
		513-10-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Econazole	5H-Benzofuro[2,1-b]azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, (6a <i>S</i> -trans)- [CAS]	277220-47-9			
ecopipam	112108-01-7	EP	230270	Anorectic/Antiobesity	Obesity
ecaprost	Prosta-8,13-dien-1-ole acid, 11,15-dihydroxy-9-(4-oxobutoxy)-, butyl ester, (11 $\alpha$ ,13 $\alpha$ ,15 $\alpha$ )- [CAS]	136992-64-3	EP	423887	Vasodilator, peripheral
Ectylurea	9,10-Secochlorella-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1 $\alpha$ ,13 $\alpha$ ,25,35,52,7 $\alpha$ )- [CAS]	95-04-5			Peripheral vascular disease
ED-71	3H-Pyrazo-3-one, 2,4-dihydro-5-methyl-2-phenyl-, [CAS]	10421-92-8	EP	184206	Osteoporosis treatment
edaravone		89-25-8	JP	62108814	Infarction, cerebral
Edatrexate		80576-83-6			
Edetate Calcium		62-33-9			
Disodium		139-33-3			
Edetate Disodium		64-02-8			
Edetate Sodium		150-38-9			
Edetate Trisodium	Butanamide, N-[2-[[4,5-dimethyl-3-isoxazolyl]amino]butyl]-4-(2-oxazolyl)-[1,1'-biphenyl-2'-yl]methyl-N,3,3-trimethyl-, monohydrate				
edonentan	[N-[2-[4,5-bis[[carboxy-kappaO]methyl]-10-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1, kappaN4, kappaN10]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threonol cyclic (2-7)-disulfido(3-yl)]trifluoromethanesulfonate	210891-04-6		Cardio stimulant	Heart failure
edotrectide		204318-14-9	US	6183721	Cancer, lung, small cell
edoxudine	Uridine, 2'-deoxy-5-ethyl-, [CAS]	15176-28-1	GB	1170565	Infection, herpes virus, general
Edrecolomab		156586-89-9			
Edrophonium		116-38-1			
Eflatin	Butanedioic acid, lithium salt [CAS]	1690-09-8		Antigripitis/inflam, allergic	Eczema, seborrheic



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
efaproxiral	Propanoic acid, 2-[4-[2-[(3,5-dimethylphenylamino)-2-oxoethyl]phenoxy]-2-methyl-, (CAS) 2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cydopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (S)- [CAS]	131179-95-3	US 5705521	Radiochromosensitizer	Cancer, brain
efavirenz	[2-[4-[Bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid	154598-52-4	WO 9403440	Antiviral, anti-HIV	Infection, HIV/AIDS
eflornithine	DL-Ornithine, 2-(difluoromethyl)- [CAS]	150756-35-7	GB 2311940	Antiallergic, non-asthma	Allergy, general
eforniline		70052-12-9	US 4413141	Protozoasida, dermal, topical	Infection, trypanosomiasis, African, Hirsutism
Eflornithine		119-41-5			
eflucimibe	Benzeneacetamide, Alpha-(dodecylthio)-N-(4-hydroxy-2,3,5-trimethylphenyl)- (S)- [CAS]	202340-45-2		Hypolipemic/antiatherosclerosis	Hyperlipidaemia, general
efontidipine	3-pyridinecarboxylic acid, 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(phenyl(phenyl(methyl)amino)ethyl ester, P-oxide [CAS]	111011-53-1 111011-53-3 111011-76-8	EP 230944	Antihypertensive, other	Hypertension, general
EGIS-7229	5-Chloro-4-[3-[N-[2-(3,4-dimethoxyphenylethyl)-N-methylamino]propyl]amino]-3-(2H)-pyridazinone fumarate [CAS]	150800-12-7 190333-92-7	DE 4243381	Antiarrhythmic	Arrhythmia, general
eglumegad	Bicyclic 1,0-bisoxane-2,5-dicarboxylic acid, 2-amino-, (1S,2S,5R,6S), [CAS]	176199-48-7 200216-09-1		Anxiolytic	Anxiety, general
egualen	1-Acetylene sulfonic acid, 3-ethyl-7-(1-methylethyl)-	97883-31-3 98287-30-6	EP 147915	Antidiabetic	Ulcer, gastric
Eicosapentaenoic Acid		104177-94-4			
elacofiban	3-Pyridinepropanoic acid, 5-[(3R)-1-(1-oxo-3-(4-piperidinyl)propyl)-3-piperidinyl]carbonyl]amino]-, (6S)- [CAS]	198958-88-2	WO 9741102	Antithrombotic	Thrombosis, general
Elacotin		60731-46-6			
Eledoisin		69-25-0			
eleripian	1H-Indole, 3-[(1-methyl-2-pyrrolidinyl)methyl]-5-(2-phenylsulfonyl)ethyl-, (R)- [CAS]	143322-58-1	US 5607951	Antimigraine	Migraine

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Eligodipine		119413-55-7			
Ellagic Acid		476-86-4			
Elliptinium		58337-35-2			
Eltoprazine		98224-03-4			
elvucicabine	(5-L,2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine	181785-84-2		Antiviral, other	Infection, hepatitis-B virus
eltazonan	(2Z)-4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholin-3-one monohydrochloride. [CAS]	220322-05-4 361349-20-6		Antidepressant	Depression, general
Embolin		550-24-3			
Embramine		3565-72-8			
emecastine	1-(1-Benzimidazole, 1-[2-ethoxyethyl]-2-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)]-87233-61-2 , (E)-2-butenediol (1:2) [CAS] 87233-62-3	87233-61-2 87233-62-3	EP 79545	Antiallergic, non-asthma	Rhinitis, allergic, general
Emeprolum		3614-30-0			
Emetine		483-18-1			
Emitefur		110690-43-2			
EMM-210525	17[Alpha-Acetoxy-6[Alpha-methyl-19-nor-15,23-dihydroxy-20-propyl-12-propyl-4-ene-3,20-dione+Esira-1,3,5(10)-triene-3,17-diol(17:3)]			Formulation, fixed-dose combinations	Hormone replacement therapy
Emodin		518-82-1			
emorifazone	3(2H)-Pyridazinone, 4-ethoxy-2-methyl-5-(4-morpholinyl). [CAS]	36957-41-4	JP 7224030	Anti-inflammatory	
EMR-62203			WO 8906722	Male sexual dysfunction	Impotence
emtricitabine	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis). [CAS]	143491-57-0	WO 9214743	Antiviral, anti-HIV	Infection, HIV/AIDS
Emylcamate		78-28-4			
enalapril	L-Proline, 1-[N-[(1-ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-, (S)-, (2S)-butenedioate [CAS]	76095-16-4	US 4374829	Antihypertensive, renin system	
Enalaprilat		76420-72-9			
Enallipropymal		1861-21-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Encainide		66778-36-7			
Enciprazine		68576-86-3			
Endralazine		39715-02-1			
enteric acid	Benzic acid, 2-[(2-phenylethyl)amino]-[CAS]	23049-93-6	IN 103066	Anti-inflammatory	Anesthesia
entilurane	Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro- [CAS]	13838-16-9	US 3469011	Anesthetic, Inhalation	
Enilconazole		35554-44-0			
Enitracil		59989-18-3			
ENMD-0985	3-3-amino-phthaloglutaramide				
Enocitabine		55726-47-1	US 5712291	Anticancer, other	Cancer, myeloma
Enol-3-IPA	1H-Indole-3-propanoic acid, Alpha-oxo- [CAS]	392-12-1	EP 106813	Hypnotic/Sedative	Insomnia
enoxacin	1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-5-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	74011-59-8 9005-49-6 9041-08-1	US 4350578	Quinolone antibacterial	Infection, general
enoxaparin	Heparin, [CAS]		EP 40144	Antithrombotic	Thrombosis, venous
enoximona	2H-imidazol-2-one, 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]- [CAS]	77671-31-9	EP 58948	Cardio stimulant	Heart failure
<b>Enoxolone</b>	4,5-Heptadienoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl], methyl ester, [1Alpha,2beta(1E,3R*),3Alpha]- [CAS]	471-53-4			
enprostil		73121-56-9	GB 2025431	Prostaglandin	Ulcer, duodenal
enrasentan	1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-(2-hydroxyethoxy)-4-methoxyphenyl-5-propoxy-, (1S-(1Alpha,2beta,3Alpha))- [CAS]	167266-08-8	US 5617693	Antihypertensive, other	Hypertension, pulmonary
enticapone	2-Propanamide, 2-cyano-3-(4,5-dihydroxy-3-nitrophenyl)-N,N-dienyl-, [CAS]	130929-57-6	EP 426468	Antiparkinsonian	Parkinson's disease
entecavir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylecyclopentyl)-, [CAS]	142217-69-4	EP 481754	Antiviral, other	Infection, hepatitis-B virus

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Enviomycin	3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E), [CAS]	33103-22-9			
epalrestat	L-lysine-ds-5,8,11,14,17-eicosapentanoate with L-lysine-ds-4,7,10,13,16,19-doheaxanoate	82159-09-9	EP 471 009	Symptomatic antidiabetic	Neuropathy, diabetic
Epavir	L-lysine-ds-5,8,11,14,17-eicosapentanoate with L-lysine-ds-4,7,10,13,16,19-doheaxanoate			Antiviral, other	Infection, herpes simplex virus
EPC-K1	Ascorbic acid 2 (3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethylididecyl)-2H-1-benzothien-6-yl)-hydrogen phosphate/potassium-, [CAS]	127061-56-7	EP 127471	Neuroprotective	Infarction, cerebral
eperisone	1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-phenylidene)-, [CAS]	64840-90-0	US 3995047	Muscle relaxant	Spastic paralysis
epervudine	Uridine, 2'-deoxy-5-(1-methylethyl)-, [CAS]	60136-25-8	DE 291 0260	Antiviral, other	Infection, herpes simplex virus
Ephedrine		299-42-3			
Epilcollin		26774-90-3			
Epimestrol		7004-98-0			
epinastine	1-(2-Dibutylcarbamidazyl-5- $\beta$ -glucosyl-3-amine, 8,13b-cinydro-, [CAS]	80012-43-7	DE 3009344	Anlsthma	Asthma
epinephrine	(R)-4-(1-hydroxy-2-(methylamino)-ethyl)-1,2-benzenediol	51-43-4		Formulation, inhalable, dry powder	Anaphylaxis
Epirizole		18694-40-1			
	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy- $\alpha$ -L-arabinohexopyranosyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-3-hydroxyacetyl]-1-methoxy-, (8S-cis), [CAS]	56390-09-1 56420-45-2	GB 1457632	Anticancer, antibiotic	
epirubicin		2363-59-3			
Epitostanol	Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, Gamma-lactone, methyl ester (7 $\alpha$ ,11 $\alpha$ ,17 $\alpha$ )-, [CAS]				
epiprenone		107724-20-9	EP 122232	Antihypertensive, diuretic	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
epivanserin	1-Propanone, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl), O-(2-(dimethylamino)ethoxy)oxime, (Z)-, (E)-2-butenedioate (2:1) salt [CAS]	130560-02-8	EP 373998	Anxiolytic	Schizophrenia
epiprostanol	Prosta-5,13 dien-1-olc acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9A) [alpha,11A] [alpha,13E,15S] [CAS]	35121-78-9 61849-14-7	DE 2720698	Prostaglandin	Hypertension, pulmonary
<b>Eprostane</b>		80471-63-2			
<b>Eprazinone</b>		10402-90-1			
<b>Episteride</b>		119169-78-7			
eprosartan	3-(2-Butyl-1-(4-carboxybenzyl)-1H-imidazol-5-yl)-2-(2-thienylmethyl)-2-[E]-propenoic acid	133040-01-4	EP 403159	Antihypertensive, renin system	Hypertension, general
<b>Eprozinol</b>		32665-36-4			
epitapirone	4-methyl-2-[4-(4-pyrimidin-2-yl)-piperazino-butyl]-2H,4H-1,2,4-triazin-3,5-dione	179756-65-5		Anidepressant	Depression, general
epitaplatin	Platinum, [(4S,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5]propanediacate(2-)-kappaO1,kappaO3]-, (SP-4-2)- [CAS]	146865-77-2	WO 9216539	Anticancer, alkylating	Cancer, lung, small cell
<b>Epitastigmine</b>		101246-68-3			
epitazocine	1,6-Methano-1H,4-benzazolin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, (1S)- [CAS]	72522-13-5	US 4082744	Analgesic, other	
<b>Epitibatide</b>		188627-80-7			
<b>Equilenin</b>		517-09-9			
<b>Equilin</b>		474-86-2			
ERA-923	ERA 923 [CAS]	352233-89-7	EP 802183	Female contraceptive	Contraceptive, female
erdostaine	Acetic acid, [(2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethylthio)- [CAS]	84611-23-4	EP 61386	Respiratory	Respiratory disease, general
<b>Ergocormine</b>		564-36-3			
<b>Ergocornine</b>		564-37-4			
<b>Ergolid Mesylates</b>		8067-24-1			
<b>Ergonovine</b>		60-79-7			
<b>Ergosterol</b>		57-87-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ergotamine	(5 $\alpha$ )-12'-Hydroxy-2-methyl-(phenylmethyl)ergotamine-3',5', 18-trione	113-15-5		Formulation, inhalable, systemic	Migraine
Erlitadenine	4-Quinoxalinamine, N-(3-ethylphenyl)-	23018-98-1			
erofinib	6,7-bis(2-methoxyethoxy)-monohydrochloride [CAS]	183319-69-9	WO 9630347	Anticancer, other	Cancer, lung, non-small cell
ertapenem	1-Acetyldiol(3,2,0)hept-2-ene-2-carboxylic acid, 3-[(3S,5S)-5-[(3-carboxyphenylamino)carbonyl]-3-pyrrolidinyl]ino[4,6-(1R)-1-hydroxyethyl]-4-methyl-7-oxo-, [CAS]	153773-82-1 153832-46-3 7297-25-8	WO 9315078	Beta-lactam antibiotic	Infection, GI tract
Erythritol Tetranitrate		50276-98-7			
Erythrocentaurin	Erythromycin, 2'-acetalate, octadecanoate (salt) [CAS]	96128-88-1 3521-62-8	US 4599326	Macrolide antibiotic	Infection, general
Erythromycin Adisrate		23067-13-2			
Erythromycin Estolate		3847-29-8			
Glucoseptonate					
Erythromycin					
Lactobionate					
Erythromycin					
Propionate					
Erythromycin Stearate					
erythromycin sinoprate	Erythromycin, 2'-propanoate, compd. with N-acetyl-L-cysteine (1:1) [CAS]	643-22-1			Infection, respiratory tract, lower
erythromycin	Erythromycin [CAS]	84252-03-9 114-07-8	EP 57489	Macrolide antibiotic Formulation, dermal, topical	Acne
Erythrophleine		36150-73-9			
Esaprazole		64204-55-3			
eschalogram	5-Isobenzofuran-carbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (S)- [CAS]	128195-01-0			
Esculin		531-75-9	EP 347066	Antidepressant	Depression, general
Eseridine		25573-43-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
esmolol	Benzanopropanoic acid, 4-(2-hydroxy-3-((1-methylethylamino)propoxy)-, methyl ester, (+)- [CAS]	81147-92-4	US 4387103	Antihypertensive, adrenergic	Tachycardia, supraventricular
esomeprazole	bis (5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole)	161973-10-0	US 5677192	Antispasmodic	Gastro-oesophageal reflux
estazolam	4-[[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl- [CAS]	29975-16-4	US 3987052	Hypnotic/Sedative	
estradiol	Androst-4-en-3-one, 17-hydroxy-, (17 $\beta$ )- [CAS]	58-22-0	US 5460820	Formulation, transdermal, patch	Sexual dysfunction, female
estradiol	Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )- [CAS]	50-28-2	EP 430491	Formulation, transdermal, systemic	Menopausal symptoms, general
estramustine	Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, 3-[bis(2-chloroethyl)carbamate] 17- [CAS]	2986-87-4 4891-15-0 92206-73-9			
<b>Estril</b>		50-27-1			
estrogen				Anticancer, alkylating	Cancer, prostate
<b>Estrone</b>		53-16-7	WO 9924041	Menopausal disorders	Menopausal symptoms, general
eszopiclone	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-3,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester (S) [CAS]	138729-47-2	US 5786367	Hypnotic/Sedative	Insomnia
<b>Etafedrine</b>		7681-79-0			
<b>Etafenone</b>		90-54-0			
<b>Etamiphyllin</b>		314-35-2			
<b>Etanercept</b>		185243-69-0			
<b>Etanidazole</b>		22668-01-5			
<b>Etacualone</b>		7432-25-9			
<b>Eterobarb</b>		27511-99-5			
<b>Ethacridine</b>		442-16-0			
<b>Ethacrynic Acid</b>		58-54-8			
<b>Ethadione</b>		520-77-4			
<b>Ethambutol</b>		74-55-5			
<b>Ethamivan</b>		304-84-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ethamsylate		2624-44-4			
Ethanolamine		141-43-5			
Ethaverine		486-47-5			
Ethchlorvynol		113-18-8			
Ethenzamide		938-73-8			
Ethflazide		1824-58-4			
Ethinamate		126-52-3			
Ethinyl Estradiol		57-63-6			
ethinyl estradiol	19-Norpregne-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-Propanesulfonate), (17 $\beta$ )-[CAS]	28913-23-7	DE 1949095	Formulation, modified-release, >24hr	Cancer, prostate
Ethinonamide		536-33-4			
Ethisterone		434-03-7			
Ethioheptazine		77-15-6			
Ethopropazine		522-00-9			
Ethosuximide		77-67-8			
Ethotoin		86-35-1			
Ethoxzolamide		452-35-7			
Ethylbenzotropine		524-83-4			
Ethyl Alcohol		64-17-5			
Ethyl Biscoumaracetate		548-00-5			
Ethyl Chloride		75-00-3			
Ethyl Dibunate		5560-69-0			
Ethyl Ether		60-29-7			
ethyl isopropilate	5,8,11,14,17-Eicosapentanoic acid, ethyl ester, (all-Z), [CAS]	86227-47-6	JP 61043143	Antithrombotic	Peripheral vascular disease
ethyl loflazepate	11-(1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-6-(2-fluorophenyl)-2,3-dihydro-2-oxo-, ethyl ester [CAS]	29177-84-2	US 3657223	Anxiolytic	Anxiety, general
Ethyl Loflazepate		29177-84-2			
Ethylamine		75-04-7			
Ethylene		74-85-1			
Ethylestrenol		965-90-2			
Ethylidene Dicoumarol		1821-16-5			



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ethylmethythiambutene		441-91-2			
Ethylmorphine		76-58-4			
Ethylmorphinephrine		536-24-3			
Ethynodiol		1231-93-2			
Ethynylcydine	Uridine, 3'-C-ethynyl- [CAS]	180300-49-6	WO 9618636	Anticancer, antimetabolite	Cancer, general
Etidocaine		36637-18-0			
etidronate	Phosphonic acid, (1-hydroxyethylidene)bis-, [CAS]	2809-21-4 7414-83-7			
Etidronic Acid		2809-21-4	US 4137308	Osteoporosis treatment	Osteoporosis
Etifelmin		341-00-4			
etioixine	4H-3,1-Benzoxazin-2-amine, 6-chloro-N-ethyl-4-methyl-4-phenyl- [CAS]	21715-46-8	US 3726404	Anxiolytic	
Etilefrin		709-55-7			
ellevodopa	L-Tyrosine, 3-hydroxy-, ethyl ester [CAS]	37778-37-3	US 5354885	Antiparkinsonian	Parkinson's disease
elipredol	androst-1,4-diene-17-carboxylic acid, 17-[[[dichloroacetyl]oxy]-11-hydroxy-3-oxo-, ethyl ester, (11b,17Alpha)-	198331-40-3			
Eltroxate		17365-01-4		GI inflammatory/bowel disorders	Crohn's disease
Etizolam		40054-69-1			
etidolac	Pyranol[3,4-b]indole-1-acetic acid, 1,8-dialkyl-1,3,4,9-tetrahydro- [CAS]	41340-25-4	US 3939178	Antiarthritic, other	Arthritis, osteo
Etodroxizine		17692-34-1			
etodrenamate	Benzols acid, 2-[(3-[[[fluoromethyl]phenyl]amino]-2-(2-hydroxyethyl)oxy]ethyl ester [CAS]	30544-47-9	GB 1285400	Anti-inflammatory, topical	Inflammation, general
etofibrate	3-Pyridinecarboxylic acid, 2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl ester [CAS]	31637-97-5	US 3723446	Hypolipemic/Antiatherosclerosis	
Etofrilline		519-37-9			
etofylline coibtrate	Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purin-7-yl)ethyl ester [CAS]	54504-70-0			
Etofrilline Nicotinate		13425-39-3	DE 2308626	Hypolipemic/Antiatherosclerosis	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Eto glucid		1954-28-5			
Eto midate		33125-97-2			
Eto midoline		21590-92-1			
Eto nitazene		911-65-9			
	18, 19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene, (7R,9R)-[CAS]	54048-10-1		Formulation, implant	Contraceptive, female
Eto norgastral		52042-31-1			
Eto peridone					
	Furo[3',4':5,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4-(4-O-ethylidene-8-D-glucopyranosyloxy)-5,8a,9-terahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, [5R-][5A]alpha,5aB,8aAlpha,9U(R'')]], [CAS]	33419-42-0	GB 1205960	Anticancer, other	Cancer, testicular
etoposide					
	Furo[3',4':3,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphorooxy)phenyl]-9-[[4,6-O-ethylidene-8-D-glucopyranosyloxy]-5,8a,9-terahydro-, [5R-][5A]alpha,5aB,8aAlpha,9U(R'')]], [CAS]	117091-64-2	EP 302473	Anticancer, other	Cancer, testicular
etoposide phosphate					
	2,3-Bisopridine, 5-chloro-6-methyl-3-(4-(methylsulfonyl)phenyl) [CAS]	202409-33-4	WO 9803484	Antiarthritic, other	Arthritis, osteo
etoricoxib		28189-95-7			
Eto xadrol		73-09-6			
Eto xozlin					
	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)- [CAS]	54350-48-0	US 4215215	Antipsoriasis	
etretinate					
Etryptamine		2235-90-7			
Etyne mazine		523-54-6			
Eucatropine		100-91-4			
Eugenol		97-53-0			
	Mangese, chloro[2,2'-(1,2-ethanedithylo)bis(nitro-kappaN)methylthio]bis(6-methoxyphenolato-kappaO)], (5R-5-13)-[CAS]				
EUK-134		81065-76-1	US 6046188	Cardiovascular	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
EUK-189			US	Radiochromoprotective	Chemotherapy-induced injury, general
<b>Evan's Blue</b>		314-13-6			
everolimus	Rapamycin, 42-O-(2-hydroxyethyl)- [CAS]	159351-69-6	WO	Immunosuppressant	Transplant rejection, general
exemestane	Benzamide, 2-(hexyloxy)- [CAS]	53370-90-4	GB	Antifungal	Infection, fungal, general
<b>Exemetazine</b>		105613-48-7			
	10H, 13H-Benzo[de]pyran[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, [CAS]	171335-80-1			
exatecan	Androst-1,4-diene-3,17-dione, 6-methylene-, [CAS]	107868-30-4	DE	Anticancer, other	Cancer, pancreatic
exemestane		52479-85-3		Anticancer, hormonal	Cancer, breast
<b>Exifone</b>					
	1H-Indene-3-acetic acid 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methyl)enyl-(Z)- [CAS]	59973-80-7		Anticancer, other	Polyp
exesulind		99732-49-7			
<b>Exosurf®</b>					
	2-Azolidinone, 1-(4-fluorophenyl)-3-(3S)-3-(4-fluorophenyl)-3-hydroxypropyl-4-(4-hydroxyphenyl)-, (3R,4S)-, [CAS]	163222-33-1	US	Hypolipemic/Antiatherosclerosis	Hypercholesterolemia
<b>Factor IX</b>		9001-28-9			
<b>Factor VIII</b>		9001-27-8			
<b>Factor XIII</b>		9013-56-3			
faldolindine	1H-Inden-5-ol, 2,3-dihydro-3-(1H-indazol-4-ylmethyl)-, monohydrochloride [CAS]	189363-32-0	WO	Analgesic, other	Pain, general
<b>Fadrozole</b>		102676-47-1			
	9,10-Sacchocolesta-5,7,10(19)-triene-1,3,25-triol, 26,26,26,27,27-hexafluoro-1-(Alpha,3S,5Z,7E)- [CAS]	83805-11-2	JP	Osteoporosis treatment	Hyperparathyroidism
falecalcitol	1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl), succinate (ester)- [CAS]	104227-87-4	JP	Antiviral, other	Infection, gynaecological
famciclovir					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fermolidine	Propanimidamide, 3-[2-[(aminomino)methyl]amino]-4-thiazolyl[methylthio]-N-(aminosulfonyl)- [CAS]	76924-35-6	US 4283408	Antitumor	Ulcer, duodenal
fampridine	4-pyridinamine	504-24-5		Neuroprotective	Spinal cord injury
fendoxacin	3-Quinolonecarboxylic acid, 6-fluoro-1-(5-fluoro-2-pyridinyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo, [CAS]	164150-85-0 164150-99-6	US 5496947	Quinolone antibacterial	Infection, urinary tract
<b>Fantofarone</b>		114432-13-2			
feropenem daloxate	(6R,6S)-6-[1-(R)-hydroxyethyl]-2-[2-(R)-tetrahydrofuryl]-2-penem-3-carboxylic acid-5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester			Beta-lactam antibiotic	Infection, general
feropenem	4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-(tetrahydro-2-furanyl), [5R, (3R),5Alpha,6Alpha(R*)] [CAS]	122547-49-3	EP 410727	Beta-lactam antibiotic	Infection, ocular
fastiotril	L-Alanine, N-[(2S)-3-(acetylthio)-2-(1,3-benzodioxol-5-ylmethyl)-1-oxopropyl]-phenylmethyl ester [CAS]	135038-57-2	EP 419327	Antihypertensive, renin system	Hypertension, general
fasuili	1H-1,4-Diazepine, hexahydro-1-(5-isquinolinesulfonyl)- [CAS]	103745-39-7 106829-07-7	EP 187371	Neuroprotective	Vasospasm, general
<b>Fazadinium Bromide</b>		49564-56-9			
febramate	2,4,6-(1H,3H,5H)-Pyrimidinetrione, 1-[2-[(aminocarbonyloxy]-3-butoxypropyl]-5-ethyl-5-phenyl- [CAS]	13246-02-1	US 3075983	Psychostimulant	
<b>Febuprol</b>		3102-00-9			
febuxostat	5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl- [CAS]	144060-53-7	WO 9209279	Antigout	Gout, hyperuricaemia
<b>Fedotazine</b>		123618-00-8			
febamate	1,3-Propanediol, 2-phenyl-, dicarbamate [CAS]	25451-15-4	US 4868327	Antiepileptic	Epilepsy, general
febinaac	[1,1'-Biphenyl]-4-acetic acid [CAS]	5729-52-9	EP 127840	Anti-inflammatory, topical	
felcipiline	3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-ethyl methyl ester [CAS]	72509-76-3	US 4284611	Antihypertensive, other	Hypertension, general
<b>Felypressin</b>		56-59-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Fenoxetone		59859-58-4			
Fenbenicillin	[1,1'-Biphenyl]-4-butanolic acid, Gamma-oxo- [CAS]	1926-48-3			
fenbuten		36330-85-5	US	Anti-inflammatory	
Fenbutazate		4378-36-3			
Fencamfamine		1209-98-9			
Fencamine		28947-50-4			
Fenclozic Acid		17969-20-9			
Fendiline		13042-18-7			
Fendosal		53597-27-6			
Fenethyliline		3736081			
Fenfluramine		458-24-2			
Fenipentol		583-03-9			
fenofibrate	Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxyl]-2-methyl-, 1-methyl[ethyl] ester [CAS]	26129-32-8 49562-28-9		Formulation, modified-release, <=24hr	Hyperlipidaemia, general
fenoflopan	1[4,3-Benzazaphine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)- [CAS]	67227-56-9 67227-57-0			
Fenoprofen		31879-05-7	EP	Antihypertensive, other	Hypertension, general
Fenoterol		13392-18-2			
fenoverine	10H-Phenoflazine, 10-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]acetyl- [CAS]	37561-27-6	FR	Antispasmodic	
Fenoxazoline		4846-91-7			
Fenoxedil		54063-40-0			
Fenozolone		15302-16-6			
Fenotadiol		15687-18-0			
Feniprane		3540-95-2			
Fenipverinium Bromide		125-60-0			
Fenproporex		15686-61-0			
Fenquizone		20287-37-0			
fenretinide	Retinamide, N-(4-hydroxyphenyl)- [CAS]	65646-68-6	BE	Anticancer, other	Cancer, breast

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<b>Fenspiride</b>	Proparamide, N-phenyl-N-[1-(2-phenyl)-4-piperidinyl] [CAS]	5053066			
<b>Fentanyl</b>		437-38-7		Formulation, transmucosal, systemic	Anaesthesia, adjunct
<b>Fentiazac</b>		18046-21-4			
<b>Fenticiol</b>		97-24-5			
<b>fenticonazole</b>	1-H-imidazole, 1-[2-(2,4-dichlorophenyl)-2-[[4-(phenylthio)phenyl]methoxy]ethyl]- [CAS]	72479-26-6 73151-29-8	US 4221803	Antifungal	Infection, gynaecological
<b>Fentonium Bromide</b>		5868064			
<b>fentanyl</b>		36981-91-6			
<b>fentanyl</b>	Benzamethanol, Alpha-[[2-hydroxy-1,1-dimethyl-2-(2-phenyl-1-methyl-1-phenyl)ethyl]amino]methyl-, (+)- [CAS]	67704-50-1 63075-47-8		Anti-inflammatory, topical	
<b>Feprazone</b>		30748-29-9			
<b>Ferric Sodium Edetate</b>		15708-41-5			
<b>ferruxamine B</b>			WO 9426263	Septic shock treatment	Respiratory distress syndrome, adult
<b>Ferrocholine</b>		1335-80-7			
<b>Ferrous Gluconate</b>		299-29-6			
<b>ferruxol</b>	Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite			Imaging agent	Diagnosis, cancer
<b>fesoterodine</b>	2-((1R)-3-bis(1-methylethylamino)-1-phenylpropyl)-4-((hydroxymethyl)phenyl ester, (2E)-2-butanediolate (1:1) (Salt) - [CAS]	286930-03-8			
<b>fexofenadine</b>	Benzeneacetic acid, 4-(1-hydroxy-4-(4-hydroxydiphenylmethyl)-1-piperidinyl)butyl-, Alpha, Alpha-dimethyl-, [CAS]	153439-40-8 83769-24-0 138452-21-8	US 5375693 CA 2132416	Antiallergic, non-asthma Vulnery	Incontinence Rhinitis, allergic, seasonal Wound healing
<b>fildesat</b>	Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cs)-, [CAS]	135087-85-9	EP 418834	Symptomatic antidiabetic	Neuropathy, diabetic

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fiduxosin	8-Phenyl-3-[4-((3aR,5bR)-1,3a,4,9b-tetrahydro-9-methoxy(1)benzopyrano[3,4-c]pyrrol-2(3H)-yl)butyl]pyrazino[2,3'-4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione	208993-54-8		Prostate disorders	Benign prostatic hyperplasia
finasteride	4-Azaandrosta-1-ene-17-carboxamide, N-((1,1-dimethylethyl)-3-oxo-, (5 $\alpha$ ), (17 $\beta$ )-[CAS]	98319-26-7	EP 155096	Prostate disorders	Benign prostatic hyperplasia
finrozole	Benzonitrile, 4-(3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-tetrazol-1-yl)propyl)-[CAS]	160148-16-7	EP 476944	Urological	Urinary retention
Flipexide	N-(4-Acetyl-1-piperazinyl)-4-fluorobenzamide monohydrate- [CAS]	34161-24-5			
FK-990		133920-70-4	WO 9101979	Cognition enhancer	Alzheimer's disease
Flavopiridol		146428-40-6			
flavoxate	4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinylethyl) ester [CAS]	15301-69-6 3717-88-2	US 2921070	Urological	
flecainide	Benzamide, N-[2-piperidinylmethyl]-2,5-bis(2,2,2-trifluoroethoxy)-, [CAS]	54143-56-4 54143-56-5		Formulation, modified-release, <24hr	Fibrillation, atrial
flecinoxacin	3-Quinolincarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-, [CAS]	79660-53-0 79660-72-3	US 4398029	Quinolone antibacterial	Infection, general
Flesinoxan		98206-10-1			
flibanserin	2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-, [CAS]	167933-07-5		Reproductive/gonadal, general	Sexual dysfunction, female
flociclenine	Benzoic acid, 2-[[8-(trifluoromethyl)-4-quinolinyl]amino]-, 2,3-dihydropropyl ester, [CAS]	23779-98-9	US 3644368	Analgesic, NSAID	
floximef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[6-(difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]imino]phenyl]-7-methoxy-6-oxo-, (6R)-[CAS]	92823-03-5 99665-00-6	EP 128536	Cephalosporin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Fluproprione		2295-58-1			
Fiorantyrone		519-95-8			
Flocequinan		76568-02-0			
Floxacinil		5250-39-5			
Floxuridine		50-91-9			
Flucizine		30223-48-4			
Fluanisone		1480-19-9			
flualsterone	Androst-5-en-17-one, 16-fluoro-, (16Alpha), [CAS]	112859-71-9	EP	Cardiovascular	Keratosis
fluzacort	5H-Pregna-1,4-dien[17,16-dioxazole-3,2D-dione, 21-(acetoxy)-9-fluoro-11-hydroxy-2-methyl-, (11B,15B), [CAS]	19885-56-3	US	Antipruritic/Inflamm, non-allergic	
Flucibronide		3693-39-8			
flucloxacillin		1847-24-1			
		34214-51-2		Formulation, other	Infection, general
fluonazole	1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-difluorophenyl)-Alpha-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]				
Flucytosine		2022-85-7			
		86386-73-4	EP	Antifungal	Infection, dermatological
fludarabine	9H-Purin-8-amine, 2-fluoro-9-(5-O-phosphono-6-D-arabino-furanosyl)- [CAS]	75607-67-9 21579-14-1	US	Anticancer, antineoplastic	Cancer, leukaemia, chronic lymphocytic
Fludeoxyglucose F <sub>18</sub>		105851-17-0			
Fludiazepam		3900-31-0			
Fludrocortisone		127-31-1			
Fufenamic Acid		530-78-9			
Fluindione		957-56-2			
	4-[[Imidazo[1,5-a]1,4-benzodiazepine-3-carboxylic acid, 8-fluoro-6,8-dihydro-5-methyl-5-oxo-, ethyl ester [CAS]				
flumazenil		78755-81-4	EP	Neurological	
Flumechinol		56430-99-0			
Flumequine		42835-25-6			
Flumethasone		2135-17-3			
Flumethiazide		148-56-1			



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
flunarizine	Piperazine, 1-bis(4-fluorophenyl)methyl-4-(3-phenyl-2-propenyl)-, (E)-, [CAS]	30484-77-6	GB	Antimigraine	
	Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6Alpha,11B,16Alpha)-, [CAS]	27848-84-5			
flunisolide	2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-, [CAS]	3385-03-3	US	Antilasthma	Rhinitis, allergic, general
flunitrazepam		1622-92-4			
Fluoxaprofen		66934-18-7	US	Hypnotic/Sedative	
Fluocinolone Acetonide		67-73-2			
Fluocinonide		356-12-7			
Fluocortin Butyl		41767-29-7			
Fluocortolone		152-97-6			
Fluorescein		2321-07-5			
Fluoresone		2924-67-6			
Fluorometholone		426-13-1			
Fluorosalan		4776061			
fluorouracil	2,4(1H,3H)-Pyrimidinones, 5-fluoro-, [CAS]	51-21-8		Formulation, transdermal, enhanced	Keratosis
fluoxetine	Benzenehexanamine, N-methyl-Gamma-[4-(trifluoromethyl)phenoxy]-, (+)-, [CAS]	54610-88-3	US	Antidepressant	Depression, general
Fluoxymesterone		56296-76-7			
Flupentixol		76-43-7			
Fluparalene		2709-56-0			
Fluphenazine		2119-75-7			
		69-23-8			
flupirtine	Carbamic acid, [2-amino-6-[(4-fluorophenyl)methyl]amino]-3-pyridinyl-, ethyl ester [CAS]	33400-46-2			
		56885-20-1			
		75007-66-5			
Flupredniclene Acetate		1255-35-2	US	Analgesic, other	Pain, post-operative
Fluprednisolone		53-34-9			
Fluproquazone		40507-23-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<b>Flurandrenolide</b>		1524-88-5			
<b>Flurazepam</b>		17617-23-1			
flurbiprofen	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro- Alpha-methyl- [CAS]	5104-49-4	US 3793457	Anti-inflammatory	
flurithromycin	Erythromycin, 8-fluoro-mono(ethyl butanedioate) (ester)- [CAS]	82730-23-2	EP 56291	Macrolide antibiotic	Infection, respiratory tract, lower
<b>Flurogestone</b>		2529-45-5			
<b>Flurothyl</b>		333-36-8			
<b>Fluroxene</b>		406-90-6			
<b>Fluspirilene</b>		1841-19-6			
flutamide	Propanamide, 2-methyl-N-[4-nitro-3- (trifluoromethyl)phenyl]- [CAS]	13311-84-7	US 4323364	Anticancer, hormonal	
flutazolid	Oxazolid(3,2-d)[1,4]benzoxadiazepin-6(5H)- one, 10-chloro-11b-(2-fluorophenyl)- 2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS]	27080-91-9	US 3905956	Anxiolytic	
flutazolidam	Androstene-1,4-diene-17-carboxylic acid, 6,8-difluoro-1,17-dihydroxy-1b-methyl-3- oxo-, 8-(fluoromethyl) ester, (6Alpha,11b,16Alpha,17Alpha)- [CAS]	80474-14-2 90566-53-3		Formulation, inhalable, solution	Asthma
fluticasone	2H-1,4-Benzoxadiazepin-2-one, 7-chloro-1- (cyclopropylmethyl)-5-(2-fluorophenyl)-1,3- dihydro- [CAS]	25967-29-7	GB 1253368	Anxiolytic	Psychosis, general
flutoprazepam	1H-Imidazole, 1-(2-fluorophenyl)(4- fluorophenyl)phenylmethyl- [CAS]	119006-77-8	EP 352352	Antifungal	Infection, dermatological
<b>Flutropium Bromide</b>		63516-07-4			
fluvastatin	6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1- (1-methylethyl)-1H-indol-2-yl]-5,6- dihydroxy-, monosodium salt, [R-,S-(E)- (4)-] [CAS]	93857-55-2 93857-64-1	EP 114027	Hypolipemic/initiator of atherosclerosis	Hypercholesterolaemia Depression, general, Obsessive-compulsive disorder
fluvoxamine	1-Pentanone, 5-methoxy-1-(4- (trifluoromethyl)phenyl)-O-(2- aminoethyl)oxime, (E)- [CAS]	54739-18-3 61718-82-9	GB 1535226	Antidepressant	
<b>Folic Acid</b>		59-30-3			
<b>Folinic Acid</b>		58-05-9			
<b>Fomepizole</b>		7554-65-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fomiloben	Benzamide, N-[3-chloro-2-[[methyl(2-(4-morpholinyl)-2-oxoethyl]amino)methyl]phenyl]- [CAS]	18053-31-1 24500-38-0	US 3661903	Respiratory stimulant	Eczema, general
Fomivirsen		144245-52-3			
Fomocaine		17692-39-6			
Fonazone		7456-24-8			
fondaparinux	Alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-6-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-Alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate) [CAS]	104983-28-4 114870-03-0 2454117		Anticoagulant	Thrombosis, venous
Formebolone	Androst-4-ene-3,17-dione, 4-hydroxy- [CAS]	566-48-3 2825-60-7	EP 346953	Anticancer, hormonal	Cancer, breast
formesiane					
Formocortol	Formamide, N-[2-hydroxy-5-(1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl-, (R*, R*)-(+/-), [CAS]				
formoterol	Carbanic acid, [(1S,2R)-3-[[[4-aminophenyl]sulfonyl(2-methylpropyl)amino]-1-(phenylmethyl)-2-(phosphonoxy)propyl]- C-[(3S)-tetrahydro-3-furanyl ester], [CAS]	43229-80-7 73573-87-2	GB 1415256	Antiasthma	Asthma
fosamprenavir	Phosphinocarboxylic acid, dihydroxy-, oxide, trisodium salt [CAS]	226700-81-8 34156-56-4 4428-95-9 63586-09-1		Antiviral, anti-HIV	Infection, HIV/AIDS
fosarnet		522-40-7	US 4939445	Antiviral, other	Infection, cytomegalovirus
Fosfestrol	2,4-difluoro-Alpha, Alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester)	194798-33-9 23155-02-4			
fosfluconazole	Phosphonic acid, (3-methoxyoxanyl-, (2R)-cis)- [CAS]	26016-96-8	GB 1223523	Antifungal	Infection, fungal, general
fosfomycin				Antibiotic, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fosfomycin trometamol <b>Fosfolal</b>	Phosphonic acid, (3-methoxybutyl)-, (2R- cis), compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) [CAS]	78964-86-9	EP 27937	Antibiotic, other	Infection, urinary tract
	L-Proline, 4-cyclohexyl-1-[[(2-methyl-1-(1-oxoproxy)propoxy)](4-phenylbutyl)phosphoryl]acetate, (2Alpha,4B) [CAS]	88890-14-9 98048-07-6	EP 63966	Antihypertensive, renal system	Hypertension, general
foscarnet	2,4-Hydroxypyridine, 5,5-diphenyl-3-[[[phosphono(methyl)- (CAS)	92134-88-0 93390-81-9	US 4260769	Antiepileptic	Epilepsy, generalized, tonic-clonic
fomepizole	Phosphonic acid, 1-[1-[(2-chloroethyl)(nitrosoamino)carbamoylamino]ethyl], diethyl ester [CAS]	92118-27-9	EP 117959	Anticancer, alkylating	Cancer, melanoma
fopemide	1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R) [CAS]	106560-14-9			
frovatriptan	158747-02-5	WO 9922730		Antimigraine	Migraine
fructose-1,6-diphosphate	57-48-7 488-69-7				
FTC	2-(1H-Pyrimidinone, 4-amino-5-fluoro-1-(2-hydroxymethyl)-1,3-oxadiazol-5-yl)-, (R) [CAS]				
FTY-720	1,3-Propanediol, 2-amino-2-(2-{4-oxocyclopentyl}ethyl)-, hydrochloride [CAS]	162359-56-0	WO 0408943	Antiviral, anti-HIV	Infection, HIV/AIDS
fudostein	Alanine, 3-((3-hydroxypropyl)thio)- [CAS]	13189-98-6	US 5047428	Immunosuppressant	Transplant rejection, general
fulvestrant	Estri-1,3,5,(10)-triene-3,17-diol, 7-((4,4,5,5,5-pentafluorophenyl)sulfonyl)phenyl-, (7Alpha,17B) [CAS]	129453-61-8	EP 348014	Antitussive	Cough
fuquastatin	2,4,6,8-Decatetraenedioic acid, mono(5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxypropyl-2,5-pct-6-yl) ester, [3R-] [CAS]	23110-15-8		Anticancer, hormonal	Cancer, breast
fuquastatin	[3Alpha,4Alpha(2R*,3R*)5S,6S,6E(all-E)]-			Protease inhibitor	Infection, GI tract

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Fumagillin		23110-15-8			
Furaltadone		139-91-3			
Furazabol		1239-29-8			
Furazolidone		67-45-8			
Furazollum Chloride		5118-17-2			
Furonazide		3460-67-1			
furosemide	Benzoic acid, 5-(aminosulfonyl)-4-chloro-2- [(2-furanylmethyl)amino] [CAS]	54-31-9			Hypertension, general
Fursultiamine		804-30-8			
Furthionium		7618-86-2			
Furidic Acid		06036990			
G1, YM BioSciences	1-(5-bromofur-2-yl)-2-bromo-2-nitroethene				
G25			WO 9804252	Antifungal Antimalarial	Infection, gynaecological Infection, malaria
GABA-A Alpha5 inverse agonist, Mer			WO 0206285	Cognition enhancer	Alzheimer's disease
gabapentin	Cyclohexanecarboxylic acid, 1-(aminomethyl)- [CAS]	60142-96-3	US 4153226	Antiepileptic	Epilepsy, general
	Benzoic acid, 4-[β- [(aminomonomethyl)amino]-1- oxohexyloxy]-, ethyl ester, monomethanesulfonate [CAS]	39492-01-8 58974-81-9			
gaboxate	Isosaxolol[5,4-dipyridin-3(2H)-one, 4,5,6,7- tetrahydro- [CAS]	64603-91-4	US 3751447	GI inflammatory/bowel disorders	Pancreatitis
gaboxadol		127000-20-8	CA 1125288	Hypnotic/Sedative	Sleep disorder, general
Dimeglumine					
Gadobutrol		138071-82-6			
Gadodiamide		13140-48-5			
Gadopentetic Acid		80529-93-7			
Gadoteridol		120066-54-8			
Gadoversetamide		131069-91-5			
Gadoxetic Acid		135326-11-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
galantamine	(4 <i>S</i> ,6 <i>R</i> ,8 <i>S</i> )-8-Hydroxy-3-methoxy-11-methyl-5,6,8,10,11,12-hexahydro-4 <i>H</i> -benzo[ <i>c</i> ]pyrido[3,2- <i>c</i> ][1,2]benzazepine				
Galanthamine		357-70-0		Formulation, modified-release, other	Alzheimer's disease
gallium	( $\beta$ -Alanine, 2-[(4-[(2,6-dideoxy-2-fluoro-Alpha-L-thalopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthalenyl]-2-oxyethyl ester, [CAS]	140637-82-7 140637-86-1	EP 424899	Anticancer, antibiotic	Cancer, breast
Gallamine Triethiodide		55-29-2			
Gallie Acid		149-91-7			
gallium malbiate	4 <i>H</i> -Pyran-4-one, 3-hydroxy-2-methyl-, gallium complex				
gallium nitrate	Nitric acid, gallium salt [CAS]	13494-90-1	US 4529593	Anticancer, other	Cancer, myeloma
gallopamil	Benzeneacetonitrile, Alpha-[3-[(2-[(3,4-dimethoxyphenyl)ethyl(methylamino)propyl]-3,4,5-trimethoxy-Alpha-(1-methyl)ethyl)-[CAS]	16662-47-9	GB 1367677	Antianginal	Angina, general
$\gamma$ -Aminobutyric Acid		56-12-2			
Ganaxalone		38398-32-2			
ganedovir	6 <i>H</i> -Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-[CAS]	107910-75-8 82410-32-0	EP 49072	Antiviral, other	Infection, cytomegalovirus
ganirelix	[N-Ac-D-Nal-D-pGlu-Phe-D-PalD-L-hArg(Et)2]Arg(Et)2-D-Ala[GRH-[CAS]	124904-83-4	EP 312052	Releasing hormones	Infertility, female
ganstigmine	Carisamic acid, (2-ethylphenyl)-, (3 <i>S</i> ,6 <i>S</i> )-1,2,3,3 <i>a</i> ,8,8 <i>a</i> -hexahydro-1,2 <i>b</i> ,8-trimethylpyrido[2,3- <i>g</i> ]indol-5-yl ester,				
		223585-99-7	EP 1023297	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ganoflozan	1-Piperazineacetic acid, 4-[[[SR],3-[4-[[[linol](methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-ethyl]ester [CAS]	183547-57-1	EP 741133	Antithrombotic	Thrombosis, general
garenosacch	3-Quinolincarboxylic acid, 1-cyclopropyl-8-[[[difluoromethoxy]-7-(11'-2,3-dihydro-1-methyl-1H-isobenz[5-y]-1,4-dihydro-4-oxo-1-morpholinyl)sulfonyl]oxy] [CAS]	223652-82-2		Quinolone antibacterial	Infection, respiratory tract, lower
gamocesslim	5-7 $\beta$ -macrophage inflammatory protein 2 $\alpha$ (human gene gro $\beta$ ) [CAS]	246861-96-1		Radiochemoprotective	Chemotherapy-induced injury, bone marrow, neutropenia
gatifloxacin	3-Quinolincarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-, (+)- [CAS]	112811-59-3	EP 230295	Quinolone antibacterial	Infection, respiratory tract, general
<b>Gefarnate</b>	4-Quinazolinamine, N-[3-chloro-4-fluorophenyl]-7-nitroxy-6-[3-(4-morpholinyl)propoxy] [CAS]	184475-35-2	N/O 9633980	Anticancer, other	Cancer, lung, non-small cell
gefitinib	6,6'-oxybis[2,2-dimethylhexanoate]	209789-08-2		Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general
gemcabene	Cytidine, 2'-deoxy-2', 2'-difluoro-, [CAS]	122711-03-9	GB 2136425	Anticancer, antimetabolite	Cancer, pancreatic
gemclabine	Prosta-2,13-dien-1-olc acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, methyl ester, (2E, 11A) [alpha, 13E, 15R], [CAS]	94318-79-2	GB 1540427	Prostaglandin	
gemeprost	Hexanoic acid, 5-[2-(5-dimethylphenoxy)-2,2-dimethyl-, [CAS]	25812-30-0	US 3674636	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general
gemifirozil	1,8-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxymino)-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-, [CAS]	175463-14-6	US 5969570	Quinolone antibacterial	Infection, respiratory tract, general
gemifloxacin	Gentamicin [CAS]	1403-85-3		Formulation, implant	Infection, general
gentamicin		548-62-9			
<b>Gentian Violet</b>		20831-76-9			
<b>Gentiopticin</b>					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Gentic Acid		490-79-9			
Gepefrine		18840-47-6			
geprione	2,6-Piperidinedione, 4,4-dimethyl-1-[4-(2-pyrimidinyl)-1-piperazinylbutyl]- [CAS]				
gestodene	18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 $\alpha$ h $\alpha$ h $\alpha$ ), [CAS]	109862-02-0 60262-87-3		Formulation, modified-release, other	Depression, general
gestodene + ethinyltest	18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 $\alpha$ h $\alpha$ h $\alpha$ ) mix with 19-Norpregna-13,5(10)-dien-20-yn-13,17-diol (17 $\alpha$ h $\alpha$ h $\alpha$ )		GB 1589135	Formulation, fixed-dose combinations	Contraceptive, female
Gastonorona Caproate					
Gestrinone		1263-28-7			
7-Hydroxybutyrate		18320-04-0 591-81-1			
	(4S)-11-[(E)-[1,1'-dimethyl(ethoxy)imino]methyl]-4-ethyl-4-hydroxy-1'-12-dihydro-14H-pyranol[3',4':3,7]indolizino[1,2-b]quinoline-3,14(4H)-dione				
gimatecan		292618-32-7		Anticancer, other	Cancer, brain
Giractide		24870-04-0			
Gitoxin		4562-36-1			
GL-406349	N,N'-Bis[2-N-[2-(N2,N5-dimethyl-DL-lysylamino)-ethyl]carbamoyl]1H-indol-6-yl-1H-indole-2,5-dicarboxamide				
Glafenine		3820-67-5		Antifungal	Infection, fungal, general
glaftramer	L-Glutamic acid, polymer with L-alanine, L-lysine and L-tyrosine, [CAS]	147235-92-9 28704-27-0	WO 6600908	Multiple sclerosis treatment	Multiple sclerosis, relapsing-remitting
Glibornuride		26944-48-9			
gliclazide	Benzenesulfonamide, N-[[[hexahydrocyclopenta[3,2-b]pyrrol-2(1H)-yl]amino]carbonyl]-4-methyl- [CAS]	21187-98-4	GB 1153982	Antidiabetic	Diabetes, Type II



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
glimepiride	1-[4-Pyridyl-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[4-(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo- [CAS]	93479-97-1	WO 9303724	Antidiabetic	Diabetes, Type II
<b>γ-Linolenic Acid</b>	Pyrazinecarboxamide, N-[2-[4-[[[cyclohexylamino]carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	506-26-3			
glipizide	Benzanesulfonamide, N-[cyclohexylamino]carbonyl-4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isquinolinyl)ethyl]- [CAS]	29004-61-9	US 3669866	Antidiabetic	
glitazone	3-Isosaxazolidinecarboxamide, N-[2-[4-[[[cyclohexylamino]carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	33342-06-1	GB 1277647	Antidiabetic	Diabetes, general
glisolanide		24477-37-0		Antidiabetic	Diabetes, general
<b>Glixoxepid</b>		25046-79-1			
<b>Glucametacin</b>		52443-21-7			
<b>Glucophageonic Acid</b>		87-74-1			
<b>Gluconic Acid</b>		526-95-4			
glucosamine		28031-18-4			
	D-Glucose, 2-amino-2-deoxy- [CAS]	3416-24-3	DE 1953689	Antiarthritic, other	Athritis, osteo
<b>Glucosulfone</b>		554-18-7			
glutofamilite	β-D-Glucopyranose, 1-(N,N-bis-(2-chloroethyl)phosphorodimaleate), [CAS]	132662-98-5	DE 3835772	Anticancer, alkylating	Cancer, general
<b>Glutamic Acid</b>		56-86-0			
<b>Glutaraldehyde</b>		111-30-8			
<b>Glutethimide</b>		77-21-4			
<b>Glyburide</b>		10238-21-8			
<b>Glybutiazole(e)</b>		535-65-9			
<b>Glybuzole</b>		1492-02-0			
<b>Glycerol</b>		56-81-5			
<b>Glycocyamine</b>		352-97-6			
<b>Glyco Salicylate</b>		87-28-5			
<b>Glyconiazide</b>		3691-74-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Glycopyrrolate		596-51-0			
Glyhexamide		451-71-8			
Glymidine		339-44-6			
Glypnamide		1228-19-9			
GMPP	N-acetylglucosaminyl-N-acetylmuramyl dipeptide				
Gold Sodium Thiomalate		12244-57-4		Anti-infective, other	Infection, general
Gold Sodium Thiosulfate		10233-88-2			
goserelin	Luteinizing hormone-releasing factor (pG), 6-[O-(1,1-dimethylethyl)-D-serine]-10-deglycinamide, 2-(aminocarbonylhydrazide) [CAS]	65807-02-5	US 4100274	Releasing hormones	Cancer, prostate
GPI-1485	L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-3-(3-pyridinylpropyl) ester [CAS]	186452-09-5		Antiparkinsonian	Parkinson's disease
GPI-5693	2-(Phosphonomethyl)pentanedioic acid		US 5672592	Analgesic, other	Pain, neuropathic
Grazetaskin					
granisetron	1H-indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, endo- [CAS]	107007-59-9 109889-09-0	EP 200444	Antiemetic	Chemotherapy-induced nausea and vomiting
Grepafloxacin		119914-80-2			
grisetolvin	Spiro[benzofuran-2(3H),1'-[2]cyclohexane]-3,4'-dione, 7-chloro-2,4,6-trimethoxy-6-methyl-, (1'S- trans)- [CAS]	126-07-8		Formulation, dermal, topical	Infection, dermatological
Gualacol		90-05-1			
Gualapate		852-42-6			
Gualazulene		489-84-9			
Gualifenesin		93-14-1			
gualmesal	4H-1,3-benzodioxin-4-one, 2-(2-methoxyphenoxy)-2-methyl- [CAS]	81674-79-5	GB 2098201	Anti-inflammatory	
Guamecycline		16545-11-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Guanabenz		5051-62-7			
Guanadrel		40580-59-4			
Guanethidine		55-65-2			
Guanfacine		29110-47-2			
Guanoxabenz		24047-25-4			
Guanoxan		2165-19-7			
gugulipid	Pregna-4,17(20)-diene-3,16-dione [CAS]	95975-55-6	EP 447706	Hypolipaeamic/Antiatherosclerosis	
Gusperimus		104317-84-2			
	(2)-2-Chlorotumaric acid 1-[3-[[6,7-dimethoxy-2(S)-methyl-1(R)-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinum-2-yl]propyl]			Muscle relaxant	Anaesthesia, adjunct
GW-280430A	(2S,3S,5R)-2-[3,5-difluorophenyl]-3,5-dimethyl-2-morpholinol				
GW-320659				Anorectic/Antiobesity	Obesity
GYL-10084	(+)-R-2-[3-[N-(2-benzotri-4,6-dioxanylmethyl)amino]-1-propyl]-3-(H)-pyridazinone hydrochloride				
Hachimycin		1394-02-1	US 6194411	Prostate disorders	Benign prostatic hyperplasia
Halazepam		23092-17-3			
Halcinonide		3093-35-4			
halobetasol	Pregna-1,4-diene-3,20-dione, 21-chloro-6,8-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6Alpha,11b,16b)- [CAS]	98852-54-8	US 4619521	Antipsoriasis	Psoriasis
halofantrine	9-Phenanthrene methanol, 1,3-dichloro-Alpha-[2-(diethylamino)ethyl]-6-(trifluoromethyl)- [CAS]	36167-63-2 69756-53-2	EP 138374	Antimalarial	Infection, malaria
halomelason	Pregna-1,4-diene-3,20-dione, 2-chloro-6,8-difluoro-11,17,21-trihydroxy-16-methyl-, (6Alpha,11b,16Alpha)- [CAS]	50629-82-8	US 4076737	Antipruritic/Inflamm, allergic	
Haloperidol		52-86-8			
Halopredone		57781-14-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Haloproglin		777-11-7			
Halopropane		679-84-5			
Halothane		151-67-7			
Haloxazolam		59128-97-1			
halosulfida	2(R)-Acetamid-N-benzyl-3-methoxypropionanilide		WO 9733861	Antiepileptic	Epilepsy, general
H-E-2000	16Alpha-Bromo-3,3-dihydroxy-5Alpha-androstane-17-one				Infection, HIV/AIDS
Healos			WO 9714376	Antiviral, anti-HIV	Regeneration, bone
Hematophyrin		14459-29-1			
Hepronicate		7237-81-2			
Heptabarbital		509-86-4			
Heptaminol		372-68-7			
Hetacillin		3511-16-8			
Hetastarch		9004-62-0			
Hexachlorophene		70-30-4			
Hexadimethrine		28728-55-4			
Bromide					
Hexafluorenum		317-52-2			
Bromide					
Hexamethonium		60-26-4			
Hexamide		3811-75-4			
Hexapropynate		358-52-1			
Hexedine		5980-31-4			
Hexestrol		84-16-2			
Hexestrol Bis(β-diethylaminoethyl ether)		2691-45-4			
Hexethal		144-00-3			
Hexetidine		141-94-6			
Hexobarbital		56-29-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Hexobendine		54-03-5			
Hexocyclium Methyl Sulfate		115-63-9			
Hexoprenaline	Hexend [CAS]	3215-70-1	US 5407428	Plasma substitute	Surgery adjunct
Hexylcaine		235746-51-7			
HF-0298	11 $\beta$ -hydroxy androstenedione	532-76-3			
	Benzenecacetic acid, 4-[2-hydroxy-3-[(1-methylethylamino)propoxy]-2-methyl-5-oxo-1-pentyl] ester, (2Z)-tricyclo[3.3.1.1 <sup>3,7</sup> ]hept-1-ylethyl ester, (2Z)-2-butenedioate (1:1) [salt] [CAS]			Osteoporosis treatment	Osteoporosis
HGP-2		121009-31-2		Antiglaucoma	Glaucoma
HGP-9 <sup>a</sup>	8-Azoniabicyclo[3.2.1]octane, 3-(3-ethoxy-1,3-dioxo-2-phenylpropoxy)-8,8-dimethyl-, (3-endo)-, methyl sulfate [CAS]	113932-41-5		Antiepileptic	Epilepsy, general
Hydrosein	Hydrosein- [CAS]	120250-44-4		Vasoprotective, systemic	
Histamine	Histamine	51-45-6	EP 0483468	Anticancer, immunological	Cancer, melanoma
Histapyrodine		493-80-1			
	Luteinizing hormone-releasing factor (lip), 6-[1-(phenylmethyl)-D-histidine]-9-[N-ethyl-L-prolinamide]-10-decylamide- [CAS]	76712-82-8	EP 217659	Releasing hormones	Precocious puberty
HM-101	HM-101 [CAS]	217311-70-1		Osteoporosis treatment	Osteoporosis
	(E)-4-[2-(p-methoxybenzenesulfonamide)-phenyl]ethenylpyridine-1-oxide				
HMN-214					
Homatropine		87-00-3			
Homocanfin		535-86-4			
Homochlorcyclizine		848-53-3			
Hopantenic Acid		18679-90-8			
HP-226	Glycinamide, N-acetyl-L-norleucyl-L-glutamyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tyrosyl- [CAS]	172617-89-9	EP 759770	Analgesic, other	Pain, post-operative

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<b>Hyperzine A</b>		102518-79-6			
hyaluronan	Hyaluronic acid [CAS]	9004-61-9		Formulation, other	Restenosis
<b>Hycanthone</b>		3105-97-3			
<b>Hydrocarpic Acid</b>		459-67-6			
<b>Hydralazine</b>		86-54-4			
<b>Hydrastine</b>		118-08-1			
<b>Hydrastinine</b>		6592-85-4			
<b>Hydrochlorothiazide</b>		58-93-5			
hydrocodone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (6Alpha)- [CAS]	1406-99-9 125-29-1		Formulation, modified-release, other	Pain, general
<b>Hydrocortamate</b>		76-47-1			
hydrocortisone	Pregn-4-one-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-(1-oxopropoxy)-, (11b)-[CAS]	74050-20-7 8623-7	DE 2826257	Dermatological	Unspecified
hydrocortisone butyrate propio	Pregn-4-one-3,20-dione, 11-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)-, (11b)-[CAS]	72590-77-3	DE 2010899	Antipruritic/inflamm, allergic	
<b>Hydroflumethiazide</b>		135-09-1			
hydroflurone	Morphinan-6-one,4,5-epoxy-3-hydroxy-17-methyl-, (6Alpha)-, mix with acetamide, N-(4-hydroxyphenyl)-, mix with morphinan-6-one,17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (6Alpha)-	103-90-2 16900-41-3 486-99-9			
hydroflurone		1435-55-8			
<b>Hydroquinidine</b>		522-66-7			
<b>Hydroquinone</b>		123-31-9			
<b>Hydroxocobalamin</b>		13422-51-0			
<b>Hydroxyamphetamine</b>		1518-86-1			
<b>Hydroxychloroquine</b>		118-42-3			
<b>Hydroxydione</b>		53-10-1			
<b>Hydroxypethidine</b>		468-56-4			
<b>Hydroxyphenamate</b>		50-19-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Hydroxypropyl Cellulose		9004-64-2			
Hydroxystilbamidine		495-99-8			
Hydroxytetracaine		490-98-2			
Hydroxyzine		68-88-2			
<i>Eylad, G-F 20</i>					
Hynecromone		90-33-5			
	benzenoacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1]oct-3-yl ester, [3(S)-endo]				
Hyoscyamine		101-31-5		Formulation, oral, orally-disintegrating	Ulcer, GI, general
Hypericin	Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,8,8,13-hexahydroxy-10,11-dimethyl- [CAS]	548-04-9		Anticancer, other	Cancer, brain
IACFT		180468-34-2			
Ibandronic acid	Phosphonic acid, [1-hydroxy-3-(methylphenylamino)propylidene] bis- [CAS]	114684-76-5	EP 252504	Osteoporosis treatment	Hypercalcaemia of malignancy
Ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1	GB 1551661	Cardio stimulant	Heart failure
Ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1		Formulation, mucosal, topical	Surgery adjunct
Ibuprofen	Phosphonic acid, [4-[(4-bromo-2-cyanophenylamino)carbonyl]phenyl]methyl-, diethyl ester [CAS]	206181-63-7			
Ibuprofen	1-Propanone, 2-methyl-1-[2-(1-methylethyl)pyrazol-5-yl]pyridin-3-yl- [CAS]	133208-85-2	EP 402033	Hypolipemic/Antiatherosclerosis	Hypertiglyceridaemia
Ibuprofen		50847-11-5	EP 215438	Antiallergia	Asthma
Ibuprofen		1553-60-2			
Ibuprofen	Benzenoacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-pyridylmethyl ester [CAS]	64622-45-3	DE 2658610	Antipruritic/Inflam. non-allergic	Eczema, contact

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ibuprofen	Benzenesacetic acid, Alpha-methyl-4-(2-methylpropyl)- [CAS]	15987-27-1		Formulation, modified-release, other	Inflammation, general
	Methanesulfonamide, N-[4-[4-(ethylethylamino)-1-hydroxybutyl]phenyl]- (+/-) [CAS]	53648-05-8			
Ibuprofen		122647-31-8	JP 60239458	Antiarrhythmic	Fibrillation, atrial
Ibuprofen		122647-32-9	US 6288122	Antisickling	Anaemia, sickle cell
Ibuprofen		9004-53-9		Urological	Renal failure
Ibuprofen					
Ibuprofen	5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,8-trideoxy-Alpha-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-, (7S-)- [CAS]	58857-82-9 86188-66-4	US 4471062	Anticancer, antibiotic	Cancer, leukaemia, acute lymphocytic
Ibuprofen		79944-58-4			
Ibuprofen	2-(2,3-dihydro-3,4-dihydroxy-3-methoxyphenyl)-3-(4-hydroxymethyl)-4-benzoxolone-5-yl-2,5-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one phosphatidylcholine complex	134499-06-2	EP 209038	Anticancer, hormonal	Cancer, ovarian
Ibuprofen	2,5-Cyclohexadiene-1,4-dione, 2-[(10-hydroxydecyl)-5,6-dimethoxy-3-methyl- [CAS]	58188-27-8	EP 58057	Neuroprotective	Ischaemia, cerebral
Ibuprofen	4-Hexenoic acid, 3-[(1,1-dimethylhexoxy)carbamoyl]imino]-2-hydroxy-5-oxo- [CAS]				
Ibuprofen	(GaS,4R,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis[4-(ethylethyl)-13-(benzoxyl)-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecalylidene-8-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-methano-1,3aH-oxeto [2',3',5',6'] benzo[1,2-a:5'] cyclohexa [1,2-d] dioxyl-4-yl ester, (2R,3S) [CAS]	186348-05-0	US 5264591	Anticancer, other	Cancer, colorectal
Ibuprofen		116057-75-1			



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
idaraparin	Alpha-D-Glucopyranoside, methyl O-2,3,4-tri-O-methyl-6-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-6-D-glucopyranosyl-(1-4)-O-2,3,6-tri-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-Alpha-L-idopyranuronosyl-(1-4)-tris(hydrogen sulfate) nonasodium salt [CAS]	149920-56-9	AU 699466	Antithrombotic	Thrombosis, venous
idoclamide	2-Propylamide, N-(2-hydroxyethyl)-3-phenyl- [CAS]	6961-46-2	US 3659014	Anti-inflammatory, topical	
ifenprodil	(7)-2-(4-benzyl piperidin-1-yl)-p-hydroxyphenylpropanol tartrate	23210-58-4 23210-56-2	US 3509164	Neuroprotective	
ifosfamide	2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-2-oxide [CAS]	3778-73-2	US 3732340	Anticancer, alkylating	Cancer, lung, general
iguratimod	N-[3-(Formylamino)-4-oxo-5-prenoxy-4H-chromen-7-yl] methanesulfonamide	123663-49-0	DE 3834204	Antiarthritic, other	Arthritis, rheumatoid
ileprazole	1H-Benzimidazole, 2-[(4-methoxy-3-methyl-2-pyridinyl) methyl]sulfinyl)-5-(1H-pyrrol-1-yl)- [CAS]	172152-36-2	US 5703097	Antilulcer	Ulcer, GI, general
ilomasiat	Bulanedamide, N-(hydroxy-NH-(1-(1H-indol-3-ylmethyl)-2-methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (S-(R*, S*))-[CAS]	142880-36-2	US 5892112	COPD treatment	Emphysema, smoking-related
ilopridone	Ethanone, 1-(4-[3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)propoxy]-3-methoxyphenyl)- [CAS]	133454-47-4	US 5776963	Neuroleptic	Schizophrenia
iloprost trometamol	Pentanoic acid, 5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-5-ynyl)-2(1H)-pentan-1-ylidene]- [CAS]	78919-13-8	DE 3417638	Prostaglandin	Peripheral vascular disease
ILX23-7533	1 Alpha,25-Hydroxy-16-ene vitamin D3			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Imatinib	4-((imidazol-1-yl)pyridazin-3-yl)methyl-N-(4-methyl-3-[(4-((3-syridinyl)-2-pyrimidinyl)amino)-phenyl]benzamide methanesulfonate	152459-95-5	US 5521184	Anticancer, other	Cancer, leukaemia, chronic myelogenous
Imidapril	4-imidazolidinecarboxylic acid, 3-[2-[(1-[(ethoxycarbonyl)-3-phenylpropyl]amino)-1-oxopropyl]-1-methyl-2-oxo-, [4S-, [3R'(R')], 4R']]-[CAS]	89371-37-9 89395-94-1	EP 95163	Antihypertensive, renin system, Musculoskeletal	Hypertension, general, Cachexia
Imidazole salicylate	Benzoic acid, 2-hydroxy-, compd. with 1H-imidazole (1:1) [CAS]	36384-49-5	US 4329340	Anti-inflammatory	Pain, general
Imipenem	1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[[2-[[[trimethylamino]ethyl]imino]-7-oxo-, [8R], [74431-23-5 81129-83-1 [5Alpha.6Alpha(R')]]]-[CAS]	64221-86-9 74431-23-5 81129-83-1	GB 1570990	Beta-lactam antibiotic	Infection, general
Imipramine		50-49-7			
Imipramine N-Oxide		6829-98-7			
Imiquinol	1H-imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- [CAS]	99011-02-6 318-23-0	EP 145340	Antiviral, other	Infection, human papilloma virus
Imolamine					
Impilapide	Benzeneacetamide, Alpha-cyclopentyl-4-[(2,4-dimethyl-5H-pyrido[2,3-b]indol-9-yl)methyl]-N-((1R)-2-hydroxy-1-phenylethyl)- (AlphaS)- [CAS]	177469-96-4	EP 705831	Hypolipaeamic/Arteriosclerosis	Atherosclerosis
Improsulfan		13425-98-4			
Inaperisone		99323-21-4			
Inadronate	Phosphonic acid, [(cycloheptylamino)methyl]enebis-, [CAS]	138330-18-4			
Ineacronic Acid		124351-85-5		Musculoskeletal	Hypercalcaemia of malignancy
Indalpine		63758-79-2 40507-78-6			
Indanazoline					
Indapamide	4-chloro-N-(2-methylindolin-1-yl)-3-sulfamoylbenzamide	26807-65-8	GB 1209691	Antihypertensive, diuretic	Hypertension, general
Indecanide		74517-78-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Indoxazine	Indoproline, 2-[(1H-inden-7-yl)oxy]methyl- [CAS]	65043-22-3 65043-22-3	JP 52083773	Cognition enhancer	Alzheimer's disease
Indeloxazine		65043-22-3 307190-87-5			
Indenolol	2-Propanol, 1-(1H-inden-4-(or 7-yl)oxy)-3- [(1-methylethyl)amino]- [CAS]	60607-68-3 68906-88-7	GB 1250343	Antihypertensive, adrenergic	
	D-enhyro-Pentamide, 2,3,5-trideoxy-N- (2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2- [(1,1-dimethylethyl)amino]carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl-2- (phenylmethyl), [(1S-[1Alpha(R*),2Alpha)], [CAS]	150378-17-9 157810-91-6	EP 0541168	Antiviral, anti-HIV	Infection, HIV/AIDS
Indinavir	Acetamide, N-methyl-N-(3-(3-(2- thienyl)carbonyl)pyrazolo(1,5-a) pyrimidin-7- yl)phenyl)- [CAS]	325715-02-4	US 6399621	Hypnotic/sedative	Insomnia
Indipion	1H-indazole-3-carboxamide, N-(3,9- dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)- diendo- [CAS]	160472-97-9		Antiemetic	Nausea and vomiting, general
Indisetreon				Anticancer, other	Cancer, lung, non-small cell
Indisulam	1,2-benzanad(sulfonyl)amides, N-(3-chloro- 1H-indol-7-yl)- [CAS]	165668-41-7 63610-08-2 3599-32-4			
Indobufen					
Indocyanine Green					
Indomelacin	1H-Indole-3-acetic acid, 1-(4- chlorobenzoyl)-5-methoxy-2-methyl- [CAS]	53-96-1		Formulation, modified-release, other	Inflammation, general
Indoprofen		31842-01-0 26944-12-2			
Indoramin	Benzamide, N-[1-(2-[(1H-indol-3-yl)ethyl]-4- piperidinyl)- [CAS]	38821-52-2	GB 1218570	Antihypertensive, adrenergic	
Inducterm			US 5993810	Labour inducer	Labour, induction
Infliximab		170277-31-3			
Inosine Pranobex		36703-88-5			
Inositol		87-89-8			
Inositol Niacinate		6566112			
Iobenguane		80663-95-2			
Iobenzamic Acid		3115057			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ibuprofen		136949-58-1			
Ibuprofen		10397-75-8			
Ibuprofen		16034-77-8			
Ibuprofen		440-58-4			
Ibuprofen	Ibuprofen [CAS]	7553-86-2			
Ibuprofen		606-17-7		Formulation, oral, other	Fibrosic breast disorder
Ibuprofen		92339-11-2			
Ibuprofen		577-91-3			
Ibuprofen	5-Chloro-7-(4-oxo-5-quinolinyl)	190-26-7			
Ibuprofen		75-47-8		Cognition enhancer	Alzheimer's disease
Ibuprofen		300-37-8			
Ibuprofen		87-58-1			
Ibuprofen		83-73-8			
Ibuprofen		75917-92-9			
Ibuprofen		2618-25-9			
Ibuprofen		66108-95-0			
Ibuprofen		25827-76-3			
Ibuprofen		78649-41-9			
Ibuprofen		60166-93-0			
Ibuprofen		96-83-3			
Ibuprofen		89797-00-2			
Ibuprofen		99-79-6			
Ibuprofen		96-84-4			
Ibuprofen		73334-07-3			
Ibuprofen		41473-08-9			
Ibuprofen		5579-92-0			
Ibuprofen		5579-93-1			
Ibuprofen		2276-90-6			
Ibuprofen		79770-24-4			
Ibuprofen		87771-40-2			
Ibuprofen		59017-64-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
loxilan		107793-72-6			
IP-751	(3R,4R)-(deltac)-THC-DMH-11-ole acid		WO 9401429	Analgasic, other	Pain, neuropathic
lpidacrine		62732-44-9			
	Sigmasian-15-one, 22,29-epoxy-3,4,6,7,23-pentahydroxy-, (3Alpha,4B,5Alpha,6Alpha,7B,14B,22S)-[CAS]				
IP-576022		137571-30-3	US 6046165	Antialsthma	Asthma
lpidate		5567-89-3			
		69885-17-9			
lpratropium bromide		22254-24-6		Formulation, inhalable, solution	Chronic obstructive pulmonary disease
	(endo, syn)-(3,3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azobicyclo[3.2.1]octane				
lpratropium				Formulation, inhalable, topical	Asthma
lprazochrome	Hydrazinecarboxamide, 2-[[1,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-5-oxo-8H-indol-5-ylidene]-[CAS]	7246-21-7		Haemostatic	
lpriflavone	4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl- [CAS]	35212-22-7	EP 214647	Osteoporosis treatment	Osteoporosis
lprindole		5560-72-5			
lproclozide		3544-35-2			
lpronilazid		54-92-2			
lpsapitone		95847-70-4			
	2-n-butyl-4-(spirocyclopentane-1-[[2-(tetrazol-5-yl)phenyl-4-yl)methyl]-2-imidazolin-5-one				
lpresarin		138402-11-6	WO 9114679	Antihypertensive, renin system	Hypertension, general
	Butanedioic acid, mono[[2-(acetylmethyl)-2,3-dihydro-4,6,7-trimethyl-5-benzotrianyl] ester, (4-)-[CAS]				
IRFL-042		134987-62-2	US 5114966	Cardiovascular	Atherosclerosis
	N-Cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-anine				
IRFL-165		191345-26-5	EP 865442	Antidepressant	Depression, general
Iridomyrmecin		485-43-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
irindalone	irindalone, 1-[2,4-bis-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-piperazine[ethyl], (1R-trans), [CAS]	104113-57-7 86478-43-2	EP 183349	Antidepressant	Depression, general
irinotecan	Spiro[cyclopropane-1,5'-[6H]inden-7'(6H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)-], [CAS]	97682-44-5			
irinolven		125392-76-9	US 5563176	Anticancer, other	Cancer, prostate
Iron Sorbitex		1338-18-5			
isogadine	1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl), [CAS]	57381-26-7 57381-28-9 57381-35-6	US 4657907	Antihypertensive, diuretic	Hypertension, general
IS-741	Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl], [CAS]	141283-87-8	EP 465913	GI inflammatory/bowel disorders	Pancreatitis
isagillazone	2,4-Thiazolidinedione, 5-[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl-[CAS]	161600-01-7	US 5594016	Antidiabetic	Diabetes, Type II
ISAG-247			NZ 502362	Immunosuppressant	Transplant rejection, general
Isbogrel		89667-40-3			
isepamib	D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-beta-deoxy-4-C-methyl-3-(methylamino)-6-L-arabinopyranosyl-(1-5)-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S), [CAS]	58152-01-5 58152-03-7	US 4029882	Aminoglycoside antibiotic	Infection, dermatological
isoaminile		77-51-0			
isobuty p-		94-14-4			
Amrinobenzozate					
isocarboxazid		59-63-2			
isoonazole	1-[2-[2,5-dichlorobenzoyloxy]-2-(2,4-dichlorophenyl)ethyl]	27523-40-6	GB 1244530	Antifungal	Infection, fungal, general
Isoetharine		530-08-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Isosforylthepin	1-Piperazineethanol, 4-[3-fluoro-10,11-dihydro-8-(1-methyl-2-phenyl-1H-imidazol-1-yl)-1H-imidazol-5-yl]- [CAS]	106819-39-0 106819-41-4 70931-15-9	GB 2010843	Neuroleptic	
	Ethane, 2-chloro-2-(difluoromethoxy)-, 1,1,1-trifluoro- [CAS]	26675-46-7 55-91-4	US 3653388	Anaesthetic, inhalation	Anaesthesia
	Isoflurophate		530-34-7		
Isoladol		466-40-0			
Isomethadone		503-01-5			
Isomethoprene		54-85-3			
Isoniazid		57021-61-1			
Isonixin		303-14-0			
Isopromethazine		71-81-8			
Isopropamide iodide		87-63-0			
Isopropyl Alcohol	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-oxododecyl)cyclopentyl)-, 1-methyl-2-ethyl-, (1R,1'Alpha(Z), 2S,3'Alpha,5'Alpha)- [CAS]	120375-24-2 7683-59-2	EP 269349	Prostaglandin	Glaucoma
Isopropyl unoprostone		852-87-5			
Isoproterenol		87-33-2			
Isosorbide	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	16051-77-7		Formulation, modified-release, other	Angina, general
Isosorbide dinitrate	D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate [CAS]	482-15-5 4759-48-2		Formulation, modified-release, other	Angina, general
Isosorbide mononitrate		533-32-4	US 4843096	Antiacne	Acne
Isoshipendyl	Retinoic acid, 13-oxo- [CAS]				
Isosulatham					
Isovaleryl Diethylamide					
Isoxepac		55453-87-7			
Isotixcam		34562-84-6			
Isoxsuprine		395-28-8			





Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
gabapentine	17-Oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethyl)-1H,3H,7H,10H,11H,12S,16R [CAS]	219889-84-1		Anticancer, other	Cancer, breast
J-104132	5H-Cyclopenta[b]pyridine-6-carboxylic acid, 5-(1,3-benzodioxol-5-yl)-2-butyl-7-(2[(2S)-2-carboxypropyl]-4-methoxyphenyl)-6,7-dihydro-, (5S,6R,7R) [CAS]	198279-45-7	WO 9737665	Antihypertensive, other	Heart failure
J-107088	5H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 12- $\beta$ -D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-(2-hydroxy-1-hydroxymethyl)ethylamino [CAS]	174402-32-5		Anticancer, other	Cancer, bladder
J-113337	1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazole-2-one				Pain, general
Janex-1	Phenol, 4-[(8,7-dimethoxy-4-quinazolinyl)amino]- [CAS]	202475-60-3		Anticancer, other	Cancer, leukaemia, general
josamycin	Leuconycin V, 5-acetate 4B-(3-methylbutanoate) [CAS]	16846-24-5	JP 4102759	Macrolide antibiotic	Infection, general
JTV-519	1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1'-oxo-3-{4-(phenylmethyl)-1-piperidinyl}propyl]- [CAS]	145903-06-6	WO 9212148	Cardiovascular	Infarction, myocardial
K-777			US 6287840	Protozoacide	Triclosan, trypanosomiasis, American
Kainic Acid	Kainate- [CAS]	487-79-6			
Kalimate	Kalimate- [CAS]	92354-70-8			
Kallidin		342-10-9		Urological	
KB-130015	Aspartic acid (2,6-dichloro-4-[(2-methyl-3-benzotriuranyl)methyl]phenoxyl)- [CAS]	147030-48-6		Antiarrhythmic	Arrhythmia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
KCB-328	Methanesulfonamide, N-[3-amino-4-[2-[(2,4-dimethoxyphenyl)ethyl]methyl]amino]ethoxy]phenyl-, monohydrochloride [CAS]	17796-55-3	WO 9604231	Antiarrhythmic	Arrhythmia, general
<b>Kebuzone</b>		853-34-9			
ketamine	2-[2-chlorophenyl]-2-methylamino)-cyclohexanone hydrochloride	6740-88-1		Formulation, transmucosal, nasal	Pain, post-operative
ketanserlin	2-[4-(1H,3H-Quinazolin-2-ylidene)-4-fluorobenzoyl]-1-piperidinylethyl [CAS]	74050-88-9 83846-83-7	EP 13612	Antihypertensive, other	Hypertension, general
ketazolam	4-[1-[3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-cifloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- [CAS]	27223-35-4	GB 1222294	Anxiolytic	
<b>Ketoxal</b>		27762-78-3			
<b>Ketobemidone</b>		469-79-4			
kelconazole	Piperazine, 1-acetyl-4-[4-[(2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)methyl)-1,3-dioxolan-4-yl]methoxy]phenyl-, dis- [CAS]	65277-42-1	US 4335125	Antifungal	Infection, fungal, general
ketoprofen	mono(3-benzoyl-Alpha-methylbenzenecarboxylate) [CAS]	173011-11-5	EP 502502	Formulation, transdermal, systemic	Pain, general
ketorolac	(1R)-pyrrolidine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, (+)- [CAS]	74103-08-3 74103-07-4	EP 53021	Analgesic, NSAID	
<b>Ketorolac Tromethamine</b>					
ketotifen	10-H-Benzo[4,5]cyclohepta[1,2-b]thioptene-10-one, 4,9-dihydro-4-(1-methyl-4-phenylidene)-, (E)-2-butanedicarboxylate (1:1) [CAS]	34580-13-7 34580-14-8	GB 1355539	Antiasthma	Asthma
<b>Khellin</b>		82-02-0			
knellin		9001-29-0		Dermatological	Photodamage

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
KNI-272	4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-(2-hydroxy-3-[[2-[(5-isoquinolin-1-yl)oxy]acetyl]amino]-3-methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl-, [R]-[3(2S), 3S' (R'), 4R']-[CAS]	147318-81-8	US 5644028	Antiviral, anti-HIV	Infection, HIV/AIDS
KP-103	(R)-2-[2-(4-benzophenonyl)-3-(4-methyl-1-phenyl-1H-tetrazol-1-yl)-2-butanol				
KP-157			US 6110661	Antifungal	Infection, general
KP-544			WO 9916305	Cognition enhancer	Unspecified
KRN-5500	L-glutaro-β-L-manno-Heptopyranosylamine, 4-deoxy-4-[[[(2E,4E)-1-oxo-2,4-tetraacetylenyl]amino]acetyl]amino]-N-1H-purin-6-yl-, [CAS]	151276-95-8	WO 9015811	Anticancer, antibiotic	Cancer, colorectal
KT-136	Alpha-D-Guocopyranoside, 6-D-fructofuranosyl, mixt. with 1-allyl-2-pyrrolidone homopolymer compd. with iodine [CAS]	121602-88-8		Formulation, dermal, topical	Ulcer, decubitus
KUL-7211	(-)-2-[(2S)-1,2,3,4-tetrahydro-2-[(2R)-2-hydroxy-2-(4-hydroxyphenylethyl)amino]naphthalen-7-yloxy]-N,N-dimethylacetamide hydrochloride monohydrate			Urological	Urinary calculus
KW-2170	6-[4-Pyrazol-4,5,1-dejacidin-6-one-5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[2-(hydroxyethyl)amino]acetyl]-hydrochloride [CAS]	207862-44-0		Anticancer, alkylating	Cancer, lung, non-small cell
KW-6002	11-(Purine-2,6-dione, 8-(2-(3,4-dimethoxyphenylethyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-[E])-[CAS]	155270-89-8		Antiparkinsonian	Parkinson's disease
KW-7153	3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(10-oxo-4,10-dihydrobenzo[5,2-c]1,1-benzothiepin-9-yl)propanamide 5,5 dioxide			Urological	Incontinence

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
L-355260	Urea, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl), (R) [CAS]	118101-09-0	EP 284256	Anticancer, other	Cancer, general
L-5-hydroxypyridophan	L-Tryptophan, 5-hydroxy, [CAS]	4359-09-8		Metabolic and enzyme disorders	Unspecified
L-745337	Methanesulfonamide, N-[6]-(2,4-difluorophenylthio)-2,3-dihydro-1-oxo-1H-inden-5-yl, [CAS]	158205-05-1	WO 9413535	Analgesic, NSAID	Pain, general
L-759298	Phosphonic acid, [3-[(2R,3S)-2-[(1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl], [CAS]	172673-20-0	WO 9523798	Antiemetic	Chemotherapy-induced nausea and vomiting
L-826141			WO 9722585	Asthma	Unspecified
labetalol	5-(1-hydroxy-2-(1-methyl-3-phenylpropyl)aminopropyl)sulfonamide HCl	32780-64-6 36894-08-6	US 4012444	Antihypertensive, adrenergic	
lacidipine	3,5-Pyridinedicarboxylic acid, 4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-, diethyl ester, (E) [CAS]	103890-78-4	GB 2164336	Antihypertensive, other	Hypertension, general
Lactlic Acid	D-Lactical, 4-O-6-D-galactopyranosyl- [CAS]	585-86-4		Hepatoprotective	Infection, neurological
Lactulose		4618-18-2			
lafudine	Acetamide, 2-[2-(4-arylmethyl)sulfinyl-N-[4-[(4-(1-phenyl-1-methyl-2-pyridinyl)oxy]-2-but-1-enyl)], (2-) [CAS]	118288-08-7 169899-19-8	EP 282077	Antitumor	Ulcer, gastric
Lamifiban	2[(1H)-Pyrimidin-4-amino-1-[2-(1-hydroxyethyl)-1,3-oxadiazol-5-yl], (2R-ido) [CAS]	144412-49-7			
lamivudine	1,2,4-Triazine-3,5-diamine, 6-(2,3-dichloropropenyl)- [CAS]	134678-17-4	EP 513917	Antiviral, anti-HIV	Infection, HIV/AIDS
lamotrigine		84057-84-1	EP 21121	Antiepileptic	Epilepsy, partial (focal, local)

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
landiol	Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-[[4-morpholinyl]carbonyl]amino]ethyl]amino]propoxy]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester, [S-(R*, R*)]: HCL	133242-30-5	EP 397031	Antiarrhythmic	Tachycardia, general
lanicemine	(S)-Alpha-phenyl-2-pyridine ethanamine dihydrochloride	163322-06-5		Neurological	Unspecified
laniquidar	Methyl 5,11-dihydro-11-[1-(2-{4-[(2-quinolinomethoxy)phenyl]ethyl}-4-piperidinylidene)-6H-imidazo[2,1-b][3]benzazepine-3-carboxylate	197600-46-9	WO 9734897	Radio/chemosensitizer	Cancer, general
lanocorazole	1H-imidazole-1-acetonitrile, Alpha-[(2-chlorophenyl)-1,3-dithiolan-2-ylidene], (E)-[4], [CAS]	101630-10-3	US 4738976	Antifungal	Infection, fungal, general
Lanoteplase		171870-23-8			
Lanreotide		108736-35-2			
lansoprazole	1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-[CAS]	103577-45-3	EP 174726	Antulcer	Ulcer, duodenal
lanthanum carbonate	Carbonic acid, lanthanum(3+) salt (3:2)[CAS]	587-26-8	US 5068076	Urological	Hypertrophataemia
lapatinib	4-Quinoxalinamine, N-[3-chloro-4-[(3-fluorobenzyl)methoxy]phenyl]-5-[5-[[2-[[methylsulfonyl]ethyl]amino]phenyl]uran-2-yl]	388082-78-8		Anticancer, other	Cancer, breast
laquinmod		248281-84-7		Multiple sclerosis treatment	Multiple sclerosis, general
lasofoxiene	2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-{2-[(1-pyrrolidinyl)ethoxy]phenyl}-6R-cis)-, (S)-[R*, R*]-2,3-dihydroxybutanedioate [CAS]	190791-29-8	WO 9716434	Menopausal disorders	Hormone replacement therapy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
latamoxef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[[1-(methoxy-1H-tetrazo-5-yl)thio]methyl]-8-oxo- [CAS]	64952-97-2 64953-12-4	GB 1547351	Beta-lactam antibiotic	Infection, general
latanoprost	5-Hepanoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)pyridenyl), 1-methylethyl ester, (1R- (1Alpha,2,20(R),3Alpha,5Alpha)- [CAS]	130209-82-4	WO 9002553	Prostaglandin	Glaucoma
Lauroguadine		135-43-3			
Lauroilium Acetate		146-37-2			
Lawson		83-72-7			
LAX-111	1-(2,2,2,2,2-pentafluoro-5,8,11,14,17-pentaenoxy)-3-(2,2,2,2,2-pentafluoro-5,8,11,14,17-pentaenoxy)-propane			Neuroleptic	Schizophrenia
Lazabemide	Benzenebutyric acid, 4-(2S)-3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl-, hydrazide [CAS]	103878-84-8			
LB-30057			WO 9749673	Antithrombotic	Thrombosis, venous
L-Cysteine					
Lefetamine	4-isoxazolecarboxamide, 5-methyl-4-[(4-trifluoromethyl)phenyl]- [CAS]	7262-75-1			
leflunomide	4-isoxazolecarboxamides, 5-methyl-4-[(4-trifluoromethyl)phenyl]- [CAS]	75706-12-6	EP 13376	Antiarthritic, immunological	Arthritis, rheumatoid
leflunomide	(trifluoromethyl)phenyl- [CAS]	75706-12-6	US 561073	Anticancer, other	Cancer, ovarian
Leipropyrole	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenyl)amino]-3,3-dimethyl-7-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, [2S- (2Alpha,5Alpha,6(S)-)] [CAS]	5633-16-9			
lenampicillin		80734-02-7			
lenthan	lenthan [CAS]	86273-18-9 37339-90-5	EP 61206	Pentacillin, oral	Infection, general
				Anticancer, immunological	Cancer, stomach

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<i>Levodopa</i>	3,4-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(3,3-dimethylpropyl)methylamino]-1,1-dichloride [CAS]	100427-26-7 132865-11-6	US 4705797	Antihypertensive, other	Hypertension, general
levamisole	11-Benzimidazole, 1-(phenylmethyl)-2-(1-piperazinyl)- [CAS]	143257-98-1 132449-46-8	US 5256665	Antiemetic	Nausea and vomiting, general
<i>Lesopitron</i>	Benzoic acid, 4-[(3-{1,8-dihydro-8-oxo-9H-purin-9-yl}-1-oxopropyl)amino]-, monopotassium salt [CAS]	138117-50-7	US 6338963	Antiparkinsonian	Parkinson's disease
lepirudin	4-Thiazolidinecarboxylic acid, 2-[2-[(2-ethoxy-2-oxoethyl)imino]ethyl]- [CAS]	53943-98-7	US 4032534	COPD treatment	Bronchitis, chronic
letrozole	Benzonitrile, 4,4'-[1H-12,4-thiazol-1'-ylmethylene]bis- [CAS]	112809-51-5 480-17-1 53714-56-0	EP 236940	Anticancer, hormonal	Cancer, breast
<i>Leucocyanidin</i>					
<i>Leuprolide</i>	Luteinizing hormone-releasing factor (pfp), 6-D-eucine-9-(N-ethyl-L-prolinamide)-10-deglycyamide, monacetate (salt) [CAS]	53714-56-0 74381-53-6		Formulation, implant	Cancer, prostate
leuprolide acetate	Luteinizing hormone-releasing factor (pfp), 6-D-eucine-9-(N-ethyl-L-prolinamide)-10-deglycyamide- [CAS]	53714-56-0		Formulation, implant	Cancer, prostate
leuprorelin	[midazol-2-yl]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]	152-02-3 147697-74-4 16955-80-5	US 4584305	Antiepileptic	Infection, helminth, general
<i>Levallophan</i>					
levamisole	1-Pyrolidineacetamide, Alpha-ethyl-2-oxo-, (S)- [CAS]	94535-50-9	EP 162036	Antiepileptic	Epilepsy, general
<i>Levcromakalim</i>					
levetiracetam	2-Propanol, 1-(4-(2-cyclopropylmethoxyethyl)phenoxy)-3-(1-(methylthio)amino) hydrochloride [CAS]	102767-29-2 116209-55-3		Formulation, mucosal, topical	Glaucoma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
levobunolol	1-(2H)-Naphthalene, 5-[3-[(1,1-dimethylethylamino)-2-hydroxypropoxy]-3,4-dihydro-, (S)]- [CAS]	27912-14-7 47141-42-4	US 3841152	Formulation, mucosal, topical	Glaucoma
levobupivacaine	2-Piperidinecarboxamide, 1-butyryl-N-[2,6-dimethylphenyl]-, (S)- [CAS]	27262-47-1	WO 9510276	Anaesthetic, injectable	Anaesthesia
levocabastine	4-Piperidinecarboxylic acid, 1-(4-cyano-4-(4-fluorophenyl)-2-methoxy-5-methyl-1-phenyl-, [3S-[1(3S),3(4R),4(5S)]- [CAS]	79449-98-2 79516-68-0 78547-78-7	US 438184	Antiallergic, non-asthma	Rhinitis, allergic, general
levosulizine	Acetic acid, (2S)-[4-(4-chlorophenyl)phenylmethyl]-1-phenylaziridinyl-, (R)- [CAS]	130018-77-8	WO 9408429	Antiallergic, non-asthma	Allergy, general
<b>Levodopa</b>		<b>59-92-7</b>			
levodropropizine	1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]	98291-25-5	EP 147647	Antitussive	Cough
levofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]	10086-85-4 138198-71-0 1477-40-3	EP 206283	Quinolone antibacterial	Infection, respiratory tract, lower
<b>Levomethadyl Acetate</b>		<b>2708884-0</b>			
levomoprolol	2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]	5741-22-0 77164-20-6	EP 15418	Antihypertensive, adrenergic	
levonorgestrel	18,19-Dichloroprop-4-en-20-yne-3-one, 13-ethyl-17-hydroxy-, (17 $\alpha$ H $\alpha$ H)- [CAS]	787-63-7		Formulation, implant	Contraceptive, female
<b>Levophaceterpane</b>		<b>24558-01-8</b>			
<b>Levopropoxyphene</b>		<b>2338-37-6</b>			
<b>Levorphanol</b>		<b>77-07-6</b>			
levosimendan	Propanedinitrile, [(4-(1,4,5,8-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono]-, (R)- [CAS]	131741-08-7 141505-33-1	EP 363449	Cardio stimulant	Heart failure
levosulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-, (S)- [CAS]	23672-07-3	GB 2014990	Antiemetic	Dyspepsia



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<i>Levodroxyline</i>					
levovirin	1-(3-L-ribofuranosyl-12,4-triazole-3-carboxamide			Antiviral, other	Infection, hepatitis-C virus
leixipitant	L-Leucine, N-methyl-N-[(4-(2-methyl-1H-imidazol-5-yl)pyridin-1-yl)methyl]phenylsulfonfyl, ethyl ester- [CAS]	139133-26-9	WO 9203423	Neurological	Dementia, AIDS-related
LF-15-0185	2-Pyrrolidinonecarboxamide, N-[3-[(4-(aminomethyl)benzoylamino)propyl]-1-[2,4-dichloro-5-[(2,4-dimethyl-8-quinolinyl)oxy]methyl]phenylsulfonfyl], (2S)- [CAS]	209733-45-9	FR 2759562	Neuroprotective	Head trauma
LOD-1550	2,3,6-Octatrienoic acid, 7-(3,5-bis(1,1-dimethylethyl)phenyl)-3-methyl- (2E,4E,6E)- [CAS]	179600-20-9 9002-67-9 9034-40-6		Anticancer, other	Cancer, cervical
LH					
LH-RH	1H-Benzimidazole, 5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- [CAS]	115575-11-6		Formulation, other	Psoriasis
liarazole	(1H-Pyrazine-5-carboxylic acid, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl)- [CAS]	156897-06-2		Antiarthritic, other	Arthritis, osteo
licoflone					
Licostinel	Phosphonic acid, [1-amino-3-(dimethylamino)propyl]diene]bis- [CAS]	153504-81-5			
lidacronate		63132-38-7	WO 9702827	Urological	Unspecified
Lidamide	Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- [CAS]	66871-56-5		Formulation, transdermal, patch	Pain, post-herpetic
lidocaine		137-58-6			
Lidofenin		59160-29-1 34116-28-0			
Lidoflazine					
limaprost	Prosta-2,13-dien-1-olic acid, 11,15-dihydroxy-17,20-dimethyl-9-oxo- (2E,11Alpha,13E,15S,17S)- [CAS]	74397-12-9	GB 2041368	Prostaglandin	Buerger's syndrome

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Lincomycin		154-21-2			
Lindane		58-89-9			
linexacid	Acetamide, N-(3-(3-fluoro-4-(4-morpholinylphenyl)-2-oxo-5-oxazolidinylmethyl)-6-[CAS]	165900-03-3	WO 9507271	Antibiotic, other	Infection, dermatological
Linoleic Acid		60-33-3			
Linolenic Acid		463-40-1			
Liothyronine		6893023			
Lipase		19001-62-1			
Lipo-dexamethasone palmitate	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-[(1-oxocyclohexyl)oxy]-, (11 $\beta$ ,16 $\alpha$ )-[CAS]	14899-38-6		Formulation, optimized, microemulsion	Arthritis, rheumatoid
lipo-flurbiprofen	[1-(1-biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, 1-(acetoxyethyl) ester [CAS]	91503-79-6	JP 60208910 EP 525655	Formulation, optimized, microemulsion Formulation, optimized, liposomes	Pain, cancer Respiratory distress syndrome, adult
Lipogal HA			US 5437272	Lung Surfactant	
Liquivent	perfluorooctylbromide	423-55-2			
litensilate	Carbamothioic acid, (6-methoxy-2-pyridinyl)methyl-, O-(5,6,7,8-tetrahydro-2-naphthalenyl) ester [CAS]	88678-31-3	GB 2124617	Antifungal	Infection, dermatological
lisinopril	L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-valyl]-, (S)- [CAS]	76547-98-3 83915-83-7	EP 12401	Antihypertensive, renin system	Hypertension, general
Lisofylline		100324-81-0			
lisuride	Urea, N-[(6 $\alpha$ )-9,10-didehydro-6-methylergolin-8-yl]-N,N-diethyl-, [CAS]	19875-60-6 305-13-5 18016-90-3			Acromegaly
Lithium Citrate		919-16-4			
lithium	Carbonic acid, diethyl salt [CAS]	554-13-2		Formulation, modified release, <=24hr	Depression, bipolar
litivaptan	Benzanide, N-[3-chloro-4-(6H-pyrimidin-2-yl)-7-benzotriazin-10(11H)-yl]carboxylphenyl-5-fluoro-2-methyl- [CAS]	168079-32-1	US 5738540	Cardiovascular	Heart failure
LJP-1082			US 6207160	Immunosuppressant	Thrombosis, venous

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
LUU Alpha	S-2,7,8-trimethyl-6-(6-carboxyethyl)-8-hydroxydronan				Hypertension, general
LMP-180			US 5643393	Antihypertensive, other	Asthma
LMP-420			US 5643393	Antiartirific, other	Arthritis, rheumatoid
lobaplatin	Platinum, (1,2-cyclobutanedimethanamine-N,N')bis(2-hydroxypropanoate)(2-O1,02), [SP-4-3(S),(trans)], [CAS]	135558-11-1	DE 4115559	Anticancer, alkylating	Cancer, lung, small cell
Lobeline		90-69-7			
Lobenzarit		63329-53-3			
lodoxamide	2,2'-(2-chloro-5-oxano-1,3-phenylene)dinitro[bis(2-oxoacetate)-2-amino-2-(hydroxymethyl)-1,3-propanediol (1:2)]	63810-09-3 53882-12-5			
Lofentanil		61380-40-3	US 4439445	Antiasthma	Asthma
lofepramine	Ethanone, 1-(4-chlorophenyl)-2-[(8-(10,11-dihydro-5H-benz[b]flazepin-5-yl)propyl)methylamino], [CAS]	23047-25-8 26786-32-3	GB 1177525	Antidepressant	
lofexidine	1H-imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- [CAS]	31036-80-3 790-69-2	GB 1181356	Antihypertensive, adrenergic	Hypertension, general
Loflucarban					
lomefloxacin	3-Quinolincarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- [CAS]	98079-61-7 98079-52-8			Infection, respiratory tract, lower
lomezine	Piperazine, 1-bis(4-fluorophenyl)methyl-4-[[2,3,4-trimethoxyphenyl)methyl], [CAS]	101477-54-7 101477-55-8	EP 140116	Quinolone antibacterial	
lonitidine	7-(6-oxohexylthio)pyrroline	10226-54-7	EP 159566	Antimigraine	Migraine
lonustine	Urea, N-[2-chloroethyl-N'-glycohexyl-N-nitroso- [CAS]	13010-47-4	DE 2207860	Neurological	
lonatamib	1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benz[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl], [CAS]		JP 48075526	Anticancer, alkylating	
		193275-84-2	US 5874442	Anticancer, other	Cancer, lung, non-small cell

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Lonapalene		91431-42-4			
Lonazolac		53808-88-1			
lonidamine	1H-imazole-3-carboxylic acid, 1-[(2-(4-chlorophenyl)methyl)-[CAS]	50254-59-2	DE 2310031	Radiochemosensitizer	Cancer, breast
loperamide	4-[(2-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-1-piperidine butyramide HCl	34552-83-5 53179-11-6	US 3714159	Antidiarrhoeal	Diarrhoea, general
loperamide oxide	1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-, 1-oxide, trans-[CAS]	106900-12-3	EP 219896	Antidiarrhoeal	Diarrhoea, general
loprazolam	[1H-imidazo[1,2-a][1,4]benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-[(4-methyl-1-piperazinyl)methyl]enyl-8-nitro-[CAS]	61197-73-7 61197-93-1 70111-54-5	GB 1495426	Hypnotic/Sedative	
Loprhione		106730-54-5			
loracarbef	1-Azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, [6R-[6Alpha,7R(R')]]-[CAS]	76470-66-1 121961-22-6	EP 14475	Cephalosporin, oral	Infection, respiratory tract, lower
Lorajmine		47562-08-3			
lorazepam	1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-1H-benz[5,6]pyridine)[2-pyridin-11-ylidene]-, ethyl ester-[CAS]	79784-75-5	EP 42544	Antiallergic, non-asthma	Rhinitis, allergic, general
lorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-	846-49-1			
lorazepam	Benzenesuccinimide, N-(4-chlorophenyl)-N-[1-(1-methyl-1H-pyridin-4-yl)pyridinyl]-[CAS]	59034-46-6 59723-31-6	DE 2642856	Formulation, oral, orally-disintegrating	Epilepsy, general
lorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-, [CAS]	848-75-9	US 3295249	Hypnotic/Sedative	Insomnia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
lornoxicam	2H-Thieno[2,3-ef]-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide- [CAS] 70374-39-9		EP 313835	Analgesic, NSAID	Pain, post-operative
losartan	1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl]-4-yl[methyl]-, [CAS] 124750-99-8 114798-26-4		EP 253310	Antihypertensive, renin system	Hypertension, general
losprednol	Androst-1,4-diene-17-carboxylic acid, 17-(ethoxycarbonylpropyl)-11-hydroxy-3-oxo-, chloromethyl ester, (11S,17Alpha)- [CAS] 82034-46-6		GB 2079755	Anti-inflammatory, topical	Uveitis
Lotraliban		171049-14-2			
lovastatin		75330-75-5			
Loxapine		10021977			
loxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoylamino)-5-[(3-methoxypropyl)perilylamino]-5-oxo-, (±)- [CAS] 107097-80-3		WO 8703869	GI inflammatory/bowel disorders	Pancreatitis
loxoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-oxocyclopentyl)methyl]-, [CAS] 80382-23-6 87828-36-2		EP 55588	Antiarthritic, other	Arthritis, rheumatoid
Lu-35-138	1-[3]2-[5-chloro-1-(4-fluorophenyl)-3,1H-indolyl]ethyl(methylamino)propyl-2-imidazolidone hydrochloride		WO 9516684	Neuroleptic	Psychosis, general
Lubeluzole	(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluorophenyl)-2-hydroxy-6-oxooctahydrocyclopent[blpyran-5-yl]heptanoic acid	144685-07-6			
lubiprosone		136790-76-6		Laxative	Constipation
lucanthone	Thioxanthene-9-one, 1-(2-(diethylamino)ethyl)amino-4-methyl-, [CAS] 479-50-5			Radio/chemosensitizer	Cancer, brain
Lucanthone		548-57-2			
Lumefantrine	Benzeneacetic acid, 2'-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, [CAS] 82186-77-4				
lumiracoxib		220991-20-8		Analgesic, NSAID	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
lurtolecan	11H-1,4-Dioxine[3-glypyranol[3',4':5,7]indolizino[1',2-b]quinoline 9,12BH, 14H]-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[4-methyl-1-piperazinyl]methyl-, [CAS]	155773-58-3		Formulation, optimized, liposomes	Cancer, ovarian
	Lutetium, bis(acetate-O)]8,10-diethyl-20,21-tetrakis-[2-(2-methoxyethoxy)ethoxy]ethoxy-4,15-dimethyl-3,11-trimino-3,8,16,17,18-pentamethoxy-1,18-benzodiazacycloheptasine-5,14-dipropionolito-N1,N18,N23,N24,N25), (PB 7-11-23324), [CAS]	156436-90-7	WO 9906411	Radiochemosensitizer	Atherosclerosis
lutetium texaphyrin				Anti-inflammatory	Arthritis, rheumatoid
LY-216	Zinc[2-(2,6-dichloroanilino)phenyl]acetate				
	Hexadecanamide, N-[4-[2-[2-(2-[(N-acetyl)-Alfa-neuraminosyl-(2-3)-O-8-D-galactopyranosyl-(1-4)-O-16-deoxy-Alpha-L-galactopyranosyl-(1-3)-8-D-glucopyranosyl]oxy]ethoxy]ethoxy]methyl]phenyl]-2-tetradecyl-, [CAS]	158792-45-1		Cognition enhancer	Dementia, senile, general
LY-156735	3-methyl-6-chloromelatonin		EP 615243	Hypnotic/Sedative	Sleep disorder, general
LY-293111	Benzoic acid, 2-[3-[3-[(5-ethyl-4-fluoro-2-hydroxy[1,1'-biphenyl-4-yl]oxy]propyl)-2-propyl]phenyl]- [CAS]	161172-51-8		Anticancer, other	Cancer, melanoma
LY-293558	3-isouinolincarboxylic acid, decahydro-6-[2-(11-tetrazol-5-yl)ethyl]-, [3S; (3alpha,4a)alpha, 6a] [CAS]	154652-83-2		Analgesic, other	Pain, neuropathic
LY-355703	1,4-Dioxo-8,11-diazacyclohexadec-19-ene-2,5,9,12-tetrone, 10-[(3-chloro-4-methoxyphenyl)methyl]-6,8-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-(2S,3R)-3-phenylloxiran-2-yl]ethyl-, (3S,10R,13E,16S)- [CAS]	16286-67-7	WO 9707798	Anticancer, other	Cancer, lung, non-small cell
Lyapolate		25063-27-4			
Lymecycline		982-21-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Lynestrenol		52-76-6			
Lypristin		50-57-7			
Lysine Acetylsalicylate		62952-06-1			
lysine salicylate	L-Lysine, 2-hydroxybenzoate [CAS]	59535-08-9	WO 9624331	Analgesic, NSAID	
lysophospholipids			WO 9843093	Diagnostic	Diagnosis, cancer
	Dichloro[4aR,13aR,17aR,21aR]-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-olicosahydro-1,7-dithio-7H-cibenzo[b,l][1,4,7,10]tetraazacydoheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22]nangense				
M-40403			US 6180620	Anticancer, other	Unspecified
mabuprolen	Benzeneacetamide, N-(2-hydroxyethyl)-Alpha-methyl-4-(2-methylpropyl)-, (+)- [CAS]	82821-47-4			
Mabuterol		56341-08-3	DE 3121595	Anti-inflammatory	
Macrophage Colony-Stimulating Factor		81627-83-0			
MADU					
malenide	Benzene sulfonamide, 4-(aminomethyl)-monocate [CAS]	840-50-6 13093-99-9 138-39-6		Vulnery	Burns
matosamide	Ethanesulfonic acid, 2-[2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl]thiol-, P-oxide, di-(+)- [CAS]	88859-04-5 98845-64-8	EP 393575	Anticancer, alkylating	Cancer, renal
magaldrate	Aluminum magnesium hydroxide sulfate (Al5Mg10(OH)31(SO4)2, hydrate [CAS]	74978-16-8	US 2923660	Antacid/Antiflaunt	
Magenta I		632-99-5			
Magnesium Acetylsalicylate		132-49-0			
Magnesium Carbonate Hydroxide		39409-82-0			
magnesium chloride	Magnesium chloride (MgCl2) [CAS]	7785-30-3		Formulation, oral, enteric-coated	Nutrition

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Magnesium Citrate	D-Gluconic acid, magnesium salt (2:1) [CAS]	3344-18-1			
magnesium gluconate		3632-91-5		Formulation, other	Hypertension, general
Magnesium Lactate		18317-93-6			
Magnesium Salicylate		18917-89-0			
Malathion		121-75-5			
Malotilate		59937-28-9			
Mandelic Acid		90-64-2			
Mandelic Acid Isoamyl Ester		5421045			
Mangafodipir		118248-94-5 (free acid); 155319-91-8 (hexahydrogen )			
mandipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]	89226-50-6 89226-75-5	EP 94159	Antihypertensive, other	Hypertension, general
Mannomustine	mannose-6-phosphate	551-74-6		Vulnerary	Wound healing
mannose-6-phosphate					
Maprotiline		10262-69-8			
maribavir	<sup>1</sup> H-Benzimidazol-2-amine, 5,6-dichloro-N-[(1-methylethyl)-1-β-D-ribofuranosyl]- [CAS]	176161-24-3		Antihra, other	Infection, cytomegalovirus
marimastat	N-[2,2-Dimethyl-1-(3-hydroxy-3-methylcarbamoyl)propyl]-N-(3(S)-difluoroxyl-2(R)-isobutylsuccinamide	154038-60-8	WO 9402447	Anticancer, other	Cancer, pancreatic
maxacalcitol	1,3-Cyclohexanediol, 4-methylene-5-(2-oxo-1-(1-(3-hydroxy-3-methylbutyloxy)ethyl)-7α-methyl-4H-inden-4-ylidene)ethylidene), (1S- (1Alpha(R*),3aS,4E(1S*,3R*,5Z),7aAlpha) )- [CAS]	103909-75-7	US 4891364	Hormone	Hypoparathyroidism



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mazindol	3H-imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro- [CAS]	22332-71-9	US 3763178	Anorectic/Antiobesity	Obesity
Mazipredone		13085-08-0	US 6042559	Cardiovascular	Unspecified
MCC-5723	(2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)				
MCC-478	3-(2H)-Pyridazinone, 4,5-dihydro-6-[4-(pyridinylamino)phenyl]-, monohydrochloride [CAS]	98326-32-0 98326-33-1	EP 145019	Antiviral, other	Infection, hepatitis-B virus
m-Cresyl Acetate		122-46-3		Cardio stimulant	Heart failure
MDAM	Gamma-Methylene-10-deazaaminopterin			Anticancer, antimetabolite	Cancer, general
MDI-101			US 4885311	Anilacne	Acne
MDI-403		403949-94-5	US 4877120	Anilacne	Acne
MDL-100807	4-[2-piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)- [CAS]	139230-85-6		Hypnotic/Sedative	Sleep disorder, general
mebendazole	methyl-5-benzoylbenzimidazole-2-carboxylate	31431-39-7	GB 1307306	Anthelmintic	
mebeverine	Benzoic acid, 3,4-dimethoxy-, 4-[ethyl(2-(4-methoxyphenyl)-1-methylethylamino)butyl ester [CAS]	3625-06-7		Antispasmodic	Irritable bowel syndrome
Mehydroline		524-81-2			
Mefenofen		78266-06-5			
Mebutamate		64-55-1			
meclizamine	Bicyclo(2,2,1)heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2		Neurological	Unspecified
Mechlorethamine		51-75-2			
Mechlorethamine Oxide		302-70-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
meclizem	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(hexahydro-1H-azepin-1-yl)methyl]enylamino]-3,3-dimethyl-7-oxo-, [2S-(2A)pha,5Alpha,6.beta.]-, [CAS]	32887-01-7 32887-03-9	GB 1293590	Penicillin, injectable	Infection, general
Meclizine		569-65-3			
Meclizocline		2013-58-3			
meclizofenamate	Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-, monosodium salt [CAS]	6385-02-0 644-62-2		Antiarthritic, other	Arthritis, osteo
Meclufenamic Acid		61-68-3			
Meclufenoxate		340-57-8			
Meclqualone		18598-63-5			
Mecysteine		12/06/2898			
Medazepam	Etharamine, N,N-dimethyl-2,2-diphenoxy- [CAS]	32359-34-5	FR 1M5498	Antidepressant	
medifloxamine		977-79-7			
Medrogestone		1984-15-2			
Medronic Acid	Preg-4-ene-3,20-dione, 17-(acetoxy)-6-methyl-, (6Alpha)	71-58-9 520-85-4		Formulation, fixed-dose combinations	Contraceptive, female
medroxyprogesterone		2688-66-8			
Medrysone		61-68-7			
Meferanamic Acid		17243-57-1			
Mefenorex		1227-61-8			
Mefexamide		57773-32-3			
mefloquine	4-Quinolinemethanol, Alpha-2-epidehydro-2,8-bis(trifluoromethyl)-, (R,S)-[CAs]	5230-10-7 68191-18-0	GB 1554282	Antimalarial	
Mefruside		7195-27-9			
Megestrol		595-33-5			
Meglumine		22154-43-4 131-49-7			
meglutol	2-hydroxy-2-methyl-1,3-propanedicarboxylic acid	503-49-1	US 3529449	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
melagatran	Glycine, N-[(1R)-2-[(2S)-2-[[[4-(aminomethyl)phenyl]methyl]amino]carboxyl]-1-azetidinyl]-1-glycoxyethyl-oxoethyl]-[CAS]	15976-70-2	WO 9618971	Antithrombotic	Thrombosis, general
melanocortin-4 agonist	N-[3R)-1,2,3,4-Tetrahydroquinolinium-3-ylidene]-(1R)-1-(4-chlorobenzyl)-2-(4-cyanophenyl)-4-[(1H)-1,2,4-triazol-1-ylmethyl]piperidin-1-yl]-2-oxoethylamine(1)				
melarsoprol		494-79-1		Anorectic/Antiobesity	Obesity
Melengestrol		5633-18-1			
melevodopa	Alanine, 3-(3,4-dihydroxyphenyl)-methyl ester [CAS]	7101-51-1	EP 252290	Antiparkinsonian	Parkinson's disease
Mefenamide		14417-88-0			
Meflitracen		5118-29-6			
meioxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-1,1-dioxide, [CAS]	71125-38-7	US 4233259	Antiarthritic, other	Arthritis, rheumatoid
melperone	1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-[CAS]	1822/78-3 3575-80-2	BE 651144	Neuroleptic	
Melphalan		148-82-3			
meludrine	Benzanemethanol, 2-chloro-Alpha-(((1,1-dimethylethylamino)methyl)-4-hydroxy-, (R*, R*)-2,3-dihydrobutanedioate (1:1) salt) [CAS]	134665-37-5	EP 420120	Labour inhibitor	Labour, preterm
memantine	Tricyclo[3.3.1.1 <sup>3,7</sup> ]heptan-1-amine, 3,5-dimethyl [CAS]	41100-52-1 19992-08-2	EP 392059	Cognition enhancer	Dementia, AIDS-related
MEN-10700	Acetamide, 2-[[[6R,6S,5-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azacyclo[3.2.0]hept-2-en-3-yl]methyl]methylamino]-[CAS]	195874-55-6	WO 9406803	Beta-lactam antibiotic	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
MEN-10755	5,12-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy-Alpha-L-xyo-hexopyranosyl)-2,6-dideoxy-Alpha-L-xyo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trifluoro-9-(hydroxyacetyl)-hydrochloride, (7S,8S) [CAS]	169317-77-5	WO 9509173	Anticancer, antibiotic	Cancer, breast
Menadiol		481-85-6			
Menadione		58-27-5			
Menadoxime		573-01-3			
Menbutone		3562-99-0			
Menogaril		71628-96-1			
MENT	7Alpha-Methyl-19-nortestosterone				
menthol	Cyclohexanol, 5-methyl-2-(1-methylthio)- [CAS]	1430-04-8 89-78-1		Formulation, transdermal, systemic	Contraceptive, male
Menthyl Valerate		89-47-4			
Meobentine		46464-11-3			
Meparfynol		77-75-8			
mepartirion	Partirion, methyl ester [CAS]	11121-32-7	US 3780173	Antifungal	Infection, Candida, general
Mepazine		60-89-9			
Mepenzolate Bromide		76-90-4			
Meperidine		57-42-1			
Mephenesin		59-47-2			
Mephenoxalone		70-07-5			
Mephentermine		100-92-5			
Mephentoin		50-12-4			
Mephobarbital		115-38-8			
Mepindolol		23694-81-7			
Mepitostane		21362-89-6			
mephivacaine	N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide	96-88-8		Formulation, modified-release, >24hr	Pain, post-operative
Mepixanox		17854-59-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<b>Meprednisone</b>		1247-42-3			
<b>Meprobamate</b>		57-53-4			
<b>meropenem</b>	Bufo-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl- $\alpha$ -L-mannopyranosyl)oxy]-14-hydroxy-, (8R)- [CAS]	33396-37-1	DE 1910207	Cardio stimulant	Heart failure
<b>mepizanol</b>	Phenol, 3-(4-ethynylhexahydro-1-methyl-1H-azepin-3-yl)- [CAS]	54340-55-8	GB 1285025	Anaesthetic, other	Pain, general
<b>mequitazine</b>	10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	59263-78-2	GB 1250534	Antiallergic, non-asthma	
<b>Meralain</b>		4386-35-0			
<b>Meralluride</b>		8069-64-5			
<b>Merbromin</b>		129-16-8			
<b>Mercaptopurin</b>		21259-76-7			
<b>Mercumallic Acid</b>		86-36-2			
<b>Mercuric Chloride, Ammoniated</b>		10124-48-8			
<b>Mercuric Oleate</b>		1191-80-6			
<b>Mercuric Oxycyanide</b>		1335-31-5			
<b>merfenipodib</b>	Carbanic acid, ((3-(((6-methoxy-4-(5-oxazolyloxy)amino)carbonyl)amino)phenyl)methyl)-(3S)-tetrahydro-3-furanyl ester [CAS]	19821-22-6	US 5807876	Antiviral, other	Infection, hepatitis C virus
<b>meropenem</b>	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(4-cyanoethyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[(3S*,5S*),4 $\alpha$ ,5 $\beta$ ,6(R*)]]- [CAS]	96036-03-2	EP 128587	Beta-lactam antibiotic	Infection, respiratory tract, lower
<b>Mersalyl</b>		492-18-2			
<b>Mesalazine</b>		89-57-6			
<b>Mesalazine</b>	Benzolic acid, 5-amino-2-hydroxy- [CAS]	89-57-6	WO 5541170	Formulation, oral, other	Colitis, ulcerative
<b>Mesna</b>		19767-45-4			
<b>Mesoridazine</b>		5588-33-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mestanolone		521-11-9			
Mestranol		1424-00-6			
Mestifen		72-33-3			
Metaciazepam		135-58-0			
Metampicillin		84031-17-4			
Metapramine		6489-97-0			
Metaproterenol		21730-16-5			
Metaraminol		586-06-1			
Metazocine		54-49-9			
metergoline		3734-52-9			
metformin	Cardamic acid, [(6 <i>β</i> )-1,8-dimethylergolin-8-ylmethyl]-, phenylmethyl ester [CAS]	17692-51-2 21631-37-8 2706-42-5	GB	Antiprolactin	Amenorrhea
Methacholine	imidodipic acid, N,N-dimethyl [CAS]	657-24-9		Formulation, modified-release, ~24hr	Diabetes, Type II
Methacycline		62-51-1			
Methadone		914-00-1			
Methafurylene		76-99-3			
Methamphetamine		531-06-6			
Methandriol		537-46-2			
Methandrostenedione		521-10-8			
Methantheline		72-63-9			
Methapyrilene		53-46-3			
Methaqualone		91-80-5			
Metharbital		72-44-6			
Methazalamide		50-11-3			
Methclazine		554-57-4			
Methenamine		1982-37-2			
Methenolone		100-97-0			
Methestrol		153-00-4			
Methetoin		130-73-4			
Methicillin		5696-06-0			
		132-92-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methimazole		60-56-0			
Methiodal		126-31-8			
Methionine		503-40-2			
Methionine		63-68-3			
Methisazone		1910-68-5			
Methital		467-43-6			
Methixene		02/02/4969			
Methocarbamol		532-03-6			
Methohexital		22151-68-4			
methotrexate	L-Glutamic acid, N-[4-[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl- [CAS]	59-05-2	US 2512572	Anticancer, antineoplastic	Cancer, general
Methotrimoprazine		60-99-1			
Methoxamine		390-28-3			
Methoxsalen		208-81-7			
Methoxyflurane		76-38-0			
Methoxyphenamine		93-30-1			
Methoxypropazine		61-01-8			
Methscopolamine		155-41-9			
Methsuximide		77-41-8			
Methyclothiazide		135-07-9			
Methyl Blue		28983-58-4			
Methyl Nicotinate		93-60-7			
Methyl Propyl Ether		557-17-5			
Methyl Salicylate		119-36-8			
Methyl tert-Butyl Ether		1634-04-4			
Methylbenzethonium Chloride		25155-18-4			
Methylcobalamin		13422-55-4			
methyldopa	L-tyrosine, 3-hydroxy-Alpha-methyl- [CAS]	555-30-6		Formulation, modified release, <=24hr	Hypertension, general
Methylene Blue		61-73-4			
Methylergonovine		113-42-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<b>Methylhexanamine</b>	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester [CAS]	105-41-9 113-45-1 298-59-9			
<b>Methylprednisolone</b>	Pregna-1,4-diene-3,20-dione, 21-(acetoxypoxy)-, 11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6Alpha, 11b)- [CAS]	83-43-2			
methylprednisolone aspartate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[(6-methyl-2-sulfoethylamino)-1,8-dioxocyclopropyl]-, monosodium salt, (6Alpha, 11b)- [CAS]	86401-95-8	EP	Antipruritic/Inflamm, allergic	Pruritus
<b>Methylthiouracil</b>		56-04-2			
<b>Methyltrienolone</b>		965-93-5			
<b>Methypylon</b>		125-64-4			
<b>Methyscride</b>		361-37-5			
<b>Mellazinic Acid</b>		13993-65-2			
metibranolol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1'-acetate [CAS]	22664-65-7	GB	Antihypertensive, adrenergic	
metoclopramide	Benzanilide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy-, [CAS]	364-82-5		Formulation, modified-release, <=24hr	Gastro-oesophageal reflux
<b>Metocurine Iodide</b>		7601-55-0			
<b>Metofenazate</b>		388-51-2			
metolazone	6-Quinazolinanesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-, [CAS]	17560-51-9			
<b>Metopimazine</b>		14008-44-7		Antihypertensive, diuretic	
<b>Metopon</b>		143-52-2	US	Antihypertensive, diuretic	
metoprolol	2-Propanol, 1-[4-(2-methoxyphenyl)phenoxy]-3-[(1-methylethyl)amino]-, (+)-, [CAS]	91364-01-1 95392-17-7 37350-98-6			
<b>Metrolindole</b>		54188-38-4		Formulation, modified-release, other	Hypertension, general
<b>Metrizamide</b>		31112-62-6			
<b>Metrizoic Acid</b>		1949-45-7			
<b>Metron S</b>		13946-02-6			



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mefenamic acid		54-36-4			
Mefenamic acid		672-87-7			
Mefenamic acid		31868-18-5			
Mefenamic acid		1641-17-4			
Mefenamic acid		31828-71-4			
Mefenamic acid	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-4-[[[3-imidazolidinyl]carbonyl]amino]phenylester [lamino]; 7-oxo- [2S- [2Alpha,5Alpha,6Alpha]]- [CAS]	42057-22-7 51481-65-3 72539-76-5	GB 1301961	Penicillin, injectable	Infection, general
Mefenamic acid	Benzenecarboximidic acid, 3,4,5-trihydroxy, ethyl ester, hydrochloride	95933-76-9	US 4623659	Cardiovascular	Reperfusion injury
Mefenamic acid	Dibenzol[6,6]pyrazolo[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- [CAS]	21535-47-7 24219-97-4	GB 1173783	Antidepressant	Depression, general
Mefenamic acid		116644-53-2			
Mefenamic acid		103775-75-3			
Mefenamic acid		235114-32-6			
Mefenamic acid	1H-Indazole, 1-(2,4-dichlorophenyl)-2-[2,4-dichlorophenyl]methoxyethyl	22916-47-8		Formulation, modified-release, other	Infection, Candida, general
Mefenamic acid	1H-Purine-2,6-dione, 8-[(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl] [CAS]	52093-21-7			
Mefenamic acid		151159-23-8	US 5378844	Cardiovascular	Unspecified
Mefenamic acid	4H-Indazole[1,5-a][1,4]benzodiazepine, 8-chloro-4-[2-fluorophenyl]-1-methyl- [CAS]	59467-70-8 59467-94-6	US 4280957	Anaesthetic, injectable	Infection, general
Mefenamic acid	Leucamycin V, 3,4,5-dipropionate [CAS]	35457-80-8	US 3761588	Macrolide antibiotic	Infection, general
Mefenamic acid	Leucamycin V, 3,4,5-dipropionate [CAS]	55081-07-7	JP 49124087	Macrolide antibiotic	Infection, general
Mefenamic acid	2-Thiophenecarboxylic acid, 3-[(1-methyl-2-oxo-2-[(tricyclohexyl-2-oxo-3-phenyl)amino]ethyl) ester] [CAS]	94149-41-4	EP 120534	COPD treatment	Emphysema, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]- [CAS] Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-4-oxo-8,13-epoxy-1H,9H-dilindole[1,2,3-c]h3:2,1'-impyrolo[3,4-j]l1,7-thiazodiazole-11-yl)-N-methyl-, (8 $\alpha$ ,10 $\alpha$ ,11 $\beta$ ,13 $\alpha$ )- [CAS]	42318-56-0 42794-76-3	EP 164571	Urological	Incontinence
midostaurin	Extra-4,8-dien-3-one, 11-4-(dimethylamino)phenyl-17-hydroxy-17-(1-propenyl)-, (11 $\beta$ ,17 $\beta$ )- [CAS]	120685-11-2	EP 236110	Anticancer, other	Cancer, leukaemia, acute myelogenous
mifepristone	3,4,5-Piperidinol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, [2R-(2 $\alpha$ ,3 $\alpha$ ,4 $\alpha$ ,5 $\alpha$ )]- [CAS]	84371-65-3	EP 57115	Abortifacient	Abortion
mgilitol	3,4,5-Piperidinol, 1-benzyl-2-(hydroxymethyl)-, [2R-(2 $\alpha$ ,3 $\alpha$ ,4 $\alpha$ ,5 $\alpha$ )]- [CAS]	72432-03-2	EP 55431	Antidiabetic	Diabetes, Type I
mglustat	Hydrazinium, 2-(2-carboxyethyl)-1,1-trimethyl-, inner salt [CAS]	72599-27-0	DE 2758025	Metabolic and enzyme disorders	Gaucher's disease
mildronate	Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-[5]-[CAS]	76144-81-5	WO 8001068	Cardio stimulant	Heart failure
milnacipran	[3,4'-bipyridine]-5-carbonitrile, 1,5'-dihydro-2-methyl-6-oxo- [CAS]	101152-94-7 92623-65-3	US 4478836	Antidepressant	Depression, general
Miloxacin	Ethanaminium, 2-[[[heptadecyloxy]hydroxyphosphoryl]oxy]-N,N-trimethyl-, hydroxide, inner salt [CAS]	37065-29-5	US 4313951	Cardio stimulant	Heart failure
milrinone	4-Morpholinethylaniline, N-(4-methyl-6-phenyl-5-pyridazinyl)- [CAS]	78415-72-2	US 225608	Anticancer, other	Cancer, skin, general
milfosine		53049-20-5 58066-85-6	EP 225608	Antidepressant	Depression, general
minaprine		25905-77-5 25953-17-7	GB 1345580		

Table IV

[illegible]

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mitomycin	Azirino[2,3:3,4]pyrido[1,2-a]indole-4,7-dione, 6-amino-8-[[[amino-carbonyloxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aAlpha,8b,8aAlpha,8bAlpha)]-[CAS] 50-07-7			Formulation, parenteral, other	Cancer, stomach
<b>Mitomane</b>	8,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl]amino]-[CAS]	53-19-0			
mitoxantrone	8,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl]amino]-[CAS]	63271-80-9 70476-82-3	US 4197249	Anticancer, other	Cancer, breast
mitoxantrone	8,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl]amino]-[CAS]	63271-80-9 70476-82-3		Formulation, optimized, liposomes	Cancer, general
MV-210	(3'-Fluoro-2'-3'-dideoxy guanosine)			Antiviral, other	Infection, hepatitis-B virus
mlvacurum	Isosquinolinum, 2,2'-[[1,8-dioxo-4-octene-1,3-diyl]bis(oxy-3,1'-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, [R-[R'-[E]]]-[CAS]	106881-44-3	EP 181055	Muscle relaxant	Anaesthesia, adjunct
<b>Mivazerol</b>	2-[[1H]-Pyrrolidinone, 2-[1'-1'-(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinylmethylamino]-[CAS]	125472-02-8			
mizolastine	(R)-N-(3-quinolidinyl)-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide hydrochloride	108812-45-9	EP 217700	Antiallergic, non-asthma	Rhinitis, allergic, general
<b>Mizoribine</b>	(R)-N-(3-quinolidinyl)-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide hydrochloride	50924-49-7			
MKC-733	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S), [CAS]	194083-42-0	JP 08216888	Gastroprokinetic	Gastro-oesophageal reflux
MLN-519	4-Methoxy-benzoylphenazine-11-carboxylic acid (2-(dimethylamino)-1-(R)-methyl)ethylamide	211866-70-5	WO 9915183	Neuroprotective	Ischaemia, cerebral
MLN-576				Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
modobanide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	EP 326023	Antidepressant	Depression, general
modafinil	Acetamide, 2-[(diphenylmethyl)sulfinyl]- [CAS]	69693-11-8	DE 2809625	Psychostimulant	Narcolepsy
modafinil	3-Isosquinolinecarboxylic acid, 2-[2-[(1-(ethoxycarbonyl)-5-phenylpropyl)amino]-1-oxopropyl]-12,3,4-tetrahydro-6H-1,2,4-oxathiazine-6-yl]- [CAS]	103775-10-6 103775-14-0			
Modafarotene	Umalutux- (3S-[2(R,3R)]- [CAS]	125533-88-2 2210-63-1			
Modafegiline	5-Isooxazoisaric acid, 3,4-bis(4-methoxyphenyl)- [CAS]	119386-96-8 78967-07-4	EP 26928	Analgesic, NSAID	Pain, post-operative
MOL-8131	N-[4-(aminomethyl)benzyl]-4-(S)-1-[4-(2-(4-aminophenyl)-acetamidobutyl)piperidin-4-yl]-2-(naphthalen-1-ylmethyl)-1,3-dioxo-2,3,5,6-tetrahydro-1H-1,2,4-triazolo[1,2-a]pyridazine-5(R)-carboxamide			Antiasthma	Asthma
Molindone	Syringone imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)- [CAS]	7416-34-4 25717-80-0	US 3769283	Vasodilator, coronary	
monobenzone	Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11S,16A) [CAS]	105102-22-5 83919-23-7	EP 57401	Antipyretic/inflam., allergic	Psoriasis
Monatepil		103377-41-9 103-16-2			
Monobenzone	Dodecanoic acid, monoester with 1,2,3-propanetriol [CAS]	27215-38-9	US 4885282	Dermatological	Ichthyosis
monolaurin	Cyclopropanecarboxylic acid, 1-[1,1'-[3-[2-(7-Chloro-2-quinolinyl)ethyl]phenyl]-3-[2-(1-methoxy-1-methyl)phenyl]propyl]nitro]methyl-, [CAS]	151767-02-1 158966-92-8			
montelukast				Antiasthma	Asthma
Monteplase		122007-85-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mopronone		1050-79-9			
Mopdanol		13665-88-8			
Moprolol		5741-22-0			
Moracizine	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl], ethyl ester [CAS]	29560-58-5 31893-05-3	US 3864487	Antiarrhythmic	Tachycardia, ventricular
Morazone		66336-18-1			
Moricizine		31883-05-3			
Moroxidine		3731-59-7			
Morphazinanamide		952-54-5			
Morphine	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-nelbyl- (5 $\alpha$ ), 6 $\alpha$ ], [CAS]	57-27-2 6055-06-7 64-31-3		Formulation, parenteral, other	Pain, cancer
Morphine-5-glucuronide	morphine-5-glucuronide			Formulation, inhalable, systemic	Pain, general
Mosapramine	Spiro[indazole-1,2- $\alpha$ pyridine-3(2H),4'-piperidin]-2-one, 1-[3-(3-chloro-10,11-dihydro-8H-dibenz[b,f]azepin-5-yl)propyl]hexahydro-, (+)- [CAS]	89419-40-9 98043-80-8	US 4337260	Neuroleptic	
Mosapride	Benzamide, 4-amino-5-chloro-2-ethoxy-N-[(4-(4-fluorophenyl)methyl)-2-morpholinyl]methyl, [CAS]	112885-41-3 112885-42-4	EP 243959	GI inflammatory/bowel disorders	Gastritis
Moxalactam	Gadolinium, bis(acetate-kappaO)(9,10-diehy-20,21-bis(2-(2-methoxyethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16,18,13-dithio-1,18-benzodiazacyclotetrasine-5,14-dipropionate-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7, 11-23374) [CAS]	246292-06-2			
Moxetidine		56281-36-8		Radiochemical sensitizer	Cancer, brain
Moxetipril		85856-54-8			
Moxalactam		84952-97-2			
Moxastine		3572-74-6			
Moxaverine		10539-19-2			
Moxestrol		34816-55-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moxifloxacin	3-Quinolincarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3,4-b]pyridin-5-yl)-4-oxo-, hydrochloride (4S-cis) [CAS]	188826-86-8 151095-09-2	DE 19546249	Quinolone antibacterial	Infection, respiratory tract, general
moxisylyle	Phenol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylethyl), acetate (ester), [CAS]	954-52-3 54-32-0		Male sexual dysfunction	Impotence
moxonidine	5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazo[2,5-f]-6-methoxy-2-methyl-1-yl)-[CAS]	75438-57-2	DE 2849537	Antihypertensive, other	Hypertension, general
M-PGA	(1S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isindol-2-yl)pentanedioic acid		US 5712291	Anticancer, other	Cancer, general
MPI-5010	Platinum diamminedichloro-, (SP 4-2) + (R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-benzenediol		US 6224863	Formulation, parenteral, other	Cancer, head and neck
MPI-5020	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-, [CAS]	51-21-3	US 5750146	Formulation, parenteral, other	Cancer, breast
MPL		199076-81-2		Immunostimulant, other	Vaccine adjunct
MRS-1754			US 6050461	Aniasthma	Asthma
MS-209	1-Piperazineethanol, 4-(diphenylacetyl)-Alpha-[(5-quinolinyl)oxy(methyl)-, (2E)-2-butenediolate(2:3) (salt) [CAS]	159961-49-3		Radiochemosensitizer	Cancer, breast
MS-275	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxy)carbonyl]aminomethylbenzamide				
MS-325		201688-00-8		Anticancer, antimetabolite	Cancer, lung, general
MS-377			EP 839805	Neuroleptic	Schizophrenia
Mupirocin		12650-69-0			
Muscarnine		300-54-9			
Muzollimine		55294-15-0			
MX-1013			US 6153591	Hepatoprotective	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mycophenolate mofetil	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-5-methoxy-7-methyl-3-oxo-5-isobenzofuran-2-yl)-2-(4-morpholinyl)ethyl ester, (E)- [CAS]	116890-01-4 128794-94-5	WO 9119498	Immunosuppressant	Transplant rejection, general
	4-Hexanoic acid, 6-(1,3-dihydro-4-hydroxy-5-methoxy-7-methyl-3-oxo-5-isobenzofuran-2-yl)-4-methyl-,	37415-82-8 24290-98-1			
		487-18-5 3569-99-1		Formulation, oral, enteric-coated	Transplant rejection, general
Myrophine					
N <sup>+</sup>					
(Hydroxymethyl)nicotina					
N,N,N',N'		83-81-8			
Tetraethylphthalimide					
N-Formylsulfisomidine		795-13-1			
N <sup>+</sup> -β-o-					
Glucosylsulfanilamide		53274-53-6			
N <sup>+</sup>		547-52-4			
Sulfanilysulfanilamide					
Nabilone		51022-71-0			
nabumetone	2-Bulnonone, 4-(6-methoxy-2-naphthalenyl)- [CAS]	42924-53-8	GB 1476721	Anti-inflammatory	Arthritis, osteo
N-acetylcysteine	L-Cysteine, N-acetyl- [CAS]	616-91-1		Anticancer, other	Cancer, general
N-Acetylmethionine		65-82-7			
nadifloxacin	1H-5H-Benzotriquinoline-2-carboxylic acid, 6-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+)- [CAS]	124858-35-1	US 4399134	Quinolone antibacterial	Acute
nadrol	2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- [CAS]	42200-33-9	US 4346106	Antihypertensive, adrenergic	
Nadoxolol		54063-51-3			



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
napamostat	Benzoic acid, 4- [(aminomethylamino)-6- (aminomethylamino)-2-naphthalenyl ester- [CAS]	80251-32-7 81525-10-2 82956-11-4	EP 450232	GI Inflammatory/bowel disorders	Pancreatitis
naparelin	Luteinizing hormone-releasing factor (arg), 6-[3-(2-naphthalenyl)-D-alanine]-[CAS]	78932-56-4 86220-42-0	EP 21234	Releasing hormones	Endometriosis
<b>Nafcillin</b>		147-52-4			
<b>Nafnyl</b>		31329-57-4			
naftidrofuryl	2-Furanpropanoic acid, tetrahydro- $\alpha$ - (1-naphthalenylmethyl)-, 2- (diethylamino)ethyl ester	31329-57-4		Formulation, modified-release, other	Unspecified
naftifine	1-Naphthalenemethanamine, N-methyl-N- (3-phenyl-2-propenyl)-, (E)- [CAS]	65472-88-0 65473-14-5	US 4282251	Antifungal	Infection, dermatological
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)- $\alpha$ -(1-naphthalenylmethoxy)methyl-, [CAS]	57149-07-2	US 3997666	Antihypertensive, adrenergic	Hypertension, general
nalbuphine	Morphinan-3,6,14-triol, 17- (cyclobutylmethyl)-4,5-epoxy-, [5 $\alpha$ ,6 $\alpha$ ]-[CAS]	20594-63-6 23277-43-2	US 3393197	Analgesic, other	Pain, general
<b>Nalidixic Acid</b>		389-08-2			
nalmecone	Morphinan-3,14-diol, 17- (cyclopropylmethyl)-4,5-epoxy-6- methylene-, (6 $\alpha$ )-[CAS]	55096-26-9	JP 56167687	Dependence treatment	Poisoning, drug
<b>Nalorphine</b>		62-67-9			
naloxone	Morphinan-6-one, 17-allyl-4,5 $\alpha$ -epoxy- 3,14-dihydroxy-, hydrochloride [CAS]	357-08-4 465-85-6		Septic shock treatment	Addiction, narcotic/opiate
nalrexone	Morphinan-6-one, 17-(cyclopropylmethyl)- 4,5-epoxy-3,14-dihydroxy-, (5 $\alpha$ )-[CAS]	16590-41-3 16676-29-2	US 3332950	Dependence treatment	Addiction, narcotic/opiate
NAMI	Imidazolium trans(midazole)(dimethylsulfoxide)tetraethyl boronate (tli)			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nerminidil	Guanidine, N-oxo-N'-(4-cyanophenyl)-N'-[1-(1R)-1,2-trimethylpropyl]-[CAS]	220841-11-2			
<b>Nandrolone</b>		434-22-0		Dermatological	Alopecia, general
<b>Naphazoline</b>		835-31-4			
<b>Naphthalene</b>		91-20-3			
	Methanaminium, 1-carboxy-N, N, N-trimethyl- salt with (R)-6-methoxy-Alpha-methyl-2-naphthalenesulfonic acid (1:1), sodium salt [CAS]	104124-26-7	US 4672077	Antiarthritic, other	Arthritis, rheumatoid
naproxen betaineate	2-Naphthalenesulfonic acid, 6-methoxy-Alpha-methyl-, [CAS]	26159-34-2			
naproxen	2-Naphthalenesulfonic acid, 6-methoxy-Alpha-methyl-, [CAS]	22204-53-1	GB 1211134	Analgesic, NSAID	Pain, general
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	121679-13-8	EP 303507	Antimigraine	Migraine
<b>Narceline</b>		131-28-2			
<b>Narcobarbital</b>		125-55-3			
<b>Natanyslin</b>		7681-93-8			
	D-phenylalanine, N-[(4-(1-methyl-1-phenylpyridoxyl)carbonyl)-, trans-[CAS]	105616-04-4	EP 196222	Antidiabetic	Diabetes, Type II
<b>N-Buty/deoxynojirimycin</b>		72595-27-0			
<b>N-Butylscopolammonium Bromide</b>		149-64-4			
NC-503			US 5643562	Anti-inflammatory	Amyloidosis
NC-531			US 5643562	Cognition enhancer	Alzheimer's disease
NCX-1000			WO 0061604	Hepatoprotective	Cirrhosis, hepatic
NCX-4016	Benzoic acid, 2-(acetoxy)-, 2-(nitrooxymethylphenyl) ester [CAS]	175033-39-0	WO 9718405	Symptomatic antidiabetic	Insulin-related metabolic syndrome
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitrooxy)butyl ester [CAS]	255495-26-0		GI inflammatory/bowel disorders	Inflammatory bowel disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NCC-650	Alpha-[(1,1-dimethylethylamino)methyl]-4-hydroxy-1,3-benzanedimethanol nitrate	661-19-8		Antialsthia	Alsthia
	n-Docosanol				
NE-100	Benzenethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]	149409-57-4	WO 9307113	Neuroleptic	Schizophrenia
Nealbarbital	2H-1-Benzotripan-2-methanol, Alpha,Alpha-linirobis(methylene)bis[6-fluoro-3,4-dihydro], (2R)-(R'-(S''))(1'')-[CAS]	118457-14-0 99200-09-6	EP 145067	Antihypertensive, adrenergic	Hypertension, general
nebolvid	N-[4,4-Dimethyloxyethoxy]-L-isoglutamine	163000-63-3	EP 0568312	Cognition enhancer	Unspecified
Nebracetam	Platinum, diammine[dihydroxyacetato(2-)-O1,O2], (SP-4-3)- [CAS]	97205-34-0			
nedaplatin	4H-Pyran[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,8-dihydro-4,6-dioxo-10-propyl-, [CAS]	95734-82-0 69049-75-6 69049-74-7	EP 216362	Anticancer, alkylating	
nedacronil	3H-1,2,4-Triazol-3-one, 2-[5-4-(3-chlorophenyl)-1-piperazinyl]propyl-5-ethyl-2,4-dihydro-4-[2-phenoxyethyl]-, [CAS]	82782-99-6 83366-66-9	EP 555718	Antialsthia, Ophthalmological	Rhinitis, allergic, general, Ocular disorder, general
nefarazone	1-Pyrrolidinacetamide, N-[2,6-dimethylphenyl]-2-oxo-, [CAS]	77191-36-7			
nefracetam	1H2,5-Benzoxazine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl-, [CAS]	136697-049 23327-57-3	US 4341790	Antidepressant	Depression, general
nefopam	3-Isouquinolinecarboxamide, N-(1,1-dimethylethyl)dehydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-phenylthio)butyl-, (3S-2'(2S',3S'),3Alpha,4aa,8aa), [CAS]	33404-78-3	US 3487153	Cognition enhancer Analgesic, NSAID	Dementia, senile, general
Negamycin					
nefinavir					
Nemonapride					
neostigmine				Antiviral, anti-HIV	Infection, HIV/AIDS

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
napadulant	Cyclo(3-amino-L-alanyl-L-leucyl-N-[2-(isocetyl amino)-2-deoxy-6-D-glucopyranosyl]-L-asparaglyl-L-Alpha-aspartyl-L-tryptophyl-L-phenylalanyl), (4-1)-lactam [CAS]	183747-35-5 202807-80-5 219810-59-0	WO 9628467	Antiasthma	Asthma
neramexane	1,3,3,5,5-pentamethylcyclohexylamine			Dependence treatment	Addiction, alcohol
neridronic acid	Phosphonic acid, (R-amino-1-hydroxyhexylene)bis- [CAS]	79778-41-9 466-07-8 457-87-4		Musculoskeletal	Osteogenesis imperfecta
Nerifolin					
N-Ethylamphetamine	1H-Imidazole, 1-[2-(methylthio)-1-[2-(pentyloxy)phenyl]phenyl]-, monohydrochloride, (E)- [CAS]	130773-02-3 130728-68-0	EP 445540	Antifungal	Infection, Candida, general
netconazole	D-Striplamine, O-3-deoxy-4-C-methyl-3-(methylamino)-6-L-arabinopyranosyl-(1->)-O-2,6-diamino-2,3,4,6-tetra-O-(alpha-D-glucopyranosyl)-4-amino-2,3,4,6-tetra-O-(alpha-D-glucopyranosyl)-1-(1-4)-[2-deoxy-N1-ethyl- [CAS]	56391-55-1 56391-57-2			
netilmicin	8-Hydroxy-2,2,3,3-tetra-1,4-bisazepan-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- [CAS]		GB 1473733	Aminoglycoside antibiotic	Infection, general
nevirapine		129618-40-2			
NGD-98-2			EP 429987	Antiviral, anti-HIV	Infection, HIV/AIDS
Nialamide		51-12-7	WO 9635689	Anxiolytic	Anxiety, general
Niaprazine		27367-90-4			
Nicametate		3099-52-3			
nicaraven	3-Pyridinecarboxamide, N,N'-[1-methyl-1,2-ethanediyl]bis- [CAS]	79455-30-4	EP 29602	Neuroprotective	Hemorrhage, subarachnoid
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(6-nitrophenyl), methyl 2-[methyl(phenylmethylamino)ethyl ester] [CAS]	54527-84-3 55985-32-5			
nicardipine	Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8b), 5-bromo-3-pyridinecarboxylate(ester)		US 3985758	Neuroprotective	Hypertension, general
nicarogoline		27848-84-6		Formulation, modified-release, other	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nicafetil		5868053			
Niclosamide		50-85-7			
Nicoclonate		10571-59-2			
Nicofuranose		15351-13-0			
Nicomol		27959-26-8			
Nicomorphine		639-48-5			
nicorandil	3-(2-pyridinecarboxamido, N-(2-(nitrooxy)ethyl)- [CAS]	85141-46-0	US 4792564	Vasodilator, coronary	Hypertension, general
Nicotinamide		98-92-0			
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5		Formulation, inhalable, other	Addiction, nicotine
Nicotinic Acid		59-67-6			
Nicotinic Acid Benzyl Ester		94-44-0			
Nicotinyl Alcohol		100-55-0			
nifedipine	4-(2-(nitrophenyl)-2,6-dimethyl-3,5-dicarboxyethoxy)-1,4-dihydropyridine	21829-25-4	GB 1173862	Vasodilator, coronary	Hypertension, general
nifekalant	2,4-(1H,3H)-Pyrimidin-6-yl-[(2-hydroxyethyl)](3-(4-nitrophenyl)propylamino)ethylamino]-1,3-dimethyl-, [CAS]	130638-49-0 130656-51-5			
Nifenalol		7413-36-7	EP 369627	Antiarrhythmic	Arrhythmia, general
Nifedipine		4394-00-7			
Nifuratel		4936-47-4			
Nifurfoline		3363-58-4			
Nifuroxazide		965-52-6			
Nifuroxime		6236051			
Nifurpirinol		13411-16-0			
Nifurpirazine		1614-20-6			
Nifurtimox		23256-30-6			
Nifurtinolol		1088-92-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nifurtazide	2-Thiophenecarboxylic acid, 5-nitro-, [3-(5-nitro-2-uranyl)-2-propenylidene]hydrazide [CAS]	39978-42-2	US 3847911	Antidiarrhoeal	Infection, GI tract
NIP-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0		Formulation, other	Infection, general
<b>Nikethamide</b>					
niflutamide	2,4-Imidazolidinedione, 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-[CAS]	58-26-7			
niflutamide	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	63612-50-0	US 4472382	Anticancer, hormonal	Cancer, prostate
nifvadipine	Methanesulfonamide, N-(4-nitro-2-phenoxycarbonyl)- [CAS]	75530-68-6	US 4338322	Antihypertensive, other	Hypertension, general
nifmesulide		51803-78-2	US 3840597	Anti-inflammatory	Pain, general
<b>Nimetazepam</b>					
nimetazepam	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,5-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	2011-67-8			
nimodipine		66085-59-4	EP 533014	Neuroprotective	
<b>Nimorazole</b>					
nimorazole	Urea, N-[(4-amino-2-methyl-5-pyridinyl)methyl]-N-(2-thioethyl)-N-nitroso-[CAS]	6506-37-2			
nimustine		103745-00-2			
ninopterin		42471-28-3			
		55661-38-6	GB 1374344	Anticancer, alkylating	Cancer, brain
		2178-16-0			
NIP-142	N-[4(S)(Cyclopropylamino)-3(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-methoxybenzenesacetamide				
			WO 9804542	Antiarrhythmic	Fibrillation, atrial
NIP-531	N-[3,5-Bis(trifluoromethyl)phenyl]-N-(3-[N-(1-(4-fluorobenzyl)benzimidazol-2-yl)-aminopropyl]-N-methylurea) hydrochloride				
				Antipruritic/anti-inflammatory, allergic	Eczema, atopic
niprocetidine	N-[2-[[(5-dimethylamino)methyl]furfuryl]thioethyl]-2-nitro-N-piperonyl-1,1-ethenediamine	84845-75-0	GB 2104071	Antituber	Uter, GI, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nifedipine	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 3-nitrate [CAS]	81486-22-8 89247-96-1	EP 42239	Formulation, mucosal, topical	Glaucoma
Nitrazepam	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	61-57-4			
nifedipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	63875-72-9	GB 1516793	Antihypertensive, other	Hypertension, general
nifazepam	Benzanilide, 2-(carboxy)-N-(6-nitro-2-thiazolyl)- [CAS]	55981-09-4	US 5387598	Prozoacide	Infection, GI tract
nifedipine	1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- [CAS]	104205-65-7	EP 186118	Metabolic and enzyme disorders	Cirrhosis, hepatic
nifedipine	1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)- [CAS]	4833-39-5 6514-85-8	FR 1458183	Anticancer, other	Cancer, ovarian
Nitrazepam	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, ethyl methyl ester- [CAS]	146-22-5			
nifedipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, ethyl methyl ester- [CAS]	39562-70-4	GB 1389651	Antihypertensive, other	Hypertension, general
nifedipine	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitroxybutyl) ester [CAS]	158836-71-6	EP 670825	Urological	Incontinence
Nitrofurantoin		67-20-9			
Nitrofurazone		59-87-0			
Nitroglycerin		55-03-0			
Nitromersol	1,2,3-Propanetriol, trinitrate [CAS]	133-58-4		Formulation, transdermal, patch	Angina, general
Nitronalpropan	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl 4-(nitroxybutyl) ester (AlphaS) [CAS]	163133-43-5	WO 9509831	Analgesic, NSAID	Pain, post-operative
Nitroazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-[3-(dimethylamino)propyl]-2-nitro-, monohydrochloride [CAS]	15388-39-3	NL 6608671	Antidepressant	
Nitroxoline	—	4008-48-4			
nifedipine	1,1'-Ethenediamine, N-[2-[(dimethylamino)methyl]-4-thiazolyl]methylthioethyl-N-methyl-2-nitro- [CAS]	75963-41-2	EP 49618	Anticancer	Ulcer, duodenal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nizofenone	3-(2-methylcarboxymethyl)-5-methoxy-6-hydroxy-isocoumarin	54533-85-6			
NIM-3	4-Bromo-5-(3-pyridylmethylamino)-5-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone hydrochloride		JP 08176138	Anticancer, other	Cancer, general
NIM-702				Antithrombotic	Peripheral vascular disease
N-Methylephedrine		552-79-4			
N-Methylepinephrine		554-99-4			
N-Methylglucamine		6284-40-8			
NN-414	6-chloro-3-(1-methylcyclopropylamino)-4H-imidazo[3,2-b][1,2,4]thiadiazine-1,1-dioxide			Antidiabetic	Diabetes, Type II
NNC-05-1669	(R)-1-(3-(10,11-dihydro-8H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidine carboxylic acid			Symptomatic antidiabetic	Neuropathy, diabetic
Nogalanycin	4(1H)-Quinoxaline, 2-amino-6-methyl-5-(4-pyridinylthio)-, [CAS]	1404-15-5 16246-56-4 147148-76-6	WO 9320055	Anticancer, antimetabolite	Cancer, liver
notafaxed	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+)-[CAS]	138531-51-8	WO 9529147	Cardio stimulant	Heart failure
notonitrole	1-Azoniabicyclo[2.2.2]octane, 1-(2-[3-(3,4-dichlorophenyl)-1-[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl)ethyl-4-phenyl-, chloride, (S)-[CAS]	153050-21-6	EP 591040	GI inflammatory/bowel disorders	Inflammatory bowel disease
notplanitum	(S)-Norpregna-4,8-diene-3,20-dione, 11-(acetoxy)-6-methyl-, [CAS]	56652-20-3	DE 2422533	Menstruation disorders	Menstrual disorder, general
Notmensine		24526-64-5			
Noprysulfamide		576-97-6			
Norbolethone		1235-15-0			



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nordazepam		1088-11-5			
Nordefin		6539-57-7 (unspecified); 74812-53-8 (R*, S*) (±)- form			
Nordihydroguaiaretic Acid		27686-84-6 ( <i>meso</i> -form); 500-38-9 (unspecified)			
Norelgestromin, Ethinyl Estradiol					
Norepinephrine		51-41-2			
Norethandrolone		52-78-8			
Norethindrone		68-22-4			
Norethynodrel		68-23-5			
Norfenefrine		536-21-0			
norfloxacin	3-Quinolincarboxylic acid, 1-ethyl-6-fluoro- 1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	68077-27-0 70458-96-7	US 4146719	Quinolone antibacterial	Infection, general
Norgestrone		13563-60-5			
Norgestimate		35189-28-7			
Norgestrel		6533-00-2			
Norgestrienone		848-21-5			
Norevorphanol		1531-12-0			
Normethadone		467-85-6			
Normethandrone		514-61-4			
Normorphine		466-97-7			
Norphenazone		89-25-8			
Norpipanone		561-48-8			
Norpseudoephedrine		482-39-7			
Nortriptyline		72-69-5			
Norvinisterone		6795-60-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Noscapine		128-62-1			
Novembichin		1936-40-9			
Novobiocin		303-81-1			
Noxiptilin		3362-45-6			
Noxythiolin		15599-39-0			
NS-1209	Butanoic acid, 2-[[5-[4-((dimethylamino)sulfonyl)phenyl]-1,2,6,7,8,9-hexahydro-9-methyl-2-oxo-3H-pyrido[3,2-b]isoquinolin-3-ylidene]amino]oxy]-3-hydroxy, [CAS]	254751-28-5	WO 9426747	Antiepileptic	Epilepsy, general
NS-1231	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrido-[3,2-b]isopthalene-2,3-dione-3-oxine				
NS-128			US 5063222	Neuroprotective Antiallergic, non-asthma	Ischaemia, cerebral Rhinitis, allergic, general
NS-220	2-Methyl-5-(4-[5-methyl-2-(4-methylphenyl)-4-oxazoyl]butyl)-1,3-dioxane-1,2-carboxylic acid				
NS-2330	NS 2330 [CAS]	402656-42-2		Hypolipemic/Antiatherosclerosis Cognition enhancer	Atherosclerosis Alzheimer's disease
NSA inhibitors			US 6030785	Antiviral, other	Infection, hepatitis-C virus
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-5-[[5-(1-piperidinyl)pentyl]oxy]-monohydrochloride [CAS]	178429-07-9	WO 9607641	Neuroprotective	Ischaemia, cerebral
NS-8	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrole-3-carbonitrile			Urological	Incontinence
NSC-330507	17-Allylaminoergolideamycin			Anticancer, antibiotic	Cancer, general
NSC-619534	2-chloroethyl phenyl selenone 2,5-diazolidinyl-3-pyrimoxymethyl-6-methyl-1,4-benzoquinone			Anticancer, alkylating	Cancer, general
NSC-697726				Anticancer, antibiotic	Cancer, general
N-Sulfamyl-3,4-xylamide		120-34-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NV-0027	2,4-pyrimidinediamine, 6-(cyclohexylmethoxy)-5-nitroso- [CAS]	220036-08-8		Anticancer, other	Cancer, general
NV-07	2,3,8-tri(3,4,5-trimethyl-5-sec-pentyl-2-oxime) [CAS]	53745-16-7	US 6455032	Antigripurifilamin, non-allergic	Keratosis
NVP-SRA680	(3R,4aR,10aR)-1,2,3,4,5,10-hexahydro-6-methoxy-1-methyl-2-benzoguanidine-3-carboxylic acid-4-(4-methoxyphenyl)piperazine amide, hydrogen maleate			Neurological	Unspecified
NW-1029	(S)-(-)-2-[4-(2-fluorobenzoyloxy)benzylamino]propanamide methanesulfonate				
NXY-059	GPI 22 [CAS]	168021-79-2	US 5780510	Analgesic, other	Pain, general
Nylidrin		447-41-6		Neuroprotective	Ischaemia, cerebral
NZ-314	1-imidazolidineacetic acid, 3-[(5-methoxyphenyl)methyl]-2,4,5-trifluoro- [CAS]	128043-99-2	EP 353198	Symptomatic antidiabetic	Neuropathy, diabetic
NZ-419	5-hydroxy-1-methylimidazolidine-2,4-dione		EP 412940	Urological	Renal failure
Obidoxime Chloride		114-90-9			
OC-108	OC 108 [CAS]	162602-82-2		Vasoprotective, topical	Venous insufficiency
ocetipion	Mefenone, 2-pyridinyl[7-(4-pyridinyl)pyrazole[1,5- <i>a</i> ]pyrimidin-3-yl]- [CAS]	96604-21-6	EP 128847	Anxiolytic	Generalized anxiety disorder
Octabenzone		1843-05-6			
Octacaline		13912-77-1			
Octamoxin		4684-87-1			
Octavertine		549-68-8			
ocetidine		70775-75-6			
	1-Octanamine, N,N'-(1,10-decanediyl)-1,4-bis-(4-pyridinyl)-4-ylidenebis- [CAS]	71251-02-0			
Octodrine		86767-75-1	WO 8705501	Stomatological	Pericoronitis
Octodrine		543-82-8			
Octopamine		104-14-3			
Octofamine		137-86-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
potecotide	L-Cysteineamide, D-phenylalanine-L-lysine-L-phenylalanine-D-tyrosine-L-lysine-L-threonine-N-12-hydroxy-1-(hydroxymethyl)propyl-, cyclic (2-7)-disulfide, [(R,R')]: [CAS]	83150-76-9		Formulation, fixed-dose combinations	Cancer, general
Octyl		5466-77-3			
Methoxycinnamate					
	7H-Pyridol[2,3-dg], 1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+)- [CAS]	82419-36-1	EP 47005	Quinolone antibacterial	
o-Iodohippurate		133-17-5			
olanzapine	10H-Thien[2,3-b](1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- [CAS]	132539-06-1	EP 454436	Neuroleptic	Schizophrenia
Oleandrin		465-16-7			
Oleic Acid		112-80-1			
	1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(2-(1H-tetrazol-5-yl)(1,1-biphenyl)-4-ylmethyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144690-63-4	EP 503785	Antihypertensive, renal system	Hypertension, general
olmesartan medoxomil	11-[(2S,3S)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,f]oxepin-2-acetic acid, monohydrochloride	113806-06-6 140462-76-6			
olopatadine			EP 235796	Ophthalmological	Conjunctivitis
olpadronic acid	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	63132-39-8	WO 9619998	Osteoporosis treatment	Osteoporosis
olisalazine	Benzoic acid, 3,3'-azobis(6-hydroxy- [CAS]	15722-48-2	US 4559330	GI inflammatory/bowel disorders	Colitis, ulcerative
olipiraz	3H-1,2,3-Dithiole-3-thione, 4-methyl-5-pyrazinyl [CAS]	53200-51-4			
		64224-21-1	DE 2705641	Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OIM-294DP	2-[3-(R)-(Dodecanoxy)tetradecanamido]-N-[4-(3-(R)-hydroxytetradecanamido)-5-(phosphonoxy)phenyl]-4-(phosphonoxy)butylamide				Unspecified
Omacor	ethyl 16Z,8Z,11Z,14Z,17Z-icosapentaenoate + ethyl 14Z,7Z,10Z,13Z,16Z,18Z-icosapentaenoate	81926-94-5 86227-47-8		Anticancer, immunological	Unspecified
Omacor	7H-Pyrdo(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-(2-mercapto-1-oxo-3-phenylpropylamino)-5-oxo, (4S)-(4Alpha(R*),7Alpha,10alpha)- [CAS]	167305-00-2	US 5508272	Hypolipemic/Antithrombotic	Hypertriglyceridaemia
onapatriat	7H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]butyl- [CAS]	73590-58-6	US 4255431	Antitumor	Hypertension, general
onaprazole	Ethanone, 2-[(3E,4S)-3-(1,3-benzodioxo-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl-1-(4-fluorophenyl)-, rel- [CAS]	176894-09-0		Antidepressant	Ulcer, GI, general
oniloxetine	1H-Imidazole, 1-[2-[2-(4-chlorophenoxy)ethoxy]-2-(2,4-dichlorophenyl)-1-methylethyl]-, (Z)-[CAS]	74512-12-2	EP 8804	Antifungal	Depression, general
onocozazole	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- [CAS]	96346-61-1		Infection, dermatological	
Onapristone	Benzoic acid, 4-[(1E)-3-[(2-ethoxy-2-oxoethyl)-2-propenylamino]-2-methyl-3-oxo-1-propenyl]-, 4-(aminoinnomethyl)phenyl ester, monomethanesulfonate [CAS]	96614-01-4 96614-02-5	US 4847281	Antileukemic	Chemotherapy-induced nausea and vomiting
ondansetron					
ONO-3403		181586-07-2		GI inflammatory/bowel disorders	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ONO-4128	1,4,9-Triazapirrol[6,5]undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-5-yl)methyl)-[CAS]	342394-93-8		Antiviral, anti-HIV	Infection, HIV/AIDS
ONO-3915 Ly	L-lysine (2S,7R,3R,5R)-5-chloro-3-hydroxy-2-[(E)-(S)-4-(1-ethylcyclobutyl)-4-hydroxy-1-butyl]cyclohexyl-5-heptanoate				
ONT-0683			US 5756527	Labour inhibitor	Labour, preterm
OPC-14523	2-(1H)-Quinolone, 1-[3-(4-chlorophenyl)-1-piperazinyl]propyl-3,4-dihydro-5-methoxy- [CAS]	145969-30-8	EP 512525	Radiochemosensitizer	Cancer, general
OPC-31260	Benzamide, N-[4-[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl-2-methyl-	137975-06-5	WO 9105549	Antidepressant	Depression, general
OPC-51603	(6R)-2-[1-(2-chloro-4-(1-pyrrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide			Urological	Unspecified
OPC-6535	2-Pyridinecarboxylic acid, 5-[2-(3,4-dihydroxyphenyl)-4-thiazolyl]- [CAS]	145739-56-6	WO 9209586	Antidiabetic	Diabetes, insipidus
Opinlazide	2-[(4-trifluoromethylphenyl)-N-methyl-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide	2779-55-7		GI inflammatory/bowel disorders	Inflammatory bowel disease
opioid analgesics					
Opipramol		315-72-0		Analgesic, other	Pain, general
Orazamide		2574-78-9			
orazipone	2,4-Pentanedione, 3-[(4-methylsulfonyl)phenyl]methylene)- [CAS]	137109-76-5	EP 440324		
Ora-12952	Piparazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]	210821-93-9		Antisthma	Unspecified
Ora-24448				Antidepressant	Depression, general
			US 6166008	Neuroleptic	Schizophrenia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
orlistatin	Vanicamycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl- $\alpha$ -D-arabinopyranosyl)-11-(4-chloro-1,1-biphenyl-4-ylmethyl)-4-oxo-2-L-leucine, N-formyl, 1-[3-hexyl-4-oxo-2-oxoethyl]methyl dodecyl ester, [2S-[2 $\alpha$ ](R),3S], [CAS]	171009-57-3	US 5840884	Peptide antibiotic	Infection, dermatological
orlistat		98829-58-2	EP 129748	Anorectic/Antiobesity	Obesity
ormetoprost	Pyridoline, 1,42-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl, trans- [CAS]	31477-60-8	DE 2329201	Female contraceptive	Contraceptive, female
Ornidazole		16773-42-5			
Ornithine		3397-23-7			
		70-26-8			
ornoprostil	Prost-13-en-1-olc acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11 $\alpha$ ,13 $\alpha$ ,15 $\alpha$ ,17 $\beta$ )-, [CAS]	70687-28-4	US 4278688	Prostaglandin	Ulcer, gastric
Ortic Acid		65-86-1			
Orphenadrine		83-98-7			
Orthocaine		538-25-4			
Osamid		526-18-1			
osanelant	Acetamide, N-1-[3-[(3R)-1-benzoyl-3-(4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl-N-methyl-, [CAS]	160492-66-8	EP 673928	Neuroleptic	Schizophrenia
osaterone	2-Oxapregna-4,8-diene-3,20-dione, 17-(acetoxy)-6-chloro-, [CAS]	105149-00-6	EP 193871	Prostate disorders	Benign prostatic hyperplasia
oseltamivir	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-ethyl ester, (3R,5A(pha),4B,5A(pha))- [CAS]	196618-13-0	WO 9829933	Antiviral, other	Infection, influenza virus
OSI-7336	4'-Thio-3'-D-arabino furanosyl uracine			Anticancer, antimetabolite	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OSI-7904	Penicillanic acid, 2-[5-[(1,2-dihydro-3-methyl-1-oxobenzof[quinoxalin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isindol-2-yl]- (S)- [CAS]	139987-54-5	WO 9119700	Formulation, optimized, liposomes	Cancer, general
ospemifene	Ethanol, 2-[4-[(1,2,4-chloro-1,2-diphenyl-1-hutenyl)phenoxy]- [CAS]	128607-22-7	WO 9607402	Menopausal disorders	Osteoporosis
otilonium bromide	Etharaminium, N,N-diethyl-4-N-methyl-2-[4-[(2-oxo-2-phenylbenzoyl)amino]benzoyloxy]-, bromide [CAS]	26095-59-0			
Ouabain		630-60-4	GB 1181406	Antispasmodic	Irritable bowel syndrome
Oxaceprol		33996-33-7			
Oxacillin		66-79-3			
Oxaflozane		26629-87-8			
oxaliplatin	Platinum, (1,2-cyclohexanediamine-N,N')ethanedioato(2-)-O,O', [SP-4-2-(1R,trans)]- [CAS]	61825-94-3	EP 393575	Anticancer, alkylating	Cancer, colorectal
Oxalyt-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-87-5	DE 2249274	Urological	
Oxamarin		15301-80-1			
Oxametacine		27035-30-9			
Oxamniquine		21738-42-1			
oxandrolone	2-Oxandrostane-3-one, 17-hydroxy-17-methyl-, (5 $\alpha$ ), (17 $\beta$ ), [CAS]	53-39-4	US 3128263	Reproductive/gonadal, general	Sex-chromosome abnormality, Turner's syndrome
Oxantel		36531-26-7			
Oxapropamium		541-66-2			
oxaprozin	2'-Oxazopropanoic acid, 4,5-diphenyl-, [CAS]	21256-18-8	GB 1206403	Antiarthritic, other	Arthritis, osteo
oxatomide	21-Benzimidazol-2-one, 1-[5-[4-(diphenylmethyl)-1-phenazinyloxy]-1,3-dihydro-, [CAS]	60607-34-3	GB 1576365	Antiallergic, non-asthma	Rhinitis, allergic, general
oxazepam	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	604-75-1		Formulation, oral, orally-disintegrating	Anxiety, general



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
oxazolam	Oxazol[3,2-d][1,4]benzodiazepin-6(8H)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl- [CAS]	27167-30-2	US 3772371	Anxiolytic	
oxcarbazepine	5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- [CAS]	28727-07-5 29331-92-8	DE 2011087	Antiepileptic	Epilepsy, general
Oxeladin		468-61-1			
Oxendolone		33765-68-3			
Oxethazaine		126-27-2			
Oxetorone		26020-55-3			
oxiconazole	Etanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (Z)- [CAS]	64211-45-6	GB 1514870	Antifungal	Infection, fungal, general
Oxidronic Acid		15468-10-7			
Oxiniac Acid		2398-81-4			
Oxiracetam		82613-82-5			
oxitropium	3-Oxa-9-azoniatropyldio[3,3,1,02,4]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [(S)- (1Alpha,26,46,5Alpha,75)-] [CAS]	30286-75-0	GB 1178305	Antisthma	
Oxolamine		959-14-8			
Oxolinic Acid		14098-29-4			
Oxophenarsine		538-03-4			
Oxprenolol		6452-71-7			
Oxybenzone		131-57-7			
oxybutylin	Benzoicacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butyl ester- [CAS]	5635-20-5		Formulation, modified-release, other	Incontinence
Oxycinchophen		485-89-2			
oxycardone	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5Alpha)-	75-42-6		Formulation, transmucosal, nasal	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Oxyfedrine		15687-41-9			
Oxygent	Octane, 1-bromo-1,1,2,2,3,4,4,5,5,6,6,7,7,8,8,8-heptafluoro- [CAS]	423-55-2		Hematological	Surgery adjunct
Oxymesterone		145-12-0			
Oxymetazoline		1491-59-4			
oxymetholone	Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 $\alpha$ ), (17 $\beta$ )- [CAS]	434-07-1		Hormone	Anaemia, general
Oxymethurea	(5 $\alpha$ ), 4,2-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	140-95-4			
oxymorphone		76-41-5		Formulation, modified release, immediate	Pain, general
Oxypendyl		5586-93-3			
Oxypertine		153-87-7			
Oxyphenbutazone		129-20-4			
Oxyphencyclimine		125-53-1			
Oxyphenisatin		115-33-3			
Oxyphenonium		50-10-2			
Oxypinocamphone		10136-65-9			
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6,7,8-tetrone [CAS]	2465-56-0		Antigout	Hyperuricaemia
Oxytetracycline		79-57-2			
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazol-1-yl)methyl]phenyl-, (E)- [CAS]	78712-43-3 82571-53-7	GB 2025946	Antithrombotic	Vasospasm, cerebral
P- (Benzylsulfonamido)benzoic Acid P-100		536-95-8			
P-1202	Pentanoic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]	79416-27-6	US 6313177	Antiviral, anti-HIV	Infection, HIV/AIDS
P32/68	D-[3N]-(2S,3S)-2-amino-3-methyl-pentanoyl-1,3-thiazolidine) fumarate		US 6034267	Dermatological	Keratosis
PA-824				Antidiabetic	Diabetes, Type II
			WO 9701562	Antimycobacterial	Infection, tuberculosis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PACAP 38	Pituitary adenylate cyclase-activating peptide-38 [CAS]	128606-20-2	US 5128242	Neuroprotective	Nerve injury, general
pacifloxacin	5(5,20-Epoxy-1,2-Alpha,4,7b,10b,13-Alpha-hexahydroxytax-11-en-9-one-4,10-diacetate-2-benzotriazole-13-(Alpha-phenyl)pyrrolidine)	33069-62-4		Formulation, optimized, nanoparticles	Cancer, breast
PAORE	1H-Isindol-1-one, 2-(7-chloro-1-β-naphthylidene-2-yl)-2,3-dihydro-3-(5-methyl-2-oxoethyl)- [R]- [CAS]		US 6413835	Immunostimulant, other	Vaccine adjuvant
pegadrolone		135737-32-3	US 4980779	Anxiolytic	Panic disorder
PAI Inhibits			WO 9404512	Antithrombotic	Thrombosis, venous
palidore	8H-1,4-dioxano[2,3-e]indol-8-one, 2,3,7,9-tetrahydro-2-[(phenylmethyl)(aminomethyl)-2(S)-, (2E)-2-butanediolate (1:1)]				
palivizumab		189681-71-8		Neuroleptic	Schizophrenia
	3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride	188039-54-5			
palonosetron		135729-62-3	US 5202333	Antiemetic	Chemotherapy-induced nausea and vomiting
Pamabrom		806-04-2			
Pamaquinone		491-92-9			
pamidronate	1H-Pyrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl], ethyl ester [CAS]	101001-34-7	EP 159677	Antithrombotic	Thrombosis, cerebral
	(S)-Amino-1-hydroxypropylidene(diphosphonic acid- [CAS]	40391-99-9		Formulation, Implant	Hypercalcaemia of malignancy
p-Aminobenzoic Acid		150-13-0			
p-Aminothiopyruvic Acid		61-78-9			
p-Aminopropiophenone		70-69-9			
p-Aminosalicylic Acid		85-49-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Paracetamol	4-(4-isopropylphenyl)phenol			Neuroprotective	Vasospasm, cerebral
Pancuronium		15500-66-0			
Panipenem		87726-17-8			
Pantetheine		10816-67-4			
pentoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2-[[3,4-dimethoxy-2-pyridinyl)methyl]sulfonyl] [CAS]	102826-70-7	EP 166287	Antituberc	Ulcer, duodenal
Pantothenic Acid		79-83-4			
Papaverine		58-74-2			
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2		Formulation, oral, other, modified-release	Pain, general
Parafutizide		1580-83-2			
Paraldehyde		123-63-7			
Paramethadione		115-67-3			
Paramethasone		53-33-8			
Paranyline		1729-61-9			
Parathyroid Hormone		9002-64-6			
parecoxib	Propanamide, N-[(4-{5-methyl-3-phenyl-4-oxoxazolyl}phenyl)sulfonyl]-, sodium salt [CAS]	198470-85-8	WO 9738986	Analgesic, NSAID	Pain, post-operative
Parthoxycaine		94-23-5			
Pargyline	(3-Nor-9,10-secobergsten-5,7,22-triene-1,3,25-triol, (1Alpha,3beta,22E)- [CAS]	555-57-7			
paricalcitol		131918-61-1	EP 387077	Hormone	Hyperparathyroidism
paromomycin	O-2-Amino-2-deoxy-Alpha D-glucopyranosyl-(1-4)-O-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1-3)-8-D-ribofuranosyl-(1-5)]-2-deoxy-D-streptamine	7542-37-2		Protozoacide	Infection, leishmaniasis
paroxetine	Pipridine, 3-[(1,3-benzodioxol-5-yl)oxy]methyl)-4-(4-fluorophenyl)-, (S-trans) [CAS]	61869-08-7	EP 223403	Antidepressant, formulation, oral, orally-disintegrating	Depression, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
<b>Paroxypropione</b>		70-70-2			
<b>Parsalmide</b>		30653-83-9			
	4-Bromothiopyran			Radiochemosensitizer	Cancer, melanoma
<b>Pazinacalone</b>		103255-86-9			
	7H-Pyrido[1,2,3-de]1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)- [CAS]	127045-41-4 127046-45-1 138905-87-8	DE 3913245	Quinolone antibacterial	Infection, general
<b>p-Bromoacetanilide</b>		103-88-8			
<b>PC-NSAIDS</b>			US 4818053	Formulation, other	Arthritis, general
	5-(2,6-Dichlorophenyl)-2-[[4-(diethylaminoethoxy)phenylamino]-3-pyridyl]-3-pyrimidine-7-one			Anticancer, other	Cancer, general
<b>PD-0166285</b>		19504-77-9			
<b>Peciloclin</b>					
	3-Quinolonecarboxylic acid, 1-ethyl-3-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	70459-92-3	GB 1598915	Quinolone antibacterial	Infection, urinary tract
	Somatostatin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 188-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine (human), pegylated [CAS]	218620-50-9		Somatostatin	Acromegaly
<b>Pegvisomant</b>		4396-1-4			
<b>Pellastierine</b>					
	L-Gluamic acid, N-[4-(2-amino-4,7-dihydro-4-oxo-1H-pyrido[2,3-d]pyrimidin-5-yl)ethyl]benzoyl- disodium salt [CAS]	137281-23-3 150389-23-8	US 5248775	Anticancer, antimetabolite	Cancer, mesothelioma
<b>penicillins</b>					
	4-[[Pyrrolidin-2-yl]pyrimidin-4-onyl]-5-methyl-3-(1H-tetrazol-5-yl)- [CAS]	100299-08-9 68372-19-6	US 4457932	Antisthma	Asthma
<b>Penmoline</b>		2152-34-3			
<b>Pempidine</b>		79-55-0			
<b>PEN-203</b>			US 5955446	Antiviral, other	Infection, human papilloma virus
<b>Penamcillin</b>		983-85-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
penbutolol	2-Propanol, 1-(2-cyclopropylphenoxy)-3-[(1,1-dimethylamino)-(S), sulfate (2:1) (salt) [CAS]	38363-32-5 38363-40-5	GB 1215751	Anti-hypertensive, adrenergic	
penicidovir	6H-Purine-8-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1	JP 60058982	Antiviral, other	Infection, herpes simplex virus
Penethamate	4-Piperidinol, 1-[4,2-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]- [CAS]	808-71-9			
penitridol					
Penicillamine		26864-56-2	DE 2040231	Neuroleptic	
Penicillin G		52-67-5			
Penicillin G Benzathine		61-33-6 1538-09-6			
Penicillin G Procaine		6130-64-9			
Penicillin N		525-94-0			
Penicillin O		87-09-2			
Penicillin V		87-08-1			
Penimepicycline		4599-60-4			
Penituss			US 4221778	Formulation, modified-release, other	Rhinitis, allergic, general
Pentaerythritol Chloral		78-12-6			
Pentaerythritol		2209-86-1			
Dichlorohydrin					
Pentaerythritol		597-71-7			
Pentagastin		5534-95-2			
Pentagestone		7001-56-1			
Penalylie	Starch, 2-hydroxyethyl ether [CAS]	9055-27-9	US 5407428	Plasma substitute	Surgery adjunct
Pentamethonium		541-20-8			
penitamide	Benzeneacetic acid, 4-(1,5-pentanediyloxy)bis- [CAS]	100-33-4			
Pentazocine		359-83-1		Formulation, inhalable, systemic	Infection, Pneumocystis jirovecii prophylaxis
Pentetate		12111-24-9			
Pentetic Acid		67-43-6			
Pentetreotide		138661-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Penthienate		60-44-6			
Pentifylline		1028-33-7			
Pentigetide		52087-72-3			
Pentisomide		78833-03-1			
Pentobarbital		76-74-4			
Pentolinum		52-62-0			
Pentorex		434-43-5			
pentosan	Xylan, [CAS]	37319-17-8	US	Urological	Inflammation, urinary tract
penicillin	imidazo[4,5-b][1,3]diazepin-6-ol, 3-(2-deoxy-3-O-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-26-1	US	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
pentoxifylline	11-[[Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(6-oxohexyl)-] [CAS]			Neuroprotective	Amorphous lateral sclerosis
Pentoxyl		147-61-5			
Pentritinol		1607-17-6			
Pentylentetrazole		54-95-5			
peplomycin	Bleomycinamide, N1-[3-(1-phenylethyl)aminopropyl]-, (S)- [CAS]	68247-65-8	US	Anticancer, antibiotic	
Perazine		84-97-9			
Perflubron		423-55-2			
Perfosamide		62435-42-1; 39800-16-3			
pergolide	Ergoline, 8-[(methylthio)methyl-3-oxopropyl- (8S)-, monomethanesulfonate- [CAS]	(unspecified) 59107-22-1			
Pertexiline		6621-47-2	US	Antiparkinsonian	Parkinson's disease
Perticazine		2622-26-6			
perflorine	P-perdinium, 4-[(hydroxy(octadecyloxy)phosphoryl)oxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	EP	Anticancer, other	Cancer, prostate
perillyl alcohol	1-Cyclohexene-1-methanol, 4-(1-methylethyl)- [CAS]	536-59-4	US	Anticancer, other	Cancer, breast
Permethazine		13093-88-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[(1-ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, [2S-[1'[(R'),2'Alpha,3a,7a]], compd. with 2-methyl-2-propanamine (1:1) [CAS]	107133-36-8 82834-19-0 95153-31-4	EP 46958	Antihypertensive, renin system	Hypertension, general
Perindyl	1-Piperidineethanol, Alpha-(6-phenyl-3-isoazoyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	53586-99-5 2139-25-5 2055-44-9			
perisoxal		1977-11-3	JP 04217925	Anti-inflammatory	
Perlapine		52645-53-1			
Pernethrin					
perospirone	1H-Isindole-1,3(2H)-dione, 2-[4-[4-(1,2-benzotriazol-2-yl)-1-piperazinyl]butyl]hexahydro-, cis- [CAS]	129273-38-7 150915-41-6	CA 2167004	Neuroleptic	Schizophrenia
Perphenazine		58-39-9			
Petroleum Benzin		8030-30-6	US 6331266	Antipsoriasis	Psoriasis
PH-10					
Phanquinone		84-12-8	WO 9639482	Immunological	Unspecified
Pharmaprojects No. 4994			WO 9703866	Neuroleptic	Schizophrenia
Pharmaprojects No. 5326			WO 0204426	Antiallergia	Asthma
Pharmaprojects No. 5972			US 6057346	Antiviral, anti-HIV	Infection, HIV/AIDS
Pharmaprojects No. 6362	(R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide				
Pharmaprojects No. 6446				Anorectic/Antiobesity	Obesity
Pharmaprojects No. 6560			WO 0205223	Psychostimulant	Attention deficit disorder
Pharmaprojects No. 6566			US 6465026	Genomics-based drug discovery	Cancer, brain
Pharmaprojects No. 6591			US 6239900	Formulation, other	Pain, general
Pharmaprojects No. 6743	3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]acrylamide			Antibacterial, other	Infection, general



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pharmaprojects No. 6748	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methylbenzo[c]pyrazine[1,2-a]azepin				
Phenacaine		620-98-5			
Phenacetimide		63-98-9			
Phenacetin		62-44-2			
Phenadoxone		467-84-5			
Phenallymal		115-43-5			
Phenamet		3819-34-9			
Phenazocine		127-35-5			
Phenazopyridine		136-40-3			
Phenbutamide		3149-00-6			
Phencyclidine		77-10-1			
Phendimetrazine		634-03-7			
Phenelzine		51-71-8			
Phenesterine		3546-10-9			
Phenetharbital		357-67-5			
Phenethiclin		132-93-4			
Phenetidine		90-49-3			
Phenformin		114-86-3			
Phenglutarimide		1156-05-4			
Phenindamine		82-88-2			
Phenindione		83-12-5			
Pheniprazine		55-52-7			
Pheniramine		86-21-5			
Phenmetrazine		134-49-6			
Phenobarbital		50-06-6			
Phenobutidil		554-24-5			
Phenocoll		103-97-9			
Phenocitide		78-05-7			
Phenolphthalein		77-09-8			
Phenolphthaleol		81-92-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenolsulfonphthalein		143-74-8			
Phenoltetrachlorophthal		639-44-1			
Phenoperidine		562-26-5			
Phenosulfazole		515-54-8			
Phenoxibenzamine		59-96-1			
Phenoxypipazine		3818-37-9			
Phenprobamate		673-31-4			
Phenprocoumon		435-97-2			
phenserine	Pyrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), (3aS-6S)- [CAS]	101246-66-6			
Phensuximide		86-34-0			
Phentermine		122-09-8		Cognition enhancer	Alzheimer's disease
Phentolothalein		18265-54-8			
phenibutamine	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenylamino)-monomethanesulfonate (salt) [CAS]	65-28-1 50-60-2			
Phenyl Acetyl/salicylate		134-55-4		Formulation, oral, other	Impotence
Phenyl Aminosalicylate		133-11-9			
Phenyl Salicylate		118-55-8			
Phenylbutazone		50-33-9			
Phenylephrine		61-76-7			
Phenylethanamine		7568-93-6			
Phenylmercury		102-98-7			
Phenylmethylbarbituric Acid		76-94-8			
phenylpropandamine	Benzoylethanol, Alpha-(1-aminosulfinyl)-, (R*,S*,Y+)- [CAS]	14838-15-4		Allorectic/anticoagulant, formulation, optimized, microparticles	
Phenylpropylmethylamine		93-88-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenylethanolamine		92-12-6			
Phenylamidol		553-69-5			
phenylolol	2,4-Imidazolidinedione, 5,5-diphenyl- [CAS]	57-41-0		Formulation, oral, other	Epilepsy, general
Phenethylate		510-34-9			
Phloroglucinol		108-73-6			
Pholcodine		509-67-1			
Pholedrine		370-14-9			
Phosphocreatine		67-07-2			
Phosphorylcholine		5746-40-7			
Phosphorylcholine		107-73-3			
Phthalylsulfacetamide		131-69-1			
Phthalylsulfathiazole		85-73-4			
p-Hydroxyephedrine		365-26-4			
Phylloquinone		84-80-0			
Physostigmine		57-47-6			
Phytic Acid		83-86-3			
	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)-hydrogen sulphate [CAS]	165077-23-0		Anticancer, other	Cancer, melanoma
PI-88		39640-15-8			
Piberaline		152811-62-9	WO 9318036	Antianxietytic	Fibrillation, atrial
piboserod	2H-(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-(1-butyl-4-piperidinylmethyl)-3,4-dihydro- [CAS]	62510-56-9			
Piclotrex		56386-92-0			
Picloxydine		21755-66-8			
Picoperine		10040-45-6			
Picosulfate		32828-81-2			
Picotamide		39677-19-0			
Picumast					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pidotirod	4-(1H-imidazo[5,1-b]pyridin-2-yl)-2-methyl-5-oxo-2-pyrrolidinylacetic acid, 3-[(6-oxo-2-pyrrolidinyl)phenyl]-[CAS]	121608-62-6	EP 276752	Immunomodulator, anti-infective	Infection, respiratory tract, lower
Pifarnone	Benzeneacetaldehyde, 3-benzoyl- $\alpha$ -methyl-N-(4-methyl-2-pyridinyl)-[CAS]	56208-01-6			
piketopifen		60576-13-8	GB 1436502	Anti-inflammatory, topical	
Pidralazine	2-(3H)-Furanone, 3-ethylidihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)-[CAS]	64000-73-3			
picloparine	2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenoic acid, compd. with (3S-cis)-3-ethylidihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone [CAS]	92-13-7		Formulation, implant, Stomatological	
Ploplex	7H-Pyrazolo[7,6-f]acetaldehyde, N-(2,6-dimethylphenyl)ethylaceto-, monohydrochloride [CAS]	62783-28-2	DE 2836559	Formulation, mucosal, topical	Glaucoma
plisicalinide		89069-49-2			
		89069-87-4			
Pinedolone	15,19-Epoxy-3H-pyrido[2,1-b](1,4)oxazacyclotriene, 1,7,20,21(4H,23H)-terone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethyl)-8-ethyl-, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S,4S*,5R*,6S*,9E*,12R*,14R*,5S*,16R*,18S*,19S*,26aR*) [CAS]	534-84-9	US 4554624	Antiarrhythmic	Arrhythmia, general
pinrecolimus		137071-32-0	EP 626385	Antipruritic/inflamm, allergic	Eczema, atopic
Pimefylline	Acetic acid, [2-(octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonyl)-2-pentalenyl)ethoxy]-, methyl ester, [2R-[2 $\alpha$ ,3 $\alpha$ ,3 $\alpha$ ,4 $\alpha$ ]-1E,3S*,5S*,5S*,6 $\alpha$ ]-[CAS]	10001-43-1			
piniliprost		139403-31-9		Dermatological	Ulcer, general
Piminodine		13495-09-5			
Pimobendan		74150-27-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pinoclide	2H-Benzimidazo-2-one, 1-[1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl]-1,3-dihydro- [CAS]	2062-78-4	FR M3695	Neuroleptic	
Pinacidil		85371-64-8			
pinaverium	Morpholinum, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl-, [CAS]	53251-94-8 59995-55-2	EP 406743	Antispasmodic	Irritable bowel syndrome
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propenyl)-[CAS]	52453-83-9	DE 2339790	Anxiolytic	
Pindolol		13523-86-9			
piloglaxone	2,2'-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]-, monohydrochloride (+/-) [CAS]	111025-46-8 112529-15-4	EP 193256	Antidiabetic	Diabetes, Type II
Pipacryline		1110-80-1			
Pipamazine		84-04-8			
Pipamperone		1893-33-0			
Pipazethate		2167-85-3			
Pipbuzone		27315-91-9			
Pipcurium		52212-02-9			
pibecuronium	Piparazinium, 4,4'-[[2,3,3Alpha,5Alpha,16b,17b]-3,17-bis(acetyloxy)androstane-2,16-diy]bis[1,1'-dimethyl-, [CAS]	52212-02-9 66399-57-5	GB 1398050	Muscle relaxant	Anaesthesia, adjunct
pipemidic acid	Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 6-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)- [CAS]	51940-44-4	GB 1451911	Antibacterial, other	Infection, urinary tract
Pipenzolate Bromide		125-51-9			
Piperacetazine		3819-00-9			
piperacillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(4-ethyl-2,3-doxo-1-piperazinyl)carbonyl]amino]phenyl]acetyl]amino-3,3-dimethyl-7-oxo-[2S-[2alpha,5Alpha,6b(5'S)]]- [CAS]	59703-94-3 6477-96-1	GB 1508052	Penicillin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Piprazine Adipate		142-88-1			
Piperidine		77-03-2			
Piperidolate		82-98-4			
Piperilate		4546-39-8			
piperine analogues			WO 002544	Dermatological	Vitiligo
Piperocaine		136-82-3			
Piperonal		120-57-0			
Piperoxan		59-39-2			
Piperylone		25 31-4-6			
Pipobroman		54-91-1			
Piposulfan		2808-24-4			
pibolazine	Hexadecanoic acid, 2-[1-[3-[2-[(dimethylamino)sulfonyl]-10H-phenothiazin-10-yl]propyl]-4-piperidinyl]ethyl ester [CAS]	37517-26-3 39890-99-6	US 4782077	Neuroleptic	
Pipoxolan		18174-58-8			
Pipracrol		467-60-7			
pibrozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylene], ethyl ester [CAS]	17243-64-0	US 3971794	GI inflammatory/bowel disorders	Motility dysfunction, GI, general
Piracetam		7491-74-9			
	5,12-Naphthacenedione, 10-[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-xylo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8alpha,10alpha(S)]]-[CAS]	72499-41-4			
pibarobin			US 4303785	Anticancer, antibiotic	Cancer, breast
Pirazolac		71002-09-0			
	2,6-Pyridinedimethanol, Alpha-[[[1,1-dimethyl(ethylamino)methyl]-3-hydroxy-monoacetate (salt) [CAS]	38029-10-6 38677-81-5 65652-44-0	US 3786160	Antiasthma	Asthma
Pirenexine		1043-21-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
prenzepine	8H-Pyrido[2,3-b][1,4-benzodiazepin-6-one, 5,11-dihydro-11-(4-methyl-1-piperazinyl)acetyl-] [CAS]	28797-61-7 29868-97-1	FR 1505795	Antitumor	
piretanide	Benzoic acid, 3-(aminosulfonyl)-4-phenoxyl-5-(1-pyrrolidinyl)- [CAS]	55837-27-9	US 4010273	Antihypertensive, diuretic	Hypertension, general
pirfenidone	2(1H)-Pyridinone, 5-methyl-1-phenyl- [CAS]	53179-13-8		Respiratory	Fibrosis, pulmonary
piribedil	Pyrimidine, 2,4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl [CAS]	3695-01-4	US 3299067	Vasodilator, peripheral	Parkinson's disease
Piridocaine		87-21-8			
Pirifibrate		55285-45-5			
Piritramide		302-41-0			
Piritrexim		72732-56-0			
pirindole	1H-Pyrazine[3,2,1-j]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU 276060	Antidepressant	Depression, general
pirimicol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-, Alpha phenyl-, ds-(+)) [CAS]	61477-94-9 86252-19-7	US 4112103	Antianthelmic	Tachycardia, supraventricular
Proctone		50650-76-5			
Proheptine		16378-21-5			
Promidic Acid		19562-30-2			
proxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4	US 3862319	Anti-inflammatory	
proxicam betadex	6-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide- [CAS]	121696-62-6 96684-59-8	EP 153998	Formulation, other	Pain, musculoskeletal
proxicam cinnamate	2-Frotenole acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	EP 79639	Antiarthritic, other	Inflammation, general
Prozadil		54110-25-7			
Profufen		31793-07-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
plivasatin	6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), [S-(R*,S*-(E))]- [CAS]	147526-32-7	EP 304063	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general
pivagabine	N-Triethylacetyl-4-aminobutyric acid	69542-93-4		Neurological	Anxiety, general
pivaloxyloxymethyl	Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester [CAS]	122110-53-6	EP 302349	Anticancer, other	Cancer, lung, non-small cell
<b>Pivalylbenzhydrazine</b>		306-19-4			
<b>Pivampicillin</b>		33817-20-8			
pivampicillin/pivmecillinam		98445-47-7		Penicillin, oral	Infection, general
<b>Pivcefalexin</b>		63836-75-9			
pivmedilnam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-(2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha,5Alpha,6S)]- [CAS]	32886-97-8	GB 1293590	Penicillin, oral	Infection, general
pivaxtrone	Benzo[6]isouquinoline-5,10-dione, 6,9-bis[(2-aminooethyl)amino]-, (2Z)-2-butenedioate(1:2) [CAS]	144675-97-8	EP 503537	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
pladifen	4-(8,10-dihydro-4H-benzo[4,9]oxocorupa[1,2-b]phen-4-ylidene)-1-methylpiperidine	15574-86-6	DE 2346747	Antinigraine	
<b>Pizotyline</b>		15574-96-6			
PKI-166	Phenol, 4-4-((1R)-1-phenylethylamino)-1H-pyrrolo[2,3-d]pyrindin-6-yl)- [CAS]	187724-61-4		Anticancer, other	Cancer, general
<b>p-Lactophenitide</b>		539-08-2			
<b>Platibride</b>		63394-06-8			
plasminogen activator	Plasminogen activator [CAS]	105913-11-9	EP 151966	Fibrinolytic	Infarction, myocardial
<b>Plasmocid</b>		551-01-9			
<b>Platonin</b>		3571-88-8			
<b>Plaunotol</b>		64218-02-6			
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS]	198022-66-0	EP 805145	Antifungal	Infection, Candida, general



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PLD-147	(OC-4-3)-Bis(acetoxy)(1-adamantanylethyl)amine-dichloroplatinum (IV)				Cancer, general
plecanril	1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolylpropoxy)phenyl)-5-(trifluoromethyl)- [CAS]	153168-05-9		Anticancer, alkylating	
Plicamycin		18378-89-7	US 5464848	Antiviral, other	Infection, respiratory tract, general
p-Methylclphenhydramine		19804-27-4			
PMS-801			WO 0001677	Antiviral, anti-HIV	Infection, HIV/AIDS
Pneumococcal Vaccine, Diphtheria Conjugate					
Pneumococcal Vaccine, Polyvalent					
PNU-288034	N-[(5S)-3-[4-(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methylacetamide]				
Podophyllotoxin		518-28-5		Antibiotic, other	Infection, general
polaparenc	Zinc, bis[N-(4-allyl-L-histidinato-N3,Oalpha), (T-4)- [CAS]	107587-60-7	EP 303380	Antitumor	Ulcer, duodenal
Poldine Methylsulfate		545-80-2			
Policresulen		9011-2-3			
Polidexido		9064-92-0			
polidocanol	Polyethylene glycol monododecyl ether	3055-98-0 9002-92-0		Vasoprotective, systemic	Venous insufficiency
Poliovirus Vaccine Inactivated					

Table IV

API Generic Name poly-ADPRT inhibitors	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Polyestradiol Phosphate		28014-46-2	WO 9846263	Anticancer, other	Cancer, general
Polyphenon E	Polyphenon E [CAS]	188265-33-0			Infection, human papilloma virus
Polythiazide		346-18-9		Antiviral, other	
porfimer	Phthalin [CAS]	87008-31-3	US 4882234	Anticancer, other	Cancer, lung, non-small cell
Porfirimycin		801-52-5			
posaconazole	D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-(4-(4-(1H-1,2,3)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl) [CAS]	171228-49-2	US 5714490	Antifungal	Infection, fungal, general
Posatrelin		78664-73-0			
potassium chlorides	Potassium chloride (KCl) [CAS]	7447-40-7		Formulation, oral, enteric-coated	
Potassium Gluconate		298-27-4			
Potassium		1321-14-8			
Guaiacolsulfonate		138-84-1			
Potassium p-Aminobenzoate		7722-64-7			
Potassium		9003-39-8			
Permanganate		25655-41-8			
Povidone		62756-44-9		Formulation, oral, other	Unspecified
Povidone-Iodine			DE 2633028		
PP-117	3-Pyridinemethanol, hydrochloride [CAS]			Antifungal	Infection, fungal, general
PP-2699	(-)(E)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-yliden-1-imidazolidinonitrile				

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PR-608	(S)-(-)-1,4-bis(4-fluorophenyl)butyl-4-(2-hydroxy-3-phenylaminopropyl)piperazine trifluorochloride				
Practinol		6673-35-4		Antiparkinsonian	Parkinson's disease
Primalmine		35080-11-6			
Pralidoxime		51-15-0			
pralinasan	8H-Pyridazino[1,2-a](1,2-diazepine-1-carboxamide, N-(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl)octahydro-9-(1-(1-squindolinylcarbonyl)amino)-6,10-dioxo-, (1S,8S), [CAS]	192755-52-5			
pramipexole	2,6-Benzothiazole(amine, 4,5,6,7-tetrahydro-N-(propyl-, (S)-, [CAS]	104632-28-0	EP	Antiarthritic, immunological	Arthritis, rheumatoid
pramiracetam	1-Pyrrolidineacetamide, N-(2-[(S)-1-methylethylamino]ethyl)-2-oxo-, monohydrochloride [CAS]	68497-82-1 72869-16-0 75733-50-5	186087	Antiparkinsonian	Parkinson's disease
Pramiverin		14334-40-8	US	Cognition enhancer	Amnesia
pramiridine	1,2-Dithia-3,6,11,14,17-pentazacyclopentane, cyclic peptide deriv. [CAS]	151126-32-8	US	Antidiabetic	Diabetes, Type I
Pramoxine		140-65-8			
pranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl-, methyl 3-phenyl-2-propenyl ester, (E), [CAS]	99522-79-9		Antihypertensive, other	Hypertension, general
Pranlukast	5H-[1-Benzopyrano[2,3-b]pyridine-7-acetic acid, Alpha-methyl-, [CAS]	103177-37-3	EP	Antihypertensive, other	Hypertension, general
pranoprofen	Androst-5-en-17-one, 3-hydroxy-, (3S)-, [CAS]	52549-17-4		Formulation, mucosal, topical	Ocular disorder, general
prasterone	4-(3H)-Cycloheptimidazole, 5,6,7,8-tetrahydro-2-propyl-3-[2'-(1H-tetrazol-5-yl)]-1,1'-biphenyl-4-ylmethyl-, [CAS]	53-43-0		Labour inducer	
prazosin		153804-05-8	US	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pravastatin	1-Naphthalenepropionic acid, 1,2,6,7,8,8a-hexahydro-6,6-dimethyl-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S], [1Alpha,(3S*,deltaS*)2Alpha,6Alpha,8B(R*)3,8aAlpha], [CAS]	81093-37-0 81131-70-6	US 4346227	Hypolipemic/Antiatherosclerosis	Atherosclerosis
Prazepam	2H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-, [CAS]	23655-38-6			
praziquantel	hexahydro-, [CAS]	55268-74-1	US 4001411	Schistosomicide	
prazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-[CAS]	19216-55-9 19237-64-4	US 4092315	Antihypertensive, adrenergic	Hypertension, general
Prednicarbate		73771-04-7			
prednisolone	Pregna-1,4-diene-3,20-dione, 21-(4-{4-[bis(2-chloroethyl)amino]phenyl}-1-oxobutoxy)-11,17-dihydroxy-, (11B), [CAS]	20069-24-7	GB 1272841	Anticancer, alkylating	
Prednisolone 21-Diethylaminoacetate		50-24-8 5626-34-6			
prednisolone farnesil	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy], [11B,21(2E,8E)], [CAS]	118244-44-3	EP 332143	Antiarthritic, other	Arthritis, rheumatoid
Prednisolone Sodium Phosphate		125-02-0			
Prednisone		53-03-2			
Prednival		15180-00-4			
Prednylidene		599-33-7			
pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S), [CAS]	148653-50-8		Antiepileptic	Epilepsy, general
Pregnan-3alpha-ol-20-one	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17B, (S)], [CAS]	128-20-1			
Premarin + triamegestone		74513-82-5		Menopausal disorders	Hormone replacement therapy



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
progesterone	Pregn-4-ene-3,20-dione [CAS]	57-83-0		Formulation, transmucosal, systemic	Amenorrhea
proglinetecin	11-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-(4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinylester, (+/-) [CAS]	57132-53-3 59209-40-4	GB 1467568	Anti-inflammatory	Inflammation, general
proglinide	Penitric acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+/-) [CAS]	6620-90-6	DE 1518125	Antidote	Usoar, gastric
<b>Proheptazine</b>		77-14-5			
<b>Prolactin</b>		9002-62-4			
<b>Prolintane</b>		493-92-5			
<b>Prolonum</b>		123-47-7			
<b>Promazine</b>		58-40-2			
<b>Promedol</b>		64-39-1			
<b>Promegestone</b>		34184-77-5			
promestérone	Estra-1,3,5(10)-triene, 17-methoxy-5-propoxy-, (17 $\beta$ )- [CAS]	39219-28-8	GB 1337186	Reproductive/gonadal, general	Acne
<b>Promethazine</b>		50-87-7			
<b>Promethalol</b>	Glycine, N,N-diethyl-, 4-(acet)amino phenyl ester [CAS]	54-80-8 66532-58-2 66532-98-3	US 4127671	Formulation, parenteral, other	
propacetamol	1-Propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl- [CAS]	54063-53-5	GB 1307455	Antiarhythmic	Fibrillation, ventricular
propafenone		12758-40-6			
<b>Propagermanium</b>		545-93-7			
<b>Propallylonal</b>		104-32-5			
<b>Propamidine</b>		57-55-6			
propand-1,2-diol	1,2-propanediol	1421-14-3		Formulation, dermal, topical	Infection, fungal, general
<b>Propanthidol</b>		50-34-0			
<b>Propantheline</b>		469-67-2			
<b>Proparacaine</b>		2521-92-8			
<b>Propatyl</b>	ethyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76449-31-2		Antifungal	Infection, trichomoniasis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
propentofylline	1-(4-Purine-2,6-dione-3,7-allylato-3-methyl-1-(5-(6-oxohexyl)-7-propyl)-[CAS]	55242-55-2	GB 1470220	Neuroprotective	Ischaemia, cerebral
Propicillin		551-27-9			
Propiomazine		362-29-8			
Propionic Acid		79-09-4			
propionyl L-carnitine	1-Propylaminium, 3-carboxy-N,N-bis(trimethyl-2-(1-oxopropoxy)-, chloride, (R) [CAS]	119793-66-7 20084-19-1			
Propiopocaine		3670-68-6	GB 2008578	Vasodilator, peripheral	Peripheral vascular disease
Propiram		15686-91-6			
propiverine					
Propizepine	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-9 60569-19-9		Urological	Incontinence
Propofol	Phenol, 2,6-bis(1-methylethyl)- [CAS]	10321-12-7 2078-84-8			
Propoxycaine		550-83-4	US 4056635	Anaesthetic, injectable	Anaesthesia
Propoxyphene		469-62-5			
proporanolol	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	318-88-9 626-66-6			
Propylhexedrine		101-40-6			
Propylidone		587-61-1			
Propylthiouracil		51-52-5			
Propyphenazone		479-92-5			
Proquazone		22760-18-5			
Proscarlidin		466-06-8			
Prostacyclin		35121-78-9			
Prostaglandin E <sub>1</sub>		745-65-3			
Prostaglandin E <sub>2</sub>		363-24-6			
Prostaglandin F <sub>2α</sub>		551-11-1			
Prosulimine		59-58-5			
Protein C		60202-16-6			
Prothobromine		50-39-5			
Prothipendyl		303-69-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Protiofate		58416-00-5			
Protionamide		142222-60-7			
protioic acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha, 10-dimethyl-, (7-)- [CAS]	13799-03-6	US 3450688	Anti-inflammatory	
Protoanemonin		108-28-1			
Protokylol		136-70-9			
Protoporphyrin IX		553-12-8			
Protiriplyline		438-60-8			
Pro-Urokinase		82657-92-9			
Proxazole		5686-9-3			
Proxibarbal		2537-29-3			
proxigermanium	Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanedyl)bis- [CAS]	12758-40-6	FR 2005110	Antiviral, other	Infection, hepatitis-B virus
Proxaplyline		603-00-9			
Prozapline		3426-8-2			
Prucalopride		179474-81-8			
pruifloxacin	1H,4H-[1,3]Thiazolo[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo- [CAS]	123447-62-1	EP 315828	Quinolone antibacterial	Infection, respiratory tract, general
Pseudococaine		478-73-9			
pseudoephedrine + triprolidine	Benzanemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R'-R')]-, mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]				
pseudoephedrine	Benzanemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R'-R')]- [CAS]	90-82-7, 90542-27-1, 345-78-8		Formulation, modified-release, other	Rhinitis, allergic, general
Psilocybin	Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	520-52-5		Formulation, oral, other	Infection, respiratory tract, general
PSK-3841		154892-24-2		Dermatological	Alopecia, general



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
p-Sulfanilylbenzylamine		4393-19-5			
PT-141					
Pteropterin		89-38-3	US 6051555	Male sexual dysfunction	Impotence
Piromycin		53-79-2			
PX-12	1-Methylpropyl 2-mercaptimidazolyl disulfide				
Pyranterol		15686-83-6		Anticancer, other	Cancer, general
Pyrazinamide		98-96-4			
Pyridinol Carbamate		1882-26-4			
Pyridostigmine Bromide		101-26-8			
Pyridoxal 5-Phosphate		54-47-7			
Pyridoxine		58-56-0			
Pyrimidine		91-84-9			
Pyrimethamine		58-14-0			
Pyrimidine		1740-22-3			
Pyrisuccideanol		33605-94-6			
Pyriphione		1121-30-8			
Pyrihydione		77-04-3			
Pyritinol		1098-97-1			
Pyrocatechol		120-80-9			
Pyrogallol		87-66-1			
Pyronardine		74847-35-1			
Pyrovalerone		3563-49-3			
Pyroxilin		9004-70-0			
Pyrobutamine		91-82-7			
Pyrocaine		2210-77-7			
Pyrolinitrin		1018-71-9			
Pyvinium Pamoate		3546-41-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
quazepam	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)- [CAS]	36735-22-5	US 3945039	Hypnotic/Sedative	Insomnia
<b>Quercetin</b>		117-39-9			
quetiapine	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazophenyl-1-yl)-5-piperazinyl]ethoxy], (E)-2-butanediolate (2:1) (salt) [CAS]	111974-69-7 111974-72-2			
<b>Quinacillin</b>		1596-63-0 83-89-6	EP 240228	Neuroleptic	Schizophrenia
quinacrine	N-(6-Chloro-2-methoxy-9-acridinyl)-N,N-dimethyl-1,4-pentanediamine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl			Neurological	Creutzfeldt-Jakob disease
quinagolide	Sulfamide, N,N-diethyl-N-[(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-oxo-9-phenylquinolin-3-yl)- (3 $\alpha$ ,4 $\alpha$ ,10 $\alpha$ ), (10 $\alpha$ )]- (4'-) [CAS]	87056-78-8 94424-50-7 87805-49-7	EP 77754	Antiprolactin	Hyperprolactinaemia
quinapril	3-Isoquinolinecarboxylic acid, 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-][2]R'*(R''),3R'' [CAS]	82586-55-8 85441-61-8 90243-99-5	EP 49605	Antihypertensive, renin system	Hypertension, general
quinaprilat	3-Isoquinolinecarboxylic acid, 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-][2]R'*(R''),3R'' [CAS]	82768-85-2	EP 46953	Antihypertensive, renin system	Hypertension, general
<b>Quinabpyramine</b>		20483-41-8			
<b>Quinbolone</b>		2487-63-0			
<b>Quinestradiol</b>		1169-79-5			
<b>Quinestrol</b>		152-43-2			
<b>Quinethazone</b>		773-49-4			
quinifamide	2-Furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester [CAS]	62265-68-3	US 3997542	Anticoagulant	
quinidine	Cinchonan-9-ol, 9'-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	747-45-5 56-54-2		Formulation, modified-release, other	Arrhythmia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Quinine		130-95-0			
Quinocidine		525-61-1			
Quinupramine		31721-17-2			
Quinuapristin		120138-50-3			
R-107500	cis-2,3,6,8-tetrahydro-N,N'-dimethylidibenz(c,f)isoxazolo[2,3-a]azepine-2-methanamine				
R-667	1H-Barbitimidazole, 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl-, sodium salt- [CAS]		WO 9814320	Anabolic	Anxiety, general
rapegrazole		117976-88-3 117976-90-6	WO 0204439	COPD treatment	Emphysema, general
racacacothil	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (4S)- [CAS]	112573-72-5 81110-73-8	EP 268956	Antitumor	Ulcer, gastric
Racemethorphan		510-53-2	EP 38758	Antidiarrheal	Diarrhea, general
raloxifene	Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[d]furan-3-yl]1-[2-(1-phenylethynyl)ethoxy]phenyl-, hydrochloride [CAS]	82840-04-8 84449-90-1	EP 62503	Osteoporosis treatment	Osteoporosis
ralitrexid	L-glutamic acid, N-[[6-[(1,4-dihydro-2-quinazolinyl)methyl(methylamino)-2-thenyl]carbonyl]- [CAS]	112887-68-0	EP 239362	Anticancer, antineoplastic	Cancer, colorectal
ramatroban	9H-Carbazole-9-propanoic acid, 3-[[4-(fluorophenyl)sulfonyl]aminol-1,2,3,4-tetrahydro-, (R)- [CAS]	116649-85-5	EP 242518	Antiallergic, non-asthma	Rhinitis, allergic, perennial
Ramifenazone		3615-24-5			
ramipril	Cyclopentylpyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]dihydro-, [2S-1] [(R)-], 2.alpha.,3.alpha.,6.alpha.)- [CAS]	87269-97-4 87335-19-5	EP 79022	Antihypertensive, renin system	Heart failure
ramosetron	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3 132036-88-5	EP 381422	Antiemetic	Nausea and vomiting, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ramot project No. 1097			US 5730982	Dermatological	Unspecified
Ranimustine		58994-96-0			
ranitidine	1,1-Ethenediamine, N-[2-[[[5-[[dimethylamino)methyl]-2-furanyl)methyl]thio]ethyl-N-methyl-2-nitro-][CAS]	66357-35-5			
ranitidine bismuth citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy-bismuth(3+) salt (1:1), compd. with N-[2-[[[5-[[dimethylamino)methyl]-2-furanyl)methyl]thio]ethyl-N-methyl-2-nitro-ethenediamine (1:1)- [CAS]	128345-02-0	US 4129659	Antulcer	Ulcer, duodenal
ranolazine	1-Piperazinecarbamide, N-[2,6-dimethylphenyl]-4-[2-hydroxy-3-[2-methoxyphenoxy]propyl-, (+)- [CAS]	95635-55-5 95635-56-6	EP 533281	Antulcer	Ulcer, duodenal
Raniprase		133737-86-9	EP 126449	Antilanginal	Angina, general
Rapacuronium	1H-Inden-1-amine, 2,3-dihydro-N-2-propenyl-, (R)-, [CAS]	156137-99-4			
rasagiline		161735-79-1	US 5457133	Antiparkinsonian	Parkinson's disease
Raubasine		483-04-5			
rauconazole	Benzonitrile, 4-[2-[(1R,2R)-2-(2,4-difluoropropenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl-, [CAS]	182760-06-1		Antifungal	Infection, meningitis, general
raxofloast	2-Benzofuranacetic acid, 5'-[acetyl]oxy-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	US 4990350	Symptomatic antidiabetic	Nephropathy, diabetic
razoxene	2,8-Piperazineidione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, [CAS]	214165-67-1, 214168-75-5	GB 1234936	Anticancer, other	Cancer, general
resacampide	Tetradechanic acid (1R)-1-[2-(2-[(2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxo[1,4-cyclohexadienyl]tetradecyl)amino-4-O-phosphono-6-D-glucopyranosyl]oxy)ethyl]amino)-2-oxoethyl]dodecyl ester, compd. with N,N-diethylmethanamine (1:1) [CAS]	216014-46-9		Immunostimulant, other	Vaccine adjunct
	4-Quinolonepropanoic acid, Alpha-[(4-chlorobenzyloxy)amino]-1,2-dicyclo-2-oxo- [CAS]	90698-04-7	DE 3324034	Antulcer	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rebinaast	L-valiamide, N-(2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1H-imidazolidinyl)butyl-L-leucyl-N,3-dimethyl- [CAS]	259188-38-0		Anticancer, other	Cancer, lung, non-small cell
rebosoline	Morpholine, 2-[(2-dioxypiperonyl)phenylmethyl]-, (R, S*)- [CAS]	71620-89-8, 98765-81-4	US 4229449	Anidepressant	Depression, general
<b>Remacemide</b>		128298-23-2			
remifenantol	1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-(1-oxopropyl)phenylamino-methyl ester- [CAS]	132539-07-2, 132875-61-7	EP 383579	Analgesic, other	Pain, general
remifenantol	Tricyclo[3.3.1.1 <sup>3,7</sup> ]decane-2-carboxylic acid, 2-[[1-(7-chloro-4-quinolyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]- [CAS]	146362-70-1	EP 699438	Neuroleptic	Schizophrenia
<b>Remoxipride</b>		80125-14-0			
renzapride	Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy- [CAS]	108872-41-5, 88721-77-1	JP 5818885	Gastroprokinetic	Irritable bowel syndrome
repaginide	Benzole acid, 2-ethoxy-4-[2-[(3-methyl-1-(1-piperidinyl)phenyl)butyl]amino]-2-oxoethyl-, (S)- [CAS]	135062-02-1	WO 9300337	Antidiabetic	Diabetes, Type II
repertaxin L-lysine salt	2[(R)-4-isobutylphenyl]propionyl methanesulfonamide L-lysine salt		WO 0024710	Cardiovascular	Reperfusion injury
repinotan	1,2-Benzisothiazol-3(2H)-one, 2-(4-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino)butyl-, 1,1-dioxide, monohydrochloride [CAS]	144980-29-0, 144980-77-8	US 5137901	Neuroproliferative	Ischaemia, cerebral
reprinast	4H-Pyran[3,2-d]quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, 3-methylbutyl ester [CAS]	73086-51-0	US 4298610	Asthma	
<b>Reposal</b>		3625-25-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
repotrolol	1H-Furine-2,6-dione, 7-[3-[(2-(3,5-dihydroxyphenyl)-2-hydroxyethyl)amino]propyl]-3,7-dihydro-1,3-dimethyl- [CAS]	13055-82-8 54063-54-6	FR M5969	Antiasthma	Asthma
Rescimetol		73573-42-9			
Rescimetamine		24815-24-5			
Reserpiline		131-02-2			
Reserpine		50-55-5			
Resibutogenin		465-39-4			
resiquimod	1H-Imidazo[4,5-c]quinoline-1-ethanol(ethoxymethyl)-Alpha, Alpha-dimethyl- [CAS]	144875-48-9	US 5389640	Antiviral, other	Infection, hepatitis-C virus
Resorcinol		108-46-3			
Retepase		133652-38-7			
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl), ethyl ester [CAS]	150812-12-7	DE 4200259	Antiepileptic	Epilepsy, general
retinoic acid		302-79-4		Formulation, parenteral, other	Cancer, leukaemia, acute myelogenous
Retinoid	Retinoic acid [CAS]		US 6281230	Anticancer, other	Cancer, myeloma
R-fluridipron	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl	5104-49-4		Anticancer, other	Cancer, prostate
Ribo (D) Immune Globulin (Human)					
Ritro-kinase inhibitors					
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- [CAS]	36791-04-5	WO 0156988	Antiasthma	Unspecified
Riboflavin		148-17-8	US 4211771	Antiviral, other	Infection, haemorrhagic fever
ribosamycin	D-Streptamine, O-2,6-diamino-2,6-dideoxy Alpha-D-glucopyranosyl-(1-4)-O-[(D-ribofuranosyl-(1-5))-2-deoxy- [CAS]	25546-65-0	GB 1254883	Aminoglycoside antibiotic	Infection, general
Ricinoleic Acid		141-22-0			
Ridogrel		110140-89-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rifabutin	Rifamycin XIV, 1',4'-didehydro-1'-deoxy-1,4'-dihydro-5'-(2-methylpropyl)-1-oxo-[CAS]	72559-06-9	US 4219478	Antimycobacterial	Infection, Mycobacterium avium complex
rifalazil	Rifamycin VIII, 1',4'-didehydro-1'-deoxy-1,4'-dihydro-3'-hydroxy-5'-4'-(2-methylpropyl)-1-piperazinyl-1-oxo-[CAS]	129791-82-0 129791-94-2 133633-12-2	EP 366914	Antimycobacterial	Infection, tuberculosis
rifametinone	Rifamycin, 3-[[1'-(diethylamino)ethylidene]hydrazono]methyl]-[CAS]	94188-98-6	EP 119571	Antimycobacterial	Infection, general
Rifamide	Rifamycin, 3-[(4-methyl-1-piperazinyl)imino]methyl-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinodiamine [CAS]	2750-78-7			
rifampicin + trimethoprim		61488-94-0		Formulation, fixed-dose combinations	Infection, general
Rifampin		13292-46-1			
Rifamycin SV		6398-60-3			
rifapentine	Rifamycin, 3-[(4-cyclopentyl-1-piperazinyl)imino]methyl-, [CAS]	61379-55-5	DE 2608218	Antibiotic, other	Infection, tuberculosis
rifaximin	Epoxy-pentadecal[1,11,13]trienimino[benzo(furo[4,5-e]-pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetoxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,28-octamethyl-, [2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]	80621-81-4	GB 2079270	Antibiotic, other	Infection, GI tract
rifaximinine cream	4'-deoxy-4'-methylpyridinyl[1',2'-1,2]imidazo[5,4-d]rifamycin SV	80621-81-4	BE 888985	Formulation, dermal, topical	Infection, dermatological
Rimazafone		99583-25-6			
rimenidine	2-Oxazolamine, N-(cyclopropylmethyl)-4,5-dihydro-[CAS]	54187-04-1			
riluzole	2-Benzothiazolamine, 6-[(trifluoromethoxy)-[CAS]	54249-57-9	DE 2362754	Antihypertensive, adrenergic	Hypertension, general
Rimantadine		1744-22-5	EP 50651	Neuroproliferative	Amniotic lateral sclerosis
		13392-28-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
thiazolidine	4-[4-(4-pyridyl)-2-allylpyridinium-3-ethoxy]carbonyl-3,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-, [CAS]	28610-84-8 35615-72-5	DE 2461349	Analgesic, NSAID	
thiazolidine	Androst-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11S,16Alpha,17B)- [CAS]	49697-38-3	DE 2301317	Ophthalmological	Inflammation, ocular
Rimterol	[1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N,1-piperidinyl-, monohydrochloride [CAS]	32953-89-2			
Rimonabant	1,3-Benzenediol, 2,4,6-trimethoxy-, [CAS]	158981-13-1 19403-92-0	US 5824941 US 3755251	Anorectic/Antiobesity Antiviral, other	Obesity
Rioprostil	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt	115436-72-1 105462-24-6	EP 304961	Osteoporosis treatment	Paget's disease
Risedronic Acid	4H-Pyridol[2,3-g]pyrimidin-4-one, 3-[2-[4-(fluoro-1,2-benzisoxazol-3-yl)-1-piperidinylethyl]-6,7,8,9-tetrahydro-2-methyl]- [CAS]	106256-06-2	EP 195132	Neuroleptic, formulation, optimized, microencapsulate	Schizophrenia
Ritanserlin	Benzeneethanol, 4-hydroxy-Alpha-[1-[2-(4-hydroxyphenylethylamino)ethyl]-, (R',S')- [CAS]	87051-43-2 23239-51-2 26852-09-5			
Ritipenem	2,4,7,12-Tetraazatridecan-13-ol; acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (6S-(6R',8R',10R',11R')) [CAS]	155213-87-5	WO 9414436	Antiviral, anti-HIV	Infection, HIV/AIDS
Ritonavir	Carbamic acid, ethylmethyl-, 3-[(dimethylamino)ethylphenyl] ester, (S)- [CAS]	174722-31-7 123441-03-2 129101-54-8			
Rituximab			DE 3605744	Cognition enhancer	Alzheimer's disease



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
risatriptan	1H-Indole-3-ethanamine, N,N-dimethyl-5- (1H-1,2,4-triazol-1-ylmethyl)-, [CAS]	145202-88-0 159776-67-7 144034-80-0	EP 497512	Antimigraine	Migraine
RUR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)- (3E)-, (2E)-2-butanediolate (1:1) [CAS]	183288-99-5		Cognition enhancer	Alzheimer's disease
RNA Stealth Nucleosides	5-Propyluridine			Antiviral, other	Infection, hepatitis-C virus
Ro-0394869	2-[3-(1,1-dimethyl-2-oxo-1,2,3,4-tetrahydro-1H-pyridin-5-yl)-5-methyl-1H-pyridin-2-yl]-N,N-dimethyl-2-oxo-1,2,3,4-tetrahydro-1H-pyridin-5-amine, 4-(4-methylsulfonylphenyl)-3-phenyl- [CAS]			Anticancer, antimetabolite	Cancer, general
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl- [CAS]	180384-56-9	WO 9619459	Cardiovascular	Haemorrhage, subarachnoid
Rociverine	Pyridolium, 1- [(2S,3A)1,6a,16b,17b]-17- (acetoxy)-3-hydroxy-2-(4- morpholinyl)andostan-16-yl]-1-(2- propenyl)-, bromide, [CAS]	53716-44-2 104855-17-8 104884-91-5 119302-91-9 143556-00-3			
rofecoxib	2-(5H)-Furanone, 4-(4- (methylsulfonylphenyl)-3-phenyl- [CAS]	162011-90-7	US 5474995	Analgesic, NSAID	Arthritis, osteo
rolimust	benzamide, 3-(cyclopropylmethoxy)-N- (3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)- [CAS]	162401-32-3	WO 9501338	COPD treatment	Chronic obstructive pulmonary disease
rolitamecin	Leucomyon V, 4B-butanolate 3B- propanoate [CAS]	74014-51-0	US 4242504	Macrolide antibiotic	Infection, general
Rolipram		61413-54-5			
Rolitetacycline		751-97-3			
Romuride		78113-36-7			
Ronifibrate		42597-57-9			
ropinirole	2H-Indol-2-one, 4-[2-(diethylamino)ethyl]- 1,3-dihydro-, monohydrochloride, [CAS]	91374-20-8 91374-21-9	EP 266033	Antiparkinsonian	Parkinson's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ropivacaine	2-[6-(diethylamino)carboxamido, N-(2,6-dimethylphenyl)-1-propyl-, (S)-] [CAS]	80057-98-4 98717-15-8	EP	Anaesthetic, local	Anaesthesia
<b>Roxitrolinex</b>		84088-42-6			
rosaprostil	Cyclopentanetetranoic acid, 2-hexyl-5-hydroxy- [CAS]	56695-65-9	GB	Prostaglandin	
<b>Rosaramicin</b>		35834-26-5			
<b>Rose Bengal</b>		632-68-8			
rosiglitazone	2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (2)-2-butenedioate (1:1) [CAS]	122320-73-4 195141-28-0	US	Antidiabetic	Diabetes, Type II
rosuvastatin	3-Quinolincarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- [CAS]	40034-42-2	US	Quinolone antibacterial	Infection, gonorrhea
rostaportin	Tin, dichloro(ethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kappaN23,kappaN24,kappaN25,kappaN26)-, (OC-6-13)- [CAS]	114494-17-6		Ophthalmological	Macular degeneration
rosuvastatin	6-Heptenoic acid, 7-((4-(4-fluorophenyl)-6-(1-methyl-2-pyridinyl)methyl)-5-(methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-, (S-(R', S-(E))) [CAS]	147098-20-2	JP	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general
rotiligoline	1-Naphthalenol, 5,5,7,8-tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-, (S)- [CAS]	99755-59-6	US	Antiparkinsonian	Parkinson's disease
<b>Roftraxate</b>		92071-51-7			
<b>Roxarsone</b>		121-19-7			
roxatidine	Acetamide, 2-(acetoxy)-N-[3-(3-(1-piperidinylmethyl)phenoxyl)propyl-, [CAS]	78626-28-1 83793-83-0	EP	Antilucer	Ulcer, gastric
roxifen	L-Alanine, 3-(((3-(4-(amino(1-methylphenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxy)carbonyl)-methyl ester, (R)-, [CAS]	178022-59-6	US	Antithrombotic	Thrombosis, general
<b>Roxindole</b>		112192-04-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
roxithromycin	Erythromycin 9-[O]-(2-methoxyethoxymethyl)pyrimine [CAS]	80214-85-1 80214-86-4	EP 33255	Macrolide antibiotic	Infection, general
RPR-109881A	Benzene propanoic acid, 8-(((1,1-dimethylmethoxy)carbonyl)amino)-Alpha-hydroxy-7,12a-bis((acetoxy)-1-(benzyloxy)-1,3,4,7,8,9,10,10a,12,12a,12b-dodecalyl)-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclohexa(3,4)cyclopenta (4,5) benz (1,2-b) oxet-4-yl ester, dihydrate Alpha R, beta S [CAS]	192573-38-9		Anticancer, other	Cancer, lung, general
RPR-130401	4,6-Ethano-3aH-benzof[1c]indole-3a-carboxylic acid, 1,2,3,4,9,9a-hexahydro-2-(2-methoxyphenyl)-4-oxo-2-propenyl-9-(4-methylphenyl), (8aR,4S,9S,9aR)-rel- [CAS]	210282-69-2	WO 9829990 US 6316458	Anticancer, other Anticancer, other	Cancer, general Cancer, lung, non-small cell
R-roscovilline	NTN-3a(3-hydroxyphenyl)pyridazine-3,6-diamine			Neuroprotective	Alzheimer's disease
RS-0406		131179-95-8			
RSR-13		79-58-3			
Rubijervine	1H-Pyran(3',4':3,7')indizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]	91421-42-0	US 6455514	Anticancer, other	Cancer, pancreatic
Rubitecan	9H,18-H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-b)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione 9-(((dimethylamino)methyl)-5,7,10,11-tetrahydro-, (S)- [CAS]	169936-94-0		Symptomatic antidiabetic	Retinopathy, diabetic
Rubixosaurin		169936-94-0			
Rufinamide		106308-44-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rufoxacin	7H-Pyrido[1,2,3-d:ej]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 10262-47-1 106017-08-7	EP 165375	Quinolone antibacterial	Infection, general
rupatadine	5H-Benzol[5,6]pyridole[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidenyl-, trihydrochloride- [CAS]	156611-76-6	EP 0577957	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Rutin		153-18-4			
RWJ-54428	5-Thia-1-szabloydd[4,2,0]oct-2-ene-2-carboxylic acid, 7-[(2Z)-12-amino-5-chloro-4-iazolo]([hydroxymino]acylamino)-3-[(3-[(2-aminoethyl)imino]methyl)-4-pyridinyl]thio-5-oxo-, (6R,7R)- [CAS]	189448-36-9	WO 9713772	Cephalosporin, injectable	Infection, beta-lactamase resistant
S-C139	Clean-12-en-28-olc acid, 27-[(3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-butenyl)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS]	193969-54-9	WO 9727314	Cardiovascular	Ischaemia, cerebral
S-15535	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS]	146998-34-7		Cognition enhancer	Cognitive disorder, general
S-18886	1-Naphtalenepropanoic acid, 6-[(4-chlorophenyl)sulfonylamino]-5,6,7,8-tetrahydro-2-methyl [CAS]	166537-73-5		Antithrombotic	Thrombosis, general
S-34730	7-chloro-6-sulfamoyl-2-(1H)-quinolone-3-phosphonic acid			Neuroprotective	Unspecified
S-3578	7-[6-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2Z]-ethoxymino]acetamido]-3-(1-[(N-methylamino)propyl]-1H-indazol-5-yl)pyridinium-4-methyl-3-cyphen-4-carboxylate monesulfate			Cephalosporin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
S-36496	2-[N-(4-(4-Chlorophenylsulfonylamino)butyl)-N-(3-(4-isopropylthiazol-2-yl)methoxy)benzyl]sulfamoylbenzoic acid			Aniasthma	Asthma
S-36527	2-[N-(4-(4-Chlorophenylsulfonylamino)butyl)-N-(3-(2-(4-cyclobutylthiazol-2-yl)ethyl)benzyl]sulfamoylbenzoic acid			Aniasthma	Asthma
S-5751	(1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiofophen-3-ylcarboxamido)-6,8-dimethylbicyclo[3.1.1]hept-3-yl]-5(2-heptenoic acid				
S-5810	Imidazo[4,5-d]pyran-4,3-Dipyridine, 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-phosphate (1:1) [CAS]	151486-23-8	EP 556008	Cognition enhancer	Alzheimer's disease
S-5921	2-Naphthalenecarboxylic acid, 1-(3-(4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS]	151165-96-7	WO 9308155	Hypolipemic/Antiatherosclerosis	Hypercholesterolaemia
Sabcomeline		159912-53-5			
Sabeluzole		104383-17-7			
S-Adenosylmethionine		29908-03-0			
salflamide	(S)-(+)-2,4-(3-fluorobenzyloxy)benzylamino)propanamide methanesulfonate	133865-98-1	AU 711309	Ani epileptic	Epilepsy, general
Salacetamide		487-48-9			
Salazosulfadimidine		2315-8-4			
salbutamol	1-(3-Benzenedimethanol Alpha1(1,1-dimethyl)ethyl)amino)methyl-4-hydroxy-[CAS]	18559-94-9		Formulation, inhalable, topical, dry powder	Asthma
Salicin		138-52-3	EP 451745		
Salicyl Alcohol		90-01-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Salicylamide		65-45-2			
Salicylamide O-Acetic Acid		25395-22-6			
Salicylamide		87-17-2			
Salicilic Acid		69-72-7			
Salicysulfuric Acid		89-46-2			
Salinazid		495-84-1			
salmetamol	1,3-Benzenedimethanol, 4-hydroxy- $\alpha$ -[[(6S)-4-phenylbutoxy]hexyl]amino]methyl-, (3S)-1-hydroxy-2-naphthalenecarboxylate [CAS]	80365-50-4 94749-08-3	WO 9006775	Antiasthma	Asthma
Salisolate		552-94-3			
Salverine		6376-26-7			
Samarium <sup>148</sup> Sm		154427-83-5			
Lexidronam	L-Tyrosine, N2-(methylsulfonyl)-L-tyrosyl-, [(2S)-3-amino-2-carboxypropyl]cyclopentanecarboxyl- [CAS]	129981-36-8 808-26-4	EP 359398	Antihypertensive, renin system	Hypertension, general
samparilact		110588-87-3			
Sancycline					
Saperconazole	4-[(1H)-Phenidrone, 2-amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-, dihydrochloride, [(6R)-[(1R', 2S')]]-, [CAS]	98056-39-4 62989-33-7	EP 191335	Antidepressant	Hyperphenylalaninemia
sapropterin					
sagunavir	Bulanediarnitric, N1-[6-[[[1,1-dimethyl(ethyl)amino]carbonyl]oxy]hydro-2-(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinyl)carbonyl]amino-, [(3S-[2'1'(R'), 2S'1,3Alpha,4aB,8aB)], [CAS]	127779-20-8	EP 432695	Antiviral, anti-HIV	Infection, HIV/AIDS
Saralasin		34273-10-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sareculant	Benzamide, N-[4-(4-acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl-N-methyl-, (S)- [CAS]	142001-63-6	EP 474561	Asthma	Asthma
sarizotan	3-[2-(2-dimethylamino)-2-phenyl-1H-benzopyran-2-yl)methyl]-5-(4-fluorophenyl)- [CAS]	177975-08-5		Antiparkinsonian	Parkinson's disease
sarpogrelate	Butanedioic acid, mono[2-(dimethylamino)-1-[2-(2-(3-methoxyphenyl)ethyl]phenoxymethyl]ethyl ester, [CAS]	125925-17-2	EP 398326	Antithrombotic	
Satigrel	Platinum, bis[acetato-O-amino-2-(2-oxo-2-phenyl-1-oxo-1,2,3,4-tetrahydro-2H-1,4-benzodioxin-2-yl)ethyl]phenoxymethyl]ethyl ester, [CAS]	111753-73-2			
saraplatin	Oxamplatin dichloro(cyclohexanamine)-, (C6-5-43)- [CAS]	129590-63-8	EP 328274	Anticancer, alkylating	Cancer, prostate
Satumomab	N-[3-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl-4-nitrobenzamide, HCl	144058-40-2			
SB-237376	(5-[2-phenylamino-4-pyrimidinyl]-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole			Antiarrhythmic	Fibrillation, atrial
SB-238039	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisquinolin-2-yl)ethyl]pyridoxyl]-4-quinolinecarboxamide			Anticancer, other	Cancer, general
SB-277011					
Scarlet Red		85-83-6		Neuroleptic	Schizophrenia
SCH-00013	Benzonitrile, 4-[2-(3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-5-pyridazinyl)-(2H)-pyridinyl-1-yl)oxyphenyl]- [CAS]	217963-18-3	EP 618204	Cardio stimulant	Heart failure
Sch-25663	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo[a,d] cyclohepten-5-yl]-N, N-dimethyl-ethanamine			Immunosuppressant	Inflammation, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sch-57790	1-[1-(4-methoxyphenyl)butyl]phenyl-4-cyclohexyl-alpha-(4-[(S)-4-methoxyphenyl]butyl)phenyl- [CAS]	221660-80-6		Cognition enhancer	Alzheimer's disease
Sch-63390	7H-Pyrazolo[4,3-e][1,2,4]thiazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]	174648-46-4		Antiparkinsonian	Parkinson's disease
Scillarelin		465-22-5			
Scopolamine		51-34-3			
Scopolamine N-Oxide		97-75-6			
scopolamine	Benzeneacetic acid, Alpha-(hydroxymethyl)-, 5-methyl-3-oxo-9-azatricyclo[3.3.1.0 <sup>2,4</sup> ]non-7-yl ester, [7(S)-(1Alpha,2E,4E,5Alpha,7E)-] [CAS]	51-34-3	US 4262003	Formulation, transdermal, other	Nausea and vomiting, general
SGS technology			US 6048188	Antiasthma	Unspecified
secalcifor	8,10-Di-Sercocholesta-5,7,10(19H)-trien-3,24,25-triol, (3E,5Z,7E,24R)- [CAS]	55721-11-4	EP 301167	Osteoporosis treatment	Osteocystrophy
seclidazole	1H-Imidazole-1-ethanol, Alpha,2-dimethyl-5-nitro- [CAS]	3965-95-8	FR M3270	Protozoacide	Infection, trichomoniasis
Secobarbital	Benzenethiolamine, N,Alpha-dimethyl-N-2-propenyl-, (R)- [CAS]	309-43-3			
selegiline		14611-51-9	GB 1153578	Antiparkinsonian	
Selenomethionine		1464-42-2			
Sematiide		101526-83-4			
Semotiadil		116476-13-2			
secalcitol	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-oxadiazol-5-yl)-7-methyl-4-H,10-dia-4-phen-4-ylidene)-4-methyl-2-oxo-1H-1,2,4-triazol-5-yl)- (1Alpha,1R,2E,2E,4E,5E,6E,7E,8S,9S,10S,11S)- [CAS]	134404-52-7			
Sapimostat		103928-64-3	WO 9100855	Anticancer, other	Cancer, liver
seratrodast	Benzenesulphonic acid, zeta-[2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl]-, (+)- [CAS]	103187-07-1 112665-43-7	EP 232089	Antiasthma	Asthma



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sertaconazole	(1H-imidazole, 1,2-bis(2-chlorobenzoyl)-3-ylmethoxy)-2,4-dichlorophenylethyl- [CAS]	98592-32-2	EP 151477	Antifungal	Infection, dermatological
sertindole	2-midazololidione, 1-(2,4-bis-chloro-1-(4-fluorophenyl)-1H-indol-3-yl)-1-piperidinylethyl- [CAS]	106516-24-9 79553-97-0	EP 392959	Neuroleptic	Schizophrenia
sertaline	1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)- [CAS]	79617-96-2 79617-97-3	EP 30081	Antidepressant	Depression, general
<b>Setastine</b>		64294-95-7			
sevelamer	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	152751-57-0 52757-95-6	US 5496545	Urological	Renal failure
sevoflurane	Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)- [CAS]	28523-86-6	DE 1954288	Anaesthetic, inhalation	Anaesthesia
SG-210	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-((4,5,7-trifluoro-2-benzothiazolyl)methyl)- [CAS]	143162-65-6		Symptomatic antidiabetic	Neuropathy, diabetic
sibutramine	Cyclobutylammonium, 1-(4-chlorophenyl)-N,N-dimethyl-Alpha-(2-methylpropyl)- [CAS]	106650-56-0 84485-00-7	GB 2098602	Anorectic/Antibesity	Obesity
silcanin	(4S-(4a,6a,8a,11b,13aR,13bAp,13bS))-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzof[4,3-c]pyridine-11-ol	22733-00-4	JP 37003548	Antifungal	
silersenil	Piperazine, 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl-2-hydroxy-1,2,3-propanetricarboxylate- (1:1) [CAS]	171599-83-0 133755-83-2	NWO 9428902	Male sexual dysfunction	Impotence
silodosin	1H-Indole-7-carboxamide, 2,3-dihydro-1-(5-hydroxypropyl)-5-((2R)-2-((2,2,2-trifluoroethoxy)phenoxymethyl)amino)propyl-; [CAS]	106970-54-7	EP 600675	Urological	Dysuria
<b>Silver Lactate</b>		128-00-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Silver Picrate	N-2-pyrimidinylsulfanilamide monosilver salt	146-84-9 2279908-2 68-35-9		Anti-infective, other	Infection, general
Simetride		154-82-5			
Simfibrate		14929-11-4			
simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-5-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S- [1Alpha,3Alpha,7a,8b(2S*,4S*),8aS]]- [CAS]	79902-63-9	US	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general
Sinacalcin		25126-32-3			
Sintropium Bromide		79467-19-9			
Sisomicin		32385-11-8			
sliafoxacin	3-Quinolincarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorogdopropyl)-1,4-dihydro-4-oxo-, [1S- [1Alpha(S*),2Alpha]], hydralate [1S-Hexanediamine, N,N-diethyl-N-(8-methoxy-4-methyl-3-quinolyl)-, [CAS]	12754-12-0 533529-0 57695-04-2	EP	Quinolone antibacterial	Infection, general
slimaquine	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[(4,5-methylenedioxy)-o-tolyl]acetyl-3-thiopienesulfonamide			Protozoacide	Infection, leishmaniasis
slivaxentan	Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-, [CAS]	184036-34-8	US	Antihypertensive, other	Hypertension, pulmonary
slivexostat	Butanamide, 2-[[[4-[[fluorophenyl]sulfonyl]amino]-N-(1S)-1-formyl-3-methylbutyl]-, 3-methyl-, (2S)- [CAS]	127373-06-4	EP	Respiratory	Systemic inflammatory response syndrome
SJA-3017	5-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1-ylcarbonyl-2,9-dihydro-1H-pyrrolo[3,4-b]indole-1-one	190274-53-4	EP	Ophthalmological	Cataract
SL-65-1498			EP	Anxiolytic	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SLV-306	(3S,2R)-3-[1-(2'-(Ethoxycarbonyl)-4'-phenyl-butyl)-oxy-pentane-1'-carbonylamino]-2,3,4,5-tetra-hydro-2-oxo-1H-benzapin-1-acetic acid			Antihypertensive, diuretic	Hypertension, general
SLV-308	2-(3H)-Benzoxazole, 7-(4-methyl-1-piperazinyl)-, monohydrochloride	289718-88-4		Antiparkinsonian	Parkinson's disease
Sm163 leixidronam	Samarate(5-yl)53Sm, (((1,2-ethanediylbis(nitriobis(methylene)))tetraakis(phosphonate))[(8)-N,N',OP',OP'',OP''', pentasodium, (OC-6-21)- [CAS]				
S-Methylmethionine		190368-78-8		Analgesic, other	Pain, cancer
SNP-300	N-(Anthracinonemethyl)-11-dichloro-5,6,7,8-tetrahydro-8-oxo-4H-pyrido[3,2,1-k][1]benzazocine-2-carboxamide monomethanesulfonate monohydrate	4727-40-8		Antianginal	Angina, general
SN-38	(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyreno[3',4':8,7]indolizino[1,2-b]quinidin-9-yl			Formulation, optimized, liposomes	Cancer, colorectal
SNAP-7941	(+)-methyl (4S)-3-(((3-(4-β-acetylamino)phenyl)-1-piperidinyl)propylamino) carbonyl-4-(3,4-dichlorophenyl)-5-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate hydrochloride	100288-90-6		Anxiolytic	Anxiety, general
SOA-132	2-Naphthalenecarboxamide, N-[2-[(4-(diethylmethoxy)-1-piperidinylethyl)-3-hydroxy-5-(3-pyridinylmethoxy)- [CAS]	143964-80-1		Formulation, inhalable, topical	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sobidolol	L-valiamide, N,N-dimethyl-L-valyl-N-(2-methoxy-4-(2-[1-methoxy-2-methyl-3-oxo-3-(2-phenylethyl)amino]propyl)-1-pyrrolidinyl)-1-(2-methylpropyl)-4-oxobutyl-N-methyl-, [2S-[11R(R*),2S],2R(1S*,2S*)]-[CAS]	149806-27-9	WO 9303054	Anticancer, other	Cancer, lung, non-small cell
Sobrerol		498-71-5			
sobuzoxime	Carbonic acid, 1,2-ethanedithiol[2,6-dioxo-4,1-piperazinyl(methylene)bis(2-methylpropyl) ester [CAS]	98631-95-9	EP	Anticancer, other	Cancer, lymphoma, T-cell
Sodium Arsanilate		127-85-5			
Sodium Arspenamine		1936-28-3			
Sodium Chloride					
Sodium Dibunate		14992-59-7			
Sodium Folate		6484-89-5			
Sodium Formaldehydesulfoxylate		149-44-0			
Sodium Glycerophosphate		1334-74-3			
Sodium Hyaluronate					
Sodium Iodomethanate		519-26-6			
Sodium Nitrite		7632-00-0			
Sodium Nitroprusside		14402-89-2			
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2		Psychostimulant	Narcolepsy
Sodium Phenolsulfonate		1300-51-2			
sodium phenylbutyrate	Butyric acid, 4-phenyl-, sodium salt, [CAS]	1716-12-7		Formulation, other	Hyperimmunemia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sodium phosphate	Sodium phosphate monobasic anhydrous + sodium phosphate dibasic anhydrous		US 6162464	Formulation, oral, other	Surgery adjunct
sodium prednisone sulfate	3-(3-hydroxy-5-oxo-17-one)(sodium sulfate dihydrate)		EP 380036	Formulation, mucosal, topical	Labour, induction
<b>Sodium Propionate</b>		137-40-6			
sodium silicofluoride	Benzonic acid, 2-hydroxy-, monosodium salt [CAS]	54-21-7			
<b>Sodium Tetradecyl Sulfate</b>		139-88-8			
seficonia	Acetic acid, [5-[(3-methyl-2-butenyloxy)-2-[3-[[4-[(3-methyl-2-butenyloxy)phenyl]-1-oxo-2-propenyl]phenoxy]-[CAS]	64506-49-6	GB 1523241	Antitumor	
<b>Solasulfone</b>		133-65-3			
solfenach	Butanedioic acid compd with (1S)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isouquinolinecarboxylate (1:1) [CAS]	242478-38-2		Urological	Overactive bladder
Sorbitol	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	6184-06-1	BE 883352	Hypolipemic/Antiatherosclerosis	
<b>Sorivudine</b>		50-70-4			
sotalol		77181-69-2			
<b>Soterenol</b>	Methanesulfonamide, N-[4-(1-hydroxy-2-[(1-methylethyl)amino]ethyl)phenyl]- [CAS]	3930-20-9 959-24-0		Antiarrhythmic	
<b>Sozodolonic Acid</b>		13642-52-9			
sparglumic acid	L-Glutamic acid, N-(N-acetyl-L-Aspartyl)- [CAS]	554-71-2 3108-85-2 80619-94-3		Formulation, mucosal, topical	Conjunctivitis
sparfloxacin	3-Quinolonecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-4-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, ds- [CAS]	110871-86-8	EP 2271463	Quinolone antibacterial	Infection, respiratory tract, general
<b>Sparteine</b>		90-39-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SPA-S-843	Candidin D, 18-deacetoxy-40-tamethyl-3,7-dideoxy-N3' ((dimethylamino)acetyl)-18-((2-((dimethylamino)ethylamino)carbonyl)-3,7-dihydroxy-14H-2-methyl-5-oxo cyclic 15, 16-hemiacetal, comp with L-ascorbic acid [1,12] [CAS]	202748-83-2	US 5298485	Antifungal	Infection, fungal, general
Spasmolytol	2((1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathian-4-yl- (2R,6S)-	253333-96-4			
SPD-754		160707-59-7	US 6228860	Antiviral, anti-HIV	Infection, HIV/AIDS
Spectinomycin		1695-77-8			
SPH-338	4-[[3-(4-Oxo-4,5,6,7-tetrahydroindol-5-yl)propyl]amino]benzoate ethyl ester				
Spiperone		749-02-0		Cognition enhancer	Alzheimer's disease
spirapril	1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyl)-3-phenyl]propyl]amino]-1-oxopropyl-, [8S-7(R')-(R'')], [8R'']- [CAS]	83847-97-6	EP 50800	Antihypertensive, renin system	Hypertension, general
Spirogermanium	Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, Gamma-lactone, (7R,16S)- [CAS]	41992-23-8			
spiroinoleactone	Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, Gamma-lactone, (7R,16S)- [CAS]	52-01-7	EP 124147	Formulation, dermal, topical	Acne
SR-121463	Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-ethoxy-4'-[2-(4-morpholinylethoxy)-2'-oxospiro[cyclohexane-1,3'-[3H]indol-11'(2H)-yl]sulfonyl]-3-methoxy- [CAS]	165913-78-4	WO 9715556	Cardio stimulant	Heart failure
SR-144190	Morpholine, 4-benzoyl-2-[3,4-dihydrophenyl]-2-[2-(4-[[dimethylamino]carbonyl]amino)-4-phenyl-1-piperidinylethyl]-, (2R)- [CAS]	201152-86-5	WO 9623787	Anxiolytic	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SR-146/131	1H-indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-methoxyphenyl]amino]carbonyl]-5,7-dimethyl- [CAS]	221671-61-0	WO 9815525	Anorectic/Antiobesity	Obesity
SR-271425	N-[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-yl]methylformamide		-	Anticancer, alkylating	Cancer, general
SR-27697	1H-indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolylamino]carbonyl]- [CAS]	136381-85-6	EP 452040	Anticancer, other	Cancer, pancreatic
SR-31747	Cyclohexanamine, N-[2-(3-chloro-4-cyclohexylphenyl)-2-propenyl]-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	EP 376660	Anticancer, other	Cancer, myeloma
SR-56811 SS732	Acetic acid, [[(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxyl-, ethyl ester, hydrochloride [CAS]	121524-09-2	EP 303546 US 5385900	GI Inflammatory/bowel disorders Formulation, mucosal, topical	Irritable bowel syndrome Infection, ocular
SR-760	(R)-2-[2-(4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol				
6-alethine	Propanamide, N, N'-(diisobutyl-2,1-bis(4-ethoxy)bis(5-amino)- [CAS]	946-08-2	US 6083968	Antifungal	Infection, fungal, general
SSR-149415	(2S,4R)-1-[6-chloro-1-(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide			Anticancer, Immunological	Cancer, myeloma
SSR-180575	2-[7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridin-6(5H)-indol-1-yl]-N,N-dimethylacetamide		WO 0155130	Antidepressant	Depression, general
				Neuroprotective	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SSR-181507	(3-Exo)-8-benzoyl-N-[(2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl(methyl)-8-azabicyclo[3.2.1]octane-3-methanamine HCl		US 6221879	Neuroleptic	Schizophrenia
SSR-501813	(5aS,6S,10aR)-5a,6,9,10-tetrahydro,7H,11H-8,10a-methanopyrido[2,3'-5,6]pyrrolo[2,3-d]azepine			Dependence treatment	Addiction, nicotine
SSY-101	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, transdermal, other	Angina, general
SSY-726	(+)-(R)-3-Methyl-3-(methylsulfonyl)-1-(1,2,4-triazol-1-yl)-2-(4-(trifluoromethyl)phenyl)-2-butanol		US 5147886	Antifungal	Infection, fungal, general
ST-200	1-Propanaminium, 2-(acetoxy)-3-carboxy-N,N,N-trimethyl-, chloride, (N <sup>+</sup> ) [CAS]	5080-50-2	DE 3015635	Cognition enhancer	Dementia, senile, general
Stachylin			WO 9711947	Antiviral, other	Infection, influenza virus
Stallimycin		636-47-5			
Stamplidine			US 6350736	Antiviral, anti-HIV	Infection, HIV/AIDS
Stannous Pyrophosphate		15578-26-4			
stannosporfin	(OC-6-13)-Dihydrogen dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-N21,N22,N23,N24]stannate(2-)	106344-20-1		Hepatoprotective	Hyperbilirubinaemia
Stanolone		521-18-6			
Stanozolol		10418-03-8			
	(2'H form); 302-96-5 (1'H form)				
Staph aureus ther			US 6376652	Genomics-based drug discovery	Infection, MRSA
STAT4 inhibitors			WO 9929341	Immunosuppressant	Unspecified



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
stavudine	Thymidine, 2',3'-dideoxy-3'-deoxy- [CAS]	3056-17-5	EP 501511	Antiviral, anti-HIV	Infection, HIV/AIDS
Stenbolone	Glycine, N-[1-oxo-2-[[2-phenylcarbonyl]thiolpropyl]- [CAS]	5197-58-0			
atepronin		72324-18-6			
Sibocaplate		27279-76-1			
Sibophan		15469-10-4			
Silbamide		122-06-5			
stipenbol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl- [CAS]	49763-96-4			
Streptodornase		37340-82-2		Antiepileptic	Epilepsy, general
Streptomycin		57-92-1			
Streptonicozid		5667-71-0			
Streptonigrin		3930-19-6			
Streptozocin		18883-68-4			
strontium ranelate	3-Thiophenecarboxylic acid, 5-[[bis(carboxymethyl)amino]-2-carboxy-4-oxo-6-phenyl-, strontium salt (1:2)- [CAS]	135459-87-9			
strontium-86 chloride	Strontium chloride (86SrCl <sub>2</sub> ) [CAS]	38270-50-5	EP 415650	Osteoporosis treatment	Osteoporosis
Succimer		304-55-2		Analgesic, other	Pain, cancer
Succinimide		123-56-8			
Succinylcholine		55-94-7			
Succinylcholine		71-27-2			
Succinylsulathiazole		116-43-8			
Succisulfone		5934-14-5			
Suclofenide		30279-49-3			
	Aluminum, hexadeca-4-hydroxytetraacetatehydroxide (1,3,4,6-tetra-O-sulfo-β-D-fructofuranosyl-Alpha-D-glucopyranoside tetraakis(hydrogen sulfato)(8-))hexadeca- [CAS]	54182-59-0	JP 56208233	Antifungal, Formulation, oral, other	Ulcer, general
sucralfate					
sulfentanil	Proparamide, N-[4-(methoxymethyl)-1-[2-(2-phenylphenyl)-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7	US 3998934	Analgesic, other, formulation implant	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sulfadiazine	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-4,4-dioxide, (2S-cs) [CAS]	68373-14-8	GB 2000138	Antibiotic, other	Infection, general
sulfadiazine + ampicillin		117060-71-6	US 4234579	Antibiotic, other	Infection, general
sulfadiazine	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfamoyl)amino], [2S-[2 $\alpha$ ,6 $\alpha$ ,6 $\beta$ ,6 $\gamma$ ]] [CAS]	28002-18-8 41744-40-5			
<b>Sulfentine</b>		350-12-9	GB 1289358	Penicillin, injectable	Infection, pseudomonal
sulfadiazine	Propanoic acid, 2-methyl-, dithioa[3-[(4-oxo-2-methyl-5-pyrimidinyl)methyl]formylamino]ethylidene] 3,1-propanediyl ester [CAS]	3295-46-2 61-16-3		Neurological	Unspecified
sulfadiazine	1H-Imidazole, 1-[2-[(4-chlorophenyl)methyl]-2-(2,4-dichlorophenyl)ethyl]-, (+)- [CAS]	61318-90-9 61318-91-0	US 4055652	Antifungal	Infection, fungal, general
<b>Sulesomab</b>		167747-19-5			
<b>Sulfabenzamide</b>		127-71-9			
<b>Sulfacetamide</b>		144-80-9			
<b>Sulfachlorpyridazine</b>		80-32-0			
<b>Sulfachrysoidine</b>		485-41-6			
<b>Sulfacycline</b>		17764-12-2			
<b>Sulfadiazine</b>		68-35-9			
<b>Sulfadiazine</b>		115-68-4			
<b>Sulfadimethoxine</b>		122-11-2			
<b>Sulfadoxine</b>		2447-57-6			
<b>Sulfathiazole</b>		94-19-9			
<b>Sulfaguanidine</b>		57-67-0			
<b>Sulfanole</b>		27031-08-9			
<b>Sulfaloxine Acid</b>		152-47-6			
<b>Sulfamerazine</b>		14376-16-0			
<b>Sulfamerazine</b>		127-79-7			
<b>Sulfameter</b>		651-06-9			
<b>Sulfamethazine</b>		57-68-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfamethizole		144-82-1			
Sulfamethomidine		3772-76-7			
Sulfamethoxazole		723-46-6			
Sulfamethoxypyridazine		80-35-3			
Sulfametrole		32909-92-5			
Sulfamidochrysoidine		103-12-8			
Sulfamoxole		729-98-7			
Sulfanilamide		63-74-1			
Sulfanilic Acid		121-57-3			
Sulfanilylurea		547-44-4			
Sulfaperine		599-88-2			
Sulfaphenazole		526-08-9			
Sulfaproxyline		116-42-7			
Sulfapyrazine		116-44-9			
Sulfapyridine		144-83-2			
Sulfarside		1134-98-1			
Sulfarsphenamine		618-82-6			
Sulfasalazine	Benzole acid, 2-hydroxy-5-[4-[(2-pyridinylamino)jasulfonyl]phenyl]azo]- [CAS]	599-79-1		Formulation, oral, enteric-coated	Arthritis, rheumatoid
Sulfasomizole		632-00-8			
Sulfasymazine		1984-94-7			
Sulfethiazole		72-14-0			
Sulfathiourea		515-49-1			
Sulfinalol		66264-77-5			
Sulfipyrazone		57-96-5			
Sulfiram		95-05-6			
Sulfisomidine		515-64-0			
Sulfisoxazole		127-69-5			
Sulfobromophthalein		71-67-0			
Sulfonethymethane		76-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfoniazide		3691-81-4			
Sulfonmethane		115-24-2			
Sulfonidazine		14759-06-9			
Sulfoxone		144-75-2			
sulindac	6a-5-fluoro-2-methyl-1-[p-methylsulfinyl]benzylidenelndene-3-acetic acid	38194-50-2	US	Anti-inflammatory	Inflammation, general
Sulisafin		54935-03-4			
Sulisobenzone		4065-45-6			
Sulmarin		29334-07-4			
Sulmazole		73384-60-8			
Suloctidil		54063-56-8			
Sulphan Blue		129-17-9			
sulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-[CAS]	15676-16-1		Alimentary/Metabolic, other	
sulprostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-[(methylsulfonyl)-, (1R-1[Alpha(Z),2R(1E,3R'),3Alpha)]-, [CAS]	60325-46-4	US	Prostaglandin	Abortion
sulfamycin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(aminophenylacetyl)amino]-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-yl)carbonyl)oxy)methyl ester, S, S-dioxide, (2S-), [CAS]	117060-71-6 76497-13-7	GB	Penicillin, oral	Infection, general
Sulfthame	Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]	61-56-3			
sultripide		53583-79-2	FR	Neuroleptic	Psychosis, general
Sultosilic Acid		57775-28-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sumatriptan	4H-imidazo[4,5-f]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (SR)-, (2Z)-, butenedioate (1:1) [CAS]	170386-44-8	WO 95/14020	Antiparkinsonian	Parkinson's disease
sumatriptan	1-[4-(6-(5-methanesulfonamido, 3-[2-(dimethylamino)ethyl]-4-methyl-, butenedioate (1:1)-) [CAS]	103628-46-2 103628-48-4	EP 147107	Antimigraine	Migraine
SUN-18075	1-(4-amino-2,3,5-dimethylphenoxy)-3-(4-[4-(4-fluorobenzyl)phenyl]piperazin-1-yl)propan-2(1H)-ol dimethanesulfonate			Neuroprotective	Infarction, cerebral
suplatast	Sulfinium, [2-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, [CAS]	94055-76-2	JP 59167564	Antiasthma	Asthma
Suprofen		40828-46-4			
Suramin		129-46-4			
surfactant TA	Baractant [CAS]	108778-82-1	WO 91/17766	Lung Surfactant	Respiratory distress syndrome, general
Suriclone		53813-83-5			
Suxibuzone		27470-51-5			
SYM-1010			US 5630988	Antiepileptic	Epilepsy, general
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)-, [CAS]	31137-74-3		Analgesic, other	Pain, general
SYM-2207	4-(Aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydrophthalazine-2-carboxamide			Neuroprotective	Ischaemia, cerebral
Syndiosene		87-90-1			
Syn-1263	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid			Quinolone antibacterial	Infection, peritoneum
Syn-2190	1-Azobisulfonic acid, 3-[(2E)-1-(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridyl)methoxymethyl]-2-thienylacetylaminol-2-methyl-4-oxo-, (2S,3S)-, [CAS]	214963-75-4	WO 98/47685	Antibacterial, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sym-2669	3H-1,2,4-Triazol-3-one, 4-(4-(4-(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-phenacyl)phenyl)-2,4-dihydro-2(4-(trifluoromethoxy)phenyl)methyl- [CAS]	210562-68-4	US 6153616	Antifungal	Infection, Aspergillus
Synephrine		94-07-5			
Syrosingopline		84-36-6			
T-1095	1-Propanone, 3-(5-benzofuran-1-yl)-2-hydroxy-6-(6-(6-O-methoxycarbonyl)-8-D-glucopyranosyloxy)-4-methylphenyl- [CAS]	203746-56-8	EP 863948	Antidiabetic	Diabetes, general
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutamyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutamyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutamyl-L-alanyl-L-glutamyl-L-isoleucyl-L-glutamyl-L-glutamyl-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-L-asparagyl-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutamyl-L-tyrosyl-L-leucyl-L-alanyl-L-tyrosyl-L-tryptophyl-L-alanyl-L-phenyl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]	251562-00-2	WO 9959615	Antiviral, anti-HIV	Infection, HIV/AIDS
T-3912	1-cyclopropyl-8-methyl-7-[6-methyl-6-(methoxycarbonyl)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid				
T-588	Benzo(5)thiophene-5-methanol, Alpha ((2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142035-03-3	EP 565965	Quinolone antibacterial	Infection, dermatological
T-67	Benzazanesulfonamide, 2,3,4,5,6-pentakisulfo-N-(3-fluoro-4-methoxyphenyl)- [CAS]	196533-53-0		Cognition enhancer	Alzheimer's disease
T-82			US 5190561	Anticancer, other Cognition enhancer	Cancer, liver Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TA-2005	2-[1H]-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[2-(4-methoxyphenyl)-1-methyl-ethylamino]ethyl]-monohydrochloride, [R(R', R'')], [CAS]	137888-11-0	US 4879854	Aniasthma	Asthma
	2-[1H]-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[2-(4-methoxyphenyl)-1-methyl-ethylamino]ethyl]-monohydrochloride, [R(R', R'')], [CAS]				
	2-[1H]-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[2-(4-methoxyphenyl)-1-methyl-ethylamino]ethyl]-monohydrochloride, [R(R', R'')], [CAS]		WO 109480	Formulation, inhalable, solution	Asthma
TA-883	1,5-Benzothiazepin-4(5H)-one, 3-(acetoxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (R,R,3R)-rel-(+), (2Z)-2-bulene-2-carboxylate [CAS]	122024-98-0			
	(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2-hexenamido]-N-methyl-N-[(R)-Alpha-(methylcarbamoyl)phenethyl]-2-naphthalene propionamide	170851-70-4 193079-69-5	JP 01045376	Antithrombotic	Peripheral vascular disease
tabimorelin				Releasing hormones	Growth hormone deficiency
lactacitol	9,10-Secodrostea-5,7,10(19)-trien-1,3,24-triol, (1Alpha,36,5Z,7E,24R)- [CAS]	57333-96-7 93125-94-3	EP 129003	Antipsoriasis	Keratosis
lactodinaline	Benzamide, 4-(acetylamino)-N-[2-aminophenyl]- [CAS]	112522-64-2	DE 3613571	Anticancer, other	Cancer, pancreatic
lactine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	1834-40-8 321-64-2	EP 332147	Cognition enhancer	Alzheimer's disease
Tacrolimus		104987-11-3			
	Pyrazino(1',2':1,6)pyrido(3,4-b)indole, 4-dione, 6-(1,3-benzodioxol-5-yl)-, 2,3,6,7,12,12a-hexahydro-2-methyl-, (8R, trans) [CAS]	171596-29-5	US 6143746	Male sexual dysfunction	Impotence
teladafil	1,4-Pentanediamine, N-[2-(6-dimethoxy-4-methyl-5-(3-trifluoromethyl)phenoxy)-4-quinolinyl]- [CAS]	106635-80-7 106635-81-8 80065-55-0			
telencquine			US 4617394	Antimalarial	Infection, malaria
telapostia		176067-42-8	WO 9612727	Anticancer, other	Cancer, general
TA-375	(S)-N-[2-[(1S,7S)-Tetrahydro-2H-Indeno-[5,4-b]furan-3-yl)]propanamide			Hypnotic/Sedative	Insomnia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TAK-427	2-[6-[[3-[[4-(2-phenylmethoxy)-piperidin-1-yl]-2-pyridazin-2-yl]-2-methylpropanoic acid dihydrate			Antipruritic/anti-inflamm, allergic	Eczema, atopic
TAK-559	(E)-4-[[4-[[5-methyl-2-phenyl-1,3-oxazol-4-yl]methoxy]benzoyloxy]methyl]-4-phenylbutyric acid			Antidiabetic	Diabetes, general
Taka-Diastase	7H-1,3-Dioxolo[4,5-h][2,3]benzodiazepine, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (8R)- [CAS]	9001-19-3			
talampanel		161832-65-1	US 5639751	Antiepileptic	Epilepsy, general
Talampicillin	N-[(2S,3S)-18-Carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl porphyrin-20-yl]acetyl-L-aspartic acid	47747-56-8			
talaporfin		220201-34-3			
Talastine		16188-61-7		Radiochemosensitizer	Cancer, lung, general
Talbutal		115-44-6			
Talinolol		57460-41-0			
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- [CAS]	101626-70-4	DE 3503963	Antiparkinsonian	Schizophrenia
talirelant	4-Quinolincarboxamide, 3-hydroxy-2-phenyl-N-(19)-1-phenylpropyl- [CAS]	36095-79-1	WO 9532948	GI Inflammatory/bowel disorders	Irritable bowel syndrome
talniflumate	3-Pyridinecarboxylic acid, 2-[(3-((trifluoromethyl)phenyl)amino)-1,3-dihydro-3-oxo-1-isobenzotriazin-5-yl] ester [CAS]	174638-32-9			
talirelin	L-Prolineamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]	96088-62-2	BE 858864	Anti-inflammatory	Inflammation, ocular
talirelin	Eflitanamine, 2-[4-[(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	103300-74-9	JP 61033197	Neurological	Dyskinesia, general
tamoxifen		10540-29-1	US 4536516	Anticancer, hormonal	



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tamsulosin	Benzesulfonamide, 5-[2-[(2-ethoxyphenoxy)ethyl]amino]propyl-2-methyl-, (R)- [CAS]	106133-20-4 80223-99-0	EP 34432	Prostate disorders	Benign prostatic hyperplasia
lisdopamine	4,7-Methano-1H-isindole-1,3(2H)-dione, hexahydro-2-[4-[(2-pyrimidinyl)-1-piperazinyl]butyl-, (3aAlpha,4b,7b,7aAlpha)-, 2-hydroxy-1,2,3-propanetriocarboxylate (1:1) [CAS]	112457-95-1 87760-59-0	EP 82402	Anxiolytic	Anxiety, general
Tamoxifen		9010-29-1			
Taprostone	3-Quinolincarboxamide, N-2-[4-[(2,4-dihydro-6,7-dimethoxy-2(1H)-isochinolyl)ethyl]phenylamino]carbonyl-, 4,5-dimethoxyphenyl-, [CAS]	108945-35-3			
tarquidar	6-[2-(Dimethyl-amino)ethylamino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride	206873-93-4	WO 9817648	Radiochemotensitizer	Cancer, lung, non-small cell
TAS-103		174634-09-4	WO 9532187	Anticancer, other	Cancer, lung, non-small cell
Tasosartan		145733-38-4			
Taurolidine		81-224-3			
taurine		19388-87-5			
taurine	Acetic acid, oxo[3-(1H-tetrazol-5-yl)phenylamino]-, butyl ester [CAS]	82965-25-1	US 4778816	Antiasthma	
taurine	3-Pyridinecarboxylic acid, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothioyan-6-yl)ethyl]-, ethyl ester [CAS]	119232-40-3	EP 284288	Antiparasitis	Psoriasis
Tazobactam		89786-04-9			
tazobactam + piperacillin					
TBC-3711	N-Methyl-N-propargyl-10-aminomethyl-dibenzotrioxepin	374680-51-0	JP 58225091	Antibiotic, other	Infection, general
TCH-346	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethenyl-1H-imidazole [CAS]			Cardiovascular	Heart failure
tabipranem		82200-24-6		Neuroprotective	Anyotrophic lateral sclerosis
				Beta-lactam antibiotic	Infection, streptococcal

Table IV

API Generic Name	API Chemical Name [CAS]	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fecadenoson	Adenosine, N-[(3',4')-tetrahydro-3'-furanyl]- [CAS]	204512-90-3	WO 9808855	Antiarrhythmic	Tachycardia, supraventricular
fecastemizole	1H-Benzimidazol-2-amine, 1-[(4- fluorophenyl)methyl]-N-4-piperidinyl- [CAS]	75970-99-9	US 4219559	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Technetium <sup>99m</sup> Tc Bicisate		121281-41-2			
Technetium <sup>99m</sup> Tc Meritride		125224-05-7; 104348-91-6			
Technetium <sup>99m</sup> Tc Sestamibi		106681-73-9			
Technetium <sup>99m</sup> Tc Teboroxime		104716-22-5			
Teclothiazide		4267-5-4			
Teclozan	Spiro(cyclopentane-1,9'- (3,7)diazabicyclo[3.3.1]nonane), 3,7'- bis(cyclopropylmethyl)- [CAS]	5560-78-1			
Tedisamil		90961-53-8	EP 102833	Antiarrhythmic	Fibrillation, atrial
Tefurane	2,4'(H,3'H)-Pyrimidinone, 5-fluoro-1- (tetrahydro-2-furanyl)- [CAS]	124-72-1			
Tegafur	2,4'(H,3'H)-Pyrimidinone, 5-fluoro-1- (tetrahydro-2-furanyl)-, mxt. with 2,4'(H,3'H)-pyrimidinone- [CAS]	17902-23-7	GB 1168391	Anticancer, antimetabolite	Cancer, general
Tegafur + uracil	Hydrazinecarboximidamide, 2-[(6-methoxy- 1H-indol-3-yl)methylene]-N-pentyl-, (Z)-2- butenedioate [CAS]	74578-38-4 189189-57-6 145158-71-0	EP 224895	Anticancer, antimetabolite	Cancer, breast
Tegaserod		61036-64-4		GI inflammatory/bowel disorders	Irritable bowel syndrome
Telopplanin		3424-98-4		Antiviral, other	Infection, hepatitis-B virus
Telbivudine	8-L-2'-deoxythymidine				
Telenzepine		80880-90-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
telithromycin	8-De(2,6-dioxo-3-C-methyl-3-O-methyl-Alpha-L-ribo-hexapentanoxy)oxy-11,12-dioxo-5-O-methyl-5-oxo-1,2,11-trioxo-2-oxo-11-((4-(4,5-pyridiny)-1H-imidazol-1-yl)butylamino)-[CAS]	191114-48-4	EP 690967	Macrolide antibiotic	Infection, respiratory tract, general
	3,4-Triazolidinedicarboxylic acid, 3-ethyl ester, (R)- [CAS]	122946-43-4		COPD treatment	Bronchitis, chronic
telmisartan	(1',1'-Biphenyl)-2-carboxylic acid, 4'-((1',4'-dimethyl-2-propyl(2,6-bis-1H-benzimidazol-1-yl)methyl)-[CAS]	144701-48-4	EP 502314 WO 9841261	Antihypertensive, renin system Anticancer, other	Hypertension, general Cancer, general
telomerase inhibitors					
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US 3197467	Hypnotic/Sedative	Insomnia
temiverine	Benzenecarboxylic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-1,1-dimethyl-2-butyl ester, [CAS]	129927-33-9	GB 2222828	Urological	Pollakiuria
temocapril	1,4-Thiazepine-4(6H)-acetic acid, 6-[[1-(ethoxycarbonyl)-3-phenylpropyl(aminol)ethylhydro-5-oxo-2-(2-phenyl)-, [2S-[2A]alpha,6A(R)]]-[CAS]	102090-90-4 110221-44-8 111902-57-9	US 4495188	Antihypertensive, renin system	Hypertension, general
<b>Temocillin</b>		86148-78-5			
temopocifin	Phenol, 3,3',3'',3'''-4,2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl(tetrakis-, [CAS]	122341-38-2	EP 337601	Radiochemosensitizer	Cancer, head and neck
temozolomide	imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-[CAS]	85622-93-1	DE 3231255	Anticancer, alkylating	Cancer, brain, general
tenaciprazole	1H-imidazo[4,5-b]pyridine, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfonyl)-[CAS]	113712-98-4	US 4808596	Antitumor	Ulcer, gastric
<b>Tenecteplase</b>		191588-94-0			
<b>Tenidap</b>		120210-48-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
teriposide	Euro(3',4':6,7)naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[4,6-O-(2-phenylmethylene)-8-D-glucopyranosyl]oxy]-[6R-(Alpha,5aR,8aAlpha,3R(R'))]-[CAS] 29767-20-2		US 3524844	Anticancer, other	Cancer, lymphoma, non-Hodgkin's
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)-[CAS] 147127-20-6			Antiviral, anti-HIV	Infection, HIV/AIDS
tenofovir disoproxil	2,4,8,8-tetraoxa-5-phosphorane-2,4-dithiolic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl) bis(1-methylethyl)ester, 5-oxide (R), (E)-2-butenedithiolate	202138-60-9			
Tenonitroazole		38110-35-3		Antiviral, anti-HIV	Infection, HIV/AIDS
tenoxicam	2H-Tieno[2,3-aj-1,2-triazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	59804-37-4	GB 1619811	Antiarthritic, other	
Tenazonic Acid		610-88-8			
tepenone	5,9,13,17-Nordecatrian-2-one, 5,10,14,16-tetramethyl- [CAS] 8609-52-6	3756-53-2		Antitumor	
terazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1-tetrahydro-2-furanyl)carbonyl- [CAS]	83074-08-3 63960-64-7 70024-40-7			
tertinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)-[CAS]	78628-90-5 91161-71-6	US 4112097 EP 24587	Antihypertensive, adrenergic Antifungal	Hypertension, general Infection, dermatological
terbutaline	1,3-Benzene-diol, 5-[2-(1,1-dimethyl-ethyl)amino]-4-hydroxyethyl- [CAS]	23031-25-6		Formulation, mucosal, topical	Dysmenorrhea
terconazole	Piperazine, 1-[4-[(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl]-4-(1-methylethyl)-, cis- [CAS]	67915-31-5	US 4358449	Antifungal	Vaginitis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
terfenadine	1-Piperidinebutanol, Alpha-[4-(1,1-dimethyl-4-phenyl)-4-(hydroxydiphenylmethyl)-[CAS]	50679-08-8	US 3878217	Antiallergic, non-asthma	
tergicide	Urea, N-[4-allyl-2-[[6-allyl-5-methyltergolin-8-yl]-[CAS]	37886-84-3	EP 159522	Antiprolactin	Hyperprolactinaemia
Terlipressin		14636-12-5			
Terodiline		15793-40-5			
Terofenamate		29088-18-5			
Terpin		80-53-5			
tert-butanol	2-Propanol, 1-[(3,4-dihydro-2H-1-benzothienopyran-8-yl)oxy]-3-[(1,1-dimethyl-2-ethoxy-2-hydroxy-1-hydroxyethyl)amino]-, hydrochloride, (+)- [CAS]	33580-30-2 83888-84-0 34794-94-0		Antihypertensive, adrenergic	Hyper-tension, general
tert-Pentyl Alcohol	(2S)-2-ethoxy-3-[4-(2-[4-[(methylsulfonyl)oxy]phenyl)ethoxy]phenyl]propanoic acid	75-85-4	GB 1308191		
tesaglitazar				Antidiabetic	Diabetes, Type II
tesiniferrite	Etlanamine, N,N-Diethyl-2-(2-(phenylmethyl)phenoxy)-[CAS]	92981-78-7 968-93-4		Radio/diagnostic sensitizer	Cancer, breast
Testolactone					
Testosterone	androst-4-en-3-one, 17-hydroxy-, (17 $\beta$ )-[CAS]	58-22-0 5949-44-0		Formulation, transdermal, systemic	Hormone replacement therapy
tetrabornale		80763-47-5	DE 2748794	Anodytic	Addiction, alcohol
Tetrabarbital		76-23-3			
Tetrabenazine		58-46-8			
Tetracaine		136-47-0			
Tetrachloroethylene		127-18-4			
tetrache	Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester [CAS]	94-24-6		Formulation, transdermal, systemic	Pain, general
tetracycline	2-Naphthylsuccinylsuccinimide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4A)pha,4aA]pha,5aA]pha,6a,12aA]pha)-[CAS]	60-54-8		Formulation, oral, other	Infection, oral

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tetrahydrozoline		84-22-0			
Tetrandrine		518-34-3			
Tetranolol		52094-70-9			
Tetrazepam		10379-14-3			
Tetrafosmin		127502-06-1			
tetrazoprim	2,4-Pyrimidinodiamine, 5-[3,5-dimethoxy-4-(2-methoxyethoxy)phenyl]methyl- [CAS]	53808-97-0 74515-38-1			
Tevensel®		4302-95-8	US 3992379	Trimethoprim and analogues	Infection, general
tezacilabine	Cytidine, 2'-deoxy-2'-(fluoromethyl)ene)-, (2E)- [CAS]	130306-02-4	US 5616702	Anticancer, antimetabolite	Cancer, colorectal
tezasetan	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyridinyl)-5-(1-methylethyl)- [CAS]	180384-57-0		Cardioinulant	Oedema, general
thalidomide	1H-Isindole-1(3H)-dione, 2-(2,6-dioxo-3-piperidinyl)- [CAS]	50-35-1		Dermatological	Infection, dermatological
Thenaldine		86-12-4			
Thenyldiamine		91-79-2			
Theobromine		83-67-0			
Theocifrate		54504-70-0			
theophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	83-55-9 5967-84-0		Formulation, modified-release, other	Asthma
Thiabenzazole		148-79-8			
Thiacetazone		104-06-3			
thiamylserine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (9aS,8aS)-3,3a,8,8a-tetrahydro-3a,8,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]				
Thiobarbital		145209-51-4			
Thiamine		467-38-7		Cognition enhancer	Alzheimer's disease
Thiamine		59-43-8			
Thiamine		154-87-0			
Thiamine		87-18-3			
Thiamiprine		5581-52-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thiamphenicol		15318-45-3			
Thiamphenicol		77-27-0			
Thiazesim		5845-26-1			
Thiazinamium		58-34-4			
Thiazolinobutazone		54749-86-9			
Thiazolisulfone		473-30-3			
Thibenzazoline		6028-35-9			
Thiethylperazine		1420-55-9			
Thimeronate		5964-24-8			
Thimerosal		54-64-8			
Thiobarbital		77-32-7			
Thiobutabarbital		2086-57-0			
Thiocarbarnizine		91-71-4			
Thiocarbarnone		120-02-5			
Thiocolchicine		2730-71-4			
Thiocresol		26445-03-4			
Thiolicetic Acid		62-46-4			
Thioglycerol		96-27-5			
Thioguanine		154-42-7			
Thiolinreg	L-thiolyrosine-glycyl-glycine			Anticancer, immunological	Cancer, general
Thiopental		71-73-8			
Thiopropazate		84-06-0			
Thiopropazine		316-81-4			
Thioridazine		50-52-2			
Thiothixene		5591-45-7			
Thiothixene	Thiophosphonodiformic acid				
Thiothix				Antiviral, anti-HIV	Infection, HIV/AIDS
Thiophenamil		82-99-5			
Thiram		137-26-8			
Thionylamine		83-56-9			
Thozallinone		855-05-0			
Thromboplastin		9035-58-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thurify Nicotinate		70-19-9			
Thymecacin			US 6245750	Anticancer, other	Cancer, colorectal
Thymol		89-83-8			
Thymopentin		69558-55-0			
Thymyl N-Isoamylcarbamate		578-20-1			
Thiopropric Acid		51-26-3			
Thyroxine		51-48-9			
Tiadenol		6964-20-1			
Tiagabine	3-Piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-2-butenyl-, (R)- [CAS]	115103-54-3	WO 8700171	Antiepileptic	Epilepsy, general
Tiametidine		31428-61-2			
Tianeptine	Heptanoic acid, 7-[(3-chloro-5,11-dihydro-6-methylbenzo[ <i>c</i> ]1,2-thiazoph-11-yl)amino], 5S-dioxide [CAS]	72797-41-2 60981-73-5	GB 1298951	Antidepressant	Depression, general
Tiaproide	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	GB 1394503	Neuroleptic	
Tiaprofene acid	2-Thiophenacetic acid, 5-benzoyl-Alpha-methyl- [CAS]	33005-95-7	GB 1331505	Antiarthritic, other	
Tiaramide		32527-55-2			
Tiazofurin	4-Thiazolecarboxamides, 2- $\beta$ -D-ribofuranosyl- [CAS]	60084-10-8	EP 54432	Anticancer, antimetabolite	Cancer, leukaemia, chronic myelogenous
Tibezonium		54663-47-7			
Tibolone	1 $\beta$ -Norpregn-5(10)-en-20 $\beta$ -yn-3-one, 17-hydroxy-7-methyl-, (7 $\alpha$ Alfa,17 $\alpha$ Alfa)- [CAS]	5630-53-5	EP 389035	Menopausal disorders	Hormone replacement therapy
Ticarcillin	Ticarcillin (3,2-dipyrone, 5-[2-(chlorophenyl)methyl]-4,5,6,7-tetrahydro- [CAS]	34787-01-4			
Ticlopidine		53885-35-1 55142-85-3			
Ticrynafen	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium	40180-04-9	GB 1554424	Antithrombotic	
Tifenonium		6232-92-2 144-12-7			
		7		Antispasmodic	



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tigecycline	2-Naphthylacetoxycarbonyl, 4,7-bis(dimethylamino)-9-[[[1,1'-dimethyl-4,4',5,8,6',1,1',12a-octahydro-3,10,12,12a-tetrahydro-1,11-dioxo-, (4S,4S,8R,12aR)-]CAS]	220620-09-7	EP 582829	Tetracycline	Infection, general
Tigemonam		102507-71-1			
Tiglidine		495-83-0			
Tilidine		20380-58-9			
Tilisolol		85136-71-6			
timacoxib	Benzene-sulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-68-4	WO 9619463	Alimentary/Metabolic, other	Polyp
tiudronic acid	Phosphonic acid, [[(4-chlorophenyl)thio]methyl]bis- [CAS]	89887-06-4	EP 100718	Osteoporosis treatment	Page's disease
Timentin	apizadimur, 3-(di-2-thienylmethylene)-6-methoxy-1,1-dimethyl-, [CAS]	88482-18-0		Antibiotic, other	Infection, general
tinopidium		36036-06-3	GB 1358446	Antispasmodic	
Tinipirone		57648-21-2			
timolol	(-)-1-[(butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol]maleate (1:1) salt	26830-76-8 26921-17-5	GB 1253709	Anti-hypertensive, adrenergic, anti-glaucoma	
Timonacil		444-27-9			
Tin Ethyl Etiopurpurin		113471-15-1			
tinazoline	1H-Indazole, 3-[(4,5-dihydro-1H-imidazol-2-yl)thio]- [CAS]	62882-99-9	US 3376311	Vasodilator, peripheral	
Tinidazole		19387-91-8			
Tinoridine		24237-54-5			
Tiocarlide		910-86-1			
Tiocloamarol		22619-36-8			
tiocanazole	1H-imidazole, 1-[2-(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl- [CAS]	61675-64-7 55899-73-2	US 4082966	Antifungal	Infection, fungal, general
tiopronin	Glucine, N-(2-mercapto-1-oxopropyl)- [CAS]	1953-02-2	US 3248025	Urological	Homocystinuria

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
flutropium	3-Oxo-9-azabicyclo[6.3.1.02,4]nonane, 7-((hydroxy-2-methylacetoxy)-3,9-dimethyl-, [CAS]	136310-93-5 4591-65-5	EP 418716	COPD treatment	Chronic obstructive pulmonary disease
Tioxolone		5169-78-8			
Tipepidine	3-(1H-Quinolone-6-aminyl)-4-chlorophenyl-1-methyl-4-imidazol-5-ylmethyl-4-(3-chlorophenyl)-1-methyl [CAS]	192185-68-5 192185-72-1	WO 9716443	Anticancer, other	Cancer, breast
tipranavir	N-[3-((1R)-4-Hydroxy-2-oxo-8(R)-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyren-3-yl)propylphenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	174484-41-4		Antiviral, anti-HIV	Infection, HIV/AIDS
tiqizium	2H-Quinolizinium, 3-(di-2-thenylmethylene)octahydro-5-methyl-, [CAS]	71731-59-3 20028-90-2 27314-97-2 5424-06-6	US 4205074	Antispasmodic	
tirozamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxido-, [CAS]	51-24-1	DE 2204574	Radiocontrast sensitizer	Cancer, lung, non-small cell
Tiratricol					
tirolazad	Pregna-1,4,8(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methyl-, (16Alpha)-, [CAS]	110101-65-0 110101-67-2 110101-66-1	WO 8701706	Neuroprotective	Haemorrhage, subarachnoid
tiroliban	L-Tyrosine, N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl-, [CAS]	142373-80-2 144494-85-5	EP 478363	Antithrombotic	Infarction, myocardial
tiropamide	Benzazepinopropanamide, Alpha-(benzofenimino)-4-(2-(diethylamino)ethoxy)-N,N-di-propyl-, (+)-, [CAS]	56837-29-1			
Titanium Sulfate		13825-74-6	DE 2503992	Antispasmodic	Muscle spasm, general
tiwoctol	Pregna-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropylthio)-11,17-dihydroxy-, (11S)-, [CAS]	55560-96-8 61951-99-3	GB 1475795	Antiasthmatic, non-asthma, mucosal, topical	Rhinitis, allergic, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Isazandine	2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazo-2-yl)-[CAS]	51322-75-9	GB 1429926	Muscle relaxant	Spastic paralysis
TLK-199	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenyl-, diethyl ester, (2R)-[CAS]	169692-63-9	US 5679643	Immunosuppressant, other	Myelodysplastic syndrome
TLK-286	Glycine, L-Gamma-glutamyl-3-[(2-[(bis[2-chloroethyl]amino)phosphoryloxy]ethyl)sulfonyl]-L-alanyl-2-phenyl-, (2R)-[CAS]	156392-37-7	US 5545621	Anticancer, other	Cancer, ovarian
TNF- $\alpha$ analogue			RU 2036185	Anticancer, immunological	Cancer, general
TNP-470	Pregna-1,4-diene-3,20-dione, 9-fluoro-11 $\beta$ ,17,21-trihydroxy-16 $\beta$ ,2-methyl-, 17-butyrate 21-propanoate [CAS]	129298-91-5			
TO-186	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1 $\beta$ )-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl)-(1 $\rightarrow$ 4)-2-deoxy- [CAS]	5534-02-1		Antipruritic/anti-inflamm, allergic	
lobarmycin	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	32986-56-4		Formulation, inhalable, topical	Infection, respiratory tract, general
locainide		41706-72-9	US 4218477	Antiarrhythmic	Fibrillation, ventricular
Tocampthyl		5634-42-4			
toladefine	8-Chloroadenosine 3'5'-cyclic phosphate	41941-56-4			
Tocorelate		40516-48-1		Anticancer, other	Cancer, colorectal
Todalazine		14679-73-3			
Tofenacin	5-[1-Pyrazolo[3,4-b]-1,2,4-triazolo[4,3-b]pyridine-5-yl]pyrimidin-7-ethyl-6,9-dihydro-3-(2-thienyl)-	15301-93-6			
tolimilast		185954-27-2		Antiasthma	Asthma
tolisopam	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-[CAS]	22345-47-7	GB 1334271	Anxiolytic	Anxiety, general
Tolazamide		1156-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolazoline		59-98-3			
Tolbutamide		64-77-7			
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	EP 237829	Antiparkinsonian	Parkinson's disease
tolcidate	Carbamothic acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS]	50838-36-3			
Tolciclamide		864-95-9	GB 1364407	Antifungal	Infection, dermatological
tolivemar	Benzenesulfonic acid, 4-ethenyl-, homopolymer,				
tolifenamic acid	Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- [CAS]	28038-50-8		Antibacterial, other	Infection, Clostridium, general
Tolindate		13710-19-5	DE 1543295	Anti-inflammatory	Inflammation, general
Toliprolol		27877-51-8			
Tolmetin		28333-94-0			
Tolmetin		26171-23-3			
Tolnafate		2398-86-1			
Tolnidine		4201-22-3			
Toloniium		92-31-9			
toloxatone	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	29218-27-7	GB 1250538	Antidepressant	
Tolperisone		728-88-1			
Tolpropamine		5632-44-0			
Tolrestat		82964-04-3			
tolserine	Carbamic acid, (2-methylphenyl)-, (9aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-30-9			
tolterodine	Phenol, 2-[3-[(5S)-1-methyl-1-phenylpropyl]-4-methyl-, (R)- [CAS]	124937-51-5	EP 325571	Cognition enhancer Urological	Alzheimer's disease Incontinence
tolvaptan	Benzanide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- [CAS]	150683-30-0	EP 450097	Cardiovascular	Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolycaine	Beta-D-Fructopyranose, 2,3,4,5-bis-O-(1'-methyl-ethylidene)-, sulfamate [CAS]	3686-58-6 97240-79-4			
Topiramate			EP 533483	Antiepileptic	Epilepsy, generalized, tonic-clonic
topoisomerase inhibitors			US 5733880	Anticancer, other	Cancer, general
	1H-Pyran[3,4-b:1'-indolizino][1,2-b]quinoline-3,14(4H,12H)-dione, 9-[(dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]				
topotecan	3-Pyridinesulfonamide, N-[(1'-methyl-ethylamino)carbonyl]-4-[(3-methylphenyl)amino]- [CAS]	123948-87-8	EP 321122	Anticancer, other	Cancer, ovarian
torasemide	ethyl (2R,4S)-4-[(3,5-bis-(trifluoromethyl)benzyl)(methoxycarbonylamino)-2-ethyl-6-(trifluoromethyl)-5,4-dihydroquinoline-1(2H)-carboxylate	56211-40-5	US 4018929	Antihypertensive, diuretic	Hypertension, general
torcetrapib		262362-17-0			
torclabine	3-L-2'Deoxytycine			Hypolipemic/Atherosclerosis	Atherosclerosis
torsemide	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	89778-26-7 89778-27-8		Antiviral, other	Infection, hepatitis-B virus
Torsemide		56211-40-6	EP 95875	Anticancer, hormonal	Cancer, breast
Tositumomab		208921-02-2			
tosufloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, [CAS]	100490-36-6 115964-29-9	US 4704459	Quinolone antibacterial	Infection, urinary tract
tramadol	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+)-[CAS]	27203-92-5 36282-47-0		Analgasic, other	Pain, general
Tramadoline	1H-indole-2-carboxylic acid, 1-[2-[(1'-carboxy-3-phenylpropyl)amino]-1'-oxopropyl]octahydro-, [2S-1'[(R*)],2alpha,3aAlpha,7aalpha]- [CAS]	1082-57-1			
trandolapril		87679-71-8 87679-37-6 62-63-9	DE 3151690	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tranexamic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl), trans- [CAS]	1197-18-8	US 3850405	Antifibrinolytic	Menstrual disorder, general
tranilast	Benzoic acid, 2-[(3-(4-dimethoxyphenyl)-1-oxo-2-propenyl)amino]- [CAS]	53902-12-8	US 3940422	Vulnery	Wound healing
trans-retinoic acid	Retinoic acid [CAS]	302-79-4		Anticancer, other	Cancer, general
Tranycypromine		155-09-9			
trapidil	[1,2,4] Triazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	15421-84-8	DD 55956	Vasodilator, coronary	
Trastuzumab		180288-69-1			
travoprost	5-Hepienoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl), 1-methylethylester (1R(1Alpha(Z),2E(1E,3E'),3Alpha,5Alpha) [CAS]	157283-68-6		Formulation, mucosal, topical	Glaucoma
Traxanox	1-Picridimethanol, 4-hydroxy-4-(4-hydroxyphenyl)-5-methyl-4-phenyl-, (AlphaS,1S)- [CAS]	58712-69-9			
traxoprodil	1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)- [CAS]	134234-12-1 188591-67-5		Analgesic, other	Pain, general
trazodone		19794-93-5 25332-39-2	US 4215104	Antidepressant	
Tremacamra		155576-45-7			
Trenbolone		10161-33-8			
Trenigestone		5192-84-7			
treosulfan	1,2,3,4-Butanetetrol, 1,4-dithienanesulfonate, [S-(R',R'')] [CAS]	299-75-2	WO 8401506	Anticancer, alkylating	
treptibulone	Benzenesulfonic acid, 2,4,5-trifluoro-Gamma-oxo- [CAS]	41825-92-0	GB 1387733	Antiparasmodic	
treprostinil	Prosta-5,13-dien-1-ole acid, 6,9-epoxy-11,15-dihydroxy- [CAS]	35121-78-9 61648-14-7	US 6054486	Formulation, parenteral, other	Hypertension, pulmonary
trethoin	[5Z,9Alpha,11Alpha,13E,15S] [CAS]	302-79-4		Formulation, dermal, topical	Acre
	Retinoic acid [CAS]				

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
telocinol	6,7-bisacquinolindol, 1,2,3,4-tetrahydro-1-[(3,4,5-trimethoxyphenyl)methyl], (S)-[CAS]	1858-58-6 30416-38-3 21650 42-0	ZA 6802416	Antiesthma	
TRH	TRI 50b [CAS]	24305-27-9 238214-49-9		Antithrombotic	Thrombosis, general
Triacetin		102-76-1			
Triamcinolone Acetonide		76-25-5			
Triamcinolone		31002-79-6			
Benetonide		5611-51-8			
Triamcinolone Hexacetonide					
triamcinolone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[1-methyl(ethylidene)bis(oxy)], (11 $\beta$ ,16 $\alpha$ ) [CAS]	76-25-5 124-94-7		Formulation, inhalable, topical	Asthma
Triamterene		398-01-0			
Triapine	Triapine [CAS]	238392-56-8	US 6458816	Anticancer, antimetabolite	Cancer, leukaemia, general
Triaziquone		68-76-8			
Triazolam	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazol-3-yl[1,4]benzodiazepine	28911-01-5	US 3980790	Hypnotic/Sedative	Insomnia
Tribenoside		10310-32-4			
Trichlorfon		52-68-6			
Trichlormethiazide		133-67-5			
Trichlormethine		955-77-1			
Trichloroethylene		79-01-6			
Triclobisium		79-90-3			
Triclocarban		101-20-2			
Triclotenol Piperazine		5714-82-9			
Tricloros		306-52-5			
Triclosan		3380-34-5			
Tricromyl		85-90-5			
Tridihexethyl Iodide		125-99-5			

Table IV

API Generic Name	API Chemical Name [CAS]	CAS No. 38280-01-4 112- 24-3	Patent Reference	Example of Therapeutic Use	Example of Indication
trientine	1,1,2-Ethanediamine, N,N2-bis(2-aminomethyl)- [CAS]			Metabolic and enzyme disorders	Wilson's disease
Triethanolamine		102-71-6			
Triethylenemelamine		51-18-3			
Triethylenephosphoramide		545-65-1			
Triethylenethiophosphoramide		52-24-4			
Trifluoperazine		117-89-5			
Trifluoperidol		749-13-3			
Trifluopromazine		146-54-3			
trifluoridine	Thymidine, Alpha,Alpha,Alpha-trifluoro- [CAS]	70-00-3	US 3201387	Antiviral, other	Infection, herpes virus, general
triflusal	Benzoic acid, 2-(acetoxy)-4- (trifluoromethyl)- [CAS]	322-79-2	US 4096252	Antithrombotic	Thrombosis, general
Trihydroxyphenyl		52-49-3			
trifostane	Androst-2-ene-2-carbonitrile, 4,5-epoxy- 3,17-dihydroxy-, (4Alpha,5Alpha,17b)- [CAS]	13647-35-3	US 3296255	Anticancer, hormonal	Cancer, breast
Trifluazolin		35795-16-5			
trimebutine	Benzoic acid, 3,4,5-trimethoxy-, 2- (dimethylamino)-2-phenylbutyl ester, (2)-2- butenedioate (1:1) [CAS]	31-8	DE 2151716	Antispasmodic	
Trimecaine		616-68-2			
Trimeprazine		84-96-8			
Trimetazidine		5011-34-7			
Trimethadione		127-48-0			
Trimethaphan		68-91-7			
Trimethobenzamide		138-56-7			
Trimethoprim		738-70-5			
Trimetozine		635-41-6			
trimeprevale	2,4-Quinazolinodiamine, 5-methyl-5- [[3,4,5-trimethoxyphenyl]amino]methyl]- [CAS]	52126-35-5 82952-84-5	US 4391809	Antifungal	Infection, Pneumocystis [provec]



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tripramine	5H-Dibenzo[1,2-b:4,5-b']azepine-5-propanamine, 10,11-dihydro-N,N,8-trimethyl-, (2Z)-butenedioate (1:1) [CAS]	521-70-8 738-71-9		Antidepressant	
Trimoprostil		69900-72-7			
Tiroxalen		3902-71-4			
tripamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-(cyclohexyl-4,7-metheno-2H-benzodiox-5-yl)-, (3aAlpha,4Alpha,7alpha)-[CAS]	73803-48-2	JP 7305585	Antihypertensive, diuretic	Hypertension, general
Triparanol		78-41-1			
Tripeleminamine		91-81-6			
Triprolidine		486-12-4			
triprolin	Luteinizing hormone-releasing factor (pG), 6-D-tryptophan- [CAS]	124508-86-3 57773-63-4	US 4010125	Releasing hormones	Cancer, prostate
trilozine	Morpholine, 4-[thioxo(3,4,5-trimethoxyphenyl)methyl]- [CAS]	35619-65-9	US 3862138	Antitumor	
Tritioqualine	Phosphonic acid, [[d-(methylthio)phenyl]thio]methylene]bis-, disodium salt [CAS]	14504-73-5			
TRK-530		151425-92-2	WO 9410181	Antiarthritic, other	Arthritis, rheumatoid
TRK-620	2-Propenamide, N-[(5Alpha,8S)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydrooxymorphinan-6-yl]-3-(3-irany)-N-methyl-, monohydrochloride, (2E)- [CAS]	152658-17-8	WO 9315081	Antipruritic/anti-inflam, non-allergic	Pruritus
Troclolene		2244-21-5			
trofesamide	3-(2-Chloroethyl)-2-[bis(2-chloroethyl)amino]ethylhydro-2H-1,3,2-oxazaphosphorin 2-oxide	22089-22-1	GB 1186159	Anticancer, alkylating	
Troglitazone		97322-87-7			
Troleandomycin		2751-9-9			
Troloinitrate		588-42-1			
troniadinine	N-(1-acetamyl)-2-(2-dimethylamino ethoxy)acetamide	53783-83-8	DE 1941218	Antiviral, other	Infection, herpes simplex virus
Tromethamine		77-86-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tropacine		6878-98-4			
Tropesin		65189-78-8			
Tropicamide		1508-76-4			
tropine	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-carboxy-2-phenylethyl ester, (+/-) [CAS]				
tropine	1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, erub [CAS]	65189-78-8		Antiarthritic, other	
tropisetron					
Tropisetromycin					
tropium	3-Alpha-Hydroxyisopropyl (Alpha-H, 5-Alpha-H) norbornane-8,1-pyrolidinium benzoate	88669-04-9	GB 2125398	Antiemetic	Chemotherapy-induced nausea and vomiting
		10405-02-4		Urological	Poliakuria
trovafloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, (1-Alpha,5-Alpha,6-Alpha) [CAS]	147059-72-1 147059-76-4	US 5164402	Quinolone antibacterial	Infection, respiratory tract, general
trovafloxacin	2-(1H-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl), (2S-)) [CAS]	145918-75-8		Anticancer, other	Cancer, leukaemia, acute myelogenous
trovafloxacin		7085-55-4			
Troxerutin	Benzanilide, 3,4,5-trimethoxy-N-3-piperidinyl-, (+/-) [CAS]	3076105-4 997772	US 3647805	Antibulcer	Ulcer, gastric
Troxilide		81-8			
Trypan Red		574-84-1			
Trypsinamide		554-72-3			
Tryptophan		73-22-3			
TSH		9002-71-5			
	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-, 5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5-Alpha,7-Alpha, (S)] [CAS]				
TSN-09	Noramideic acid, bis(2-(ethoxycarbonyl)phenyl) ester	52485-79-7		Formulation, transdermal, patch	Pain, cancer
TU-2100			US 6180669	Anticancer	Acne

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tuaminoheptane		123-82-0			
Tubercidin		69-33-0			
Tubocurarine Chloride		57-94-3			
Tubutrol	Benzene methanol, 2-chloro-4-(1,1-dimethyl-2-phenylaminoethyl)- [CAS]	41570-61-0	DE 224737	Antiasthma	Asthma
TV-3326	N-(Propargyl-3R)aminoindan-5-yl-ethyl methyl carbamate			Cognition enhancer	Alzheimer's disease
TV-11223	Acetic acid, [2-(2,3,6,7-tetrahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadyn)-1H-inden-5-yl)ethoxy]-, [1S- (1Alpha(R),2S,3aAlpha,7aAlpha)]- [CAS]	140694-43-5	US 4837342	Antithrombotic	Unspecified
TV-12553	6,7,8,5-Tetrahydro-2-methyl-5H-cyclopenta[b]pyridine-3-carboxylguanidine maleate				
TVB-3216	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2	US 6258629	Antiarhythmic	Unspecified
Tybamate		4268-36-4		Formulation, modified-release, other	Angina, general
tyloxapol	4-(1,1,3,3-tetraethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	25301-02-4		Formulation, inhalable, topical	Cystic fibrosis
Tymazoline		24243-97-8			
Tyramine		51-67-2			
Tyropanoate		7246-21-1			
Ubenimex		58970-76-6			
ufenamate	Benzoic acid, 2-[(3-(trifluoromethyl)phenyl)aminol-, butyl ester [CAS]	67330-25-0	BE 861852	Antiinflammatory, non-allergic	
Undecylenic Acid		112-38-9			
Unoprostone		120373-36-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
URS-8880	4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazo[1-h]imidazol-1-yl]benzenesulfonamide [CAS]				
Uracil Mustard		66-75-1			
Uralyt-U	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:5:6), hydrate [CAS]	55049-48-4	US 4406535	Urological	Anti-inflammatory
Urapidil	2,4-[1(1,3H)-Pyrimidin-2-ylidene, 6-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl- [CAS]	34661-75-1	GB 1309324	Antihypertensive, adrenergic	Hypertension, general
urea	Urea [CAS]	57-13-6		Antipsoriasis	
Uredepa		302-49-8			
Urethan		51-79-6			
Uridine 5'-Triphosphate		63-39-8			
Urinastatin		80449-31-6			
ursodeoxycholic acid	3[alpha,7[alpha]-dihydroxy-5[alpha]-cholestan-24-olic acid [CAS]	128-13-2		Formulation, other, Cirrhosis, primary biliary, hepatic dysfunction, biliary calculus	Cirrhosis, primary biliary
Ursodiol		128-13-2			
Usitacell			US 6063773	Formulation, mucosal, topical	Contraceptive, female
Uzarin		20231-81-6			
valaciclovir	L-Valine, 2-[2-amino-1,6-dihydro-6-oxo-9H-purin-9-ylmethoxy]ethyl ester [CAS]	124832-26-4	EP 308065	Antiviral, other	Infection, herpes simplex virus
Valacyclovir		124832-26-4			
valdecoxib	Benzenesulfonamide, 4-[6-methyl-3-phenyl-4-isoxazolyl]- [CAS]	181695-72-7	US 5656257	Antiarthritic, other	Arthritis, rheumatoid
Valdepharmide		512-48-1			
Valiethamate		90-22-2			
valganciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-ylmethoxy)-3-hydroxypropyl ester [CAS]	175685-59-5	EP 694647	Antiviral, other	Infection, cytomegalovirus
Valnoctamide		175685-60-8			
		4171-113-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
valaciclovir	L-Valine (SR), 3-[(2-amino-1,6-dihydro-6-oxo-3H-purin-9-yl)methyl]-4-[(1-oxooctadecyl)oxy]butyl ester [CAS]	195156-77-5		Antiviral, other	Infection, herpes simplex virus
valproate	Pentanoic acid, 2-propyl-, [CAS]	7684-70-8		Antiepileptic	Epilepsy, generalized, tonic-clonic
<b>Valproic Acid</b>		1069-06-5	US 4998731		
<b>Valpromide</b>		99-66-1			
		2430-27-5			
valroacemide	Pentanamide, N-(2-amino-2-oxoethyl)-2-propyl- [CAS]	92282-58-3	US 5565358	Antiepileptic	Epilepsy, general
	Pentanoic acid, 2-(1,2,3,4,5,6,11-hexahydro-2,5,12-ethoxyoxy-7-methoxy-6,11-dioxo-4-(2,3,6-tetrayoxy-3-(trifluoroacetyl)amino)-Alpha-L-lyxofuranopropoxy)oxy)-2-[(pentafluorophenyl)-2-oxoethyl ester (2S-dis)-[CAS]	56124-62-0	US 4035566	Anticancer, antibiotic	Cancer, bladder
valrubicin	L-Valine, N-(1-oxopentyl)-N-[2-(1H-tetrazol-5-yl)-1,1'-biphenyl]-4-yl(methyl)-[CAS]	137862-53-4	EP 443963	Antihypertensive, renin system	Hypertension, general
<b>Valisartan</b>		121584-18-7			
<b>Valisopodar</b>					
wardenafil	Piperazine, 1-(3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-N](1,2,4)-triazin-2-yl)-4-sulphophenyl)sulfonyl)-4-ethyl- [CAS]	224785-60-4		Male sexual dysfunction	Sexual dysfunction, male, general
varespladib	Acetic acid, (S-(aminooxocetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy-, [CAS]	172732-88-2		Septic shock treatment	Septis
<b>Vaccine</b>		172733-42-5	EP 075110		
valantidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2:1:14, (diphenylmethyl)-1-piperazinylphenylethyl methyl ester, [CAS]	116308-55-5	EP 257616	Neuroprotective	Hypertension, general
VEA		133743-71-2	US 6007817	Radiochemosensitizer	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
vecuronium	Piperidium, 1- [2,3,5,6,10,16a,17b,17c]-3,17- bicyclo[2.2.1]hept-2-yl-1-methyl-, [CAS]	80700-72-8	US 4237126	Muscle relaxant	Anesthesia, adjunct
Velinacrine	Cyclohexanol, 1,2-dimethylamino-1-(4- methoxyphenyl)ethyl-, [CAS]	104675-29-8 93413-69-5 96300-78-4	US 2227743	Antidepressant	Depression, general
Verapamil	Benzeneacetic acid, Alpha-(3-[2-(3,4- dimethoxyphenyl)ethyl]amino)propyl- 1,3,4-dimethoxy-alpha-(1-methylethyl)- [CAS]	66644-81-3			
verapamil	23H,25H-Benzodiporphine-9,13- dipropionic acid, 18-ethenyl-4,4a-dihydro- 3,4-bis(methoxycarbonyl)-4a,8,14,19- tetramethyl-, monomethyl ester, trans- [CAS]	52-53-9		Formulation, modified-release, other	Hypertension, general
voriporfin	Piperazine, 1-(3,4-dimethoxybenzoyl)-4- (1,2,3,4-tetrahydro-2-oxo-6-quinolyl)- [CAS]	129497-76-5	US 5238940	Ophthalmological	Macular degeneration
vesaritone	Benzene carboximidamide, N,3,4,5- tetrahydroxy-, [CAS]	81840-15-5	GB 2086896	Cardiostimulant	Heart failure
Vetrabutine	Benzene carboximidamide, N,3,4,5- tetrahydroxy-, [CAS]	3735-45-3			
VF-233	9H-Purin-6-amine, 9-β-D-arabino furanosyl-, [CAS]	85933-74-7	US 4623659	Cardiovascular	Reperfusion injury
vidarabine	5-Fluorouracil, 2,4-dihydroxy-, [CAS]	58-17-4	US 6403597	Male sexual dysfunction	Premature ejaculation
Vigabatrin	5-Hydroxyisovaleric acid, 4-amino-, [CAS]	24355-66-9 68506-86-5 60643- 86-9	GB 1159290	Antiviral, other	Infection, herpes virus, general
Viloxazine	2-Benzofuran carboxamide, 5-[4-[4-(5- cyano-1H-indol-3-yl)butyl]-1-piperazinyl]- [CAS]	163521-12-8	GB 1472525	Antiepileptic	Epilepsy, partial (focal, focal)
Vimoxazine	4-(4-ethoxy-1,2,3,4-tetrahydroquinolin-2-yl)- 1,2,3,4-tetrahydroquinolin-2-yl-, [CAS]	46817-91-8	EP 648767	Antidepressant	Depression, general
Vinborel	2-(2,3,4,5-tetrahydro-1H-benzofuran-2-yl)- 1,2,3,4-tetrahydroquinolin-2-yl-, [CAS]	21363-10-8			
Vinbarbital	2-(2,3,4,5-tetrahydro-1H-benzofuran-2-yl)- 1,2,3,4-tetrahydroquinolin-2-yl-, [CAS]	125-44-0			
Vinblastine	2-(2,3,4,5-tetrahydro-1H-benzofuran-2-yl)- 1,2,3,4-tetrahydroquinolin-2-yl-, [CAS]	865-21-4			
vinorelbine	Eburnamenin-14(15H)-one, (3α,16α)-, [CAS]	474-00-0 4690-88-0	DE 1932245	Cognition enhancer	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Vincamine		1617-90-9			
Vincanate	Vincalutecoblastine, 22-oxo-, sulfate (1:1) (salt) [CAS]	70704-03-9			
Vincisline		2058-78-2			
		57-22-7	EP	Formulation, parenteral, other	Cancer, general
Vindesine	Vincalutecoblastine, 3-(aminocarbonyl)-O <sub>4</sub> -deacetyl-3-de(methoxycarbonyl)- [CAS]	53643-48-4			Cancer, leukaemia, acute lymphocytic
		59917-39-4	GB	Anticancer, other	
Vinflunine	Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-dihydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azepino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2R,3R,4S,5A)pha,12R,16Alpha)- [CAS]	102552-95-1	FR	Anticancer, other	Cancer, general
Vinorelbine	C'-Nonvincaleucoblastine, 3',4'-dihydro-4'-deoxy- [CAS]	71486-22-1	EP	Anticancer, other	Cancer, lung, non-small cell
Vinopocaine	Eburnamenine-14-carboxylic acid, ethyl ester, (3Alpha,16Alpha)- [CAS]	42971-09-5	GB	Cognition enhancer	Cognitive disorder, general
Vinyl Ether		109-93-3			
Vinybital		2430-49-1			
Viquidil		84-55-9			
Viridin		3306-62-3			
Vismidine		477-32-7			
Vitamin A		68-26-8			
Vitamin B12	Vitamin B12 [CAS]	68-19-9		Formulation, transmucosal, nasal	Anaemia, general
Vitamin C	L-Ascorbic acid [CAS]	50-81-7		Formulation, modified-release, <=24hr	Nutrition
Vitamin D <sub>2</sub>		50-14-6			
Vitamin D <sub>3</sub>		67-97-0			
Vitamin K <sub>2</sub>		83-70-5			
Vitamins, Prenatal					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
VLA-4 antagonists	(R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-(4-biphenyl)-methyl-4-methyl-2,5-dioximidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP 842943	Antiasthma	Asthma
VNP-40101M	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine		US 6040338	Anticancer, alkylating	Cancer, general
voglibose	D-spi-isoalot, 3,4-dideoxy-4-[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-[CAS]	83480-29-9	EP 56194	Antidiabetic	Diabetes, Type II
voriconazole	4-Pyrimidinethanol, Alpha (2,4-difluorophenyl)-5-fluoro-6-methyl-Alpha-(1H,4,2,4-tetra-1-ynenyl)-, (R) (R,S)-[CAS]				
Vorozole	7-[3-[4-(2-Quinolylmethyl)-1-piperazinylpropoxy]-3,4-dihydro-2H-1,4-benzothiazine-3-one	137234-62-9	EP 440372	Antifungal	Infection, fungal, general
VUF-K-8788		129731-10-8			
Warfarin		81-81-2		Antiasthma	Asthma
WF-10	Tetrachloroacoxide [CAS]	92047-76-2		Radiochemoprotective	Chemotherapy-induced injury, bone marrow, general
WMC-79	2-[3-[4-(6-oxo-6H-2,10b-diazacanthrin-5-ylamino)propyl]-piperazin-1-yl]propyl-5-nitro-2-azaphenylene-1,3-dione				
wound healing matrix					
WIP-170			US 5897880	Anticancer, other	Cancer, colorectal
xalproden	Pyridine, 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-[3-(trifluoromethyl)phenyl]-[CAS]	90494-79-4	US 6531121	Formulation, transdermal, patch	Ulcer, diabetic
xamoterol	4-Morpholinacetic acidamide, N-[2-(2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino]ethyl-, (+)-[CAS]	135354-020-8	EP 101381	Cytokine	Unspecified
		73210-73-8		Neuroprotective	Anyotropic lateral sclerosis
		81801-12-9	GB 2002748	Cardostimulant	Heart failure



Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Xanomeline		131986-45-3			
Xanthinol Nicotinate		437-74-1			
Xenilofiban		149620-74-6			
Xenbucic		959-10-4			
Xibemolol		81584-06-7			
xibornol	Phenol, 4,5-dimethyl-2,4,7,7-tetramethyl-2,2,1-hept-2-yl-, exo-[CAS]	13741-18-9	GB 1208774	Antibacterial, other	Infection, general
ximeagatren	Glycine, N-((R)-cyclohexyl-2-((2S)-2-(((4-(hydroxyamino)imino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl ester [CAS]	192939-46-1		Antithrombotic	Thrombosis, venous
Ximoprofen		56187-89-4			
xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US 3567777	Antihypertensive, diuretic	
xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-3-methyl-6-methylene-, (8S)- [CAS]	77287-89-9		Analgesic, other	Pain, cancer
XR-5116	2,5-Piperazinedione, 3-[[5-[(2-(dimethylamino)ethyl)amino]-2-(thienyl)methyl]-6-(phenylmethylene)-, monohydrochloride, (3Z,6Z)- [CAS]	174766-49-5	WO 9632190	Anticancer, other	Cancer, general
XR-5944	N,N'-(1,2-ethanediyldis(mino-2,1-ethanediyldis(9-methylphenazine-1-carboxamide)				
Xylometazoline		526-36-3	EP 934278	Anticancer, other	Cancer, general
Xylose		58-86-6			
YH-1885	2-Pyrimidinamine, 4-(2,4-dihydro-1-methyl-2(1H)-isouquinolyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	176307-42-1	WO 9605177	Antitumor	Ulcer, GI, general
YM-511	Benzonitrile, 4-[[[4-bromophenyl]methyl]-4H-1,2,4-triazol-4-ylamino]- [CAS]	148969-05-0	WO 9305027	Anticancer, hormonal	Cancer, breast

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
YM-598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethanesulfonamide				
<b>Yotilimbine</b>					
YT-146	Adenosine, 2-(1-octynyl)- [CAS]	146-48-5		Anticancer, other	Cancer, prostate
	Thiazolidine, 3-(2,3-dihydro-1H-imidaz-2-ylacetamido)-4-(1-pyrrolidinylcarbamoyl)-, (R)- [CAS]	90596-75-1	US 5270304	Anti-inflammatory	Inflammation, general
Z-321	(1H-imidazo-5-acetic acid, 2H)-4-chlorophenylsulfonamido(methyl)-2,3-dihydro, monosodium salt [CAS]	130845-58-0	EP 372484	Cognition enhancer	Dementia, senile, general
Z-335	Carbamate acid, [3-[2-methoxy-4-[[[2-methylphenyl)sulfonyl]amino]carbonyl]phenyl(methyl)-1-methyl-1H-imidaz-5-yl]-, cyclopentyl ester [CAS]	146731-14-8	JP 92506077	Antithrombotic	Peripheral vascular disease
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	107753-78-8	EP 199543	Antiasthma	Asthma
<b>Zalcitabine</b>		7481-89-2	US 4879277	Antiviral, anti-HIV	Infection, HIV/AIDS
<b>Zalcitabine</b>		109826-26-8			
zaleplon	Acetamide, N-[3-(3-cyanopyrazol-1,5-yl)pyrimidin-7-yl]phenyl-N-ethyl- [CAS]	151319-34-5	EP 776898	Hypnotic/Sedative	Insomnia
zalcitabine	Dibenzol[b,f]hept-2-ene-1,10,11-trihydro-10-oxo- [CAS]	74711-43-6	JP 5505282	Anti-inflammatory	
zanamivir	5-Acetanido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glucaro-D-galacto-non-2-enoic acid [CAS]	139110-80-8	WO 9116320	Antiviral, other	Infection, Influenza virus
zanatepazil	1-Propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- [CAS]	142852-50-4	EP 487071	Cognition enhancer	Alzheimer's disease
<b>Zatebradine</b>		85175-67-3			
ZD-0473	Platinum, aminomethylenedichloro(2-methylpyridine)- (SF-4-3)- [CAS]	181630-15-9	EP 727430	Anticancer, alkylating	Cancer, ovarian
ZD-0947	N-acetylcolchicol-O-phosphate		WO 9528388	Urological	Overactive bladder
ZD-6126	1H-Tetrazolo-5-bulanic acid, Alpha-((4-((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzyloxy) (S)- [CAS]			Anticancer, other	Cancer, general
ZD-9331		153537-73-6	GB 226-0946	Anticancer, antimetabolite	Cancer, pancreatic

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zabulirine	2(1H)-Pyrimidinone, 1,4-D-ribofuranosyl- [CAS]	3890-10-6		Anticancer, other	Cancer, general
zelandopam	7,8-isiquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-, [CAS]	138086-00-7	JP 03190618	Vasodilator, renal	Hypertension, general
Zenarestat		112733-06-9			
Ziconotide	Thymidine, 3'-azido-3'-deoxy- [CAS]	107452-89-1	US 4724232	Antiviral, anti-HIV	Infection, HIV/AIDS
zidovudine	Urea, N-(1-benzofuran-2-ylthio)-N'-hydroxy- [CAS]	30516-87-1	EP 279263	Antiasthma	Asthma
zileuton		111406-87-2			
Zimeldine		56775-88-3			
zinc acetate	hexakis(m-acetato)-m4-oxotetrazinc	12129-82-7		Antiviral, other	Infection, herpes simplex virus prophylaxis
zinc ascorbate	Hexanoic acid, 6-(acetylaminio), zinc salt (2:1)- [CAS]	70020-71-2	EP 369088	Anticancer	Ulcer, duodenal
zinc bupropfenate		76416-90-5		Anti-inflammatory, topical	Inflammation, dermal
Zinc p-Phenolsulfonate		127-82-2			
Zinc Salicylate		16283-36-6			
Zinostatin		9014-2-2			
zincosatin simlamer		123760-07-6	EP 136791	Anticancer, antibiotic	Cancer, liver
Zipprol		34758-83-3			
Zibraidone	2H-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	122883-93-6 146939-27-7	EP 281309	Neuroleptic	Schizophrenia
zofenopril	L-Proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)- [1(R'),2Alpha,4Alpha]- [CAS]	75176-37-3 81872-10-8 81938-43-4	GB 2026327	Antihypertensive, renin system	Hypertension, general
zofenopril + HCTZ	L-Proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)- 4'((R'),2Alpha,4Alpha)- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7-sulfonamide, 1,1-dioxide [CAS]				
zoledronic acid	Phosphonic acid, [1-hydroxy-2(1H-imidazol-1-yl)ethylidene]bis- [CAS]	118072-93-8 165800-09-6	EP 531253	Formulation, fixed-dose combinations Osteoporosis treatment	Hypertension, general Hypercalcaemia of malignancy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zolmidine	2-(6-methylsulfonylphenyl)imidazo[1,2-a]pyridine	1222-57-7	US 3318680	Anticancer	Gastritis
zolmitriptan	2-Oxazolidinone, 4-[(6-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl], [6]- [CAS]	139284-17-8	WO 9118897	Antimigraine	Migraine
zolpidem	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-[(4-methylphenyl)-(R,R'-R'')-2,3-dihydroxybutanedioate (2:1)] [CAS]	99294-93-6 82626 48-0	EP 50563	Hypnotic/Sedative	Insomnia
<b>Zomepirac</b>	1-(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-[(1H-imidazol-1-yl)-6-nitro-2,3-dioxo- [CAS]	333369-31-2			
zonanpanel	1H-pyrazole-4-carboxamide, N-(aminomino methyl)-5-cyclopropyl-1-(6-quinolinyl),	210245-80-0		Neuroprotective	Ischaemia, cerebral
zoniporide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	249296-45-5 68291-97-4 68291-98-5		Cardiovascular	Unspecified
zonisamide	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2	GB 2025931	Antiepileptic	Epilepsy, generalized, tonic-clonic
zopiclone		110703-94-1	GB 1356680	Hypnotic/Sedative	Insomnia
<b>Zopolresiat</b>		54083-22-6	-		
<b>Zorubicin</b>	1-Piperazineethanol, 4-(1,1-difluoro-1,3a,6,10b-tetrahydrobenzo[e]cyclopropa[cyclohexen-6-yl)-Alpha-(5-quinolinoyloxy)methyl-, [(R)-(1a,6a,10a,10b)- [CAS]	167465-36-3		Radio/chemosensitizer	Cancer, leukaemia, acute myelogenous
zosuquidar	Ethanamine, 2-[(8-chlorodibenzolb-[f]piperidin-10-yl)oxy]-N,N-dimethyl-, [CAS]	26615-21-4	GB 1247067	Neuroleptic	Schizophrenia
zotepine	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	0162775	WO 0162775	Antiarthritic	Arrhythmia, general
ZP-123					
Z-tamoxifen		10540-29-1		Anticancer, hormonal	Cancer, colorectal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zuclopentixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-, (Z)-(CAS)	53772-83-1 982,24-9 85721-05-7 64035-00-5	EP 270282	Neuroleptic	Psychosis, general

**CLAIMS:**

1. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and co-crystal former are hydrogen bonded to each other.
2. The pharmaceutical co-crystal composition according to claim 1, wherein:
  - (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
  - (b) the API is selected from an API of Table IV;
  - (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
  - (d) the API is a liquid at room temperature;
  - (e) the API is a solid at room temperature;
  - (f) the API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
  - (g) the co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring,

thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (h) the difference in  $pK_a$  between the API and the co-crystal former does not exceed 2;
- (i) the solubility of the co-crystal is increased as compared to the API;
- (j) the dose response of the co-crystal is increased as compared to the API;
- (k) the dissolution of the co-crystal is increased as compared to the API;
- (l) the bioavailability of the co-crystal is increased as compared to the API;
- (m) the stability of the co-crystal is increased as compared to the API;
- (n) a difficult to salt or unsaltable API is incorporated into the co-crystal;
- (o) the hygroscopicity of the co-crystal is decreased as compared to the API;
- (p) an amorphous API is crystallized as a component of the co-crystal;
- (q) the form diversity of the co-crystal is decreased as compared to the API; or
- (r) the morphology of the co-crystal is modulated as compared to the API.

3. A pharmaceutical co-crystal composition, comprising: an API, a co-crystal former, and a third molecule; wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.

4. The pharmaceutical co-crystal composition according to claim 3, wherein:

- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (b) the API is selected from an API of Table IV;
- (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (d) the API is a liquid at room temperature;

- (e) the API is a solid at room temperature;
- (f) the API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (g) the co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
- (h) the difference in  $pK_a$  between the API and the co-crystal former does not exceed 2;
- (i) the solubility of the co-crystal is increased as compared to the API;
- (j) the dose response of the co-crystal is increased as compared to the API;
- (k) the dissolution of the co-crystal is increased as compared to the API;
- (l) the bioavailability of the co-crystal is increased as compared to the API;
- (m) the stability of the co-crystal is increased as compared to the API;
- (n) a difficult to salt or unsaltable API is incorporated into the co-crystal;
- (o) the hygroscopicity of the co-crystal is decreased as compared to the API;



- (p) an amorphous API is crystallized as a component of the co-crystal;
  - (q) the form diversity of the co-crystal is decreased as compared to the API; or
  - (r) the morphology of the co-crystal is modulated as compared to the API.
5. A pharmaceutical co-crystal composition, comprising: a first and a second API, wherein each API is either a liquid or a solid at room temperature, and wherein the APIs are hydrogen bonded to a molecule.
6. The pharmaceutical co-crystal composition according to claim 5, wherein:
- (a) the first API is hydrogen bonded to the second API;
  - (b) an API is selected from an API of Table IV;
  - (c) each API is selected from an API of Table IV;
  - (d) an API is a liquid at room temperature and the other API is a solid at room temperature;
  - (e) each API is a solid at room temperature;
  - (f) an API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
  - (g) each API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo,

organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (h) the difference in  $pK_a$  between the first API and the second API does not exceed 2;
- (i) the solubility of the co-crystal is increased as compared to an API;
- (j) the dose response of the co-crystal is increased as compared to an API;
- (k) the dissolution of the co-crystal is increased as compared to an API;
- (l) the bioavailability of the co-crystal is increased as compared to an API;
- (m) the stability of the co-crystal is increased as compared to an API;
- (n) a difficult to salt or unsaltable API is incorporated into the co-crystal;
- (o) the hygroscopicity of the co-crystal is decreased as compared to an API;
- (p) an amorphous API is crystallized as a component of the co-crystal;
- (q) the form diversity of the co-crystal is decreased as compared to an API; or
- (r) the morphology of the co-crystal is modulated as compared to an API.

7. A pharmaceutical co-crystal composition, comprising: a first and a second co-crystal former, wherein each co-crystal former is a solid at room temperature, and wherein both co-crystal formers are hydrogen bonded to a molecule.

8. The pharmaceutical co-crystal composition according to claim 7, wherein:
- (a) the first co-crystal former is hydrogen bonded to the second co-crystal former;
  - (b) a co-crystal former is selected from a co-crystal former of Table I or Table II;
  - (c) each co-crystal former is selected from a co-crystal former of Table I or Table II;

- (d) a co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (e) each co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (f) the difference in  $pK_a$  between the first co-crystal former and the second co-crystal former does not exceed 2;
- (g) the solubility of the co-crystal is increased as compared to a co-crystal former;
- (h) the dose response of the co-crystal is increased as compared to a co-crystal former;
- (i) the dissolution of the co-crystal is increased as compared to a co-crystal former;
- (j) the bioavailability of the co-crystal is increased as compared to a co-crystal former;
- (k) the stability of the co-crystal is increased as compared to a co-crystal former;
- (l) a difficult to salt or unsaltable API is incorporated into the co-crystal;

- (m) the hygroscopicity of the co-crystal is decreased as compared to a co-crystal former;
  - (n) an amorphous API is crystallized as a component of the co-crystal;
  - (o) the form diversity of the co-crystal is decreased as compared to a co-crystal former; or
  - (p) the morphology of the co-crystal is modulated as compared to a co-crystal former.
9. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, or ibuprofen.
10. The pharmaceutical co-crystal composition according to claim 1, 3, 5, or 7, further comprising a pharmaceutically acceptable diluent, excipient, or carrier.
11. A co-crystal comprising an API and a co-crystal former selected from the group consisting of:
- (a) carbamazepine and saccharin;
  - (b) carbamazepine and nicotinamide;
  - (c) carbamazepine and trimesic acid;
  - (d) celecoxib and nicotinamide;
  - (e) olanzapine and nicotinamide;
  - (f) celecoxib and 18-crown-6;
  - (g) itraconazole and succinic acid;
  - (h) itraconazole and fumaric acid;
  - (i) itraconazole and L-tartaric acid;
  - (j) itraconazole and L-malic acid;
  - (k) itraconazoleHCl and DL-tartaric acid;
  - (l) modafinil and malonic acid;

- (m) modafinil and glycolic acid;
- (n) modafinil and maleic acid;
- (o) topiramate and 18-crown-6;
- (p) 5-fluorouracil and urea;
- (q) hydrochlorothiazide and nicotinic acid;
- (r) hydrochlorothiazide and 18-crown-6;
- (s) hydrochlorothiazide and piperazine;
- (t) acetaminophen and 4,4'-bipyridine;
- (u) phenytoin and pyridone;
- (v) aspirin and 4,4'-bipyridine;
- (w) ibuprofen and 4,4'-bipyridine;
- (x) flurbiprofen and 4,4'-bipyridine;
- (y) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;
- (z) carbamazepine and p-phthalaldehyde;
- (aa) carbamazepine and 2,6-pyridinedicarboxylic acid;
- (bb) carbamazepine and 5-nitroisophthalic acid;
- (cc) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid; and
- (dd) carbamazepine and benzoquinone.

12. A process for preparing a pharmaceutical co-crystal composition comprising an API and a co-crystal former, comprising:

- (a) providing an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature;
- (b) grinding, heating, co-subliming, co-melting, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase, wherein the API and co-crystal former are hydrogen bonded to each other;
- (c) isolating co-crystals formed thereby; and

- (d) incorporating the co-crystals into a pharmaceutical composition.
13. The process of claim 12, wherein:
- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
  - (b) the API is selected from an API of Table IV;
  - (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
  - (d) the API is a liquid at room temperature;
  - (e) the API is a solid at room temperature;
  - (f) the API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
  - (g) the co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
  - (h) the difference in  $pK_a$  between the API and the co-crystal former does not exceed 2.

14. A process for preparing a pharmaceutical co-crystal composition comprising an API, a co-crystal former, and a third molecule, comprising:
- (a) providing an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature;
  - (b) grinding, heating, co-subliming, co-melting, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase, wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other;
  - (c) isolating co-crystals formed thereby; and
  - (d) incorporating the co-crystals into a pharmaceutical composition.
15. The process of claim 14, wherein:
- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
  - (b) the API is selected from an API of Table IV;
  - (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
  - (d) the API is a liquid at room temperature;
  - (e) the API is a solid at room temperature;
  - (f) the API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (g) the co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
  - (h) the difference in  $pK_a$  between the API and the co-crystal former does not exceed 2.
16. A process for preparing a pharmaceutical co-crystal composition comprising a first and a second API, comprising:
- (a) providing a first and a second API, wherein each API is either a liquid or a solid at room temperature;
  - (b) grinding, heating, co-subliming, co-melting, or contacting in solution the APIs under crystallization conditions, so as to form a solid phase, wherein the APIs are hydrogen bonded to a molecule;
  - (c) isolating co-crystals formed thereby; and
  - (d) incorporating the co-crystals into a pharmaceutical composition.
17. The process of claim 16, wherein:
- (a) the first API is hydrogen bonded to the second API;
  - (b) an API is selected from an API of Table IV;
  - (c) each API is selected from an API of Table IV;
  - (d) an API is a liquid at room temperature and the other API is a solid at room temperature;
  - (e) each API is a solid at room temperature;
  - (f) an API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone,



thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

- (g) each API has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
- (h) the difference in  $pK_a$  between the first API and the second API does not exceed 2.

18. A process for preparing a pharmaceutical co-crystal composition comprising a first and a second co-crystal former, comprising:

- (a) providing a first and a second co-crystal former, wherein each co-crystal former is a solid at room temperature;
- (b) grinding, heating, co-subliming, co-melting, or contacting in solution the co-crystal formers under crystallization conditions, so as to form a solid phase, wherein both co-crystal formers are hydrogen bonded to a molecule;
- (c) isolating co-crystals formed thereby; and
- (d) incorporating the co-crystals into a pharmaceutical composition.

19. The process of claim 18, wherein:

- (a) the first co-crystal former is hydrogen bonded to the second co-crystal former;
- (b) a co-crystal former is selected from a co-crystal former of Table I or Table II;
- (c) each co-crystal former is selected from a co-crystal former of Table I or Table II;
- (d) a co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (e) each co-crystal former has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine; or
- (f) the difference in  $pK_a$  between the first co-crystal former and the second co-crystal former does not exceed 2.

20. The process of claim 12, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, or ibuprofen.

21. The process of claim 12, further comprising: incorporating a pharmaceutically acceptable diluent, excipient, or carrier.
22. A process of preparing a co-crystal comprising an API and a co-crystal former, comprising:
- (a) providing an API and a co-crystal former;
  - (b) grinding, heating, co-subliming, co-melting, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase; and
  - (c) isolating co-crystals formed thereby;

wherein the API and the co-crystal former, respectively, are selected from the group consisting of: carbamazepine and saccharin, carbamazepine and nicotinamide, carbamazepine and trimesic acid, celecoxib and nicotinamide, olanzapine and nicotinamide, celecoxib and 18-crown-6, itraconazole and succinic acid, itraconazole and fumaric acid, itraconazole and tartaric acid, itraconazole and malic acid, itraconazoleHCl and tartaric acid, modafinil and malonic acid, modafinil and glycolic acid, modafinil and maleic acid, topiramate and 18-crown-6, 5-fluorouracil and urea, hydrochlorothiazide and nicotinic acid, hydrochlorothiazide and 18-crown-6, hydrochlorothiazide and piperazine, acetaminophen and 4,4'-bipyridine, phenytoin and pyridone, aspirin and 4,4'-bipyridine, ibuprofen and 4,4'-bipyridine, flurbiprofen and 4,4'-bipyridine, flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene, carbamazepine and p-phthalaldehyde, carbamazepine and 2,6-pyridinedicarboxylic acid, carbamazepine and 5-nitroisophthalic acid, carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid, and carbamazepine and benzoquinone.

23. A process for modulating the solubility of an API for use in a pharmaceutical composition, which process comprises:
- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;

- (b) isolating the co-crystal, wherein the co-crystal has a modulated solubility as compared to the API; and
  - (c) incorporating the co-crystal having modulated solubility into a pharmaceutical composition.
24. The process of claim 23, wherein the solubility of the co-crystal is increased as compared to the API.
25. A process for modulating the dose response of an API for use in a pharmaceutical composition, which process comprises:
- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
  - (b) isolating the co-crystal, wherein the co-crystal has a modulated dose response as compared to the API; and
  - (c) incorporating the co-crystal having modulated dose response into a pharmaceutical composition.
26. The process of claim 25, wherein the dose response of the co-crystal is increased as compared to the API.
27. A process for modulating the dissolution of an API for use in a pharmaceutical composition, which process comprises:
- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
  - (b) isolating the co-crystal, wherein the co-crystal has a modulated dissolution as compared to the API; and

- (c) incorporating the co-crystal having modulated dissolution into a pharmaceutical composition.
28. The process of claim 27, wherein the dissolution of the co-crystal is increased as compared to the API.
29. A process for modulating the bioavailability of an API for use in a pharmaceutical composition, which process comprises:
- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
  - (b) isolating the co-crystal, wherein the co-crystal has a modulated bioavailability as compared to the API; and
  - (c) incorporating the co-crystal having modulated bioavailability into a pharmaceutical composition.
30. The process of claim 29, wherein the bioavailability of the co-crystal is increased as compared to the API.
31. A process for increasing the stability of an API for use in a pharmaceutical composition, which process comprises:
- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
  - (b) isolating the co-crystal, wherein the co-crystal has increased stability as compared to the API; and
  - (c) incorporating the co-crystal having increased stability into a pharmaceutical composition.

32. A process for the incorporation of a difficult to salt or unsaltable API for use in a pharmaceutical composition, which process comprises:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal;
- (c) incorporating the co-crystal having a difficult to salt or unsaltable API into a pharmaceutical composition.

33. A process for decreasing the hygroscopicity of an API for use in a pharmaceutical composition, which process comprises:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has decreased hygroscopicity as compared to the API; and
- (c) incorporating the co-crystal having decreased hygroscopicity into a pharmaceutical composition.

34. A process for crystallizing an amorphous API for use in a pharmaceutical composition, which process comprises:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal;
- (c) incorporating the co-crystal into a pharmaceutical composition.

35. A process for decreasing the form diversity of an API for use in a pharmaceutical composition, which process includes:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has decreased form diversity as compared to the API; and
- (c) incorporating the co-crystal having decreased form diversity into a pharmaceutical composition.

36. A process for modulating the morphology of an API for use in a pharmaceutical composition, which process includes:

- (a) grinding, heating, co-subliming, co-melting, or contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (b) isolating the co-crystal, wherein the co-crystal has a different morphology as compared to the API; and
- (c) incorporating the co-crystal having modulated morphology into a pharmaceutical composition.

37. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an amino-pyridine functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) water;
- (e) an alcohol;
- (f) a primary amine;

- (g) a secondary amine;
- (h) a carbonyl;
- (i) a sulfoxo moiety;
- (j) an ether;
- (k) an ester;
- (l) an aromatic N;
- (m) a cyano moiety;
- (n) a nitro moiety;
- (o) a chloride moiety;
- (p) a bromide moiety;
- (q) a primary amide where the interaction distance is between about 2.97 and about 3.07 angstroms;
- (r) a secondary amide where the interaction distance is between about 2.70 and about 3.20 angstroms;
- (s) a secondary amide where the interaction distance is between about 2.75 and about 3.17 angstroms;
- (t) a carboxylic acid where the interaction distance is between about 2.72 and about 3.07 angstroms;
- (u) a carboxylic acid where the interaction distance is between about 2.54 and about 2.82 angstroms;
- (v) water where the interaction distance is between about 2.72 and about 3.15 angstroms;
- (w) water where the interaction distance is between about 2.65 and about 3.15 angstroms;
- (x) an alcohol where the interaction distance is between about 2.78 and about 3.14 angstroms;
- (y) an alcohol where the interaction distance is between about 2.63 and about 3.06 angstroms;
- (z) a primary amine where the interaction distance is between about 2.85 and about 3.25 angstroms;



- (aa) a secondary amine where the interaction distance is between about 2.83 and about 3.25 angstroms;
- (bb) a carbonyl where the interaction distance is between about 2.87 and about 3.10 angstroms;
- (cc) a sulfoxo moiety where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (dd) an ether where the interaction distance is between about 2.84 and about 3.20 angstroms;
- (ee) an ester where the interaction distance is about 3.09 angstroms;
- (ff) an ester where the interaction distance is between about 2.85 and about 3.16 angstroms;
- (gg) an aromatic N where the interaction distance is between about 2.78 and about 3.25 angstroms;
- (hh) a cyano moiety where the interaction distance is between about 2.83 and about 3.30 angstroms;
- (ii) a nitro moiety where the interaction distance is between about 2.85 and about 3.28 angstroms;
- (ji) a chloride moiety where the interaction distance is between about 3.10 and about 3.45 angstroms; or
- (kk) a bromide moiety where the interaction distance is between about 3.27 and about 3.48 angstroms.

38. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a primary amine functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;

- (g) an alcohol;
- (h) a carbonyl;
- (i) a sulfoxo moiety;
- (j) a sulfonyl;
- (k) an ether;
- (l) an ester;
- (m) an aromatic N;
- (n) a cyano moiety;
- (o) a nitro moiety;
- (p) a chloride moiety;
- (q) a bromide moiety;
- (r) a primary amide where the interaction distance is between about 2.73 and about 3.20 angstroms;
- (s) a secondary amide where the interaction distance is between about 2.65 and about 3.20 angstroms;
- (t) a carboxylic acid where the interaction distance is between about 2.74 and about 3.15 angstroms;
- (u) a carboxylic acid where the interaction distance is between about 2.72 and about 3.12 angstroms;
- (v) an amino-pyridine where the interaction distance is between about 3.10 and about 3.24 angstroms;
- (w) a sulfonamide where the interaction distance is between about 2.86 and about 3.17 angstroms;
- (x) water where the interaction distance is between about 2.65 and about 3.17 angstroms;
- (y) an alcohol where the interaction distance is between about 2.63 and about 3.26 angstroms;
- (z) a carbonyl where the interaction distance is between about 2.64 and about 3.15 angstroms;
- (aa) a sulfoxo moiety where the interaction distance is between about 2.70 and about 3.10 angstroms;

- (bb) a sulfonyl where the interaction distance is between about 2.93 and about 3.12 angstroms;
  - (cc) an ether where the interaction distance is between about 2.75 and about 3.25 angstroms;
  - (dd) an ester where the interaction distance is between about 2.90 and about 3.20 angstroms;
  - (ee) an ester where the interaction distance is between about 2.74 and about 3.27 angstroms;
  - (ff) an aromatic N where the interaction distance is between about 2.92 and about 3.26 angstroms;
  - (gg) a cyano moiety where the interaction distance is between about 2.83 and about 3.30 angstroms;
  - (hh) a nitro moiety where the interaction distance is between about 2.75 and about 3.17 angstroms;
  - (ii) a chloride moiety where the interaction distance is between about 3.07 and about 3.50 angstroms; or
  - (jj) a bromide moiety where the interaction distance is between about 3.23 and about 3.60 angstroms.
39. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a primary sulfonamide functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:
- (a) water;
  - (b) an alcohol;
  - (c) a primary amine;
  - (d) a secondary amine;
  - (e) a sulfonyl;
  - (f) an ether;
  - (g) an ester;
  - (h) a cyano moiety;
  - (i) a nitro moiety;

- (j) a chloride moiety;
- (k) water where the interaction distance is about 2.87 angstroms;
- (l) an alcohol where the interaction distance is between about 2.85 and about 3.07 angstroms;
- (m) a primary amine where the interaction distance is between about 2.85 and about 3.20 angstroms;
- (n) a secondary amine where the interaction distance is between about 2.85 and about 3.20 angstroms;
- (o) a sulfonyl where the interaction distance is between about 2.85 and about 3.20 angstroms;
- (p) an ether where the interaction distance is between about 2.90 and about 3.20 angstroms;
- (q) an ester where the interaction distance is between about 2.85 and about 3.12 angstroms;
- (r) a cyano moiety where the interaction distance is about 3.00 angstroms;
- (s) a nitro moiety where the interaction distance is between about 3.00 and about 3.20 angstroms; or
- (t) a chloride moiety where the interaction distance is between about 3.20 and about 3.32 angstroms.

40. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a primary amide functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a secondary amide;
- (b) a carboxylic acid;
- (c) an amino-pyridine;
- (d) an aromatic N;
- (e) water;
- (f) an alcohol;
- (g) a secondary amine;
- (h) a carbonyl;

- (i) a sulfonyl;
- (j) an ether;
- (k) an ester;
- (l) a cyano moiety;
- (m) a nitro moiety;
- (n) a chloride moiety;
- (o) a bromide moiety;
- (p) a secondary amide where the interaction distance is between about 2.70 and about 3.15 angstroms;
- (q) a carboxylic acid where the interaction distance is between about 2.40 and about 2.80 angstroms;
- (r) a carboxylic acid where the interaction distance is between about 2.80 and about 3.25 angstroms;
- (s) an amino-pyridine where the interaction distance is between about 2.90 and about 3.20 angstroms;
- (t) an amino-pyridine where the interaction distance is between about 2.80 and about 3.10 angstroms;
- (u) an aromatic N where the interaction distance is between about 2.90 and about 3.21 angstroms;
- (v) water where the interaction distance is between about 2.60 and about 3.00 angstroms;
- (w) water where the interaction distance is between about 2.70 and about 3.07 angstroms;
- (x) an alcohol where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (y) an alcohol where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (z) a secondary amine where the interaction distance is between about 2.80 and about 3.10 angstroms;
- (aa) a secondary amine where the interaction distance is between about 3.00 and about 3.15 angstroms;

- (bb) a carbonyl where the interaction distance is between about 2.80 and about 3.15 angstroms;
- (cc) a sulfonyl where the interaction distance is between about 2.90 and about 3.00 angstroms;
- (dd) an ether where the interaction distance is between about 2.80 and about 3.10 angstroms;
- (ee) an ester where the interaction distance is between about 2.70 and about 3.05 angstroms;
- (ff) a cyano moiety where the interaction distance is between about 3.00 and about 3.30 angstroms;
- (gg) a nitro moiety where the interaction distance is between about 2.90 and about 3.07 angstroms;
- (hh) a chloride moiety where the interaction distance is between about 3.10 and about 3.60 angstroms; or
- (ii) a bromide moiety where the interaction distance is between about 3.30 and about 3.80 angstroms.

41. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a secondary amide functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a carboxylic acid;
- (c) an amino-pyridine;
- (d) a sulfonamide;
- (e) an aromatic N;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a carbonyl;
- (k) a sulfonyl;

- (l) an ether;
- (m) an ester;
- (n) a cyano moiety;
- (o) a nitro moiety;
- (p) a chloride moiety;
- (q) a bromide moiety;
- (r) a primary amide where the interaction distance is between about 2.70 and about 3.15 angstroms;
- (s) a carboxylic acid where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (t) a carboxylic acid where the interaction distance is between about 2.40 and about 3.05 angstroms;
- (u) an amino-pyridine where the interaction distance is between about 2.70 and about 3.20 angstroms;
- (v) an amino-pyridine where the interaction distance is between about 2.75 and about 3.17 angstroms;
- (w) a sulfonamide where the interaction distance is between about 2.70 and about 3.00 angstroms;
- (x) an aromatic N where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (y) water where the interaction distance is between about 2.40 and about 3.10 angstroms;
- (z) water where the interaction distance is between about 2.60 and about 3.10 angstroms;
- (aa) an alcohol where the interaction distance is between about 2.50 and about 3.04 angstroms;
- (bb) an alcohol where the interaction distance is between about 2.50 and about 3.20 angstroms;
- (cc) a primary amine where the interaction distance is between about 2.65 and about 3.20 angstroms;

- (dd) a secondary amine where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (ee) a carbonyl where the interaction distance is between about 2.70 and about 3.07 angstroms;
- (ff) a sulfonyl where the interaction distance is between about 2.60 and about 3.25 angstroms;
- (gg) an ether where the interaction distance is between about 2.70 and about 3.16 angstroms;
- (hh) an ester where the interaction distance is between about 2.80 and about 3.16 angstroms;
- (ii) a cyano moiety where the interaction distance is between about 2.90 and about 3.30 angstroms;
- (jj) a nitro moiety where the interaction distance is between about 2.80 and about 3.10 angstroms;
- (kk) a chloride moiety where the interaction distance is between about 2.90 and about 3.40 angstroms; or
- (ll) a bromide moiety where the interaction distance is between about 3.10 and about 3.50 angstroms.

42. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an alcohol functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) an aromatic N;
- (g) water;
- (h) a primary amine;
- (i) a secondary amine;



- (j) a carbonyl;
- (k) a sulfonyl;
- (l) an ether;
- (m) an ester;
- (n) a cyano moiety;
- (o) a nitro moiety;
- (p) a chloride moiety;
- (q) a bromide moiety;
- (r) a primary amide where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (s) a primary amide where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (t) a secondary amide where the interaction distance is between about 2.50 and about 3.04 angstroms;
- (u) a secondary amide where the interaction distance is between about 2.50 and about 3.20 angstroms;
- (v) a carboxylic acid where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (w) a carboxylic acid where the interaction distance is between about 2.40 and about 2.90 angstroms;
- (x) an amino-pyridine where the interaction distance is between about 2.60 and about 3.06 angstroms;
- (y) an amino-pyridine where the interaction distance is between about 2.75 and about 3.15 angstroms;
- (z) a sulfonamide where the interaction distance is between about 2.80 and about 3.07 angstroms;
- (aa) an aromatic N where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (bb) water where the interaction distance is between about 2.40 and about 3.03 angstroms;

- (cc) a primary amine where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (dd) a secondary amine where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (ee) a carbonyl where the interaction distance is between about 2.40 and about 3.05 angstroms;
- (ff) a sulfonyl where the interaction distance is between about 2.40 and about 3.15 angstroms;
- (gg) an ether where the interaction distance is between about 2.40 and about 3.00 angstroms;
- (hh) an ester where the interaction distance is between about 2.50 and about 3.10 angstroms;
- (ii) a cyano moiety where the interaction distance is between about 2.40 and about 3.10 angstroms;
- (jj) a nitro moiety where the interaction distance is between about 2.45 and about 3.05 angstroms;
- (kk) a chloride moiety where the interaction distance is between about 2.60 and about 3.30 angstroms; or
- (ll) a bromide moiety where the interaction distance is between about 3.00 and about 3.50 angstroms.

43. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a carboxylic acid functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) an amino-pyridine;
- (d) an aromatic N;
- (e) water;
- (f) an alcohol;
- (g) a primary amine;

- (h) a secondary amine;
- (i) a carbonyl;
- (j) an ether;
- (k) an ester;
- (l) a cyano moiety;
- (m) a nitro moiety;
- (n) a chloride moiety;
- (o) a bromide moiety;
- (p) a primary amide where the interaction distance is between about 2.80 and about 3.25 angstroms;
- (q) a primary amide where the interaction distance is between about 2.40 and about 2.80 angstroms;
- (r) a secondary amide where the interaction distance is between about 2.70 and about 3.10 angstroms;
- (s) a secondary amide where the interaction distance is between about 2.40 and about 3.05 angstroms;
- (t) an amino-pyridine where the interaction distance is between about 2.50 and about 2.80 angstroms;
- (u) an amino-pyridine where the interaction distance is between about 2.70 and about 3.00 angstroms;
- (v) an aromatic N where the interaction distance is between about 2.54 and about 2.94 angstroms;
- (w) water where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (x) water where the interaction distance is between about 2.40 and about 3.00 angstroms;
- (y) an alcohol where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (z) an alcohol where the interaction distance is between about 2.50 and about 2.90 angstroms;

- (aa) a primary amine where the interaction distance is between about 2.70 and about 3.10 angstroms;
  - (bb) a secondary amine where the interaction distance is between about 2.70 and about 3.10 angstroms;
  - (cc) a carbonyl where the interaction distance is between about 2.40 and about 3.00 angstroms;
  - (dd) an ether where the interaction distance is between about 2.50 and about 3.00 angstroms;
  - (ee) an ester where the interaction distance is between about 2.40 and about 3.05 angstroms;
  - (ff) an ester where the interaction distance is between about 2.40 and about 3.10 angstroms;
  - (gg) a cyano moiety where the interaction distance is between about 2.50 and about 2.80 angstroms;
  - (hh) a nitro moiety where the interaction distance is between about 2.70 and about 3.05 angstroms;
  - (ii) a chloride moiety where the interaction distance is between about 2.80 and about 3.20 angstroms; or
  - (jj) a bromide moiety where the interaction distance is between about 3.00 and about 3.30 angstroms.
44. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a carbonyl functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:
- (a) a primary amide;
  - (b) a secondary amide;
  - (c) a carboxylic acid;
  - (d) an amino-pyridine;
  - (e) a secondary sulfonamide;
  - (f) water;
  - (g) an alcohol;

- (h) a primary amine;
  - (i) a secondary amine;
  - (j) a primary amide where the interaction distance is between about 2.83 and about 3.15 angstroms;
  - (k) a secondary amide where the interaction distance is between about 2.70 and about 3.07 angstroms;
  - (l) a carboxylic acid where the interaction distance is between about 2.40 and about 3.00 angstroms;
  - (m) an amino-pyridine where the interaction distance is between about 2.87 and about 3.10 angstroms;
  - (n) a secondary sulfonamide where the interaction distance is between about 2.76 and about 3.22 angstroms;
  - (o) water where the interaction distance is between about 2.55 and about 3.05 angstroms;
  - (p) an alcohol where the interaction distance is between about 2.40 and about 3.05 angstroms;
  - (q) a primary amine where the interaction distance is between about 2.64 and about 3.15 angstroms; or
  - (r) a secondary amine where the interaction distance is between about 2.64 and about 3.15 angstroms.
45. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a cyano group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:
- (a) a primary amide;
  - (b) a secondary amide;
  - (c) a carboxylic acid;
  - (d) an amino-pyridine;
  - (e) a primary sulfonamide;
  - (f) a secondary sulfonamide;
  - (g) water;

- (h) an alcohol;
- (i) a primary amine;
- (j) a secondary amine;
- (k) a primary amide where the interaction distance is between about 3.01 and about 3.30 angstroms;
- (l) a secondary amide where the interaction distance is between about 2.90 and about 3.30 angstroms;
- (m) a carboxylic acid where the interaction distance is between about 2.57 and about 3.00 angstroms;
- (n) an amino-pyridine where the interaction distance is between about 2.84 and about 3.33 angstroms;
- (o) a primary sulfonamide where the interaction distance is about 2.99 angstroms;
- (p) a secondary sulfonamide where the interaction distance is between about 2.83 and about 3.00 angstroms;
- (q) water where the interaction distance is between about 2.78 and about 3.20 angstroms;
- (r) an alcohol where the interaction distance is between about 2.72 and about 3.13 angstroms;
- (s) a primary amine where the interaction distance is between about 2.84 and about 3.27 angstroms; or
- (t) a secondary amine where the interaction distance is between about 2.84 and about 3.30 angstroms.

46. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a sulfonyl group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a primary sulfonamide;
- (d) a secondary sulfonamide;

- (e) water;
- (f) an alcohol;
- (g) a primary amine;
- (h) a secondary amine;
- (i) a primary amide where the interaction distance is about 2.92 angstroms;
- (j) a secondary amide where the interaction distance is between about 2.95 and about 3.25 angstroms;
- (k) a primary sulfonamide where the interaction distance is between about 2.85 and about 3.10 angstroms;
- (l) a secondary sulfonamide where the interaction distance is between about 2.85 and about 3.20 angstroms;
- (m) water where the interaction distance is between about 2.84 and about 3.00 angstroms;
- (n) an alcohol where the interaction distance is between about 2.65 and about 3.15 angstroms;
- (o) a primary amine where the interaction distance is between about 2.93 and about 3.32 angstroms; or
- (p) a secondary amide where the interaction distance is between about 2.75 and about 3.32 angstroms.

47. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an aromatic N as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) water;
- (f) an alcohol;
- (g) a primary amine;
- (h) a secondary amine;

- (i) a primary amide where the interaction distance is between about 2.90 and about 3.21 angstroms;
- (j) a secondary amide where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (k) a carboxylic acid where the interaction distance is between about 2.54 and about 2.94 angstroms;
- (l) an amino-pyridine where the interaction distance is between about 2.70 and about 3.20 angstroms;
- (m) water where the interaction distance is between about 2.60 and about 3.15 angstroms;
- (n) an alcohol where the interaction distance is between about 2.50 and about 3.00 angstroms;
- (o) a primary amine where the interaction distance is between about 2.92 and about 3.26 angstroms; or
- (p) a secondary amine where the interaction distance is between about 2.73 and about 3.25 angstroms.

48. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an ether functional group as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is between about 2.80 and about 3.10 angstroms;



- (k) a secondary amide where the interaction distance is between about 2.70 and about 3.16 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 2.50 and about 3.02 angstroms;
- (m) an amino-pyridine where the interaction distance is between about 2.80 and about 3.20 angstroms;
- (n) a sulfonamide where the interaction distance is less than about 3.20 angstroms;
- (o) water where the interaction distance is between about 2.40 and about 3.15 angstroms;
- (p) an alcohol where the interaction distance is between about 2.40 and about 3.00 angstroms;
- (q) a primary amine where the interaction distance is between about 2.75 and about 3.25 angstroms; or
- (r) a secondary amine where the interaction distance is between about 2.60 and about 3.25 angstroms.

49. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a chloride moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is between about 3.10 and about 3.60 angstroms;

- (k) a secondary amide where the interaction distance is between about 2.90 and about 3.30 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 2.80 and about 3.30 angstroms;
- (m) an amino-pyridine where the interaction distance is between about 3.10 and about 3.45 angstroms;
- (n) a sulfonamide where the interaction distance is less than about 3.35 angstroms;
- (o) water where the interaction distance is between about 2.70 and about 3.30 angstroms;
- (p) an alcohol where the interaction distance is between about 2.50 and about 3.30 angstroms;
- (q) a primary amine where the interaction distance is between about 3.00 and about 3.50 angstroms; or
- (r) a secondary amine where the interaction distance is between about 2.90 and about 3.40 angstroms.

50. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an organochloride moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is between about 3.18 and about 3.21 angstroms;

- (k) a secondary amide where the interaction distance is between about 3.20 and about 3.27 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 2.90 and about 3.23 angstroms;
- (m) an amino-pyridine where the interaction distance is between about 3.28 and about 3.33 angstroms;
- (n) a sulfonamide where the interaction distance is less than about 3.50 angstroms;
- (o) water where the interaction distance is between about 2.79 and about 3.26 angstroms;
- (p) an alcohol where the interaction distance is between about 2.90 and about 3.29 angstroms;
- (q) a primary amine where the interaction distance is between about 3.21 and about 3.29 angstroms; or
- (r) a secondary amine where the interaction distance is between about 3.26 and about 3.30 angstroms.

51. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises a bromide moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) an alcohol;
- (f) a primary amine;
- (g) a secondary amine;
- (h) a primary amide where the interaction distance is between about 3.30 and about 3.80 angstroms;
- (i) a secondary amide where the interaction distance is between about 3.10 and about 3.80 angstroms;

- (j) a carboxylic acid where the interaction distance is between about 3.00 and about 3.30 angstroms;
- (k) an amino-pyridine where the interaction distance is between about 3.20 and about 3.50 angstroms;
- (l) an alcohol where the interaction distance is between about 3.00 and about 3.50 angstroms;
- (m) a primary amine where the interaction distance is between about 3.20 and about 3.60 angstroms; or
- (n) a secondary amine where the interaction distance is between about 3.10 and about 3.60 angstroms.

52. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an organobromide moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) a sulfonamide;
- (f) water;
- (g) an alcohol;
- (h) a primary amine;
- (i) a secondary amine;
- (j) a primary amide where the interaction distance is less than about 3.50 angstroms;
- (k) a secondary amide where the interaction distance is less than about 3.50 angstroms;
- (l) a carboxylic acid where the interaction distance is between about 3.01 and about 3.31 angstroms;
- (m) an amino-pyridine where the interaction distance is less than about 3.50 angstroms;

- (n) a sulfonamide where the interaction distance is less than about 3.50 angstroms;
- (o) water where the interaction distance is between about 3.14 and about 3.27 angstroms;
- (p) an alcohol where the interaction distance is between about 2.90 and about 3.36 angstroms;
- (q) a primary amine where the interaction distance is less than about 3.50 angstroms; or
- (r) a secondary amine where the interaction distance is between about 3.20 and about 3.39 angstroms.

53. The pharmaceutical co-crystal composition according to claims 1, 3, 5, or 7, wherein the API or co-crystal former comprises an organoiodide moiety as a hydrogen bonded moiety and another hydrogen bonded moiety comprises:

- (a) a primary amide;
- (b) a secondary amide;
- (c) a carboxylic acid;
- (d) an amino-pyridine;
- (e) an aromatic N;
- (f) an alcohol;
- (g) a primary amine;
- (h) a secondary amine;
- (i) a primary amide where the interaction distance is less than about 3.80 angstroms;
- (j) a secondary amide where the interaction distance is less than about 3.80 angstroms;
- (k) a carboxylic acid where the interaction distance is less than about 3.80 angstroms;
- (l) an amino-pyridine where the interaction distance is less than about 3.80 angstroms;

- (m) an aromatic N where the interaction distance is between about 2.70 and about 3.23 angstroms;
- (n) an alcohol where the interaction distance is between about 2.90 and about 3.48 angstroms;
- (o) a primary amine where the interaction distance is between about 3.25 and about 3.42 angstroms; or
- (p) a secondary amine where the interaction distance is between about 2.71 and about 2.87 angstroms.

54. The pharmaceutical co-crystal composition according to claims 1 or 3, wherein the API forms a dimeric primary amide structure via hydrogen bonds with an  $R^2$  (8) motif, and further wherein the composition comprises:

- (a) at least one hydrogen bond donor;
- (b) at least two hydrogen bond donors;
- (c) at least three hydrogen bond donors;
- (d) at least four hydrogen bond donors;
- (e) at least one hydrogen bond acceptor;
- (f) at least two hydrogen bond acceptors;
- (g) at least one hydrogen bond donor and one hydrogen bond acceptor;
- (h) at least two hydrogen bond donors and one hydrogen bond acceptor;
- (i) at least one hydrogen bond donor and two hydrogen bond acceptors;
- (j) at least two hydrogen bond donors and two hydrogen bond acceptors; or
- (k) at least three hydrogen bond donors and one hydrogen bond acceptor.

55. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
  - (i) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 3.77, 9.63, and 17.78 degrees;

- (ii) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 9.63, 20.44, and 22.10 degrees;
- (iii) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 14.76 and 21.19 degrees;
- (iv) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 3.77 and 19.31 degrees;
- (v) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 17.78 and 20.44 degrees;
- (vi) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises a peak at 3.77 degrees; or
- (vii) said co-crystal is a celecoxib:nicotinamide co-crystal and said X-ray diffraction pattern comprises a peak at 17.78 degrees;
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a celecoxib:nicotinamide co-crystal and said DSC thermogram comprises an endothermic transition at about 130 degrees C; or
- (c) the co-crystal is characterized by a Raman spectrum comprising peaks expressed in terms of  $\text{cm}^{-1}$ , wherein:
  - (i) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises peaks at 1599, 1162, and 1044;
  - (ii) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises peaks at 1618, 1044, and 796;
  - (iii) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises peaks at 1599 and 1044;
  - (iv) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises a peak at 1044;
  - (v) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises a peak at 1618; or
  - (vi) said co-crystal is a celecoxib:nicotinamide co-crystal and said Raman spectrum comprises a peak at 1599.

56. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
  - (i) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 8.73, 13.13, and 18.45 degrees;
  - (ii) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 8.73, 11.89, and 17.75 degrees;
  - (iii) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 16.37, 18.45, and 23.11 degrees;
  - (iv) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 17.75 and 20.75 degrees;
  - (v) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 8.73 and 13.13 degrees;
  - (vi) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 11.89 and 22.37 degrees;
  - (vii) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 8.73 degrees;
  - (viii) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 11.89 degrees; or
  - (ix) said co-crystal is a celecoxib:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 17.75 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a celecoxib:18-crown-6 co-crystal and said DSC thermogram comprises an endothermic transition at about 190 degrees C.

57. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:



- (i) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 11.07, 13.83, and 18.03 degrees;
- (ii) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 10.79, 16.13, and 18.51 degrees;
- (iii) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 12.17, 18.03, and 21.43 degrees;
- (iv) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 11.07 and 18.03 degrees;
- (v) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 12.17 and 18.51 degrees;
- (vi) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 16.13 and 21.43 degrees;
- (vii) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 11.07 degrees; or
- (viii) said co-crystal is a topiramate:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 13.83 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a topiramate:18-crown-6 co-crystal and said DSC thermogram comprises an endothermic transition at about 135 degrees C.

58. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
  - (i) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 4.89, 8.65, and 17.15 degrees;

- (ii) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 17.15, 23.95, and 25.53 degrees;
- (iii) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 8.65, 19.71, and 26.71 degrees;
- (iv) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 4.89 and 17.15 degrees;
- (v) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 8.65 and 23.95 degrees;
- (vi) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises peaks at 23.95 and 25.53 degrees;
- (vii) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises a peak at 4.89 degrees; or
- (viii) said co-crystal is an olanzapine:nicotinamide form I co-crystal and said X-ray diffraction pattern comprises a peak at 17.15 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is an olanzapine:nicotinamide form I co-crystal and said DSC thermogram comprises an endothermic transition at about 126 degrees C.

59. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 8.65, 17.53, and 24.19 degrees;

- (b) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 11.87, 14.53, and 19.69 degrees;
- (c) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 8.65, 17.53, and 18.09 degrees;
- (d) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 11.87 and 17.53 degrees;
- (e) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 8.65 and 14.53 degrees;
- (f) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises peaks at 11.87 and 24.19 degrees;
- (g) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises a peak at 8.65 degrees;
- (h) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises a peak at 17.53 degrees; or
- (i) said co-crystal is an olanzapine:nicotinamide form II co-crystal and said X-ray diffraction pattern comprises a peak at 11.87 degrees.

60. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 6.41, 12.85, and 18.67 degrees;
- (b) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 12.85, 21.85, and 24.37 degrees;

- (c) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 14.91, 18.67, and 21.85 degrees;
  - (d) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 6.41 and 12.85 degrees;
  - (e) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 6.41 and 18.67 degrees;
  - (f) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises peaks at 12.85 and 18.67 degrees;
  - (g) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises a peak at 6.41 degrees;
  - (h) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises a peak at 12.85 degrees; or
  - (i) said co-crystal is an olanzapine:nicotinamide form III co-crystal and said X-ray diffraction pattern comprises a peak at 18.67 degrees.
61. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 3.01, 16.17, and 17.29 degrees;
    - (ii) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.01, 15.87, and 24.47 degrees;

- (iii) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.05, 20.41, and 22.27 degrees;
- (iv) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 3.01 and 17.29 degrees;
- (v) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.01 and 16.17 degrees;
- (vi) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.05 and 22.27 degrees;
- (vii) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 3.01 degrees;
- (viii) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 16.17 degrees; or
- (ix) said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 17.29 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazole:succinic acid co-crystal and said DSC thermogram comprises an endothermic transition at about 160 degrees C.

62. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
  - (i) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.61, 5.89, and 10.57 degrees;
  - (ii) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.23, 19.05, and 20.79 degrees;

- (iii) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.51, 16.23, and 16.93 degrees;
  - (iv) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.61 and 20.79 degrees;
  - (v) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 5.89 and 19.05 degrees;
  - (vi) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.57 and 16.23 degrees;
  - (vii) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 4.61 degrees;
  - (viii) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 5.89 degrees;
  - (ix) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 10.57 degrees; or
  - (x) said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 19.05 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazole:fumaric acid co-crystal and said DSC thermogram comprises an endothermic transition at about 180 degrees C.
63. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.13, 6.19, and 8.49 degrees;

- (ii) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.19, 16.13, and 17.23 degrees;
  - (iii) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.49, 18.07, and 20.79 degrees;
  - (iv) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.13 and 8.49 degrees;
  - (v) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.19 and 20.79 degrees;
  - (vi) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 16.13 and 17.23 degrees;
  - (vii) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 4.13 degrees;
  - (viii) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 6.19 degrees; or
  - (ix) said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 8.49 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazole:L-tartaric acid co-crystal and said DSC thermogram comprises an endothermic transition at about 181 degrees C.

64. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
  - (i) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.07, 8.85, and 17.05 degrees;

- (ii) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.93, 20.49, and 22.85 degrees;
  - (iii) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.85, 15.93 and 26.17 degrees;
  - (iv) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.07 and 17.05 degrees;
  - (v) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.85 and 21.27 degrees;
  - (vi) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.07 and 8.85 degrees;
  - (vii) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises a peak at 6.07 degrees;
  - (viii) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises a peak at 8.85 degrees; or
  - (ix) said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said X-ray diffraction pattern comprises a peak at 17.05 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazole:L-malic acid co-crystal and said DSC thermogram comprises an endothermic transition at about 154 degrees C.
65. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 3.73, 10.95, and 13.83 degrees;



- (ii) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 16.53, 17.75, and 19.65 degrees;
  - (iii) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.95, 16.53, and 21.11 degrees;
  - (iv) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 3.73 and 10.95 degrees;
  - (v) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 13.83 and 17.75 degrees;
  - (vi) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises peaks at 16.53 and 19.65 degrees;
  - (vii) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 3.73 degrees;
  - (viii) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 10.95 degrees; or
  - (ix) said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said X-ray diffraction pattern comprises a peak at 17.75 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a *cis*-itraconazoleHCl:DL-tartaric acid co-crystal and said DSC thermogram comprises an endothermic transition at about 162 degrees C.
66. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (i) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 5.11, 9.35, and 16.87 degrees;
- (ii) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 16.87, 18.33, and 19.53 degrees;
- (iii) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 9.35, 19.53, and 22.89 degrees;
- (iv) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 5.11 and 9.35 degrees;
- (v) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 16.87 and 19.53 degrees;
- (vi) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises peaks at 18.33 and 22.89 degrees;
- (vii) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises a peak at 5.11 degrees;
- (viii) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises a peak at 9.35 degrees; or
- (ix) said co-crystal is a modafinil:malonic acid form I co-crystal and said X-ray diffraction pattern comprises a peak at 16.87 degrees;
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a modafinil:malonic acid form I co-crystal and said DSC thermogram comprises an endothermic transition at about 106 degrees C; or
- (c) the co-crystal is characterized by a Raman spectrum comprising peaks expressed in terms of  $\text{cm}^{-1}$ , wherein:
  - (i) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1004, 633, and 265;

- (ii) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1032, 1601, and 767;
- (iii) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1004 and 633;
- (iv) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1183 and 767; or
- (v) said co-crystal is a modafinil:malonic acid form I co-crystal and said Raman spectrum comprises peaks at 1601 and 718.

67. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 5.90, 9.54, and 20.01 degrees;
- (b) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 15.79, 18.02, and 21.66 degrees;
- (c) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 9.54, 20.01, and 25.30 degrees;
- (d) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 5.90 and 9.54 degrees;
- (e) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 5.90 and 20.01 degrees;
- (f) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 9.54 and 20.01 degrees;

- (g) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 5.90 degrees; or
- (h) said co-crystal is a modafinil:malonic acid form II co-crystal and said X-ray diffraction pattern comprises peaks at 9.54 degrees.

68. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.51, 15.97, and 20.03 degrees;
- (b) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 14.91, 19.01, and 22.75 degrees;
- (c) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.97, 25.03, and 25.71 degrees;
- (d) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 9.51 and 15.97 degrees;
- (e) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 20.03 and 25.03 degrees;
- (f) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.97 and 25.03 degrees;
- (g) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises a peak at 9.51 degrees;
- (h) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises a peak at 15.97 degrees; or
- (i) said co-crystal is a modafinil:glycolic acid co-crystal and said X-ray diffraction pattern comprises a peak at 20.03 degrees.

69. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.69, 6.15, and 9.61 degrees;
  - (b) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.23, 19.97, and 21.83 degrees;
  - (c) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.69, 10.23, and 21.83 degrees;
  - (d) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.69 and 19.97 degrees;
  - (e) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 6.15 and 9.61 degrees;
  - (f) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises peaks at 4.69 and 6.15 degrees;
  - (g) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises a peak at 4.69 degrees;
  - (h) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises a peak at 9.61 degrees; or
  - (i) said co-crystal is a modafinil: maleic acid co-crystal and said X-ray diffraction pattern comprises a peak at 19.97 degrees.
70. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a 5-fluorouracil: urea co-crystal and said X-ray diffraction pattern comprises peaks at 11.23, 13.27, and 16.93 degrees;
    - (ii) said co-crystal is a 5-fluorouracil: urea co-crystal and said X-ray diffraction pattern comprises peaks at 12.69, 20.37, and 25.55 degrees;
    - (iii) said co-crystal is a 5-fluorouracil: urea co-crystal and said X-ray diffraction pattern comprises peaks at 17.93, 23.65, and 26.87 degrees;

- (iv) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises peaks at 11.23 and 16.93 degrees;
- (v) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises peaks at 23.65 and 32.49 degrees;
- (vi) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises peaks at 13.27 and 25.55 degrees;
- (vii) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises a peak at 11.23 degrees;
- (viii) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises a peak at 16.93 degrees; or
- (ix) said co-crystal is a 5-fluorouracil:urea co-crystal and said X-ray diffraction pattern comprises a peak at 25.55 degrees;
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a 5-fluorouracil:urea co-crystal and said DSC thermogram comprises an endothermic transition at about 208 degrees C; or
- (c) the co-crystal is characterized by a Raman spectrum comprising peaks expressed in terms of  $\text{cm}^{-1}$ , wherein:
  - (i) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 1347, 1024, and 757;
  - (ii) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 644, 545, and 472;
  - (iii) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 1680 and 1347;
  - (iv) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 1347 and 757; or
  - (v) said co-crystal is a 5-fluorouracil:urea co-crystal and said Raman spectrum comprises peaks at 1024 and 757.

71. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.57, 13.23, and 21.13 degrees;
- (b) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 14.31, 17.89, and 26.57 degrees;
- (c) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.57, 21.13, and 25.73 degrees;
- (d) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 8.57 and 21.13 degrees;
- (e) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 13.23 and 26.57 degrees;
- (f) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises peaks at 17.89 and 24.41 degrees;
- (g) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 8.57 degrees;
- (h) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 13.23 degrees; or
- (i) said co-crystal is a hydrochlorothiazide:nicotinic acid co-crystal and said X-ray diffraction pattern comprises a peak at 21.13 degrees.

72. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 9.97, 11.57, and 15.67 degrees;
- (b) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 14.53, 19.05, and 20.31 degrees;
- (c) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 16.61, 20.65, and 23.63 degrees;

- (d) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 9.97 and 10.43 degrees;
- (e) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 12.83 and 15.67 degrees;
- (f) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises peaks at 14.53 and 20.31 degrees;
- (g) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 10.43 degrees;
- (h) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 12.83 degrees; or
- (i) said co-crystal is a hydrochlorothiazide:18-crown-6 co-crystal and said X-ray diffraction pattern comprises a peak at 20.31 degrees.

73. The co-crystal according to claim 11, wherein the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

- (a) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 6.85, 13.75, and 18.71 degrees;
- (b) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 15.93, 23.27, and 24.17 degrees;
- (c) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 18.17, 20.93, and 27.75 degrees;
- (d) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 6.85 and 18.71 degrees;
- (e) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 13.75 and 23.27 degrees;
- (f) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises peaks at 15.93 and 24.17 degrees;
- (g) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises a peak at 6.85 degrees;



- (h) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises a peak at 13.75 degrees; or
- (i) said co-crystal is a hydrochlorothiazide:piperazine co-crystal and said X-ray diffraction pattern comprises a peak at 18.71 degrees.

74. The co-crystal according to claim 11, wherein the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is an acetaminophen:4,4-bipyridine:water co-crystal and said DSC thermogram comprises an endothermic transition at about 58 degrees C.

75. The co-crystal according to claim 11, wherein:

- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
  - (i) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises peaks at 5.2, 15.1, and 16.7 degrees;
  - (ii) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises peaks at 11.1, 16.2, and 17.8 degrees;
  - (iii) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises peaks at 5.2 and 15.1 degrees;
  - (iv) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises peaks at 15.1 and 19.4 degrees;
  - (v) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises a peak at 5.2 degrees; or
  - (vi) said co-crystal is a phenytoin:pyridone co-crystal and said X-ray diffraction pattern comprises a peak at 15.1 degrees; or
- (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a phenytoin:pyridone co-crystal and said DSC thermogram comprises an endothermic transition at about 233 degrees C.

76. The co-crystal according to claim 11, wherein the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is an aspirin:4,4-bipyridine co-crystal and said DSC thermogram comprises an endothermic transition at about 95 degrees C.
77. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 3.4 and 6.9 degrees;
    - (ii) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 3.4 and 10.4 degrees;
    - (iii) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 10.4 and 17.3 degrees;
    - (iv) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises a peak at 3.4 degrees; or
    - (v) said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises a peak at 10.4 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is an ibuprofen:4,4-bipyridine co-crystal and said DSC thermogram comprises an endothermic transition at about 119 degrees C.
78. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 16.8, 18.1, and 20.0 degrees;
    - (ii) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 18.1, 21.3, and 25.0 degrees;

- (iii) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 16.8 and 19.0 degrees;
  - (iv) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises peaks at 17.1 and 21.3 degrees;
  - (v) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises a peak at 16.8 degrees; or
  - (vi) said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said X-ray diffraction pattern comprises a peak at 19.0 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a flurbiprofen:4,4-bipyridine co-crystal and said DSC thermogram comprises an endothermic transition at about 163 degrees C.
79. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises peaks at 3.6, 17.3, and 18.4 degrees;
    - (ii) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises peaks at 17.3, 19.1, and 23.8 degrees;
    - (iii) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises peaks at 18.1 and 22.3 degrees;
    - (iv) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises peaks at 3.6 and 18.4 degrees;
    - (v) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises a peak at 3.6 degrees; or

- (vi) said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said X-ray diffraction pattern comprises a peak at 19.1 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a flurbiprofen:trans-1,2-bis-(4-pyridyl) ethylene co-crystal and said DSC thermogram comprises an endothermic transition at about 164 degrees C.
- 80. The co-crystal according to claim 11, wherein:
  - (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises peaks at 8.5, 11.9, and 15.1 degrees;
    - (ii) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises peaks at 10.6, 14.4, and 18.0 degrees;
    - (iii) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises peaks at 11.9 and 23.7 degrees;
    - (iv) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises peaks at 8.5 and 14.4 degrees;
    - (v) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises a peak at 8.5 degrees; or
    - (vi) said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said X-ray diffraction pattern comprises a peak at 11.9 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:p-phthalaldehyde co-crystal and said DSC thermogram comprises an endothermic transition at about 128 degrees C.

81. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 8.8, 13.2, and 15.6 degrees;
    - (ii) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 13.2, 15.6, and 20.4 degrees;
    - (iii) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 8.8 and 26.4 degrees;
    - (iv) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises peaks at 13.2 and 15.6 degrees;
    - (v) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises a peak at 8.8 degrees; or
    - (vi) said co-crystal is a carbamazepine:nicotinamide co-crystal and said X-ray diffraction pattern comprises a peak at 15.6 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:nicotinamide co-crystal and said DSC thermogram comprises an endothermic transition at about 157 degrees C.
82. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises peaks at 6.9, 13.6, and 15.3 degrees;
    - (ii) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises peaks at 14.0, 20.2, and 28.3 degrees;

- (iii) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises peaks at 12.2 and 21.3 degrees;
  - (iv) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises peaks at 14.0 and 20.2 degrees;
  - (v) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises a peak at 14.0 degrees; or
  - (vi) said co-crystal is a carbamazepine:saccharin co-crystal and said X-ray diffraction pattern comprises a peak at 21.3 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:saccharin co-crystal and said DSC thermogram comprises an endothermic transition at about 177 degrees C.
83. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.14 and 17.44 degrees;
    - (ii) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises peaks at 15.29 and 21.17 degrees;
    - (iii) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.14 and 15.29 degrees;
    - (iv) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises peaks at 21.17 and 31.41 degrees;
    - (v) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises a peak at 10.14 degrees; or

- (vi) said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said X-ray diffraction pattern comprises a peak at 17.44 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:5-nitroisophthalic acid co-crystal and said DSC thermogram comprises an endothermic transition at about 191 degrees C.
84. The co-crystal according to claim 11, wherein:
- (a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.89, 12.23, and 16.25 degrees;
    - (ii) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.89, 17.05, and 18.47 degrees;
    - (iii) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises peaks at 12.23 and 17.05 degrees;
    - (iv) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises peaks at 10.89 and 21.95 degrees;
    - (v) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises a peak at 10.89 degrees; or
    - (vi) said co-crystal is a carbamazepine:trimesic acid co-crystal and said X-ray diffraction pattern comprises a peak at 16.25 degrees; or
  - (b) the co-crystal is characterized by a DSC thermogram, wherein said co-crystal is a carbamazepine:trimesic acid co-crystal and said DSC thermogram comprises an endothermic transition at about 273 degrees C.

85. The co-crystal of claim 1, specifically excluding a co-crystal selected from the group consisting of: nabumetone:2,3-naphthalenediol, fluoxetine HCl:benzoic acid, fluoxetine HCl:succinic acid, acetaminophen:piperazine, acetaminophen:theophylline, theophylline:salicylic acid, theophylline:p-hydroxybenzoic acid, theophylline:sorbic acid, theophylline:1-hydroxy-2-naphthoic acid, theophylline:glycolic acid, theophylline:2,5-dihydroxybenzoic acid, theophylline:chloroacetic acid, bis(diphenylhydantoin):9-ethyladenine acetylacetone solvate, bis(diphenylhydantoin):9-ethyladenine 2,4-pentanedione solvate, 5,5-diphenylbarbituric acid:9-ethyladenine, bis(diphenylhydantoin):9-ethyladenine, 4-aminobenzoic acid:4-aminobenzonitrile, sulfamididine:salicylic acid, 8-hydroxyquinolinium 4-nitrobenzoate:4-nitrobenzoic acid, sulfaproxyline:caffeine, retro-inverso-isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-(N-((2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl)-L-histidylamino)butyrate:cinnamic acid monohydrate, benzoic acid:isonicotinamide, 3-(2-N',N'-(dimethylhydrazino)-4-thiazolylmethylthio)-N''-sulfamoylpropionamidine:maleic acid, diglycine hydrochloride ( $C_2H_5NO_2:C_2H_6NO_2^+Cl^-$ ), octadecanoic acid:3-pyridinecarboxamide, cis-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide hydrochloride:oxalic acid, trans-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide oxalate:oxalic acid dihydrate, bis(1-(3-((4-(2-isopropoxyphenyl)-1-piperazinyl)methyl)benzoyl)piperidine)succinate:succinic acid, bis(p-cyanophenyl)imidazolymethane:succinic acid, cis-1-((4-(1-imidazolylmethyl)cyclohexyl)methyl)imidazole:succinic acid, (+)-2-(5,6-dimethoxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline:(+)-dibenzoyl-D-tartaric acid, raclopride:tartaric acid, 2,6-diamino-9-ethylpurine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:bis(2-aminopyridine), 5,5-diethylbarbituric acid:acetamide, 5,5-diethylbarbituric acid:KI, 5,5-diethylbarbituric acid:urea, bis(barbital):hexamethylphosphoramide, 5,5-diethylbarbituric acid:imidazole, barbital:1-methylimidazole, 5,5-diethylbarbituric acid:N-methyl-2-pyridone, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine:5,5-diethylbarbituric acid, bis(barbital):caffeine, bis(barbital):1-methylimidazole, bis(beta-cyclodextrin):bis(barbital) hydrate, tetrakis(beta-cyclodextrin):tetrakis(barbital), 9-ethyladenine:5,5-diethylbarbituric acid,



barbital: $N'$ -(*p*-cyanophenyl)- $N$ -(*p*-iodophenyl)melamine, barbital:2-amino-4-(*m*-bromophenylamino)-6-chloro-1,3,5-triazine, 5,5-diethylbarbituric acid: $N,N'$ -diphenylmelamine, 5,5-diethylbarbituric acid: $N,N'$ -bis(*p*-chlorophenyl)melamine,  $N,N'$ -bis(*p*-bromophenyl)melamine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid: $N,N'$ -bis(*p*-iodophenyl)melamine, 5,5-diethylbarbituric acid: $N,N'$ -bis(*p*-tolyl)melamine, 5,5-diethylbarbituric acid: $N,N'$ -bis(*m*-tolyl)melamine, 5,5-diethylbarbituric acid: $N,N'$ -bis(*m*-chlorophenyl)melamine,  $N,N'$ -Bis(*m*-methylphenyl)melamine:barbital,  $N,N'$ -bis(*m*-chlorophenyl)melamine:barbital tetrahydrofuran solvate, 5,5-diethylbarbituric acid: $N,N'$ -bis(*tert*-butyl)melamine, 5,5-diethylbarbituric acid: $N,N'$ -di(*tert*-butyl)melamine, 6,6'-diquinolyl ether:5,5-diethylbarbituric acid, 5-*tert*-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid,  $N,N'$ -bis(4-carboxymethylphenyl)melamine:barbital ethanol solvate,  $N,N'$ -bis(4-*tert*-butylphenyl)melamine:barbital, tris(5,17- $N,N'$ -bis(4-amino-6-(butylamino)-1,3,5-triazin-2-yl)diamino-11,23-dinitro-25,26,27,28-tetrapropoxycalix(4)arene):hexakis(diethylbarbituric acid) toluene solvate,  $N,N'$ -bis(*m*-fluorophenyl)melamine:barbital,  $N,N'$ -bis(*m*-bromophenyl)melamine:barbital acetone solvate,  $N,N'$ -bis(*m*-iodophenyl)melamine:barbital acetonitrile solvate,  $N,N'$ -bis(*m*-trifluoromethylphenyl)melamine:barbital acetonitrile solvate, aminopyrine:barbital,  $N,N'$ -bis(4-fluorophenyl)melamine:barbital,  $N,N'$ -bis(4-trifluoromethylphenyl)melamine:barbital, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine:barbital, hydroxybutyrate:hydroxyvalerate, 2-aminopyrimidine:succinic acid, 1,3-bis(((6-methylpyrid-2-yl)amino)carbonyl)benzene:glutaric acid, 5-*tert*-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, bis(dithiobiuret-S,S')nickel(II):diuracil, platinum 3,3'-dihydroxymethyl-2,2'-bipyridine dichloride: $AgF_3CSO_3$ , 4,4'-bipyridyl:isophthalic acid, 4,4'-bipyridyl:1,4-naphthalenedicarboxylic acid, 4,4'-bipyridyl:1,3,5-cyclohexane-tricarboxylic acid, 4,4'-bipyridyl:tricarballic acid, urotropin:azelaic acid, insulin:C8-HI (octanoyl- $N^C$ -LysB29-human insulin), isonicotinamide:cinnamic acid, isonicotinamide:3-hydroxybenzoic acid, isonicotinamide:3- $N,N$ -dimethylaminobenzoic acid, isonicotinamide:3,5-bis(trifluoromethyl)-benzoic acid, isonicotinamide:d,l-mandelic acid,

isonicotinamide:chloroacetic acid, isonicotinamide:fumaric acid monoethyl ester,  
 isonicotinamide:12-bromododecanoic acid, isonicotinamide:fumaric acid,  
 isonicotinamide:succinic acid, isonicotinamide:4-ketopimelic acid,  
 isonicotinamide:thiodiglycolic acid, 1,3,5-cyclohexane-tricarboxylic  
 acid:hexamethyltetramine, 1,3,5-cyclohexane-tricarboxylic acid:4,7-phenanthroline, 4,7-  
 phenanthroline:oxalic acid, 4,7-phenanthroline:terephthalic acid, 4,7-phenanthroline:  
 1,3,5-cyclohexane-tricarboxylic acid, 4,7-phenanthroline:1,4-naphthalenedicarboxylic  
 acid, pyrazine:methanoic acid, pyrazine:ethanoic acid, pyrazine:propanoic acid,  
 pyrazine:butanoic acid, pyrazine:pentanoic acid, pyrazine:hexanoic acid,  
 pyrazine:heptanoic acid, pyrazine:octanoic acid, pyrazine:nonanoic acid,  
 pyrazine:decanoic acid, diammine-(deoxy-quanyl-quanyl-N<sup>7</sup>,N<sup>7</sup>)-platinum:tris(glycine)  
 hydrate, 2-aminopyrimidine:p-phenylenediacetic acid, bis(2-aminopyrimidin-1-  
 ium)fumarate:fumaric acid, 2-aminopyrimidine:indole-3-acetic acid, 2-  
 aminopyrimidine:N-methylpyrrole-2-carboxylic acid, 2-aminopyrimidine:thiophen-2-  
 carboxylic acid, 2-aminopyrimidine:(+)-camphoric acid, 2,4,6-Trinitrobenzoic acid:2-  
 aminopyrimidine, 2-aminopyrimidine:4-aminobenzoic acid, 2-  
 aminopyrimidine:bis(phenoxyacetic acid), 2-aminopyrimidine:(2,4-  
 dichlorophenoxy)acetic acid, 2-aminopyrimidine:(3,4-dichlorophenoxy)acetic acid, 2-  
 aminopyrimidine:indole-2-carboxylic acid, 2-aminopyrimidine:terephthalic acid, 2-  
 aminopyrimidine:bis(2-nitrobenzoic acid), 2-aminopyrimidine:bis(2-aminobenzoic acid),  
 2-aminopyrimidine:3-aminobenzoic acid, 2-hexenoic acid:isonicotinamide, 4-  
 nitrobenzoic acid:isonicotinamide, 3,5-dinitrobenzoic acid:isonicotinamide:4-  
 methylbenzoic acid, 2-amino-5-nitropyrimidine:2-amino-3-nitropyridine, 3,5-  
 dinitrobenzoic acid:4-chlorobenzamide, 3-dimethylaminobenzoic acid:4-  
 chlorobenzamide, fumaric acid:4-chlorobenzamide, oxine:4-nitrobenzoic acid, oxine:3,5-  
 dinitrobenzoic acid, oxine:3,5-dinitrosalicylic acid, 3-[2-(N<sup>1</sup>,N<sup>1</sup>-dimethylhydrazino)-4-  
 thiazolylmethylthio]-N<sup>2</sup>-sulfamoylpropionamide:maleic acid, 5-fluorouracil:9-  
 ethylhypoxanthine, 5-fluorouracil:cytosine dihydrate, 5-fluorouracil:theophylline  
 monohydrate, stearic acid:nicotinamide, cis-1-{{4-(1-  
 imidazolylmethyl)cyclohexyl}methyl}imidazole:succinic acid, CGS18320B:succinic  
 acid, sulfaproxyline:caffeine, 4-aminobenzoic acid:4-aminobenzonitrile, 3,5-

dinitrobenzoic acid:isonicotinamide:3-methylbenzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-(dimethylamino)benzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-hydroxy-3-methoxycinnamic acid, isonicotinamide:oxalic acid, isonicotinamide:malonic acid, isonicotinamide:succinic acid, isonicotinamide:glutaric acid, isonicotinamide:adipic acid, benzoic acid:isonicotinamide, mazapertine:succinate, betaine:dichloronitrophenol, betainepyridine:dichloronitrophenol, betainepyridine:pentachlorophenol, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:methyl 2,4-dihydroxybenzoate, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxypropiophenone, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxyacetophenone, squaric acid:4,4'-dipyridylacetylene, squaric acid:1,2-bis(4-pyridyl)ethylene, chloranilic acid:1,4-bis[(4-pyridyl)ethynyl]benzene, 4,4'-bipyridine:phthalic acid, 4,4'-dipyridylacetylene:phthalic acid, bis(pentamethylcyclopentadienyl)iron:bromanilic acid, bis(pentamethylcyclopentadienyl)iron:chloranilic acid, bis(pentamethylcyclopentadienyl)iron:cyananilic acid, pyrazinotetrathiafulvalene:chloranilic acid, phenol:pentafluorophenol, co-crystals of itraconazole, and co-crystals of topiramate.




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3




FIG. 4






FIG. 5A




FIG. 5B




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10A






FIG. 10B




FIG. 11




FIG. 12




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C






FIG. 14D




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 38A




FIG. 38B





FIG. 39A




FIG. 39B




FIG. 40A



FIG. 40C




FIG. 40B




FIG. 40D




FIG. 41A




FIG. 41C




FIG. 41B




FIG. 41D




FIG. 42A




FIG. 42C




FIG. 42B




FIG. 42D




FIG. 43A




FIG. 43B




FIG. 44A






FIG. 44B




FIG. 45




FIG. 46




FIG. 47




FIG. 48




FIG. 49




FIG. 50




FIG. 51A




FIG. 51B






FIG. 52A




FIG. 52B




FIG. 53A




FIG. 53B




FIG. 54A




FIG. 54B




FIG. 55A




FIG. 55B




FIG. 56





FIG. 57





Dissolution profiles into 0.1 N HCl at 25 °C  
 SporanoX Beads (amorphous freebase) (Rectangle)  
 I-Malate (Inverted triangle)  
 I-Tartrate (Oval)  
 Succinate (Triangle)  
 Crystalline Freebase (Diamond)

FIG. 58




FIG. 59






FIG. 61